,Article,Date,Symbol,Time,Title,Url
0,"   By Nadia Damouni, Jessica Toonkel and Soyoung Kim | NEW YORK  NEW YORK Drugmakers Valeant Pharmaceuticals International Inc (VRX.TO), Actavis Plc ACT.N and Mylan Inc (MYL.O) have all expressed interest in buying Pfizer Inc's (PFE.N) branded generics business, but no active discussions are going on at this time, according to three people close to the matter.The ""established products"" unit, which makes off-patent drugs, had global sales of $7 billion in the first nine months of 2013, accounting for 18 percent of Pfizer's revenue. Pfizer said in July it planned to separate its commercial operations into three units -- two mainly for patent-protected brands and the third for generics.According to the people close to the matter, Pfizer is aware of each of the companies' interest but is not yet ready to entertain a deal as it prepares the groundwork for a potential separation of the generics business. It has said the review could take three years.Pfizer, Valeant, Actavis and Mylan all declined to comment. All the sources asked not to be named because they were not authorized to speak with the media.A deal for the business -- which houses medicines that have lost market exclusivity, as well as mature, patent-protected products that are expected to lose exclusivity through 2015 -- could catapult a buyer like Valeant into the ranks of the biggest pharmaceutical companies in the world, but several hurdles remain.The Pfizer generics business is far bigger than the three pharmaceutical companies. Valeant had $3.7 billion in revenue in the first nine months of 2013, while Mylan and Actavis posted revenues of $5.10 billion and $5.9 billion, respectively.Structuring a deal would also be a challenge because a sale could incur heavy taxes for Pfizer. One way to reduce the tax bill would be to use a structure known as a Reverse Morris Trust, according to the people close to the matter.In that structure, a company spins off a unit that it wants to divest and that unit merges with a smaller company, with the smaller company running the combined entity. Overall, the transaction allows a parent company to sell a subsidiary in a tax-free manner. It is not clear whether Pfizer would entertain such a deal structure.Another challenge for potential buyers is the lack of historical financial information for the generics business, as Pfizer's efforts to split its commercial operations is a work in progress.Still, such a deal could be attractive, as it could immediately boost the buyer's earnings and increase its presence outside of North America, most importantly in emerging markets where many companies need to expand. Valeant has kept no secret of its desire to grow through acquisitions. Its chief executive officer, Michael Pearson, said this month that the company wants to become one of the world's top five pharmaceutical companies by market capitalization by the end of 2016, largely through acquisitions.Pearson also said that Valeant, which bought contact lens maker Bausch & Lomb Holdings Inc for $8.7 billion in August, is looking at a merger of equals as well as smaller deals. He said it will look this year to pull off one acquisition of a similar size as its Bausch purchase.Valeant also held talks with Actavis about a potential combination last year, although those discussions did not lead to a deal, according to media reports at the time.Meanwhile, Actavis completed a $8.5 billion deal to buy Warner Chilcott Plc in October, months after rejecting a takeover offer from Mylan.(Reporting by Nadia Damouni, Jessica Toonkel and Soyoung Kim in New York; Editing by Paritosh Bansal and Leslie Adler)",2014-01-14,MYL,"Tue Jan 14, 2014 | 6:23am EST","Exclusive: Valeant, Actavis, Mylan eye Pfizer's generics unit",http://www.reuters.com//article/us-pfizer-valeant-idUSBREA0D0CZ20140114?type=companyNews
1,"  ZURICH Pharmaceutical group Roche said it secured an injunction from an Indian court banning generic drug makers Biocon and Mylan from comparing their copycat versions of Roche's Herceptin breast cancer treatment to the original.Mylan and Biocon, which co-developed breast cancer drugs CANMab and Hertraz they say are biosimilars of Herceptin, are no longer allowed to refer to Herceptin or its manufacturing process, safety, efficacy and sales when communicating about their drugs, the New Delhi High Court ruled on Wednesday.India's Biocon and U.S.-based Mylan launched CANMab and Hertraz in India this year after Roche decided last summer not to pursue a patent application for Herceptin in India, paving the way for generic drugmakers to produce cheaper copies, known as biosimilars because they are not identical to the original drug.""Roche has filed and secured an injunction against Biocon and Mylan. The injunction prevents the companies from comparing their products to Herceptin,"" Roche spokeswoman Silvia Dobry said in an emailed statement on Friday.She said Roche had taken this action to make sure Biocon and Mylan's products really had demonstrated comparable efficacy and safety to Roche's drug. ""It is unclear if the products meet the criteria for biosimilar products,"" she said.Biocon and Mylan won approval from the Indian drug regulator in November for marketing a generic version of Herceptin. Biocon said in a statement on its website the injunction was ""an extremely shocking, but not unexpected development"", adding Roche was trying to prevent Indian patients from accessing a more affordable trastuzumab, the generic name of Herceptin.""We are confident that once we are heard by the court, this injunction placing certain limits on promotional activities will not stand,"" Biocon said. Mylan could not immediately be reached for comment.Western pharmaceutical companies are keen to tap into India's $13 billion drug market, but there are concerns about the level of protection for intellectual property in the country, where generic medicines account for more than 90 percent of drug sales.(Reporting by Silke Koltrowitz; Editing by Elaine Hardcastle)",2014-02-07,MYL,"Fri Feb 7, 2014 | 11:41am EST",Roche bans rivals from comparing copycat drugs to Herceptin,http://www.reuters.com//article/us-roche-injunction-idUSBREA161B420140207?type=companyNews
2,"  ZURICH Feb 7 Pharmaceutical group Roche  said it secured an injunction from an Indian court banning generic drug makers Biocon and Mylan  from comparing their copycat versions of Roche's Herceptin breast cancer treatment to the original.Mylan and Biocon, which co-developed breast cancer drugs CANMab and Hertraz they say are biosimilars of Herceptin, are no longer allowed to refer to Herceptin or its manufacturing process, safety, efficacy and sales when communicating about their drugs, the New Delhi High Court ruled on Wednesday.India's Biocon and U.S.-based Mylan launched CANMab and Hertraz in India this year after Roche decided last summer not to pursue a patent application for Herceptin in India, paving the way for generic drugmakers to produce cheaper copies, known as biosimilars because they are not identical to the original drug.""Roche has filed and secured an injunction against Biocon and Mylan. The injunction prevents the companies from comparing their products to Herceptin,"" Roche spokeswoman Silvia Dobry said in an emailed statement on Friday. She said Roche had taken this action to make sure Biocon and Mylan's products really had demonstrated comparable efficacy and safety to Roche's drug.""It is unclear if the products meet the criteria for biosimilar products,"" she said. Biocon and Mylan won approval from the Indian drug regulator in November for marketing a generic version of Herceptin.Biocon said in a statement on its website the injunction was ""an extremely shocking, but not unexpected development"", adding Roche was trying to prevent Indian patients from accessing a more affordable trastuzumab, the generic name of Herceptin. ""We are confident that once we are heard by the court, this injunction placing certain limits on promotional activities will not stand,"" Biocon said.Mylan could not immediately be reached for comment.Western pharmaceutical companies are keen to tap into India's $13 billion drug market, but there are concerns about the level of protection for intellectual property in the country, where generic medicines account for more than 90 percent of drug sales.",2014-02-07,MYL,"Fri Feb 7, 2014 | 11:33am EST",Roche bans rivals from comparing copycat drugs to Herceptin,http://www.reuters.com//article/roche-injunction-idUSL5N0LC36W20140207?type=companyNews
3,"  (Corrects ninth paragraph to show Forest Labs, not Mylan, as best performer on the S&P 500)* U.S. home builder sentiment plunges in February* Coke shares fall after results, weigh on Dow industrials* Forest Labs shares jump, Actavis to purchase* Dow flat, S&P up 0.2 pct, Nasdaq up 0.7 pctBy Rodrigo CamposNEW YORK, Feb 18 U.S. stocks edged up on Tuesday, following Wall Street's biggest gain of the year, as merger activity boosted confidence there is still value in the market even as the S&P 500 nears a record high.The Nasdaq Composite was up for an eighth straight session, a streak not seen since early July. Economic reports were disappointing, but following a recent pattern, soft data was mostly dismissed by the market and blamed on the weather. U.S. homebuilder confidence suffered its largest one-month drop ever in February, and the New York Federal Reserve's gauge of manufacturing was weaker than expected.""We're going to see weather as a huge brush over a lot of economic data, mostly if it is related to the consumer,"" said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.""People don't go out and look at homes in crappy weather.""Forest Laboratories was the best performer on the S&P 500 after Actavis said it would acquire the specialty pharmaceuticals company in a cash and stock deal valued at about $25 billion. ""This has everything to do with the changing face of healthcare and how we pay for it in the United States,"" said Fort Pitt's Forrest.""If there was one big deal, there could be others.""Forest Labs shares soared 29.5 percent to $92.43 and was the best performer on the S&P 500. Shares of generic drug makers Teva and Mylan rose on the news. Teva was last up 3.4 percent at $45.69 and Mylan, up 5.3 percent at $48.56, was the best performer on the Nasdaq 100. Mylan shares hit a record intraday high. The Dow Jones industrial average fell 7.58 points or 0.05 percent, to 16,146.81, the S&P 500 gained 2.89 points or 0.16 percent, to 1,841.52 and the Nasdaq Composite  added 29.265 points or 0.69 percent, to 4,273.29.Coca-Cola Co reported global sales volumes below expectations and its stock fell 3.8 percent to $37.47, weighing on the Dow.With few obvious justifications for stocks climbing further, investors are left in the position they were in at the beginning of the year: unsure about the economy and earnings, but facing an environment where few other assets offer the same potential return as the equity market.Tesla Motors Inc shares hit an all-time high following a report Apple's mergers and acquisitions chief, Adrian Perica, met Tesla Chief Executive Elon Musk last year, sparking speculation Apple could be interested in buying the electric car maker.Tesla shares rose 3.2 percent to $204.54 after hitting a record intraday high of $205.72. Apple shares were up 0.9 percent at $548.98.U.S.-traded shares of BlackBerry Ltd jumped 6.6 percent to $9.58. Dan Loeb's Third Point LLC Hedge fund disclosed a 10-million-share stake in the Canadian company.Swedish mobile phone game maker King, best known for the hit Candy Crush Saga, is planning a U.S. stock market debut which could value it at more than $5 billion and trigger a flurry of technology company listings.    (Reporting by Rodrigo Campos; Editing by Bernadette Baum and Nick Zieminski)",2014-02-18,MYL,"Tue Feb 18, 2014 | 3:15pm EST",CORRECTED-US STOCKS-M&A keeps market adrift; Nasdaq winning streak powers on,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LN1G520140218?type=companyNews
4,"  Feb 18 Generic drugmaker Actavis Plc  said it would acquire specialty pharmaceuticals company Forest Laboratories Inc in a cash and stock deal valued at about $25 billion.Actavis will pay the equivalent of $89.48 per share, representing a premium of 25 percent to Forest's Friday close. The offer comprises $26.04 in cash and 0.3306 Actavis shares for every Forest share. Dublin-based Actavis, whose biggest competitors include Teva Pharmaceuticals Industries Ltd and Mylan Inc, has recently been acquiring specialty branded drug makers to boost profit margins and sales. Forest, which acquired privately held drugmaker Aptalis in January for $2.9 billion, faces a patent cliff on several of its biggest drugs, including Alzheimer's treatment Namenda.   (Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)",2014-02-18,MYL,"Tue Feb 18, 2014 | 7:07am EST",Actavis to buy Forest Labs in $25 bln deal,http://www.reuters.com//article/actavis-forestlabs-idUSL3N0LN3BC20140218?type=companyNews
5,"   By Jonathan Stempel  Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.The lawsuit accuses Celgene of maintaining unlawful monopolies over Revlimid, which treats disorders caused by poorly formed blood cells; and Thalomid, which treats lesions associated with a variation of Hansen's Disease, or leprosy.Revlimid is a branded version of lenalidomide, and is a derivative of thalidomide, a drug introduced in the 1950s for which Thalomid is a branded version. Mylan said both drugs can cost more than $100,000 for a year's supply.In its lawsuit filed in the U.S. District Court in Newark, New Jersey, Mylan accused Celgene of using federal limits on the distribution of Revlimid and Thalomid, which were designed to promote the drugs' safety, as a pretext to keep generic drug makers from obtaining their own samples. Mylan said this prevents generic drug makers from conducting ""bioequivalence"" tests required by U.S. regulators before generic drugs can be launched.""The effect of Celgene's conduct is that no generic manufacturer, including Mylan, has been able to bring generic versions of Thalomid and/or Revlimid to market,"" Mylan said. ""Through its illegal actions, Celgene has foreclosed Mylan from even attempting to enter the market."" Greg Geissman, a Celgene spokesman, declined to comment. Celgene is based in Summit, New Jersey, and Mylan is based in Canonsburg, Pennsylvania.The lawsuit seeks to force Celgene to sell Mylan enough Revlimid and Thalomid at market prices to allow for bioequivalence testing. It also seeks compensation for Mylan's inability to sell generic versions of both, and triple damages. In a February 13 regulatory filing, Celgene said it sold $4.28 billion of Revlimid and $244.5 million of Thalomid in 2013, together accounting for nearly 70 percent of all revenue.Celgene also said its exclusive U.S. rights, whether through patents or primary regulatory approvals, to Revlimid and Thalomid expire in 2027 and 2023, respectively.The case is Mylan Pharmaceuticals Inc v. Celgene Corp, U.S. District Court, District of New Jersey, No. 14-02094.(Reporting by Jonathan Stempel in New York; editing by Andrew Hay)",2014-04-03,MYL,"Thu Apr 3, 2014 | 7:08pm EDT","Mylan sues Celgene for blocking Revlimid, Thalomid generics",http://www.reuters.com//article/us-celgene-mylan-lawsuit-idUSBREA322B520140403?type=companyNews
6,"   By Jonathan Stempel | April 3  April 3 Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.The lawsuit accuses Celgene of maintaining unlawful monopolies over Revlimid, which treats disorders caused by poorly formed blood cells; and Thalomid, which treats lesions associated with a variation of Hansen's Disease, or leprosy.Revlimid is a branded version of lenalidomide, and is a derivative of thalidomide, a drug introduced in the 1950s for which Thalomid is a branded version. Mylan said both drugs can cost more than $100,000 for a year's supply.In its lawsuit filed in the U.S. District Court in Newark, New Jersey, Mylan accused Celgene of using federal limits on the distribution of Revlimid and Thalomid, which were designed to promote the drugs' safety, as a pretext to keep generic drug makers from obtaining their own samples. Mylan said this prevents generic drug makers from conducting ""bioequivalence"" tests required by U.S. regulators before generic drugs can be launched.""The effect of Celgene's conduct is that no generic manufacturer, including Mylan, has been able to bring generic versions of Thalomid and/or Revlimid to market,"" Mylan said. ""Through its illegal actions, Celgene has foreclosed Mylan from even attempting to enter the market."" Greg Geissman, a Celgene spokesman, declined to comment. Celgene is based in Summit, New Jersey, and Mylan is based in Canonsburg, Pennsylvania.The lawsuit seeks to force Celgene to sell Mylan enough Revlimid and Thalomid at market prices to allow for bioequivalence testing. It also seeks compensation for Mylan's inability to sell generic versions of both, and triple damages. In a February 13 regulatory filing, Celgene said it sold $4.28 billion of Revlimid and $244.5 million of Thalomid in 2013, together accounting for nearly 70 percent of all revenue.Celgene also said its exclusive U.S. rights, whether through patents or primary regulatory approvals, to Revlimid and Thalomid expire in 2027 and 2023, respectively.The case is Mylan Pharmaceuticals Inc v. Celgene Corp, U.S. District Court, District of New Jersey, No. 14-02094.   (Reporting by Jonathan Stempel in New York; editing by Andrew Hay)",2014-04-03,MYL,"Thu Apr 3, 2014 | 6:57pm EDT","Mylan sues Celgene for blocking Revlimid, Thalomid generics",http://www.reuters.com//article/celgene-mylan-lawsuit-idUSL1N0MV2A820140403?type=companyNews
7,"  * Payrolls roughly in line with expectations* E*Trade and Netflix weigh on S&P 500 and Nasdaq* Mylan up on report of Meda AB buy* Dow off 0.8 pct; S&P 500 off 1.1 pct; Nasdaq down 2.4 pct   (Updates to late afternoon)By Caroline ValetkevitchNEW YORK, April 4 U.S. stocks fell sharply on Friday as momentum shares like Netflix and TripAdvisor sold off for a second straight session, putting the Nasdaq on track for its second-worst day of the year.The big drop in momentum stocks overshadowed the day's relatively strong March jobs data, which helped the Dow and S&P 500 hit intraday record highs early in the session. Momentum names - typically high-growth companies mostly in the tech and biotech sectors that led 2013's rally - have sold off in recent weeks but appeared to stabilize earlier this week.Two weeks ago, a drop in Gilead Sciences' stock, after U.S. lawmakers asked it to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, set off a wave of losses in other biotech and momentum names.""For the past couple of weeks, the high beta, high risk, high reward type plays have been underperfoming the larger-cap S&P 500 and even the Dow,"" said Joe Bell, senior equities analyst with Schaeffer's Investment Research.He said it's hard to say whether this is indicative of a longer-term pullback for the market, but he pointed out that ""in the short-term, it's a concern. I think you want to see some of those names come back into leadership here."" The Dow Jones industrial average fell 136.34 points or 0.82 percent, to 16,436.21. The S&P 500 lost 20.59 points or 1.09 percent, to 1,868.18. The Nasdaq Composite  dropped 100.875 points or 2.38 percent, to 4,136.865.The Nasdaq is well below its intraday high for the year of 4,371.706, which was set on March 6.The Nasdaq biotech index dropped 3.5 percent and on track for a loss for the week. It has fallen 17 percent since reaching a high on Feb. 25. For the day, Biogen Idec Inc was down 4.1 percent at $2899.58, while Gilead Sciences was down 1.8 percent at $72.69.The S&P 500's top seven percentage decliners were Nasdaq names. E*Trade Financial slid 8.1 percent to $20.36, Netflix dropped 4.6 percent to $338.49, and TripAdvisor  fell 6.4 percent to $85.50.The S&P 500 earlier touched a record high of 1,897.28, the third time this week that the index had set an intraday record, while the Dow hit an intraday record high of 16,631.63.Stocks opened higher on optimism spurred by the nonfarm payrolls report, which showed employers added 192,000 jobs in March, just shy of the 200,000 forecast, after hiring 197,000 in February. The unemployment rate was unchanged at 6.7 percent. With a solid pace of hiring for a second month, the economy appears to be recovering from a winter slowdown.Mylan Inc rose 1.9 percent to $50.81 after a report said the company was looking to acquire Swedish rival Meda AB . Meda, though, said on Friday that it had rejected Mylan's takeover approach. On Thursday, Mylan sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.Halozyme Therapeutics Inc plunged 25.3 percent to $8.66 after the company said it was temporarily halting enrollment of patients and dosing of its cancer drug in a mid-stage trial on patients with pancreatic cancer, after the recommendation of an independent safety committee.     (Additional reporting by Chuck Mikolajczak; Editing by Bernadette Baum, Nick Zieminski and Jan Paschal)",2014-04-04,MYL,"Fri Apr 4, 2014 | 3:41pm EDT",US STOCKS-Momentum stocks tumble; Nasdaq falls more than 2 pct,http://www.reuters.com//article/markets-usa-stocks-idUSL1N0MW1FA20140404?type=companyNews
8,"  * Payrolls roughly in line with expectations* E*Trade and Netflix weigh on S&P 500 and Nasdaq* Mylan up on report of Meda AB buy* Dow off 0.5 pct; S&P 500 off 0.9 pct; Nasdaq down 2.4 pct   (Updates to afternoon, changes byline)By Caroline ValetkevitchNEW YORK, April 4 The Nasdaq tumbled more than 2 percent on Friday as momentum stocks like Netflix and TripAdvisor sold off for a second straight session.The big drop in momentum stocks overshadowed the day's relatively strong March jobs data, which helped the Dow and S&P 500 hit intraday record highs early in the session. Momentum names - typically high-growth companies mostly in the tech and biotech sectors that led 2013's rally - have sold off in recent weeks but appeared to stabilize earlier this week.Two weeks ago, a drop in Gilead Sciences' stock, after U.S. lawmakers asked it to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, set off a wave of losses in other biotech and momentum names.""It's a surprise how violent the selloff in some of these momentum stocks is. They have had an enormous run up, and you can come up with all kinds of things as reasons. But my sense is if you need to sell something to pay the big capital gains from last year ... they might be good candidates to sell,"" said Eric Kuby, chief investment officer at North Star Investment Management Corp in Chicago. The Nasdaq biotech index was last down 3.5 percent and 1 percent lower for the week. It has dropped 17 percent since reaching a high on Feb. 25.On the day, Biogen Idec Inc was down 3.7 percent at $290.83, while Gilead Sciences was down 2.6 percent at $72.05.The S&P 500's top seven percentage decliners were Nasdaq names. E*Trade Financial was down 7.5 percent at $20.50, Netflix dropped 4.2 percent to $337.72 and TripAdvisor was down 7 percent at $84.93. The Dow Jones industrial average fell 84.9 points or 0.51 percent, to 16,487.65, the S&P 500 lost 16.79 points or 0.89 percent, to 1,871.98 and the Nasdaq Composite  dropped 100.27 points or 2.37 percent, to 4,137.47.The S&P 500 earlier touched a record high of 1,897.28, the third time this week that the index had set an intraday record, while the Dow hit an intraday record high of 16,631.63.Stocks opened higher on optimism spurred by the nonfarm payrolls report, which showed employers added 192,000 jobs in March, just shy of the 200,000 forecast, after hiring 197,000 in February. The unemployment rate was unchanged at 6.7 percent. With a solid pace of hiring for a second month, the economy appears to be recovering from a winter slowdown.Mylan Inc rose 4.2 percent to $51.95 after a report said the company was looking to acquire Swedish rival Meda AB . Meda, though, said on Friday that it had rejected Mylan's takeover approach. On Thursday, Mylan sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.Halozyme Therapeutics Inc plunged 27.8 percent to $8.36 after the company said it was temporarily halting enrollment of patients and dosing of its cancer drug in a mid-stage trial on patients with pancreatic cancer, after the recommendation of an independent safety committee.     (Additional reporting by Chuck Mikolajczak; editing by Bernadette Baum, Nick Zieminski and Jan Paschal)",2014-04-04,MYL,"Fri Apr 4, 2014 | 1:59pm EDT",US STOCKS-Momentum stocks sell off for 2nd day; Nasdaq down 2 pct,http://www.reuters.com//article/markets-usa-stocks-idUSL1N0MW17P20140404?type=companyNews
9,"   By Sven Nordenstam and Mia Shanley | STOCKHOLM  STOCKHOLM Swedish generic drugmaker Meda AB rejected a takeover approach by U.S. rival Mylan Inc to create a combined company worth around $24 billion.The generic drugs sector has seen a wave of mergers recently as companies selling popular copycat versions of blockbuster medicines have been hit by a dwindling number of patent expirations and are looking to cut costs.Meda said on Friday it had been contacted about an indicative proposal to combine the two businesses but its board had decided to reject the proposal.""All continued discussions between Meda and Mylan have been terminated without further actions,"" it said in a statement.Shares in Meda closed up 14 percent at 110.6 Swedish crowns valuing the company at 33.4 billion Swedish crowns ($5.1 billion) while Mylan stock rose 4.2 percent to $51.94 by 1627 GMT valuing that firm at $19.3 billion.Media reports said Mylan was exploring a bid at a significant premium.""Given that this deal makes too much financial sense for both parties, we believe that there is an exceedingly high likelihood that it still will occur,"" analysts at Cowen said in a research note.Mylan, which had already said it wanted to make a big acquisition this year, said it was ""considering a wide range of possible opportunities"", but would not comment further.Meda, which makes specialty products, over-the-counter drugs and branded generics, has long been viewed as a takeover target in a rapidly consolidating generics drug sector where economies of scale are important. If any deal was pitched at a level similar to Actavis's bid for Forest Labs in February, it would imply a 25 percent premium to Meda's share price before the news, giving a $7.9 billion deal value, including Meda's $2.3 billion in debt.Buying Meda would boost Mylan's presence outside the United States and give it access to Meda's distribution channels in Europe and some emerging markets, where Meda has grown quickly in recent years.An acquisition would also boost Mylan's position in specialty pharmaceuticals where it focuses on respiratory and allergy medicines, which is a key area for Meda as well.Of Meda's $2 billion 2013 sales, more than 80 percent were outside the United States.Among potential buyers, Mylan was well placed to make a move, bankers and analysts said. It could also take advantage of lower corporate tax rates as the company's purchase would increase the percentage of revenues coming from overseas, allowing it to move its tax domicile outside of the U.S. Rivals Actavis and Valeant already lowered their tax rates with moves to Ireland. Moreover, bankers noted, Valeant recently bought Bausch & Lomb which it is busy integrating, whereas Actavis' $25 billion acquisition of Forest has not yet closed.A year ago India's Sun Pharmaceutical Industries Ltd held talks to buy Meda for between $5 billion and $6 billion in a bid to boost its generics business in developed markets, sources with knowledge of the matter said at the time.Analysts in Mumbai said they doubted Sun would be interested in buying Meda now, since the talks last year foundered mainly on valuation and Meda's stock price has risen sharply since its $4 billion market valuation at the time.Both Meda and Mylan are valued at around 10 times 2014 forecast earnings before interest, depreciation and amortization (EBITDA), including debt, according to Thomson Reuters data. ""Sun has not done any expensive acquisitions. It doesn't look like a valuation number that Sun Pharma is generally comfortable with,"" said Aditya Khemka of Ambit Capital.A Sun Pharma spokesman declined to comment.Meda's biggest owner is Stena Sessan Rederi AB, controlled by the Olsson business family, which owns 22.7 percent of shares meaning it could block any takeover attempt.The generic drugs sector has had a good run in the past decade by selling copycat versions of medicines but as times have got harder, growth and profit margins have come under pressure, with mergers seen as one way to improve efficiencies.Recent deals in the sector have led to savings of about 8 percent of sales, analysts estimate, and Mylan said in February it was open to looking at makers of branded drugs and deals outside of the United States to add to future earnings.The Pennsylvania-based firm, which last year bought Agila, a unit of India's Strides Arcolab Ltd for $1.6 billion, had appointed advisers to help it put together a deal for Meda, people familiar with the matter said.Chief Executive Heather Bresch told analysts in February the company planned a major transaction this year that would add to future earnings.($1 = 6.5481 Swedish crowns)(Additional reporting by Ben Hirschler and Sophie Sassard in London, Zeba Siddiqui in Mumbai, and Caroline Humer and Soyoung Kim in New York; Editing by David Holmes and Elaine Hardcastle)",2014-04-04,MYL,"Fri Apr 4, 2014 | 1:23pm EDT",Swedish drugmaker Meda spurns Mylan takeover approach,http://www.reuters.com//article/us-meda-mylan-idUSBREA3310020140404?type=companyNews
10,"  (Adds Meda shares, Mylan comment, valuation detail, quote)By Sven Nordenstam and Mia ShanleySTOCKHOLM, April 4 Swedish generic drugmaker Meda AB rejected a takeover approach by U.S. rival Mylan Inc to create a combined company worth around $24 billion.The generic drugs sector has seen a wave of mergers recently as companies selling popular copycat versions of blockbuster medicines have been hit by a dwindling number of patent expirations and are looking to cut costs.Meda said on Friday it had been contacted about an indicative proposal to combine the two businesses but its board had decided to reject the proposal.""All continued discussions between Meda and Mylan have been terminated without further actions,"" it said in a statement.Shares in Meda closed up 14 percent at 110.6 Swedish crowns valuing the company at 33.4 billion Swedish crowns ($5.1 billion) while Mylan stock rose 4.2 percent to $51.94 by 1627 GMT valuing that firm at $19.3 billion.Media reports said Mylan was exploring a bid at a significant premium.""Given that this deal makes too much financial sense for both parties, we believe that there is an exceedingly high likelihood that it still will occur,"" analysts at Cowen said in a research note.Mylan, which had already said it wanted to make a big acquisition this year, said it was ""considering a wide range of possible opportunities"", but would not comment further. Meda, which makes specialty products, over-the-counter drugs and branded generics, has long been viewed as a takeover target in a rapidly consolidating generics drug sector where economies of scale are important.If any deal was pitched at a level similar to Actavis's  bid for Forest Labs in February, it would imply a 25 percent premium to Meda's share price before the news, giving a $7.9 billion deal value, including Meda's $2.3 billion in debt.Buying Meda would boost Mylan's presence outside the United States and give it access to Meda's distribution channels in Europe and some emerging markets, where Meda has grown quickly in recent years.An acquisition would also boost Mylan's position in specialty pharmaceuticals where it focuses on respiratory and allergy medicines, which is a key area for Meda as well.Of Meda's $2 billion 2013 sales, more than 80 percent were outside the United States. Among potential buyers, Mylan was well placed to make a move, bankers and analysts said. It could also take advantage of lower corporate tax rates as the company's purchase would increase the percentage of revenues coming from overseas, allowing it to move its tax domicile outside of the U.S.Rivals Actavis and Valeant already lowered their tax rates with moves to Ireland. Moreover, bankers noted, Valeant recently bought Bausch & Lomb which it is busy integrating, whereas Actavis' $25 billion acquisition of Forest has not yet closed.A year ago India's Sun Pharmaceutical Industries Ltd  held talks to buy Meda for between $5 billion and $6 billion in a bid to boost its generics business in developed markets, sources with knowledge of the matter said at the time.Analysts in Mumbai said they doubted Sun would be interested in buying Meda now, since the talks last year foundered mainly on valuation and Meda's stock price has risen sharply since its $4 billion market valuation at the time. Both Meda and Mylan are valued at around 10 times 2014 forecast earnings before interest, depreciation and amortisation (EBITDA), including debt, according to Thomson Reuters data.""Sun has not done any expensive acquisitions. It doesn't look like a valuation number that Sun Pharma is generally comfortable with,"" said Aditya Khemka of Ambit Capital.A Sun Pharma spokesman declined to comment.Meda's biggest owner is Stena Sessan Rederi AB, controlled by the Olsson business family, which owns 22.7 percent of shares meaning it could block any takeover attempt.The generic drugs sector has had a good run in the past decade by selling copycat versions of medicines but as times have got harder, growth and profit margins have come under pressure, with mergers seen as one way to improve efficiencies.Recent deals in the sector have led to savings of about 8 percent of sales, analysts estimate, and Mylan said in February it was open to looking at makers of branded drugs and deals outside of the United States to add to future earnings.The Pennsylvania-based firm, which last year bought Agila, a unit of India's Strides Arcolab Ltd for $1.6 billion, had appointed advisers to help it put together a deal for Meda, people familiar with the matter said.Chief Executive Heather Bresch told analysts in February the company planned a major transaction this year that would add to future earnings.($1 = 6.5481 Swedish crowns)   (Additional reporting by Ben Hirschler and Sophie Sassard in London, Zeba Siddiqui in Mumbai, and Caroline Humer and Soyoung Kim in New York; Editing by David Holmes and Elaine Hardcastle)",2014-04-04,MYL,"Fri Apr 4, 2014 | 1:18pm EDT",UPDATE 4-Swedish drugmaker Meda spurns Mylan takeover approach,http://www.reuters.com//article/meda-mylan-idUSL5N0MW15G20140404?type=companyNews
11,"  * Payrolls roughly in line with expectations* E*Trade and Netflix weigh on the S&P 500 and the Nasdaq* Mylan up on report of Meda AB buy* Dow off 0.4 pct; S&P 500 off 0.7 pct; Nasdaq down 2.3 pct   (Recasts lead, headline, updates prices, adds quotes)By Chuck MikolajczakNEW YORK, April 4 The Nasdaq tumbled more than 2 percent on Friday, led by another selloff in momentum stocks like Netflix and TripAdvisor, as investors ignored relatively strong March jobs data. Momentum stocks, representing high-growth companies mostly in the tech and biotech sectors that led 2013's rally, have been under pressure in recent days as investors have shifted away from these names. After appearing to stabilize earlier in the week, internet and biotech stocks fell for a second straight session.The Nasdaq biotech index lost 3.3 percent. It has dropped 17 percent since reaching a high on Feb. 25. Biogen Idec Inc fell 3.6 percent to $291. Gilead Sciences  dropped 2.4 percent.""The market (as a whole) hasn't rolled over, but these bigger high-flyers are taking it on the chin, which suggests some people are changing their ideals,"" said Michael Matousek, head trader at U.S. Global Investors Inc in San Antonio, which manages about $1.3 billion. ""They don't want to be in growth names. They want to be more defensive."" The S&P 500's top seven decliners were Nasdaq names, led by E*Trade Financial, down 7.5 percent at $20.50. Netflix  dropped 4.2 percent to $337.72.""You've got some big names in there. There is a high correlation inside of those groups,"" said Keith Bliss, senior vice president of Cuttone & Co in New York. ""Managers tend to trade the entire group as opposed to individual names. So that, of course, is hitting the Nasdaq and everybody else."" The Dow Jones industrial average fell 65.95 points, or 0.40 percent, to 16,506.60. The Standard & Poor's 500 Index  slid 13.90 points, or 0.74 percent, to 1,874.87. The Nasdaq Composite Index dropped 96.22 points, or 2.27 percent, to 4,141.52.The S&P 500 earlier touched a record high of 1,897.28, the third time this week that the index has set an intraday record.Equities opened higher on optimism spurred by the nonfarm payrolls report, which showed that employers added 192,000 jobs in March, just shy of the 200,000 forecast, after hiring 197,000 in February. The unemployment rate was unchanged at 6.7 percent. With a solid pace of hiring for a second month, the economy appears to be recovering from a winter slowdown.Mylan Inc rose 3.7 percent to $51.68 after a report said the company was looking to acquire Swedish rival Meda AB . Meda, though, said on Friday that it had rejected Mylan's takeover approach. On Thursday, Mylan sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.Halozyme Therapeutics Inc plunged 29.1 percent to $8.22 after the company said it was temporarily halting enrollment of patients and dosing of its cancer drug in a mid-stage trial on patients with pancreatic cancer, after the recommendation of an independent safety committee.     (Editing by Bernadette Baum, Nick Zieminski and Jan Paschal)",2014-04-04,MYL,"Fri Apr 4, 2014 | 12:56pm EDT","US STOCKS-Momentum stocks slide anew, dragging equities lower",http://www.reuters.com//article/markets-usa-stocks-idUSL1N0MW10I20140404?type=companyNews
12,"  * Payrolls roughly in line with expectations* Mylan up on report of Meda AB buy* Boeing considers Mercury Systems acquisition* Indexes off: Dow 0.05 pct, S&P 0.21 pct, Nasdaq 1.4 pct   (Updates to open)By Chuck MikolajczakNEW YORK, April 4 U.S. stocks dipped on Friday and the Nasdaq fell sharply as weakness in momentum stocks weighed on indexes and erased earlier gains in the wake of the March payrolls report. After appearing to stabilize earlier in the week, momentum stocks such as biotechs fell for a second straight session. The Nasdaq biotech index lost 2.8 percent. Biogen Idec Inc  fell 4.3 percent to $288.98.""You've got some big names in there. There is a high correlation inside of those groups,"" said Keith Bliss, senior vice-president at Cuttone & Co in New York. ""Managers tend to trade the entire group as opposed to individual names. So that of course, is hitting the Nasdaq and everybody else.""Equities opened higher on optimism spurred by the nonfarm payrolls report, which showed jobs rose by 192,000 in March, just shy of the 200,000 forecast, after rising 197,000 in February. The unemployment rate was unchanged at 6.7 percent. With a solid pace of hiring for a second month, the economy appears to be recovering from a winter slowdown. ""Overall, people are taking this as a sign there isn't some sort of underlying weakness in the economy,"" said Kate Warne, investment strategist at Edward Jones in St. Louis.""It has fit into people's belief that most of the weakness we saw earlier was due to the weather and not something really changing about the economy.""The Dow Jones industrial average was down 8.89 points, or 0.05 percent, at 16,563.66. The Standard & Poor's 500 Index was down 4.04 points, or 0.21 percent, at 1,884.73. The Nasdaq Composite Index was down 59.74 points, or 1.41 percent, at 4,178.00. The S&P earlier touched a record high of 1897.28, the third time this week that the index has set an intraday record.Mylan Inc rose 4.8 percent to $52.24 after a report said the company was looking to acquire Swedish rival Meda AB . Mylan also sued Celgene Corp  on Thursday to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.Boeing Inc is considering buying Mercury Systems Inc , a supplier of digital signal and image processing systems to the aerospace and defense industry, according to two people familiar with the matter. Mercury shares gained 3.9 percent to $13.75. Boeing inched up 0.1 percent at $128.91.CarMax Inc, fell 2.8 percent to $46.25 after the largest retailer of used cars reported fourth-quarter results.Halozyme Therapeutics Inc plunged 25.4 percent to $8.65 after the company said it was temporarily halting enrolment of patients and dosing of its cancer drug in a mid-stage trial on patients with pancreatic cancer, after the recommendation of an independent safety committee.     (Editing by Bernadette Baum and Nick Zieminski)",2014-04-04,MYL,"Fri Apr 4, 2014 | 11:51am EDT",US STOCKS-Wall St dips as momentum stocks drag; Nasdaq slumps,http://www.reuters.com//article/markets-usa-stocks-idUSL1N0MW0XM20140404?type=companyNews
13,"  * Payrolls roughly in line with expectations* Mylan up on report of Meda AB buy* Boeing considers Mercury Systems acquisition* Dow up 0.15 pct, S&P up 0.17 pct, Nasdaq down 0.24 pct   (Updates to open)By Chuck MikolajczakNEW YORK, April 4 U.S. stocks advanced slightly on Friday, pulling back after the S&P 500 earlier scaled a fresh high, as the March payrolls report suggested the economy may be gaining momentum. Nonfarm payrolls rose by 192,000 in March, just shy of the 200,000 forecast, after rising 197,000 in February. The unemployment rate was unchanged at 6.7 percent. With a solid pace of hiring for a second month, the economy appears to be recovering from a winter-linked slowdown earlier in the year.""Overall, people are taking this as a sign there isn't some sort of underlying weakness in the economy,"" said Kate Warne, investment strategist at Edward Jones in St. Louis.""It has fit into people's belief that most of the weakness we saw earlier was due to the weather and not something really changing about the economy."" The Dow Jones industrial average was up 25.50 points, or 0.15 percent, at 16,598.05. The Standard & Poor's 500 Index  was up 3.20 points, or 0.17 percent, at 1,891.97. The Nasdaq Composite Index was down 10.08 points, or 0.24 percent, at 4,227.66.The S&P touched a record high of 1897.28, the third time this week that the index has set an intraday record. Mylan Inc rose 5.8 percent to $52.73 after a report said the company was looking to acquire Swedish rival Meda AB . Mylan also sued Celgene Corp  on Thursday to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.Anadarko Petroleum Corp gained 3 percent to $101.93. The company said Thursday it would pay more than $5 billion to clean up areas across the United States polluted by nuclear fuel, wood creosote and rocket fuel waste, resolving a long-running lawsuit.Boeing Inc is considering buying Mercury Systems Inc , a supplier of digital signal and image processing systems to the aerospace and defense industry, according to two people familiar with the matter. Mercury shares jumped 6.9 percent to $14.15. Boeing was up 0.6 percent at $129.57.CarMax Inc, fell 3.7 percent to $45.79 after the largest retailer of used cars reported fourth-quarter results.Halozyme Therapeutics Inc plunged 22 percent to $8.99 after the company said it was temporarily halting enrolment of patients and dosing of its cancer drug in a mid-stage trial on patients with pancreatic cancer, after the recommendation of an independent safety committee.     (Editing by Bernadette Baum and Nick Zieminski)",2014-04-04,MYL,"Fri Apr 4, 2014 | 10:08am EDT","US STOCKS-Wall Street up slightly on payrolls, earlier scaled new high",http://www.reuters.com//article/markets-usa-stocks-idUSL1N0MW0PM20140404?type=companyNews
14,"  STOCKHOLM, April 4 Meda :  * Shares rise 11 percent in resumed trading after says rejects Mylan takeover approach  * For a full story, please double click  ",2014-04-04,MYL,"Fri Apr 4, 2014 | 9:42am EDT",BRIEF-Meda shares surge after says spurns Mylan takeover approach,http://www.reuters.com//article/meda-mylan-shares-brief-idUSWEB00L8020140404?type=companyNews
15,"  STOCKHOLM, April 4 Swedish drug maker Meda  said on Friday U.S. generics firm Mylan had contacted Meda and proposed to buy it but that the board had rejected the indicative proposal.""All continued discussions between Meda and Mylan have been terminated without further actions,"" Meda said in statement.  Shares in Meda were halted on Friday following media reports that Mylan was looking into buying it.   (Reporting by Sven Nordenstam) ",2014-04-04,MYL,"Fri Apr 4, 2014 | 9:11am EDT",Meda says rejects Mylan proposal to buy it,http://www.reuters.com//article/meda-mylan-idUSWEB00L7Y20140404?type=companyNews
16,"  (Adds Essar Energy, PSA Peugeot Citroen, Mercator, Mauser, Mylan, Deoleo)April 25 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:** General Electric is in talks with Alstom  to take over its global power business and a deal could be announced in the coming days, two sources familiar with the matter said on Friday.** Alpha Bank, Greece's fourth-largest lender, said on Friday it was looking into proposals to expand, including the possible acquisition of Citibank's Greek operations.** Poland's state railways operator PKP relaunched the sale of its telecoms arm TK Telekom, having failed to find a buyer at the right price last year, two market sources told Reuters on Friday.** Mazda Motor Corp has agreed with Ford Motor  to start talks to sell the U.S. carmaker all of its stake in a joint venture that runs the Flat Rock plant in the United States, Chief Executive Officer Masamichi Kogai said on Friday.** Oji Holdings said on Friday that it and government-backed Innovation Network Corp of Japan will buy the pulp, paper and packaging business of New Zealand's Carter Holt Harvey Ltd for about NZ$1.037 billion ($888.50 million).** Germany's BASF said on Friday it would sell a plant in Norway and cut jobs around the world as it tries to boost profits at its health and nutrition business.** Prestige Brands Holdings Inc, a marketer and distributor of healthcare and cleaning products, said it would buy rival Insight Pharmaceuticals Corp for $750 million in cash to expand its range of feminine care products.** German utility EnBW has formally acquired a 7.43 percent stake British bank Barclays held on behalf of the company in smaller peer MVV Energie, MVV said on Friday.** Thailand's top oil and gas explorer, PTT Exploration and Production Pcl, said on Friday it was considering plans to dilute its holding in the Montara oil field off Australia after several delays and rising costs.** Nokia on Friday said the sale of its once-dominant handset business to Microsoft has been closed after the companies agreed to leave two factories in India and Korea out of the deal.** The Carlo Tassara Group has sold a 4.7 percent stake in Poland's mid-tier bank Alior Bank at 79 zlotys ($26.01) per share, the bank confirmed on Friday. On Wednesday, market sources told Reuters that Carlo Tassara found buyers for a stake valued at almost 261 million zlotys ($86 million).** British asset manager Marshall Wace is to buy a controlling stake in U.S. investment firm Eaglewood Capital Management, looking to capitalize on growth in peer-to-peer and online lending where Eaglewood is already involved.** Cable & Wireless Communications has sold its stake in Monaco Telecom to French entrepreneur Xavier Niel, chief executive and founder of low-cost telecoms provider Iliad , for 322 million euros ($445 million).** Telecoms group Swisscom said it had submitted a non-binding offer worth 230 million Swiss francs ($260.7 million) to buy PubliGroupe's shares in two local directory businesses, creating the potential for a takeover battle.** German diversified healthcare group Fresenius SE  said its Kabi unit was forming a joint venture with Russia's Sistema and Zenitco Finance Management LLC.** NTT DoCoMo Inc, Japan's biggest telecom network by subscribers, will sell its stake in its loss-making Indian mobile phone joint venture to partner Tata Group, people with direct knowledge of the matter said on Friday. ** Dell Inc Chief Executive Michael Dell is likely to sell his corporate gardening company ValleyCrest to KKR & Co LP's  Brickman unit, the Financial Times reported.** London's largest and most expensive office building, HSBC Holding Plc's global headquarters, is up for sale and could fetch over 1.1 billion pounds ($1.85 billion), a record price for the British market, the Financial Times reported.** Private equity firm KKR & Co LP plans to allow investors to sell parts of their stake in buyout funds through a new private market run by Nasdaq OMX Group Inc, the Wall Street Journal reported on Thursday, citing people familiar with the matter.** Allergan Inc approached Shire Plc in recent months about a possible takeover but was rebuffed, according to people familiar with the matter, in the latest example of a U.S. drugmaker seeking to buy an overseas rival to lower its tax rate.** Privately owned activist fund Relational Investors LLC disclosed a 9.08 percent stake in Clean Harbors Inc, saying the hazardous waste manager is ""undervalued,"" according to a regulatory filing.** Software company Bazaarvoice Inc has agreed to undo a 2012 merger with a rival that had been challenged by the U.S. government, the Justice Department said on Thursday. ** Private equity firm Warburg Pincus has agreed to take a majority stake in software startup PayScale, which offers compensation data to individuals and companies.** The Gores Group has put Sage Automotive Interiors up for sale more than two years after buying the company, three sources said.** Canadian Industry Minister James Moore said on Thursday he plans to announce a decision soon on whether or not to approve Telus Corp's C$350 million ($317 million) bid for Mobilicity.** Department store chain Sears Canada is not actively pursuing any asset sales but would consider opportunities that would ""substantially"" add value, the company's chief executive said on Thursday.** Pioneers Holding plans to use a capital increase to help finance the acquisition of a 60 percent stake in real estate investment firm Rooya Group, a senior executives said.** A bid for London-listed Essar Energy Plc by its majority shareholder materially undervalues the company and should be rejected, an independent committee set up to examine the offer reiterated on Friday. Essar Global Fund Ltd (EGFL), which owns about 77 percent of the India-focused resources company, had last month offered 70 pence per share for the stake it does not already own.** Shareholders of PSA Peugeot Citroen on Friday approved by a large majority the rescue deal that makes Chinese carmaker Dongfeng and the French state core shareholders of the struggling French carmaker.** Slovenia's largest food retailer Mercator said on Friday that it had reached a deal on restructuring its 1 billion euro ($1.38 billion) debt with creditor banks, clearing the last hurdle for its takeover by Croatian rival Agrokor.** U.S. generic drugmaker Mylan has made a new and improved bid for Meda, valuing its Swedish rival at more than $9 billion, a source familiar with the matter said on Friday.** Buyers are lining up for Germany-based packaging group Mauser with final bids due to be submitted on Monday, banking sources said on Friday. The sale of Mauser by Dubai International Capital, the international investment arm of sovereign wealth fund of the government of Dubai, could fetch around 1.25 billion euros ($1.73 billion), one of the banking sources said.** Private equity firm CVC has finalized a deal to buy 29.99 percent of Spain's Deoleo, the world's biggest bottled olive oil company, followed by a full takeover bid at 0.38 euro per share, Deoleo said on Friday. Spanish banks Bankia and Banco Mare Nostrum have agreed to sell their 16.5 percent and 4.85 percent stakes, while Dcoop olive cooperative - which tried to block the CVC deal and increase its influence in Deoleo - will sell an 8.64 percent stake.   ($1 = 1.17 New Zealand dollars)  ($1 = 0.72 euros)  ($1 = 0.88 Swiss francs)  ($1 = 0.59 British pounds)  ($1 = 1.10 Canadian dollars)  ($1 = 3.04 Polish zlotys)   (Compiled by Avik Das and Ankit Ajmera in Bangalore)",2014-04-25,MYL,"Fri Apr 25, 2014 | 4:04pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0NH3F520140425?type=companyNews
17,"   By Soyoung Kim and Niklas Pollard | NEW YORK/STOCKHOLM  NEW YORK/STOCKHOLM U.S. generic drugmaker Mylan (MYL.O) has made a new and improved bid for Meda MEDAa.ST valuing its Swedish rival at around $9 billion including debt, a person familiar with the matter said on Friday.Mylan raised its all-stock offer to 145 crowns per share this week after its first attempt at a merger with a 130 per share offer was rejected by Meda earlier this month, the person said, asking not to be named because the matter is not public.Excluding debt, the new bid is worth about $6.7 billion based on shares outstanding and represents a roughly 50 percent premium over Meda's share price before reports of the original offer.Trading in Meda shares was halted in Stockholm earlier on Friday after the Financial Times first reported Mylan hiked its takeover offer, triggering a 10 percent jump in the stock. A Meda spokesperson declined to comment on the report. Mylan was not immediately available for comment.The sweetened offer comes amid a flurry of healthcare deals this week including medical device maker Zimmer Holdings Inc's ZMH.N $13.4 billion acquisition of rival Biomet; a $20 billion asset swap between Novartis AG NOVN.VX and GlaxoSmithKline Pharmaceuticals PLC (GSK.L); and Eli Lilly and Co's (LLY.N) acquisition of Novartis' animal health business for $5.4 billion. The generic drugs sector has seen a wave of mergers recently as companies selling popular copycat versions of blockbuster medicines have been hit by a dwindling number of patent expirations and are looking to cut costs.Meda rebuffed Mylan's initial takeover approach in early April, saying it had been contacted about an indicative proposal to combine the two businesses but that its board had opted to reject the proposal. An acquisition of Meda would boost Mylan's presence outside the United States with access to distribution channels in Europe and some emerging markets. It would also boost Mylan's position in specialty pharmaceuticals where it focuses on respiratory and allergy medicines, which is a key area for Meda as well.Among potential buyers, Mylan was well placed to make a move, bankers and analysts have said. It could also take advantage of lower corporate tax rates as the purchase would increase the percentage of revenues coming from overseas, allowing it to move its tax domicile outside the United States.Meda's biggest owner is Stena Sessan Rederi AB, controlled by the Olsson business family, which owns 22.7 percent of shares, meaning it could block any takeover attempt.(Reporting by Soyoung Kim in New York, Niklas Pollard and Alistair Scrutton; Editing by Alex Smith, Mark Potter, Jane Merriman and Nick Zieminski)",2014-04-25,MYL,"Fri Apr 25, 2014 | 3:30pm EDT",Mylan raises bid for Sweden's Meda generic drugmaker,http://www.reuters.com//article/us-meda-mylan-idUSBREA3O1H120140425?type=companyNews
18,"  * Mylan offering 145 SEK/share for Sweden's Meda* Meda rebuffed an approach earlier this month* Shares rose 10 pct before trading halt   (Adds background on healthcare M&A)By Soyoung Kim and Niklas PollardNEW YORK/STOCKHOLM, April 25 U.S. generic drugmaker Mylan has made a new and improved bid for Meda  valuing its Swedish rival at around $9 billion including debt, a person familiar with the matter said on Friday.Mylan raised its all-stock offer to 145 crowns per share this week after its first attempt at a merger with a 130 per share offer was rejected by Meda earlier this month, the person said, asking not to be named because the matter is not public. Excluding debt, the new bid is worth about $6.7 billion based on shares outstanding and represents a roughly 50 percent premium over Meda's share price before reports of the original offer.Trading in Meda shares was halted in Stockholm earlier on Friday after the Financial Times first reported Mylan hiked its takeover offer, triggering a 10 percent jump in the stock. A Meda spokesperson declined to comment on the report. Mylan was not immediately available for comment.The sweetened offer comes amid a flurry of healthcare deals this week including medical device maker Zimmer Holdings Inc's  $13.4 billion acquisition of rival Biomet; a $20 billion asset swap between Novartis AG and GlaxoSmithKline Pharmaceuticals PLC ; and Eli Lilly and Co's  acquisition of Novartis' animal health business for $5.4 billion.The generic drugs sector has seen a wave of mergers recently as companies selling popular copycat versions of blockbuster medicines have been hit by a dwindling number of patent expirations and are looking to cut costs. Meda rebuffed Mylan's initial takeover approach in early April, saying it had been contacted about an indicative proposal to combine the two businesses but that its board had opted to reject the proposal.An acquisition of Meda would boost Mylan's presence outside the United States with access to distribution channels in Europe and some emerging markets. It would also boost Mylan's position in speciality pharmaceuticals where it focuses on respiratory and allergy medicines, which is a key area for Meda as well.Among potential buyers, Mylan was well placed to make a move, bankers and analysts have said. It could also take advantage of lower corporate tax rates as the purchase would increase the percentage of revenues coming from overseas, allowing it to move its tax domicile outside the United States.Meda's biggest owner is Stena Sessan Rederi AB, controlled by the Olsson business family, which owns 22.7 percent of shares, meaning it could block any takeover attempt.   (Reporting by Soyoung Kim in New York, Niklas Pollard and Alistair Scrutton; Editing by Alex Smith, Mark Potter, Jane Merriman and Nick Zieminski)",2014-04-25,MYL,"Fri Apr 25, 2014 | 3:26pm EDT",UPDATE 3-Mylan raises bid for Sweden's Meda generic drugmaker,http://www.reuters.com//article/meda-mylan-idUSL6N0NH45X20140425?type=companyNews
19,"  STOCKHOLM, April 25 Meda :  * Spokesperson says declines comment on report of Mylan bid   ",2014-04-25,MYL,"Fri Apr 25, 2014 | 10:59am EDT",BRIEF-Meda declines comment on report of Mylan bid,http://www.reuters.com//article/meda-mylan-spox-idUSWEB00M3J20140425?type=companyNews
20,"   By Olivia Oran, Soyoung Kim and Nadia Damouni | NEW YORK  NEW YORK Allergan Inc approached Shire Plc in recent months about a possible takeover but was rebuffed, according to people familiar with the matter, in the latest example of a U.S. drugmaker seeking to buy an overseas rival to lower its tax rate.The preliminary approach for Shire, which is based in Ireland and has a market value of $33 billion, did not progress to serious discussions between the two companies, the sources said.Since then Allergan has received an unsolicited $47 billion takeover offer from Valeant Pharmaceuticals International Inc teamed up with activist investor Bill Ackman's Pershing Square Capital Management.Analysts have suggested one way for the Botox maker to defend against the unsolicited bid would be to acquire foreign drugmakers such as Shire, Jazz Pharmaceuticals Plc or Alkermes Plc.One of the sources said it was unclear if Allergan would try to revive talks with Shire, or pursue another target as a means to remain independent. Representatives for Allergan and Shire declined to comment.In a process known as inversion, U.S. drugmakers are looking to relocate their headquarters to other countries with lower tax rates. These companies are eying potential targets that are based in Ireland in particular because of a low 12.5 percent corporate tax rate, compared to 35 percent in the United States.Recent deals that have been driven by tax advantages include generic drugmaker Actavis Plc's $8.5 billion acquisition of Dublin-based Warner Chilcott and Perrigo Company Plc's $8.6 billion acquisition of Elan. Generic drugmaker Mylan Inc is also looking at acquisition targets that are based outside of the United States because of competitive pressures from rivals with a less burdensome tax structure, people familiar with the matter said.Valeant's offer for Allergan comes amid a flurry of healthcare deals this week including medical device company Zimmer Holdings Inc's $13.4 billion acquisition of rival Biomet; a $20 billion asset swap between Novartis AG and GlaxoSmithKline Pharmaceuticals PLC; and Eli Lilly and Co's acquisition of Novartis' animal health business for $5.4 billion. Those deals have driven healthcare M&A volumes to $153.3 billion so far this year, the highest year-to-date level since Thomson Reuters has started tracking data. Pharmaceutical deals have accounted for 71 percent of overall healthcare deals.Valeant has been on a buying spree since 2010 and last year acquired contact lens maker Bausch & Lomb Holdings. Chief Executive Michael Pearson said in January the drugmaker wants to become one of the world's top five pharmaceutical companies by market capitalization by the end of 2016, largely through acquisitions.Pearson said on Tuesday Allergan Chief Executive David Pyott and the company's board had been unwilling to discuss a merger with Valeant. In a letter to Allergan, Valeant said it would have preferred to negotiate a deal in private.Allergan said in a statement on Tuesday that it has received the offer, and will carefully consider the proposal and ""pursue the course of action that it believes is in the best interests of the company's stockholders.""(Reporting by Olivia Oran, Soyoung Kim and Nadia Damouni in New York; Editing by Lisa Shumaker, Bernard Orr)",2014-04-25,MYL,"Thu Apr 24, 2014 | 8:18pm EDT",Exclusive: Allergan approached Shire about takeover but rebuffed -sources,http://www.reuters.com//article/us-shire-allergan-idUSBREA3N2JI20140425?type=companyNews
21,"  * Meda board says deal lacks support of biggest shareholder* Meda shares drop 7.9 pct after rising 10 pct on Friday* Approach comes against backdrop of healthcare M&A flurry   (Adds detail, background, shares, quotes)By Sven NordenstamSTOCKHOLM, April 28 Swedish drugmaker Meda  rejected an improved takeover offer from U.S. generics firm Mylan which one person familiar with the matter said valued Meda at around $9 billion including debt, driving its shares sharply back down.The new offer comes amid a flurry of deals in the industry as it restructures in the face of health spending cuts and cheap generic competition. U.S. firm Pfizer confirmed its interest in Britain's AstraZeneca on Monday in what would be one of the biggest pharma deals ever.American drugmakers are also eyeing potential takeover targets abroad as they look to relocate their headquarters to other countries with lower tax rates.Mylan's sweetened all-stock offer was worth 145 crowns per share, a person familiar with the matter said - which would represent a premium of about 50 percent over Meda's share price before news of the U.S. firm's original approach emerged earlier this month.However the Meda board said the firm's biggest shareholder did not back a deal. Its biggest investor by far is Stena Sessan Rederi AB - controlled by the Olsson business family - which owns a 22.7 stake and can block any takeover attempt.The board also said it was confident in Meda's future as an independent firm. Meda, which makes speciality products, over-the-counter drugs and branded generics, has long been viewed as a takeover target in the sector. It has returned to growth due to new allergy medicine Dymista and a strong contribution from emerging markets where it has invested to drive sales in recent years.Its sales grew by 4 percent last year on a like-for-like basis and adjusted for currency swings, up from zero growth the previous year. The company has forecast similar growth this year with improved profit margins.Meda shares were down 7.9 percent at 1324 GMT, giving up most of the gains they made on Friday when they rose 10 percent on news of the improved offer.The new offer followed a rejection by Meda's board earlier this month of a 130 crowns per share offer from Mylan, according to the source familiar with the matter.The latest approach would value Meda's outstanding shares at $6.7 billion. The drugmaker also had net debt of $2.3 billion at the end of last year. This would mean a multiple of about 14 times analysts' forecast for Meda's 2014 earnings before interest, tax, depreciation and amortisation (EBITDA) on an enterprise value basis. Mylan trades at about 10 times forecast earnings, according to Thomson Reuters data.THIRD TIME? The share price premium is also higher than the 30 percent Pfizer said it had proposed for AstraZeneca in January, and higher the roughly 25 percent premium generic drug maker Actavis  offered for Forest Labs in February. ""We believe Mylan may come back a third time,"" Pareto Securities said in a research note, adding that a bid between 135 and 145 crowns would have implied ""very decent pricing"".Pareto said the board's faith in Meda's growth prospects meant a buyer may have to look at 2015 projections to buy the firm now. ""We believe this would imply a share price of SEK 160,"" Pareto said.""We do also believe that the board has concluded that Mylan is the distressed entity and not Meda, as Meda is a potential target for many companies.""Meda reported sales of 13.1 billion crowns ($2.0 billion) last year and EBITDA of 3.7 billion crowns. Analysts on average expect earnings to grow by 10 percent in 2014, and by 14 percent in 2015, according to Thomson Reuters data.Apart from tax savings, Meda would boost Mylan's presence outside the United States and give it access to Meda's distribution channels in Europe and some emerging markets, where Meda has grown quickly in recent years.Rejecting Mylan's latest approach, the Meda board said in its statement: ""The board's decision is based on a strong belief in the continued potential of Meda as a stand-alone company and the assumption that a transaction cannot be completed as it lacks sufficient support from Meda's largest shareholder.""Meda's chairman Bert-Ake Eriksson, who is also the chief executive of Stena Sessan Rederi, declined to comment further as the letter Meda's board had received from Mylan was confidential. Mylan was not immediately available for comment.The second and third-biggest shareholders in Meda are Swedish pension funds groups Swedbank Robur and AMF Pension with 4.86 percent and 2.7 percent stakes respectively as of the end of December, according to Thomson Reuters data.Swedbank Robur did not immediately reply to a request for comment, while AMF Pension declined to comment.         (Additional reporting by Helena Soderpalm; Editing by Mark Potter and Pravin Char)",2014-04-28,MYL,"Mon Apr 28, 2014 | 9:39am EDT",UPDATE 2-Drugmaker Meda's shares fall back after it snubs new Mylan bid,http://www.reuters.com//article/meda-mylan-idUSL6N0NK19820140428?type=companyNews
22,"  STOCKHOLM, April 28 Meda :  * Shares fall 8 percent after says rejects new offer from Mylan  to buy it  ",2014-04-28,MYL,"Mon Apr 28, 2014 | 3:01am EDT",BRIEF-Meda shares fall 8 percent after rejects new offer from Mylan,http://www.reuters.com//article/meda-brief-idUSWEB00M4Q20140428?type=companyNews
23,"  STOCKHOLM Swedish drugmaker Meda MEDAa.ST has rejected an improved takeover offer from U.S. generics firm Mylan (MYL.O), saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.The new all-stock offer was worth 145 crowns per share, a person familiar with the matter said on Friday, and follows a rejection by Meda's board earlier this month of a previous offer.Mylan's improved offer comes amid a flurry of recent healthcare deals, including medical device maker Zimmer Holdings Inc's ZMH.N $13.4 billion acquisition of rival Biomet, a $20 billion-plus asset swap between Novartis NOVN.VX and GlaxoSmithKline (GSK.L) and an offer by Canada's Valeant (VRX.TO) to buy Botox maker Allergan (AGN.N) for $47 billion. ""The Board's decision is based on a strong belief in the continued potential of Meda as a stand-alone company and the assumption that a transaction cannot be completed as it lacks sufficient support from Meda's largest shareholder,"" Meda said in a statement. Meda's biggest shareholder is Stena Sessan Rederi AB, controlled by the Olsson business family, which owns 22.7 percent of shares, meaning it could block any takeover attempt. Share trading in Meda was halted on Friday after news of the fresh offer, valuing the firm at around $9 billion including debt, was first reported by the Financial Times.(Reporting by Sven Nordenstam, Editing by Mark Potter)",2014-04-28,MYL,"Mon Apr 28, 2014 | 2:52am EDT",Meda board rejects new Mylan offer,http://www.reuters.com//article/us-meda-mylan-idUSBREA3R0HA20140428?type=companyNews
24,"  (Adds Finnair, Neste Oil, updates Meda)HELSINKI, April 28 The following stocks may be affected by newspaper reports and other factors on Monday:MEDA The Swedish drug maker said on Monday it had rejected a new offer from U.S. generics firm Mylan to acquire it. Meda's U.S. rival Mylan had made an improved offer of 145 crown per share. Trade in Meda shares was halted late on Friday after the news, first reported by the Financial Times, saw the stock shoot up 10 percent.For more on the company, double clickFINNAIR The airline will continue negotiations with its personnel over pay cuts and increasing working hours. Finnair Chief Operations Officer Ville Iho told national broadcaster Yle that both sides are ready for a 5-percent cut in pay, and continue discussions about increasing work by 10 percent. Deadline for the talks is Monday.For more on the compnay, double clickNESTE OIL Finnish oil refiner and German industrial gases maker Linde  will invest 100 million euros in a new hydrogen plant at Neste Oil's Porvoo refinery.For more on the company, double click SWEDBANK The Swedish bank reported first-quarter profits in line with market expectations and said events in Ukraine would probably further delay an expected increase in credit demand in the Baltic countries.For more on the company, double clickNORDIC IPO: AFRICAN PETROLEUM Australian oil exploration firm African Petroleum hopes to list its shares on the Oslo Axess stock market and could complete the process by the end of May, daily Dagens Naeringsliv reported on Monday.Separately, daily Finansavisen said African Petroleum plans to raise between 100-200 million crowns ($17-$33 million) in cash to fund its growth plans. For a list of IPOs in the Nordics, click onVISMA Private equiry firm KKR & Co has cut its stake in Norwegian IT and accounting firm Visma to 31.1 percent from 77 percent in a transaction valuing Visma at 21 billion crowns ($3.5 billion), daily Dagens Naeringsliv reported on Monday.Private equity fund Cinven bought a 31.3 percent stake in the sale. KKR bought its stake in 2010 when the overall value of Visma stood at 11 billion crowns.For more on the company, click on UPONOR The Finnish plastic pipe maker reported first-quarter adjusted operating profit of 8.6 million euros, beating analyst expectation and up 41 percent from the same period a year earlier.For more on the company, click on** For a summary of upcoming results and forecasts, double click on** For the western European company diary covering earnings, shareholder meetings, news conferences and analysts' meetings, click on or type in the code and hit the f9 button.** Double click on for Swedish indices,  for Danish indices, for Finnish indices and for Norwegian indices** For real-time moves on Nordic blue-chip indices double click on,, and** For constituent stock moves highlight the above codes in the command box and press the f3 button on your keyboard** For Nordic top news items, double click on** For the latest news on Nordic stock price moves double click on(Reporting by Helsinki, Copenhagen, Oslo and Stockholm newsrooms)",2014-04-28,MYL,"Mon Apr 28, 2014 | 2:44am EDT",NORDIC STOCKS - Factors to watch on April 28,http://www.reuters.com//article/markets-nordics-factors-idUSL6N0NK1CA20140428?type=companyNews
25,"  STOCKHOLM, April 28 Swedish drug maker Meda  said on Monday it had rejected a new offer from U.S. generics firm Mylan to acquire it.""The Board's decision is based on a strong belief in the continued potential of Meda as a stand-alone company and the assumption that a transaction cannot be completed as it lacks sufficient support from Meda's largest shareholder,"" Meda said in a statement.  Shares in Meda were halted on Friday after news that Mylan had returned with an improved offer worth 145 crowns per share after Meda rejected an earlier indicative proposal.     (Reporting by Sven Nordenstam, editing by Mia Shanley) ",2014-04-28,MYL,"Mon Apr 28, 2014 | 2:14am EDT",Meda rejects Mylan proposal,http://www.reuters.com//article/meda-mylan-idUSWEB00M4920140428?type=companyNews
26,"  MUMBAI, April 29 Indian generic drugmaker Wockhardt Ltd denied on Tuesday a media report that said U.S. drugmakers Mylan Inc and Pfizer Inc  were in talks with the company to buy some of its assets.Wockhardt cited the media report as saying that Mylan was in talks to buy its domestic business, while Pfizer was also in the race to buy some asset, as the Indian company planned to focus only on overseas markets. Shares in Wockhardt, which has been hit by a rash of regulatory sanctions due to poor manufacturing quality, ended up 12.1 percent at their highest close in nine months, having risen as much as 17.3 percent during the day in a weak Mumbai market.  ""Presently we do not believe that there is any information/announcement of the nature sought by you,"" Wockhardt said in a statement to the exchanges. ""In the event that there is any development that requires disclosure, we will make the same immediately in accordance with regulatory requirements.""      (Reporting by Zeba Siddiqui in Mumbai; Editing by Anand Basu)",2014-04-29,MYL,"Tue Apr 29, 2014 | 8:48am EDT",Wockhardt denies media report on asset sale talks,http://www.reuters.com//article/wockhardt-stake-sale-idUSL3N0NL3CF20140429?type=companyNews
27,"   By Anjuli Davies, Sophie Sassard and Olivia Oran | LONDON/NEW YORK  LONDON/NEW YORK Allergan Inc (AGN.N), facing an unsolicited bid from Valeant Pharmaceuticals International Inc (VRTX.O), is preparing to approach Shire Plc (SHP.L) about a potential takeover, even though the Irish drugmaker rebuffed a previous overture, people familiar with the matter said on Monday.A bid by Allergan for Shire, which has a market value of $32 billion, would underscore how keen the U.S. dermatology drugmaker is to stay independent.Valeant teamed up with activist investor Bill Ackman earlier this month to make an unsolicited $47 billion offer for Allergan. Valeant has expanded through a series of acquisitions over the past few years. But Allergan has been reluctant to sell to it in part because of Valeant's reputation for cutting costs and spending little on research and development.Allergan had held talks in recent months with Shire about a potential takeover, but those did not pan out, Reuters reported last week.  The sources said Allergan is still interested in a deal with Shire and is planning a fresh approach, with the Valeant bid now also in the background.Allergan could come back for a bid as soon as the next few days, one person added. The plan has yet to be finalized and could change, cautioned the sources, who asked not to be named because the matter is not public. It is not clear if Shire would be open to entering into merger discussions.A representative of Allergan declined to comment, while Shire could not be immediately reached for comment. Valeant and Ackman's hedge fund Pershing Square declined to comment.Allergan's shares closed down 1.3 percent on Monday on the New York Stock Exchange. Shire's shares closed up 2.4 percent in London before the news of Allergan's renewed interest. A combination of Allergan and Shire would create a pharmaceutical giant with a combined market value of nearly $72 billion and annual sales of more than $11 billion.Analysts have suggested one way for the Botox maker to defend against the unsolicited bid would be to acquire foreign drugmakers such as Shire, Jazz Pharmaceuticals Plc (JAZZ.O) or Alkermes Plc (ALKS.O).A combination with Shire would help Allergan gain its top selling ADHD drug Vyvanse. It would also gain drugs for rare diseases like Elaprase for Hunter syndrome and Replagal for Fabry disease. Pharmaceutical companies are interested in developing or buying orphan drugs which affect a small patient population because there are fewer hurdles to regulatory approval, have lower marketing costs and can command high prices.Still, the Valeant bid could also complicate attempts by Allergan to find a white knight or buy someone else. As part of their strategy, Ackman bought a 9.7 percent stake in Allergan, becoming its largest shareholder.A transaction would add to a frenzy of deal-making currently going on in the healthcare sector, as the industry restructures amid healthcare spending cuts and competition from cheap generics.Deals totaling more than $153 billion have been struck so far this year, the highest year-to-date level since Thomson Reuters began tracking data. Pharmaceutical deals have accounted for 71 percent of overall healthcare deals. Buying Shire, which is based in Dublin, would also play to an increasingly popular trend that is driving M&A in healthcare and some other sectors these days: It could help lower Allergan's tax rate.In a process known as inversion, U.S. drugmakers seek to relocate their headquarters to other countries with lower tax rates. These companies are eying potential targets that are based in Ireland in particular because of a low 12.5 percent corporate tax rate, compared to 35 percent in the United States.Bankers say the tax benefits of inversion are driving several other deals in healthcare and beyond. On Monday, for example, Pfizer Inc (PFE.N) said it had approached Britain's AstraZeneca Plc (AZN.L) (AZN.N) to reignite a potential $100 billion takeover, in what would be the biggest foreign acquisition of a British company and one of the largest pharmaceutical deals. <ID: nL6N0NK194>That deal, if it were to happen, would also come with tax advantages. Pfizer could redomicile to Britain and enjoy lower tax rates, thanks to attractive incentives to companies that manufacture and hold patents in the country.Generic drugmaker Mylan Inc (MYL.O) is also looking at acquisition targets that are based outside of the United States because of competitive pressures from rivals with a less burdensome tax structure, and it has made an unsuccessful bid for Swedish drugmaker Meda MEDAa.ST.(Reporting by Anjuli Davies and Sophie Sassard in London, Additional reporting by Olivia Oran and Soyoung Kim in New York; Editing by Cynthia Osterman)",2014-04-29,MYL,"Mon Apr 28, 2014 | 8:19pm EDT",Exclusive: Allergan eyes new takeover bid for Shire - sources,http://www.reuters.com//article/us-shire-allergan-exclusive-idUSBREA3R16Y20140429?type=companyNews
28,"  (Corrects spelling of Willkie in paragraph 18 from 'Wilkie')By Olivia Oran and Soyoung KimNEW YORK May 1 Rumors about a massive healthcare deal were circulating in industry circles, months before Pfizer Inc disclosed its $100 billion pursuit of Britain's AstraZeneca Plc , according to several industry bankers and lawyers.As rivals and bankers assessed what it could mean for different companies in the industry, one aspect touched nearly everyone: what it could mean for an increasingly popular U.S. tax loophole.U.S. healthcare companies worried that if a household name like Pfizer changed its domicile to Britain to lower its tax rate as a result of a deal with AstraZeneca, it would spur Congress into action and close the tax arbitrage opportunity, called tax inversion, for everyone else, these people said.The fear of such an outcome - even though it is likely many months, if not years, away - added new urgency to companies such as Botox-maker Allergan Inc and generic drugmaker Mylan Inc that were already looking at European targets, people familiar with these situations said.Allergan declined to comment. Its CEO David Pyott has said that he would be uncomfortable doing a deal where the tax benefit, and not strategy, was the principal driver. Mylan could not be immediately reached for comment.Now that Pfizer's plans are out in the open, pitching by bankers on inversion targets has reached a fever pitch. While tax arbitrage deals have so far largely been in the pharmaceutical sector, bankers and lawyers said U.S. technology, consumer and industrial companies are also now looking into the possibility of doing a tax inversion deal.One banker, who declined to be identified because he is actively advising companies on such deals, said the Pfizer plan ""will get people to try to move a lot quicker"" so that they can get a deal ""grandfathered in"" before any possible law change. WASHINGTON WORRIES Tax inversions allow U.S. companies, which face one of the highest tax rates in the world - a federal tax rate of 35 percent, and an overall rate that can be close to 40 percent including state and local taxes - to move to a lower-tax country by buying or creating a new holding company.Since 2008, about two dozen U.S. companies have used the strategy, versus about the same number over the previous 25 years, according to a Reuters review of transactions.Ireland, the Netherlands, Switzerland, Canada and Britain lately have been the most common destinations of U.S. companies seeking new tax domiciles. The U.K. tax rate for companies is due to drop to 20 percent from 21 percent next year. [ID: nL2N0NG26G]This year, most of those deals have happened in healthcare, which is in the midst of an unprecedented bout of deal-making. More than $153 billion worth of deals have already been announced so far this year in the sector, the highest since Thomson Reuters began tracking data. Several more are in the works, and many of those have tax arbitrage as one of the crucial drivers for the transaction as well. [ID: nL3N0NL480] As the industry had feared, Pfizer's plans have triggered concerns in Washington, with lawmakers calling for comprehensive tax reform. On Wednesday, a U.S. Treasury official said the Obama administration is seeking ways to curb tax-dodging by U.S. businesses that reincorporate overseas. [ID: nL2N0NM1RG]""Inversion transactions illustrate the need for comprehensive business tax reform that would lower corporate tax rates and limit the ability of multinationals to shift income outside the U.S.,"" the Treasury official said, noting that     the administration knows such deals ""are occurring and aren't being caught by the current rules.""Analysts and lawmakers say the chances of Congress passing a new law anytime before the November mid-term U.S. elections are slim given the gridlock between Democrats and Republicans over the tax reform question. They expect Congress to take up tax reform sometime next year.""Without some kind of tax reform in this country, there are huge benefits to large multinationals re-domiciling into more tax-friendly jurisdictions,"" Ray McGuire, Citigroup Inc's  global head of corporate and investment banking, told an M&A panel at the Milken Institute Global Conference in Los Angeles earlier this week. NOT ALL ARBITRAGE While tax advantages have become a major driver for deals, bankers and lawyers said their clients in general are thinking of business needs first when assessing potential targets.The frenzied dealmaking in healthcare comes as the industry restructures amid healthcare spending cuts and competition from cheap generics.""People may be pitching clients to do inversions now because of a concern that the rules may change over time, but the companies we deal with every day are thoughtful about these things and do not just chase deals for tax purposes alone,"" said Gordon Caplan, a partner at Willkie Farr & Gallagher LLP.Buying AstraZeneca, for example, would boost Pfizer's pipeline of cancer drugs and generate significant cost savings. But it would also allow it to re-domicile to Britain and enjoy lower tax rates. [ID: nL6N0NK194]U.S. drugmaker Mylan, which has been seeking to buy Swedish drugmaker Meda AB, was looking to do an inversion deal because it was at a disadvantage compared to foreign generic rivals, people close to the matter said. Major competitors include Teva Pharmaceuticals Industries Ltd , which is based in Israel, and Actavis Plc, which re-domiciled to Ireland through a 2013 acquisition of Warner Chilcott. Both face lower tax rates.Mylan, these people said, is also worried that if it doesn't complete an acquisition, it would be bought by another company that has already completed an inversion.Similarly, Allergan first approached Shire Plc in recent months in part because of the tax arbitrage opportunity. But now it, too, faces the prospect of being swallowed up by an unwanted bidder, Valeant Pharmaceuticals International Inc  in partnership with activist investor Bill Ackman. That has prompted Allergan to consider once again making a bid for Shire, despite being rebuffed when it made a previous overture, sources told Reuters earlier this week. [ID: nL2N0NK21P]""There is a sense that the government will change the tax rules, when and if they get around to rewriting the tax code as they have talked about doing,"" said one M&A lawyer who is working on these deals and therefore did not want to be identified. ""So if people want to do these deals they better do them soon.""   (Additional reporting by Kevin Drawbaugh in Washington and Greg Roumeliotis in Los Angeles; Editing by Paritosh Bansal, Martin Howell)",2014-05-01,MYL,"Thu May 1, 2014 | 9:47am EDT",CORRECTED-Pfizer's designs on AstraZeneca stir tax envy among rivals,http://www.reuters.com//article/usa-tax-mergers-idUSL2N0NN0KO20140501?type=companyNews
29,"  (For more Reuters DEALTALKS, double click on )By Olivia Oran and Soyoung KimNEW YORK May 1 Rumors about a massive healthcare deal were circulating in industry circles, months before Pfizer Inc disclosed its $100 billion pursuit of Britain's AstraZeneca Plc , according to several industry bankers and lawyers.As rivals and bankers assessed what it could mean for different companies in the industry, one aspect touched nearly everyone: what it could mean for an increasingly popular U.S. tax loophole.U.S. healthcare companies worried that if a household name like Pfizer changed its domicile to Britain to lower its tax rate as a result of a deal with AstraZeneca, it would spur Congress into action and close the tax arbitrage opportunity, called tax inversion, for everyone else, these people said.The fear of such an outcome - even though it is likely many months, if not years, away - added new urgency to companies such as Botox-maker Allergan Inc and generic drugmaker Mylan Inc that were already looking at European targets, people familiar with these situations said.Allergan declined to comment. Its CEO David Pyott has said that he would be uncomfortable doing a deal where the tax benefit, and not strategy, was the principal driver. Mylan could not be immediately reached for comment.Now that Pfizer's plans are out in the open, pitching by bankers on inversion targets has reached a fever pitch. While tax arbitrage deals have so far largely been in the pharmaceutical sector, bankers and lawyers said U.S. technology, consumer and industrial companies are also now looking into the possibility of doing a tax inversion deal.One banker, who declined to be identified because he is actively advising companies on such deals, said the Pfizer plan ""will get people to try to move a lot quicker"" so that they can get a deal ""grandfathered in"" before any possible law change. WASHINGTON WORRIES Tax inversions allow U.S. companies, which face one of the highest tax rates in the world - a federal tax rate of 35 percent, and an overall rate that can be close to 40 percent including state and local taxes - to move to a lower-tax country by buying or creating a new holding company.Since 2008, about two dozen U.S. companies have used the strategy, versus about the same number over the previous 25 years, according to a Reuters review of transactions.Ireland, the Netherlands, Switzerland, Canada and Britain lately have been the most common destinations of U.S. companies seeking new tax domiciles. The U.K. tax rate for companies is due to drop to 20 percent from 21 percent next year. [ID: nL2N0NG26G]This year, most of those deals have happened in healthcare, which is in the midst of an unprecedented bout of deal-making. More than a $153 billion worth of deals have already been announced so far this year in the sector, the highest since Thomson Reuters began tracking data. Several more are in the works, and many of those have tax arbitrage as one of the crucial drivers for the transaction as well. [ID: nL3N0NL480] As the industry had feared, Pfizer's plans have triggered concerns in Washington, with lawmakers calling for comprehensive tax reform. On Wednesday, a U.S. Treasury official said the Obama administration is seeking ways to curb tax-dodging by U.S. businesses that reincorporate overseas. [ID: nL2N0NM1RG]""Inversion transactions illustrate the need for comprehensive business tax reform that would lower corporate tax rates and limit the ability of multinationals to shift income outside the U.S.,"" the Treasury official said, noting that     the administration knows such deals ""are occurring and aren't being caught by the current rules.""Analysts and lawmakers say the chances of Congress passing a new law anytime before the November mid-term U.S. elections are slim given the gridlock between Democrats and Republicans over the tax reform question. They expect Congress to take up tax reform sometime next year.""Without some kind of tax reform in this country, there are huge benefits to large multinationals re-domiciling into more tax-friendly jurisdictions,"" Ray McGuire, Citigroup Inc's  global head of corporate and investment banking, told an M&A panel at the Milken Institute Global Conference in Los Angeles earlier this week. NOT ALL ARBITRAGE While tax advantages have become a major driver for deals, bankers and lawyers said their clients in general are thinking of business needs first when assessing potential targets.The frenzied dealmaking in healthcare comes as the industry restructures amid healthcare spending cuts and competition from cheap generics.""People may be pitching clients to do inversions now because of a concern that the rules may change over time, but the companies we deal with every day are thoughtful about these things and do not just chase deals for tax purposes alone,"" said Gordon Caplan, a partner at Wilkie Farr & Gallagher LLP.Buying AstraZeneca, for example, would boost Pfizer's pipeline of cancer drugs and generate significant cost savings. But it would also allow it to re-domicile to Britain and enjoy lower tax rates. [ID: nL6N0NK194]U.S. drugmaker Mylan, which has been seeking to buy Swedish drugmaker Meda AB, was looking to do an inversion deal because it was at a disadvantage compared to foreign generic rivals, people close to the matter said. Major competitors include Teva Pharmaceuticals Industries Ltd , which is based in Israel, and Actavis Plc, which re-domiciled to Ireland through a 2013 acquisition of Warner Chilcott. Both face lower tax rates.Mylan, these people said, is also worried that if it doesn't complete an acquisition, it would be bought by another company that has already completed an inversion.Similarly, Allergan first approached Shire Plc in recent months in part because of the tax arbitrage opportunity. But now it, too, faces the prospect of being swallowed up by an unwanted bidder, Valeant Pharmaceuticals International Inc  in partnership with activist investor Bill Ackman. That has prompted Allergan to consider once again making a bid for Shire, despite being rebuffed when it made a previous overture, sources told Reuters earlier this week. [ID: nL2N0NK21P]""There is a sense that the government will change the tax rules, when and if they get around to rewriting the tax code as they have talked about doing,"" said one M&A lawyer who is working on these deals and therefore did not want to be identified. ""So if people want to do these deals they better do them soon.""   (Additional reporting by Kevin Drawbaugh in Washington and Greg Roumeliotis in Los Angeles; Editing by Paritosh Bansal, Martin Howell)",2014-05-01,MYL,"Thu May 1, 2014 | 1:00am EDT",DEALTALK-Pfizer's designs on AstraZeneca stir tax envy among rivals,http://www.reuters.com//article/usa-tax-mergers-idUSL2N0NM2Y120140501?type=companyNews
30,"   By Sven Nordenstam | STOCKHOLM  STOCKHOLM Swedish drugmaker Meda MEDAa.ST, a recent takeover target of U.S. rival Mylan Inc (MYL.O), said on Wednesday acquisitions could double its size in two years and that it considered itself a predator and not prey in a consolidating pharma industry.Meda, which last month spurned two takeover approaches from the U.S. generic drugs firm, said major acquisitions were again ""a top subject"" for the company.""Either you eat or you will be eaten,"" Meda Chief Executive Jorg-Thomas Dierks told a conference call. ""And I think that it is quite logical that we prefer to eat and not to be eaten.""Meda was built through the acquisitions of other companies and product portfolios, and doubling sales in two years would be a repeat of Meda's performance in the years 2006 to 2008.Last year Meda had sales of 13 billion Swedish crowns ($2 billion), an almost 17-fold increase from a decade ago. Dierks said acquisitions were necessary to complement organic growth and still key to Meda's strategy after a pause of a couple of years.""I see absolutely no reason why we should not double our size within the timeframe of two years,"" he said, adding that acquisitions would either complement Meda's existing product portfolio, or be of a ""transformational, strategic"" kind.""What we see in the industry is that it is an industry of consolidation, and as I said before it is very simple. You will belong to the winners or you will belong to the losers, and there is nothing in between."" Meda has been seen as takeover candidate for years in an industry which is trying to cut costs and add specialized expertise as it faces pressures on prices from healthcare service providers in developed countries seeking to restrict their spending.A flurry of multi-billion dollar deals and bids in recent months is set to make this year the busiest ever for M&A in the healthcare sector with Pfizer's (PFE.N) $106 billion offer for AstraZeneca (AZN.L) on May 2 the biggest proposed deal so far.Meda's earnings before interest, tax, depreciation and amortization (EBITDA) rose to 1,010 million crowns in the first quarter from 923 million in the same period last year. The result was in line with the mean forecast of 1,018 million crowns in a Reuters poll of analysts. On a like-for-like basis, sales rose by 3 percent, but in Russia and Ukraine sales fell because of the political and economic uncertainty there, Meda said.Meda's shares fell 2.5 percent by 1114 GMT while the broader Stockholm market index .OMXSPI was down 0.4 percent.Meda repeated it expected organic sales growth, which excludes exchange rate movements and acquisitions, to this year be in line with the 4 percent advance seen in 2013 while its operating margin (EBITDA) is expected to improve on last year's 28.5 percent.Link to full report: r.reuters.com/xyd29v(Additional reporting by Rebecka Roos; Editing by Greg Mahlich)",2014-05-07,MYL,"Wed May 7, 2014 | 7:48am EDT","Sweden's Meda says it a predator, not prey in drugs industry consolidation",http://www.reuters.com//article/us-meda-idUSBREA460FA20140507?type=companyNews
31,"  (Refiled to remove extraneous text character in headline)* CEO says ""We prefer to eat and not to be eaten""* CEO says major acquisitions a top subject for company* CEO says company could double in size in two years* Q1 EBITDA 1.010 bln SEK vs forecast 1.018 bln in Reuters pollBy Sven NordenstamSTOCKHOLM, May 7 Swedish drugmaker Meda , a recent takeover target of U.S. rival Mylan Inc , said on Wednesday acquisitions could double its size in two years and that it considered itself a predator and not prey in a consolidating pharma industry.Meda, which last month spurned two takeover approaches from the U.S. generic drugs firm, said major acquisitions were again ""a top subject"" for the company. ""Either you eat or you will be eaten,"" Meda Chief Executive Jorg-Thomas Dierks told a conference call. ""And I think that it is quite logical that we prefer to eat and not to be eaten.""Meda was built through the acquisitions of other companies and product portfolios, and doubling sales in two years would be a repeat of Meda's performance in the years 2006 to 2008.Last year Meda had sales of 13 billion Swedish crowns ($2 billion), an almost 17-fold increase from a decade ago. Dierks said acquisitions were necessary to complement organic growth and still key to Meda's strategy after a pause of a couple of years.""I see absolutely no reason why we should not double our size within the timeframe of two years,"" he said, adding that acquisitions would either complement Meda's existing product portfolio, or be of a ""transformational, strategic"" kind.""What we see in the industry is that it is an industry of consolidation, and as I said before it is very simple. You will belong to the winners or you will belong to the losers, and there is nothing in between.""Meda has been seen as takeover candidate for years in an industry which is trying to cut costs and add specialised expertise as it faces pressures on prices from healthcare service providers in developed countries seeking to restrict their spending. A flurry of multi-billion dollar deals and bids in recent months is set to make this year the busiest ever for M&A in the healthcare sector with Pfizer's $106 billion offer for AstraZeneca on May 2 the biggest proposed deal so far.Meda's earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1,010 million crowns in the first quarter from 923 million in the same period last year. The result was in line with the mean forecast of 1,018 million crowns in a Reuters poll of analysts..On a like-for-like basis, sales rose by 3 percent, but in Russia and Ukraine sales fell because of the political and economic uncertainty there, Meda said.Meda's shares fell 2.5 percent by 1114 GMT while the broader Stockholm market index was down 0.4 percent.Meda repeated it expected organic sales growth, which excludes exchange rate movements and acquisitions, to this year be in line with the 4 percent advance seen in 2013 while its operating margin (EBITDA) is expected to improve on last year's 28.5 percent.Link to full report: r.reuters.com/xyd29v  ($1=6.5021 Swedish crowns)   (Additional reporting by Rebecka Roos; Editing by Greg Mahlich)",2014-05-07,MYL,"Wed May 7, 2014 | 7:40am EDT","UPDATE 2-Sweden's Meda says it a predator, not prey in drugs industry consolidation",http://www.reuters.com//article/meda-idUSL6N0NT1RC20140507?type=companyNews
32,"  STOCKHOLM May 7 Swedish drug maker Meda , a recent takeover target of U.S. rival Mylan Inc , said it was well placed to make large acquisitions of its own after posting first-quarter profits in line with expectations and maintaining its year forecast.Meda's earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1,010 million Swedish crowns ($155 million) in the first quarter from 923 million in the same period last year. The result was in line with the average forecast of 1,018 million crowns given in a Reuters poll of analysts.Meda's shares were down 1.7 percent at 117.0 crowns while the broader Stockholm market index was down 0.6 percent. Chief Executive Officer Jorg-Thomas Dierks made the following comments during a conference call on Wednesday: ON ACQUISITIONS:  ""I see absolutely no reason why we should not double our size within the timeframe of two years.""""Either you eat our you will be eaten. And I think that it is quite logical that we prefer to eat and not to be eaten.""""It is not a defence strategy, it is a strategy I am looking forward to as CEO here. What we see in the industry is that it is an industry of consolidation and as I said before it is very simple. You will belong to the winners or you will belong to the loosers and there is nothing in between.""     (Reporting by Rebecka Roos; editing by Niklas Pollard)",2014-05-07,MYL,"Wed May 7, 2014 | 6:41am EDT",EXECUTIVE VIEW-Meda CEO says company could double size in two years,http://www.reuters.com//article/meda-idUSL6N0NT3G120140507?type=companyNews
33,"  STOCKHOLM May 7 Swedish drug maker Meda , a recent takeover target of U.S. rival Mylan Inc , posted first-quarter profits in line with expectations on Wednesday and repeated its outlook for 2014.Meda, which last month spurned two takeover approaches from U.S. generics maker Mylan, said earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1,010 million Swedish crowns ($155 million) from a year-ago 923 million.The outcome was in line with a mean forecast in a Reuters poll of analysts for earnings to rise to 1,018 million crowns. . On a like-for-like basis sales grew by 3 percent in the quarter compared to a year ago. Meda repeated it expected organic sales growth, which excludes impact of currency swings and acquisitions, this year to be in line with the 4 percent chalked up in 2013 while its operating margin (EBITDA) was seen improving from last year's 28.5 percent. Link to full report: r.reuters.com/xyd29v  ($1 = 6.5021 Swedish Crowns)   (Reporting by Sven Nordenstam)",2014-05-07,MYL,"Wed May 7, 2014 | 2:13am EDT","Meda Q1 core profit in line with forecasts, repeats outlook",http://www.reuters.com//article/meda-idUSWEB00MRL20140507?type=companyNews
34,"  May 15 Mylan Inc said a U.S. district court dismissed a case by Israeli drugmaker Teva Pharmaceutical Industries Ltd intended to block the U.S. health regulator from approving generic versions of Teva's multiple sclerosis drug Copaxone.U.S. generic drugmaker Mylan said it had intervened in the lawsuit in support of the U.S. Food and Drug Administration.  ""Following the court's decision against Teva, we continue to see no barrier to FDA approval of Mylan's generic Copaxone following patent expiry,"" Mylan CEO Heather Bresch said in a statement.    (Reporting by Esha Dey in Bangalore; Editing by Savio D'Souza) ",2014-05-15,MYL,"Thu May 15, 2014 | 7:29am EDT",Mylan: US court dismisses Teva's move to block copies of MS drug,http://www.reuters.com//article/mylan-lawsuit-idUSL3N0O14ZS20140515?type=companyNews
35,"  LONDON U.S. drugmaker Mylan is recalling batches of the injectable antibiotic clarithromycin made in India due to possible impurities, Britain's healthcare regulator said on Wednesday.The Medicines and Healthcare products Regulatory Agency, or MHRA, said the decision was due to the potential for small particles of white material to be present in individual vials.The Mylan recall is being made on behalf of Strides Arcolab International and relates to Agila-branded supplies, the MHRA added. The Pennsylvania-based company bought Agila, a unit of India's Strides Arcolab, for $1.6 billion last year. The issue with the Agila antibiotic follows a series of quality problems affecting medicines manufactured in India that have tarnished the country's reputation as a supplier of cheap generic drugs.   (Reporting by Ben Hirschler, editing by David Evans)",2014-06-18,MYL,"Wed Jun 18, 2014 | 10:29am EDT",UK says Mylan recalls batches of Indian-made antibiotic,http://www.reuters.com//article/us-mylan-india-britain-idUSKBN0ET1RM20140618?type=companyNews
36,"  LONDON U.S. drugmaker Mylan is recalling batches of the injectable antibiotic clarithromycin made in India due to possible impurities, Britain's healthcare regulator said on Wednesday.The Medicines and Healthcare products Regulatory Agency, or MHRA, said the decision was due to the potential for small particles of white material to be present in individual vials.The Mylan recall is being made on behalf of Strides Arcolab International and relates to Agila-branded supplies, the MHRA added. The Pennsylvania-based company bought Agila, a unit of India's Strides Arcolab, for $1.6 billion last year. The issue with the Agila antibiotic follows a series of quality problems affecting medicines manufactured in India that have tarnished the country's reputation as a supplier of cheap generic drugs.   (Reporting by Ben Hirschler, editing by David Evans)",2014-06-18,MYL,"Wed Jun 18, 2014 | 10:28am EDT",UK says Mylan recalls batches of Indian-made antibiotic,http://www.reuters.com//article/us-mylan-india-britain-idUSKBN0ET1R820140618?type=companyNews
37,"  LONDON, June 18 U.S. drugmaker Mylan is recalling batches of the injectable antibiotic clarithromycin made in India due to possible impurities, Britain's healthcare regulator said on Wednesday.The Medicines and Healthcare products Regulatory Agency, or MHRA, said the decision was due to the potential for small particles of white material to be present in individual vials. The Mylan recall is being made on behalf of Strides Arcolab International and relates to Agila-branded supplies, the MHRA added. The Pennsylvania-based company bought Agila, a unit of India's Strides Arcolab, for $1.6 billion last year.  The issue with the Agila antibiotic follows a series of quality problems affecting medicines manufactured in India that have tarnished the country's reputation as a supplier of cheap generic drugs.   (Reporting by Ben Hirschler, editing by David Evans)",2014-06-18,MYL,"Wed Jun 18, 2014 | 10:15am EDT",UK says Mylan recalls batches of Indian-made antibiotic,http://www.reuters.com//article/mylan-india-britain-idUSL6N0OZ1RI20140618?type=companyNews
38,"  LONDON U.S. drugmaker Mylan is recalling batches of the injectable antibiotic clarithromycin made in Poland due to possible impurities, Britain's healthcare regulator said on Wednesday.The Medicines and Healthcare products Regulatory Agency, or MHRA, said the decision was due to the potential for small particles of white material to be present in individual vials.The Mylan recall is being made on behalf of Strides Arcolab International and relates to Agila-branded supplies, the MHRA added. The Pennsylvania-based company bought Agila, a unit of India's Strides Arcolab, for $1.6 billion last year.  (This corrected version of the story fixes the headline and first paragraph to show drug made in Poland not India)  (Reporting by Ben Hirschler; Editing by David Evans)",2014-06-19,MYL,"Thu Jun 19, 2014 | 7:25am EDT",UK says Mylan recalls batches of Polish-made antibiotic,http://www.reuters.com//article/us-mylan-india-britain-idUSKBN0EU12E20140619?type=companyNews
39,"  (Corrects in headline and first paragraph to show drug made in Poland not India)LONDON, June 18 U.S. drugmaker Mylan is recalling batches of the injectable antibiotic clarithromycin made in Poland due to possible impurities, Britain's healthcare regulator said on Wednesday. The Medicines and Healthcare products Regulatory Agency, or MHRA, said the decision was due to the potential for small particles of white material to be present in individual vials.  The Mylan recall is being made on behalf of Strides Arcolab International and relates to Agila-branded supplies, the MHRA added. The Pennsylvania-based company bought Agila, a unit of India's Strides Arcolab, for $1.6 billion last year.   (Reporting by Ben Hirschler; Editing by David Evans)",2014-06-19,MYL,"Thu Jun 19, 2014 | 7:04am EDT",CORRECTED-UK says Mylan recalls batches of Polish-made antibiotic,http://www.reuters.com//article/mylan-india-britain-idUSL6N0OZ1RI20140619?type=companyNews
40,"  (Adds details of drugs to be divested, share price, other pharma deals)WASHINGTON, June 30 Generic drugmaker Actavis Plc has won U.S. approval to buy specialty pharmaceuticals company Forest Laboratories on condition it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.The deal was valued at about $25 billion when it was announced in February.The companies have agreed to relinquish their right to diltiazem hydrochloride extended release capsules, which are used to treat hypertension and some anginas. They also agreed to sell three medicines - ursodiol tablets used to treat cirrhosis of the liver, propranolol hydrochloride extended release capsules used to treat hypertension, and lamotrigine orally disintegrating tablets used to prevent seizures. Shareholders of both companies have already approved the proposed transaction.Dublin-based Actavis, whose biggest competitors include Teva Pharmaceuticals Industries and Mylan, has recently been acquiring specialty branded drug makers to boost profit margins and sales. Forest, which acquired privately held drugmaker Aptalis in January for $2.9 billion, faces a patent cliff on several of its biggest drugs, including Alzheimer's treatment Namenda. It recently won antitrust approval to buy Furiex Pharmaceuticals Inc in a transaction worth about $1.46 billion.Actavis shares closed at $194.88, down 22 cents, and Forest Labs closed at $88.57, down 77 cents, in U.S. trading.    (Reporting by Diane Bartz; Editing by Ros Krasny, Sandra Maler and Peter Cooney)",2014-06-30,MYL,"Mon Jun 30, 2014 | 5:48pm EDT",UPDATE 1-U.S. allows Actavis Plc's purchase of Forest Labs with conditions,http://www.reuters.com//article/forestlabs-actavis-plc-ftc-idUSL2N0PB2F220140630?type=companyNews
41,"   By Soyoung Kim | NEW YORK  NEW YORK U.S. generic drugmaker Mylan Inc is in advanced talks to acquire a multibillion-dollar portfolio of established products from Abbott Laboratories, people familiar with the matter said.The proposed transaction, which is in late-stage discussions, would see Mylan acquire a big chunk of Abbott's Europe-based mature drugs for several billion dollars, said the people, who asked not to be named because the matter is not public.The acquisition of the foreign assets, according to some of the people, could also allow the U.S. company to change its tax address to overseas, a practice known as inversion that has become popular among healthcare companies seeking to cut their tax bills and gain access to cash held offshore.The exact value of Mylan's bid could not be learned, but people familiar with the matter previously told Reuters that Abbott was looking to sell a portfolio of mature drugs that could fetch more than $5 billion.    A deal could come as soon as next week, but the discussions are continuing and could still fall apart, the people cautioned.Abbotts established pharmaceuticals division is headquartered in Basel, Switzerland and had 2013 sales of roughly $5 billion. About half of the sales come from emerging markets, and the remainder from other international markets.    Representatives for Mylan declined to comment, while Abbott did not respond to requests for comment. A potential deal with Abbott would come after Mylan's failed attempt to buy Swedish drugmaker Meda AB earlier this year. Meda in April rejected Mylan's revised $6.7 billion takeover bid, saying its biggest shareholder did not back a deal.Mylan was looking to do an inversion deal partly because it was at a disadvantage compared with foreign rivals as well as other U.S. generic drugmakers that have redomiciled to a low-tax country.Major competitors include Teva Pharmaceuticals Industries Ltd, which is based in Israel, and Actavis Plc, which re-domiciled to Ireland through a 2013 acquisition of Warner Chilcott. Both face lower tax rates. Tax inversions allow U.S. companies, which face one of the highest tax rates in the world - a federal tax rate of 35 percent, and an overall rate that can be close to 40 percent, including state and local taxes - to move to a lower-tax country by buying or creating a new holding company.The deal would add to a flurry of dealmaking in the healthcare sector, which more than tripled to $317.4 billion in the first half of 2014 from the same period last year. Reuters first reported in May that Abbott has tapped Morgan Stanley to find a buyer for the off-patent drugs so that it can free up resources to invest in high-growth areas.Other large pharmaceutical companies including GlaxoSmithKline Plc, Sanofi SA and Merck & Co Inc are also looking to shed older drugs, many of which have lost patent protection and face shrinking sales.Faced with healthcare spending cuts and generic competition, the pharmaceutical industry is undergoing a major restructuring, with companies playing to their strengths by building up certain businesses and divesting others. (Reporting by Soyoung Kim in New York; Editing by Chris Reese, Gunna Dickson and Diane Craft)",2014-07-11,MYL,"Fri Jul 11, 2014 | 7:23pm EDT",Exclusive: Mylan near multibillion-dollar deal for Abbott drug assets - sources,http://www.reuters.com//article/us-mylan-abbott-exclusive-idUSKBN0FG2BT20140711?type=companyNews
42,"   By Ransdell Pierson  Generic drugmaker Mylan Inc said on Monday it would buy Abbott Laboratories' branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.The deal gives Mylan a wide array of Abbott brands that have annual sales of almost $2 billion in those markets, including gastroenterology drug Creon, pain drug Brufen and influenza vaccine Influvac.It has been structured to help Mylan reduce its tax bill, by moving its tax address outside the United States, a practice known as tax inversion that has become popular among healthcare companies. ""We see Mylan creating a platform for potential future acquisitions with this deal,"" thanks to revenue from the Abbott products and a lowered tax rate of 20 to 21 percent in the first full year and high-teens later on, said JP Morgan analyst Chris Schott.Mylan shares were up 2.7 percent at $51.55 on the Nasdaq in early afternoon, while Abbott shares were up almost 1 percent at $41.66 on the New York Stock Exchange. Abbott will transfer assets - now sold in Europe, Japan, Canada, Australia and New Zealand - to a new publicly traded company in the Netherlands that will also include Mylan's existing businesses.Abbott will receive 105 million shares of the combined company, giving it an ownership stake of about 21 percent that is worth $5.3 billion based on Mylan's closing stock price on Friday.  Abbott will continue to sell its branded generics, however, in emerging markets, where strong sales growth is expected because of rising numbers of middle-class patients. By contrast, its sales of generics in developed markets have been steadily declining in recent years due to price pressures in Europe.Although the deal would hurt Abbott's 2015 earnings, the suburban Chicago company said it plans relatively quickly to sell its stake in the new company and use the proceeds to boost Abbott's earnings, such as by acquiring more medical devices or buying back its shares.""While we have a very positive view toward Mylan stock, we do not expect to be a long-term shareholder in Mylan,"" Abbott Chief Executive Miles White told investors in a conference call on Monday. Reuters had reported on Friday that Mylan was in advanced talks to buy a multibillion-dollar portfolio of established products from Abbott. The deal gives Mylan a portfolio of more than 100 specialty and branded generic pharmaceutical products in five major therapeutic areas including cardio/metabolic and gastrointestinal. (Reporting by Ransdell Pierson in New York and Shailesh Kuber in Bangalore; editing by Sriraj Kalluvila and Matthew Lewis)",2014-07-14,MYL,"Mon Jul 14, 2014 | 1:03pm EDT","Mylan to buy Abbott generics, cut taxes, in $5.3 billion deal",http://www.reuters.com//article/us-mylan-abbott-idUSKBN0FJ10F20140714?type=companyNews
43,"  (Adds analyst comments, details of deal, company background, stock prices)By Ransdell PiersonJuly 14 Generic drugmaker Mylan Inc said on Monday it would buy Abbott Laboratories' branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.The deal gives Mylan a wide array of Abbott brands that have annual sales of almost $2 billion in those markets, including gastroenterology drug Creon, pain drug Brufen and influenza vaccine Influvac.It has been structured to help Mylan reduce its tax bill, by moving its tax address outside the United States, a practice known as tax inversion that has become popular among healthcare companies.""We see Mylan creating a platform for potential future acquisitions with this deal,"" thanks to revenue from the Abbott products and a lowered tax rate of 20 to 21 percent in the first full year and high-teens later on, said JP Morgan analyst Chris Schott. Mylan shares were up 2.7 percent at $51.55 on the Nasdaq in early afternoon, while Abbott shares were up almost 1 percent at $41.66 on the New York Stock Exchange.Abbott will transfer assets - now sold in Europe, Japan, Canada, Australia and New Zealand - to a new publicly traded company in the Netherlands that will also include Mylan's existing businesses. Abbott will receive 105 million shares of the combined company, giving it an ownership stake of about 21 percent that is worth $5.3 billion based on Mylan's closing stock price on Friday.Abbott will continue to sell its branded generics, however, in emerging markets, where strong sales growth is expected because of rising numbers of middle-class patients. By contrast, its sales of generics in developed markets have been steadily declining in recent years due to price pressures in Europe.Although the deal would hurt Abbott's 2015 earnings, the suburban Chicago company said it plans relatively quickly to sell its stake in the new company and use the proceeds to boost Abbott's earnings, such as by acquiring more medical devices or buying back its shares. ""While we have a very positive view toward Mylan stock, we do not expect to be a long-term shareholder in Mylan,"" Abbott Chief Executive Miles White told investors in a conference call on Monday.Reuters had reported on Friday that Mylan was in advanced talks to buy a multibillion-dollar portfolio of established products from Abbott.The deal gives Mylan a portfolio of more than 100 specialty and branded generic pharmaceutical products in five major therapeutic areas including cardio/metabolic and gastrointestinal.(Reporting by Ransdell Pierson in New York and Shailesh Kuber in Bangalore; editing by Sriraj Kalluvila and Matthew Lewis)",2014-07-14,MYL,"Mon Jul 14, 2014 | 1:00pm EDT","UPDATE 2-Mylan to buy Abbott generics, cut taxes, in $5.3 bln deal",http://www.reuters.com//article/mylan-abbott-idUSL4N0PP32V20140714?type=companyNews
44,"  * AbbVie raises bid to 53.20 pounds/share from 51.15* Deal values Shire at 31 bln pounds* Bid comprises 24.44 stg cash and 0.8960 new AbbVie shares* Shire shares hit record high, trading at 50.00   (Adds analyst comment; updates share moves)By Kate HoltonLONDON, July 14 Shire Plc, which sells drugs for rare diseases, succumbed to an increased 31 billion pounds ($53 billion) takeover offer from Abbvie Inc on Monday, signaling the conclusion to a lengthy courtship largely motivated by tax benefits.Dublin-based Shire said it would recommend the deal, the latest in a list of mergers proposed by U.S. companies seeking to cut tax rates. It comes less than seven weeks after the collapse of Pfizer Inc's $118 billion bid for AstraZeneca Plc, also motivated in part by tax factors.Chicago-based AbbVie, which also wants to diversify its product lineup, increased the offer to 53.20 pounds per share on Sunday, following a request from Shire after it had rejected four previous bids.Citing people familiar with the matter, Reuters had reported on Saturday that Shire had asked AbbVie to sweeten its offer to near 53 pounds per share in order for it to recommend the deal. Shire said the new bid comprised 24.44 pounds in cash and 0.8960 new AbbVie share for each Shire share, giving Shire investors about 25 percent ownership of the combined entity.""This deal makes a lot of sense for AbbVie as it would lower its tax rate from 22 percent to 13 percent, reduce dependence on Humira, broaden the (drug) pipeline, and provide some opportunities for operational synergies,"" BMO Capital Markets analyst Alex Arfaei said in a research note.AbbVie gets nearly 60 percent of its revenue from rheumatoid arthritis drug Humira, the world's top-selling medicine, which loses U.S. patent protection in late 2016.BMO is estimating the combination would increase AbbVie's earnings per share by 9 percent in 2015 and 17 percent in 2016. AbbVie shares were down 1.4 percent at $54.19 on the New York Stock Exchange, while Shire was up 1.6 percent in London after earlier hitting an all-time high of 50.45 pounds.AbbVie would lower its corporate tax rate by moving its tax base to Britain, a tactic known as inversion. Analysts at Barclays estimated the move would provide an estimated $1.3 billion in tax savings by 2020.""Strategically, AbbVie acquires Shire's quality growth assets in platforms including rare diseases, neuroscience and ophthalmology, easing investor concerns about overreliance on Humira and offering future growth opportunities,"" Barclays said. FEW INVERSION TARGETS Analyst Alistair Campbell at banking group Berenberg said there were few other British drugmakers that would suit a tax inversion takeover because about 20 percent of shareholders post-deal must be shareholders in the target company.""You can't go for small companies,"" he said. ""Glaxo  is too big, Astra has had an approach from Pfizer and Shire has now gone.""Smith & Nephew Plc, Europe's largest maker of artificial joints, has been seen as a possible target. U.S.-based Stryker Corp has said it would not bid for the company after reports linking it with a deal circulated in May.Sweden's Meda AB rejected an improved takeover offer from U.S. generic drugmaker Mylan Inc in April, which could have helped reduce taxes.The approach for Shire has been far less controversial than the move for AstraZeneca. While headquartered in Dublin, Shire  is managed from Boston and has most of its sales in the United States, resulting in a relatively small business footprint in Britain.Shire Chief Executive Flemming Ornskov had said he was happy for the company to be sold at the right price.   ($1 = 0.5877 British Pounds)   (Additional reporting by Bill Berkrot in New York; Editing by Louise Heavens, David Holmes and Jonathan Oatis)",2014-07-14,MYL,"Mon Jul 14, 2014 | 11:52am EDT",UPDATE 4-Shire ready to bow to AbbVie's increased $53 bln offer,http://www.reuters.com//article/shire-abbvie-idUSL6N0PP17H20140714?type=companyNews
45,  July 14 Generic drugmaker Mylan Inc said it would buy Abbott Laboratories' specialty and branded generics business outside the United States in an all-stock transaction valued at about $5.3 billion.Abbott will receive 105 million shares of the combined company worth.   (Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila),2014-07-14,MYL,"Mon Jul 14, 2014 | 6:41am EDT","Mylan to buy Abbott's non-US specialty, branded generics assets",http://www.reuters.com//article/mylan-abbott-idUSL4N0PP31H20140714?type=companyNews
46,"   By Natalie Huet | PARIS  PARIS Sanofi (SASY.PA) has held talks with Abbott Laboratories (ABT.N), Mylan (MYL.O) and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.The 25-page document, a copy of which was circulated by the CGT union on Wednesday, details a plan presented to the company's investment committee on May 6 dubbed the ""Phoenix project"".It shows Sanofi is considering whether to sell, carve out or create a joint venture for a portfolio of some 200 mature drugs that includes blood thinner Plavix, anti-epileptic Depakine and antibiotic Pyostacine.The portfolio currently accounts for annual sales of about 2.1 billion euros but these are projected to drop by two-fifths in the next decade as European countries tighten healthcare budgets and impose lower drug prices.No decision has yet been made on the portfolio, a Sanofi spokesman said.  ""Materials and studies on different topics are regularly presented to the investment committee, and it doesn't always take action or render decisions based on presented materials,"" he said in an emailed statement.    Reuters had reported in April that Sanofi was looking to sell a multi-billion portfolio of mature products, as drugmakers worldwide seek to shed non-core assets and focus on high-growth areas. The Phoenix project aims to minimize exposure to price cuts, reduce Sanofi's manufacturing in Europe and free up cash, according to the document. It would concern six manufacturing and distribution sites and some 2,600 staff in Europe, mainly in France, Spain, Italy and Germany.     The document shows that as of May, Sanofi had begun talks with Abbott, Mylan and private equity firms TPG and Warburg Pincus as potential buyers or venture partners.    It adds that Pfizer (PFE.N), Otsuka (4768.T) and Teva (TEVA.TA) were not interested in the portfolio, while talks with AstraZeneca (AZN.L) and GSK (GSK.L) were still pending.     The CGT union said in a statement it planned to bring the document to the attention of the French government to denounce what it called Sanofi's ""capitalist Monopoly game"" and to protect local jobs.     ""It shows that management's strategy is to withdraw from Europe and particularly from France,"" the union said.    Drug companies are increasingly looking to shed smaller divisions they view as non-core so they can better focus on their mainstay products. They have also shown willingness to consider large asset swaps with rivals to exit weaker businesses and reinforce core areas where they are already top players. ($1 = 0.7388 Euros) (Editing by James Regan; Editing by Elaine Hardcastle)",2014-07-16,MYL,"Wed Jul 16, 2014 | 8:54am EDT","Sanofi held talks with Abbott, Mylan about mature drugs: document",http://www.reuters.com//article/us-sanofi-sale-idUSKBN0FL1AA20140716?type=companyNews
47,"  (Adds CEO comments, details on formula sales, updates shares)By Ransdell PiersonJuly 16 Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday as demand for its recently-recalled infant formulas began to recover and profit margins improved for other business segments.Sales of nutritional products, the company's biggest product line which includes Similac infant formula and Ensure beverages for adults, rose 1.6 percent to $1.73 billion, following declines in previous quarters.""The business seems to be stabilizing,"" said Edward Jones analyst Jeff Windau. ""Customers are getting more comfortable now with the quality of Abbott's formulas, so we expect better growth in the second half of the year.""A recall of pediatric milk formula brands in China and Vietnam last August, due to fears an ingredient provided by an outside supplier might be contaminated, crimped sales of the products by $40 million in the second quarter. But that was less than the $75 million hit seen in the prior quarter. Abbott said it is quickly recapturing share in the affected markets, having just introduced several new products and by opening a new Similac manufacturing plant in China.""We're recovering as well as we could in that one-year time frame,"" Abbott Chief Executive Miles White told analysts on a conference call. ""We're getting back to the track we want to be on.""Abbott said it earned $466 million, or 30 cents per share, in the quarter. That compared with $476 million, or 30 cents, in the year-earlier period, when Abbott took charges for cost-saving initiatives and other expenses. Excluding special items, Abbott earned 54 cents per share, topping Wall Street expectations of 51 cents. The company said the outperformance was due to improved profit margins for its diagnostics and vascular products.Global company sales rose 1.9 percent to $5.55 billion, a bit above Wall Street estimates of $5.52 billion.Diagnostics posted the best showing in the quarter, growing 4.8 percent to $1.19 billion, with double digit sales growth in the United States. Sales of medical devices rose 1.2 percent to $1.37 billion. Abbott early last year spun off its branded patent-protected prescription drugs into a new publicly traded company, Abbvie Inc, but continued to sell generic medicines.Abbott generics have suffered declining sales over the past year and hurt overall company results. But the flat sales in the second quarter, of $1.22 billion, were a welcome contrast to the 6.6 percent slump seen in the prior quarter.In a move cheered by investors, Abbott on Monday said it would sell its generics business in developed markets outside the United States to Mylan Inc in a deal valued at $5.3 billion. But Abbott will continue to sell its generic brands in fast-growing emerging markets.The suburban Chicago-based company raised its full-year profit forecast to between $2.19 and $2.29 per share, from  $2.16 to $2.26 per share.Company shares slipped 0.3 percent at $41.04 in morning trading on the New York Stock Exchange, amid modest declines for the drug sector.   (Reporting by Ransdell Pierson; Editing by Franklin Paul, Jeffrey Benkoe and Nick Zieminski)",2014-07-16,MYL,"Wed Jul 16, 2014 | 11:11am EDT","UPDATE 3-Abbott beats profit estimate, infant formulas rebound",http://www.reuters.com//article/abbott-results-idUSL2N0PR0JJ20140716?type=companyNews
48,"  * Sanofi mulls fate of 200 older drugs including Plavix* Portfolio has sales of 2.1 bln eur, enterprise value 6.3 bln eur* Sanofi also held talks with TPG and Warburg Pincus* Sanofi says no decision has yet been made* Some 2,600 staff potentially concerned in Europe   (Adds Sanofi and union comment)By Natalie HuetPARIS, July 16 Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters. The 25-page document, a copy of which was circulated by the CGT union on Wednesday, details a plan presented to the company's investment committee on May 6 dubbed the ""Phoenix project"".It shows Sanofi is considering whether to sell, carve out or create a joint venture for a portfolio of some 200 mature drugs that includes blood thinner Plavix, anti-epileptic Depakine and antibiotic Pyostacine.The portfolio currently accounts for annual sales of about 2.1 billion euros but these are projected to drop by two-fifths in the next decade as European countries tighten healthcare budgets and impose lower drug prices. No decision has yet been made on the portfolio, a Sanofi spokesman said.""Materials and studies on different topics are regularly presented to the investment committee, and it doesn't always take action or render decisions based on presented materials,"" he said in an emailed statement.Reuters had reported in April that Sanofi was looking to sell a multi-billion portfolio of mature products, as drugmakers worldwide seek to shed non-core assets and focus on high-growth areas. The Phoenix project aims to minimise exposure to price cuts, reduce Sanofi's manufacturing in Europe and free up cash, according to the document. It would concern six manufacturing and distribution sites and some 2,600 staff in Europe, mainly in France, Spain, Italy and Germany.The document shows that as of May, Sanofi had begun talks with Abbott, Mylan and private equity firms TPG and Warburg Pincus as potential buyers or venture partners.It adds that Pfizer, Otsuka and Teva  were not interested in the portfolio, while talks with AstraZeneca and GSK were still pending.The CGT union said in a statement it planned to bring the document to the attention of the French government to denounce what it called Sanofi's ""capitalist Monopoly game"" and to protect local jobs.""It shows that management's strategy is to withdraw from Europe and particularly from France,"" the union said.Drug companies are increasingly looking to shed smaller divisions they view as non-core so they can better focus on their mainstay products. They have also shown willingness to consider large asset swaps with rivals to exit weaker businesses and reinforce core areas where they are already top players.  ($1 = 0.7388 Euros)   (Editing by James Regan; Editing by Elaine Hardcastle)",2014-07-16,MYL,"Wed Jul 16, 2014 | 8:53am EDT","UPDATE 1-Sanofi held talks with Abbott, Mylan about mature drugs -document",http://www.reuters.com//article/sanofi-sale-idUSL6N0PR3AK20140716?type=companyNews
49,"  PARIS, July 16 Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.The 25-page document, a copy of which was circulated by the CGT union on Wednesday, details a plan presented to the company's investment committee on May 6 dubbed the ""Phoenix project"". It shows Sanofi is considering whether to sell, carve out or create a joint venture for a portfolio of some 200 mature drugs that includes blood thinner Plavix. The portfolio currently accounts for annual sales of about 2.1 billion euros but these are projected to nearly halve in the next decade as European countries rein in healthcare budgets and impose lower drug prices. No decision has yet been made on the portfolio, a Sanofi spokesman said.  ($1 = 0.7388 Euros)   (Reporting by Natalie Huet; Editing by James Regan)",2014-07-16,MYL,"Wed Jul 16, 2014 | 7:47am EDT","Sanofi held talks with Abbott, Mylan on mature drugs -document",http://www.reuters.com//article/sanofi-sale-idUSL6N0PR2Q320140716?type=companyNews
50,"   By Natalie Grover  Political opposition to tax-inversion deals will not stop Mylan Inc's (MYL.O) purchase of some non-U.S. businesses from Abbott Laboratories (ABT.N), Chief Executive Heather Bresch said, even as some companies have backed away from such tax arrangements.Mylan is looking at further ""strategic"" deals in the near future, Bresch added on Thursday, as the company trimmed the top end of its revenue outlook for the year - sending its shares down as much as 5.3 percent.Mylan's deal to buy Abbott's specialty and generics business in developed markets outside the United States will move its tax address to the Netherlands, cutting costs because of lower corporate tax rates there.President Barack Obama and a string of lawmakers have opposed such tax inversions and pledged action to discourage them but Bresch played down the risk.She said it would be challenging to change the U.S. tax code to stop inversion without punishing other foreign companies, which would hit the health sector as nearly half of the drugs and medical devices sold in America come from elsewhere.""Being punitive and not allowing us to be competitive, I do not believe, is in our country's best interest, and I hope that prevails at the end of the day,"" Bresch told analysts on a  post-earnings conference call.""We're obviously continuing to pay U.S. taxes, as well as a lot of these foreign companies are paying U.S. taxes and creating U.S. jobs."" The Abbott deal, announced in July, gives Mylan access to Abbott's specialty and generics business as well as moving its tax address.Nine tax-inversion deals have been agreed by U.S. companies this year although drugs retailer Walgreen Co WAG.N decided not to move offshore in its full takeover of Europe's Alliance Boots [ABN.UL], following fierce criticism of the practice. Meanwhile, Mylan is still out shopping. Bresch raised the prospect of other deals even before the completion of the Abbott deal, due early next year.""There's a lot of opportunities out there, and we are looking at everything,"" she told analysts. Operationally, Mylan was more downbeat as it shaved the top end of its revenue and earnings forecasts for this year, citing delays in approval from the U.S. Food and Drug Administration for key generic drugs that it plans to launch this year.A generic version of Teva Pharmaceutical Industries Ltd's (TEVA.TA) (TEVA.N) multiple sclerosis treatment, Copaxone, and Pfizer Inc's (PFE.N) blockbuster Celebrex, an anti-inflammatory treatment for arthritis, have both been delayed by the FDA.Mylan said it still expected to launch them in the fourth quarter, adding that a delayed launch of Copaxone to next year would not affect its updated revenue and profit forecast for this year.  The drugmaker forecast full-year 2014 revenue in a range of $7.8 billion to $8.0 billion and earnings of $3.25-$3.45 per share, a forecast that includes a fourth-quarter launch of generic Copaxone and Celebrex.It had earlier forecast full-year revenue of $7.8 billion to $8.2 billion and earnings of $3.25-$3.60 per share.Analysts on average expect full-year 2014 earnings of $3.37 per share on sales of $7.7 billion, according to Thomson Reuters I/B/E/S.Mylan posted a second-quarter adjusted net profit attributable to shareholders of $273.3 million, or 69 cents per share - a penny shy of the average analyst estimate.Mylan shares fell as low as $45.36 before recovering much of their lost ground to trade on the Nasdaq at $47.63 by early afternoon. (Editing by Rodney Joyce and Kirti Pandey)",2014-08-07,MYL,"Thu Aug 7, 2014 | 1:45pm EDT",Mylan presses on with tax-inversion Abbott deal,http://www.reuters.com//article/us-mylan-results-idUSKBN0G71HZ20140807?type=companyNews
51,"  * CEO: Tax-inversion deals do not stop companies paying US taxes* CEO: Mylan looking at additional ""strategic"" deals* Co cuts top end of 2014 profit, sales outlook* Expects key drug launches in fourth quarter despite FDA delay   (Adds CEO comment, conference call details; updates shares)By Natalie GroverAug 7 Political opposition to tax-inversion deals will not stop Mylan Inc's purchase of some non-U.S. businesses from Abbott Laboratories, Chief Executive Heather Bresch said, even as some companies have backed away from such tax arrangements.Mylan is looking at further ""strategic"" deals in the near future, Bresch added on Thursday, as the company trimmed the top end of its revenue outlook for the year - sending its shares down as much as 5.3 percent.Mylan's deal to buy Abbott's specialty and generics business in developed markets outside the United States will move its tax address to the Netherlands, cutting costs because of lower corporate tax rates there.President Barack Obama and a string of lawmakers have opposed such tax inversions and pledged action to discourage them but Bresch played down the risk. She said it would be challenging to change the U.S. tax code to stop inversion without punishing other foreign companies, which would hit the health sector as nearly half of the drugs and medical devices sold in America come from elsewhere.""Being punitive and not allowing us to be competitive, I do not believe, is in our country's best interest, and I hope that prevails at the end of the day,"" Bresch told analysts on a  post-earnings conference call.""We're obviously continuing to pay U.S. taxes, as well as a lot of these foreign companies are paying U.S. taxes and creating U.S. jobs.""The Abbott deal, announced in July, gives Mylan access to Abbott's specialty and generics business as well as moving its tax address. Nine tax-inversion deals have been agreed by U.S. companies this year although drugs retailer Walgreen Co decided not to move offshore in its full takeover of Europe's Alliance Boots, following fierce criticism of the practice.Meanwhile, Mylan is still out shopping. Bresch raised the prospect of other deals even before the completion of the Abbott deal, due early next year.""There's a lot of opportunities out there, and we are looking at everything,"" she told analysts.Operationally, Mylan was more downbeat as it shaved the top end of its revenue and earnings forecasts for this year, citing delays in approval from the U.S. Food and Drug Administration for key generic drugs that it plans to launch this year. A generic version of Teva Pharmaceutical Industries Ltd's   multiple sclerosis treatment, Copaxone, and Pfizer Inc's blockbuster Celebrex, an anti-inflammatory treatment for arthritis, have both been delayed by the FDA.Mylan said it still expected to launch them in the fourth quarter, adding that a delayed launch of Copaxone to next year would not affect its updated revenue and profit forecast for this year.The drugmaker forecast full-year 2014 revenue in a range of $7.8 billion to $8.0 billion and earnings of $3.25-$3.45 per share, a forecast that includes a fourth-quarter launch of generic Copaxone and Celebrex.It had earlier forecast full-year revenue of $7.8 billion to $8.2 billion and earnings of $3.25-$3.60 per share.Analysts on average expect full-year 2014 earnings of $3.37 per share on sales of $7.7 billion, according to Thomson Reuters I/B/E/S.Mylan posted a second-quarter adjusted net profit attributable to shareholders of $273.3 million, or 69 cents per share - a penny shy of the average analyst estimate.Mylan shares fell as low as $45.36 before recovering much of their lost ground to trade on the Nasdaq at $47.63 by early afternoon.   (Editing by Rodney Joyce and Kirti Pandey)",2014-08-07,MYL,"Thu Aug 7, 2014 | 1:38pm EDT",UPDATE 2-Mylan presses on with tax-inversion Abbott deal,http://www.reuters.com//article/mylan-results-idUSL4N0QD46G20140807?type=companyNews
52,"  Aug 7 Generic drug maker Mylan Inc  narrowed its full-year revenue and earnings forecast, citing delays in U.S. Food and Drug Administration approval of key products.The company narrowed its revenue forecast range to $7.8 billion-$8 billion from $7.8 billion-$8.2 billion.  Mylan also narrowed its full-year earnings forecast range to $3.25-$3.45 per share from $3.25-$3.60.          (Reporting by Natalie Grover in Bangalore; Editing by Kirti Pandey) ",2014-08-07,MYL,"Thu Aug 7, 2014 | 6:48am EDT","Mylan narrows full-year revenue, profit forecast",http://www.reuters.com//article/mylan-results-idUSL4N0QD43S20140807?type=companyNews
53,"   By Brendan Pierson  A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.Hospira filed a lawsuit in U.S. District Court in Maryland on Tuesday asking for a temporary restraining order against the FDA, saying the agency's decision to allow generic Precedex went against its own rules.The FDA said Monday that drugmakers could sell generic Precedex as long as the label left out information about uses of the drug covered by Hospira's patent, which covers ""intensive care unit sedation."" U.S. District Judge Jarrod Hazel said in his order on Tuesday that Hospira was likely to win its suit because the FDA's decision was ""at odds with relevant authority"" and ""tantamount to a change of the rules.""The judge said that allowing such a change could cause people to lose faith in the process for approving drugs. Mylan Inc, a drug company that had already won FDA approval to make generic Precedex, joined the lawsuit on the FDA's side on Tuesday, arguing that it would be harmed by a temporary restraining order.However, Judge Hazel found that any harm to Mylan or other generic drugmakers ""would pale in comparison"" to the harm Hospira would suffer without the restraining order. Hospira said in its lawsuit that it would lose ""tens of millions of dollars"" if the FDA's decision was not overturned. Precedex accounted for 11 percent of Hospira's global net sales of $4.1 billion in 2013, according to the company's most recent annual report.Sandoz Inc, the generic arm of Swiss drugmaker Novartis AG, was set to start selling generic Precedex in December under a settlement of patent litigation with Hospira. According to court papers, Sandoz expected to have an exclusive right to sell the generic drug for six months.Sandoz intervened in Hospira's suit against the FDA on Tuesday, arguing that it would be wrongly deprived of the six-month exclusivity period if the FDA's decision was allowed to stand. An FDA representative declined to comment. Mylan, Hospira and Sandoz did not immediately return requests for comment.The case is Hospira v. Burwell, U.S. District Court, District of Maryland, No. 8:14-cv-02662. (Reporting by Brendan Pierson; Editing by Ted Botha and Dan Grebler)",2014-08-20,MYL,"Wed Aug 20, 2014 | 12:34pm EDT",U.S. judge blocks FDA rule allowing generic versions of Hospira drug,http://www.reuters.com//article/us-health-hospira-idUSKBN0GK1RJ20140820?type=companyNews
54,"   By Brendan Pierson  Aug 20 A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.Hospira filed a lawsuit in U.S. District Court in Maryland on Tuesday asking for a temporary restraining order against the FDA, saying the agency's decision to allow generic Precedex went against its own rules.The FDA said Monday that drugmakers could sell generic Precedex as long as the label left out information about uses of the drug covered by Hospira's patent, which covers ""intensive care unit sedation.""U.S. District Judge Jarrod Hazel said in his order on Tuesday that Hospira was likely to win its suit because the FDA's decision was ""at odds with relevant authority"" and ""tantamount to a change of the rules."" The judge said that allowing such a change could cause people to lose faith in the process for approving drugs.Mylan Inc, a drug company that had already won FDA approval to make generic Precedex, joined the lawsuit on the FDA's side on Tuesday, arguing that it would be harmed by a temporary restraining order. However, Judge Hazel found that any harm to Mylan or other generic drugmakers ""would pale in comparison"" to the harm Hospira would suffer without the restraining order. Hospira said in its lawsuit that it would lose ""tens of millions of dollars"" if the FDA's decision was not overturned.Precedex accounted for 11 percent of Hospira's global net sales of $4.1 billion in 2013, according to the company's most recent annual report. Sandoz Inc, the generic arm of Swiss drugmaker Novartis AG, was set to start selling generic Precedex in December under a settlement of patent litigation with Hospira. According to court papers, Sandoz expected to have an exclusive right to sell the generic drug for six months.Sandoz intervened in Hospira's suit against the FDA on Tuesday, arguing that it would be wrongly deprived of the six-month exclusivity period if the FDA's decision was allowed to stand.An FDA representative declined to comment. Mylan, Hospira and Sandoz did not immediately return requests for comment.The case is Hospira v. Burwell, U.S. District Court, District of Maryland, No. 8:14-cv-02662.   (Reporting by Brendan Pierson; Editing by Ted Botha and Dan Grebler)",2014-08-20,MYL,"Wed Aug 20, 2014 | 12:33pm EDT",U.S. judge blocks FDA rule allowing generic versions of Hospira drug,http://www.reuters.com//article/health-hospira-idUSL2N0QQ1JZ20140820?type=companyNews
55,"  * Sells U.S. rights for blood clot drug to Mylan* Diluted headline EPS up 29 pct* Sales up 51 percent   (Adds drug rights sale)By Tiisetso MotsoenengJOHANNESBURG, Sept 10 Aspen Pharmacare  is to sell the rights to market a blood clot drug in the United States to rival Mylan Inc for up to $300 million, it said on Wednesday, a move that would help Africa's top generic drugmaker pay down debt.Mylan will pay an initial $225 million and the rest would be held by a third party until payment is due on meeting certain conditions. Aspen would retain all the rights to sell the thrombosis drug elsewhere in the world.The sale, prompted by Aspen's lack of sales representation in the United States, forms part of wider review of its portfolio to improve returns, Deputy Chief Executive Gus Attridge said. Shares in Aspen were up 4.3 percent at 336.92 rand by 1344 GMT, outpacing an almost 1 percent fall in the blue-chip JSE Top-40 index.Aspen, which also on Wednesday reported a rise in full-year profits which missed growth forecasts, acquired the drugs from GlaxoSmithKline last year as part of an aggressive push into overseas markets.Last year it spent around 20 billion rand on acquisitions including buying a Merck & Co. Inc plant in the Netherlands and a Nestle drugs and infant nutrition plant in Mexico. But the spending has increased its borrowings to around nearly 30 billion rand,  putting its net debt to EBITDA ratio at around 3.3 times -- above the company's stated target of less than three times.Attridge said the company's strong cash flow, as well as the sale of underperforming assets and marketing rights, would help push the debt-to-EBITDA multiple back down.Aspen reported an almost one-third rise to 10.16 rand in headline earnings per share in the year to end June, missing a consensus estimate of 10.71 rand in a Reuters poll of 12 analysts, as a weak home market weighed. Headline EPS, the most widely watched profit measure in South Africa, strips out certain one-off items.Sales jumped 51 percent to 31.4 billion rand ($2.87 billion) with sales from its South Africa business flat while acquisitions resulted in revenue more than tripling in Europe and Latin America.Domestic rival Adcock Ingram posted a hefty nine-month loss of 179.5 cents a share last month, compared with a profit of 271.7 cents a year earlier due to restructuring  writedowns and as a weaker rand currency pushed up imported raw materials costs that regulated price increases are often not sufficient to fully recover.Adcock makes virtually all of its profits in a heavily regulated home market where a weak economy and high personal debt has stunted consumer spending.(1 US dollar = 10.9535 South African rand)   (REditing by Stella Mapenzauswa and Greg Mahlich)",2014-09-10,MYL,"Wed Sep 10, 2014 | 11:18am EDT",UPDATE 2-S.Africa's Aspen to sell U.S. drug rights to Mylan for up to $300 mln,http://www.reuters.com//article/aspen-results-idUSL5N0RB2U820140910?type=companyNews
56,"   By Natalie Grover and Zeba Siddiqui | Sept 15  Sept 15 Epirus Biopharmaceuticals Inc  said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.The company's Indian partner, Ranbaxy Laboratories Ltd , will sell a copycat version of Johnson & Johnson's  and Merck & Co Inc's infliximab, an anti-inflammatory drug with annual sales of about $6 billion.The market for copycat biotech drugs, known as biosimilars, is becoming more lucrative as patents expire on older, high-priced antibody drugs that rank among the pharmaceutical industry's biggest sellers.With changing regulations and a looming biotech patent cliff, the global market for biosimilars is forecast to rise to $24 billion in 2019 from about $1.2 billion last year, according to market research firm Frost & Sullivan. (bit.ly/1oR6jQf)Infliximab, sold under the brand name Remicade, is used to treat rheumatoid arthritis, Crohn's Disease, psoriasis and other inflammatory conditions. In India, it sells at about 70,000 rupees ($1,150) per month. Like its main rivals, Amgen Inc's Enbrel and AbbVie Inc's Humira, the drug works by blocking a protein called tumor necrosis factor.Epirus, a Boston-based biopharmaceutical company that focuses on developing biosimilar drugs for sale, said it would launch the Remicade biosimilar in India under the name Infimab by the first quarter of 2015. Chief Executive Amit Munshi, citing various estimates, said the Indian market for Remicade was worth $8 million to $10 million a year. He declined to say how much Infimab would cost or to estimate how many patients might use the drug.The drug will be made in Mumbai by India's Reliance Life Sciences, part of billionaire Anil Ambani's Reliance Group Holdings.Remicade copycats are already being sold elsewhere. South Korean drugmaker Celltrion Inc won approval in July for its version in Japan and is hoping for U.S. approval in 2015. Epirus is also in talks with Ranbaxy, as well as other Indian and international companies, about expanding sales of its biosimilar drugs in other regions, Munshi told Reuters.""Ranbaxy has, under their license, quite a few markets in southeast Asia and North Africa,"" he said. ""We're also working with other partners in places like Latin America.""Ranbaxy is not the only Indian drugmaker to explore production of biosimilar drugs. Dr. Reddy's Laboratories Ltd , for example, is developing biosimilars with Germany's Merck KGaA.Biocon Ltd has a tie-up with Mylan Inc, while Lupin Ltd has entered a deal to sell a biosimilar version of Sanofi SA's blockbuster insulin, Lantus, in India.   (Editing by Robin Paxton)",2014-09-15,MYL,"Mon Sep 15, 2014 | 4:08pm EDT","Epirus, Ranbaxy win India approval for arthritis drug copy",http://www.reuters.com//article/epirus-biosimilars-idUSL3N0RD52B20140915?type=companyNews
57,"   By Saqib Iqbal Ahmed | NEW YORK  NEW YORK Mylan Inc (MYL.O) saw unusual options activity on Thursday and the stock rallied sharply after rumors of the company being approached for a possible deal, a day before it issued a positive earnings outlook.Mylan's shares were up 8 percent at $50.28 on Friday in heavy trading. The company raised its third-quarter adjusted profit forecast, citing stronger-than-expected operational performance. At one point on Thursday, shares were up 13 percent, with market sources citing merger rumors involving the company and Israeli drugmaker Teva Pharmaceutical Industries (TEVA.TA) (TEVA.N). A spokeswoman for Teva, the world's largest generic drugmaker and Israel's biggest company, said the company does not comment on market rumors. Mylan did not immediately respond to a request for comment. Some bullish bets Thursday on Mylan's call options in the nearest expiration suggest that traders were banking on a positive catalyst for the stock in the very near term, said optionMonster.com lead analyst David Russell.   More than 25,000 Mylan calls traded on Thursday, outnumbering puts by a ratio of 6.8 to 1, according to Trade Alert data.  Bets on Mylan shares touching $50 and others on the shares hitting $47 by Oct. 18 were among the most popular options on the company and traded 5,799 and 3,116 times, respectively, on Thursday, according to Livevol Inc data.While Mylan is an attractive asset in a consolidating specialty pharmaceutical market, JP Morgan sees the company remaining focused on staying independent, the brokerage said in a note to clients on Friday. In July, Mylan said it would pay $5.3 billion for Abbott Laboratories' (ABT.N) branded specialty and generics business in developed markets outside the United States.  (Reporting by Saqib Iqbal Ahmed; Editing by Chris Reese)",2014-10-03,MYL,"Fri Oct 3, 2014 | 1:18pm EDT",Mylan options see unusual bullish bets Thursday,http://www.reuters.com//article/us-mylan-options-idUSKCN0HS1MC20141003?type=companyNews
58,"  (Adds details, share movements)Oct 6 Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio.Durata's shares were trading up 77 percent at $24.55 premarket, above Actavis' offer of $23 per share in cash.Actavis will pay up to an additional $5 per share if Durata's lead drug, dalvance, achieves certain milestones, the companies said. Dalvance is designed to treat acute bacterial skin and skin structure infections, or ABSSSI, which affect the deep tissue or are associated with an underlying disease such as diabetes.The European Medicines Agency is expected to announce its decision on a marketing authorization application for dalvance, known generically as dalbavancin, in the first half of 2015. Actavis, which anticipates closing the deal in late 2014 or early 2015, expects the deal to add to earnings by the end of the first year.Dublin-based Actavis, whose biggest competitors include Teva Pharmaceuticals Industries and Mylan, has been acquiring specialty branded drug makers to boost profit margins and sales. Salix Pharmaceuticals Ltd had reportedly been in contact with Actavis about a potential sale.Salix's shares were down 1 percent at $150.90 premarket on Monday. Actavis stock was inactive premarket.BofA Merrill Lynch is Durata's financial adviser and Wilmer Cutler Pickering Hale and Dorr LLP is its legal adviser. Actavis' legal adviser is Debevoise & Plimpton LLP.   (Reporting by Ankur Banerjee in Bangalore; Editing by Sriraj Kalluvila and Savio D'Souza)",2014-10-06,MYL,"Mon Oct 6, 2014 | 9:24am EDT",UPDATE 1-Actavis to buy Durata in a deal valued at about $675 mln,http://www.reuters.com//article/durata-therap-ma-actavis-idUSL3N0S12OH20141006?type=companyNews
59,"  (Corrects paragraph 5 to say the EpiPen is produced my Mylan Inc, not Pfizer Inc)Oct 9 Impax Laboratories Inc said it gained access to an emergency anti-allergen injection, epinephrine, by acquiring two privately held Pennsylvania drugmakers for $700 million.Epinephrine is used to fight sudden allergic reactions such as severe rashes and swelling of the windpipe.Impax said it bought Lineage Therapeutics Inc, which sells a generic epinephrine drug administered through its USP auto-injector system, and Tower Holdings Inc.Tower, which like Lineage is based in Horsham, Pennsylvania, makes Adrenaclick, the branded version of the Lineage drug.Both products compete with Mylan Inc's EpiPen, far and away the leader in the nearly $1 billion market. Impax's shares rose 11.2 percent to $26.52 in premarket trading on Thursday.Four out of every 100 children in the United States have a food allergy, according to the U.S. Centers for Disease Control and Prevention. Most allergic reactions are caused by food, insect stings, medications and materials such as latex.Impax's deal comes nearly two months after the U.S. Food and Drug Administration raised concerns about the company's factory in Taiwan, casting doubt on the future of its experimental Parkinson's drug, Rytary. Impax moved its manufacturing operations to Taiwan in June last year after the FDA cited problems in it manufacturing plant in California.Rytary is the only drug the company is developing on its own. Nearly 94 percent of Impax's second-quarter revenue of $188 million came from the sale of generic products. Hayward, California-based Impax said the deal would add about 90 cents per share to 2015 earnings.Analysts currently expect the company to report earnings of 75 cents per share in 2015.Thursday's deal includes seven generic products and a drug to treat parasitic worm infections, Albenza.Tower Holdings and Lineage Therapeutics are expected to generate revenue of $215 million-$225 million in 2014, Impax said.Up to Wednesday's close, Impax's stock had dropped 5.2 percent this year.    (Reporting by Vidya L Nathan in Bangalore; Editing by Ted Kerr)",2014-10-09,MYL,"Thu Oct 9, 2014 | 12:35pm EDT",CORRECTED-UPDATE 1-Impax buys anti-allergy injection makers for $700 mln,http://www.reuters.com//article/towerholdings-ma-impax-idUSL3N0S43SE20141009?type=companyNews
60,"   By Caroline Humer and Ransdell Pierson  Drugmakers Abbott Laboratories (ABT.N) and Mylan Inc (MYL.O) on Wednesday declined to explain in detail why they changed the terms of a $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and reincorporate for tax purposes in the Netherlands.Analysts and banking experts said the changes were almost certainly aimed at protecting tax gains from the so-called ""inversion"" deal, one of several to surface in recent months in which U.S. companies seek to shift their tax domiciles abroad.The altered contract for the deal came a month after the Treasury Department made changes to U.S. tax rules aimed at discouraging inversion deals, which the Obama administration sees as a threat to the U.S. corporate tax base.""The (tax law) changes from Treasury are making people re-look at deal terms, and deals are not as favorable now,"" said Edward Jones analyst Jeff Windau. ""That's what happened here, there had to be some tweaks"" in the Abbott/Mylan contract.Windau said many investors had feared the new Treasury rules might derail the deal, and they took comfort in statements by both Abbott and Pittsburgh-based Mylan on Wednesday that the transaction would go through in the first quarter of 2015. ""People assume this has to do with proposed regulatory  actions by Treasury,"" said Josh Jennings, an analyst with Cowen and Co. ""I don't know what their advisors told them to do. I would have appreciated more information.""Concern about the Treasury rule changes prompted AbbVie (ABBV.N), an Abbott spinoff, earlier this week to walk away from its planned $55 billion purchase of Ireland-based drugmaker Shire Plc (SHP.L).Provisions of the Abbott/Mylan deal have been changed, Mylan said in a regulatory filing on Wednesday. One change is that Mylan will get better pricing terms at Abbott facilities that will make and supply products for Mylan. Another change, Mylan said, is that it will issue 110 million shares in the newly formed company to Abbott, 5 million more than the original terms dictated. Abbott plans to transfer generic drugs that it sells in Europe, Japan, Canada, Australia and New Zealand to a new company in the Netherlands that would also include Mylan's existing businesses. Mylan shareholders will now own 78 percent of the company and Abbott will own 22 percent. The original terms called for a 79 percent/21 percent split.Under long-standing Treasury rules, a company that wants to take up tax citizenship in a new country must be less than 80-percent owned by its original U.S. investors. That rule was tightened last month to make it harder for companies to evade the 80-20 rule by slimming down on the U.S. side, or bulking up on the non-U.S. side, through financial maneuvers.Christopher Geier, partner in charge of the investment banking practice at Sikich, a professional services firm in Naperville, Illinois, said the contract changes apparently were made to help ensure that old Mylan shareholders own less than 80 percent of the new company. As for why the companies have not more fully explained the tweaks to their deal, Geier said, To the extent they can do these things and not violate any sort of disclosure things they will, and you almost cant blame them for that.Abbott spokesman Scott Stoffel and Mylan spokeswoman Nina Devlin said they could not comment about the contract changes, beyond the limited details included in their separate regulatory filings and on an Abbott conference call.Abbott earlier on Wednesday said its third-quarter sales, including generics to be sold to Mylan which are now considered discontinued products, rose 4.7 percent to $5.6 billion, which was in line with Wall Street expectations. (Additional reporting by Kevin Drawbaugh in Washington and Bill Berkrot in New York; Editing by Eric Effron and Lisa Shumaker)",2014-10-22,MYL,"Wed Oct 22, 2014 | 6:23pm EDT","Abbott, Mylan silent on why changing tax-inversion terms",http://www.reuters.com//article/us-abbott-m-a-mylan-idUSKCN0IB1KI20141022?type=companyNews
61,"  (Adds analyst, banker comments, companies declining explanations)By Caroline Humer and Ransdell PiersonOct 22 Drugmakers Abbott Laboratories  and Mylan Inc on Wednesday declined to explain in detail why they changed the terms of a $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and reincorporate for tax purposes in the Netherlands.Analysts and banking experts said the changes were almost certainly aimed at protecting tax gains from the so-called ""inversion"" deal, one of several to surface in recent months in which U.S. companies seek to shift their tax domiciles abroad.The altered contract for the deal came a month after the Treasury Department made changes to U.S. tax rules aimed at discouraging inversion deals, which the Obama administration sees as a threat to the U.S. corporate tax base.""The (tax law) changes from Treasury are making people re-look at deal terms, and deals are not as favorable now,"" said Edward Jones analyst Jeff Windau. ""That's what happened here, there had to be some tweaks"" in the Abbott/Mylan contract. Windau said many investors had feared the new Treasury rules might derail the deal, and they took comfort in statements by both Abbott and Pittsburgh-based Mylan on Wednesday that the transaction would go through in the first quarter of 2015.""People assume this has to do with proposed regulatory  actions by Treasury,"" said Josh Jennings, an analyst with Cowen and Co. ""I don't know what their advisors told them to do. I would have appreciated more information.""Concern about the Treasury rule changes prompted AbbVie , an Abbott spinoff, earlier this week to walk away from its planned $55 billion purchase of Ireland-based drugmaker Shire Plc. Provisions of the Abbott/Mylan deal have been changed, Mylan said in a regulatory filing on Wednesday. One change is that Mylan will get better pricing terms at Abbott facilities that will make and supply products for Mylan. Another change, Mylan said, is that it will issue 110 million shares in the newly formed company to Abbott, 5 million more than the original terms dictated.Abbott plans to transfer generic drugs that it sells in Europe, Japan, Canada, Australia and New Zealand to a new company in the Netherlands that would also include Mylan's existing businesses. Mylan shareholders will now own 78 percent of the company and Abbott will own 22 percent. The original terms called for a 79 percent/21 percent split. Under long-standing Treasury rules, a company that wants to take up tax citizenship in a new country must be less than 80-percent owned by its original U.S. investors. That rule was tightened last month to make it harder for companies to evade the 80-20 rule by slimming down on the U.S. side, or bulking up on the non-U.S. side, through financial maneuvers.Christopher Geier, partner in charge of the investment banking practice at Sikich, a professional services firm in Naperville, Illinois, said the contract changes apparently were made to help ensure that old Mylan shareholders own less than 80 percent of the new company.As for why the companies have not more fully explained the tweaks to their deal, Geier said, ""To the extent they can do these things and not violate any sort of disclosure things they will, and you almost can't blame them for that.""Abbott spokesman Scott Stoffel and Mylan spokeswoman Nina Devlin said they could not comment about the contract changes, beyond the limited details included in their separate regulatory filings and on an Abbott conference call.Abbott earlier on Wednesday said its third-quarter sales, including generics to be sold to Mylan which are now considered discontinued products, rose 4.7 percent to $5.6 billion, which was in line with Wall Street expectations.   (Additional reporting by Kevin Drawbaugh in Washington and Bill Berkrot in New York; Editing by Eric Effron and Lisa Shumaker)",2014-10-22,MYL,"Wed Oct 22, 2014 | 6:22pm EDT","UPDATE 2-Abbott, Mylan silent on why changing tax-inversion terms",http://www.reuters.com//article/abbott-ma-mylan-idUSL2N0SH17V20141022?type=companyNews
62,"  Oct 22 Abbott Laboratories and Mylan Inc  on Wednesday said they would go ahead with their $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and set up headquarters in the Netherlands, but they tweaked the terms of the transaction.The move comes after the U.S. Treasury on Sept. 22 made changes to the corporate tax rules that govern such ""inversion"" merger deals, in which companies move their operations to countries with lower taxes than in the United States. The new rules raise the bar for this tax treatment and also make it harder to reap other tax benefits of an inversion.About ten U.S. companies had deals in the works when the Treasury changed the rules. Some, including Salix Pharmaceuticals and former Abbott business Abbvie, pulled out of their own inversion-based deals, while others decided to go forward with their deals.Investors and analysts were not certain where Abbott and Mylan would fall. ""The positive takeaway is that Abbott still plans to close its deal with Mylan in the first quarter of 2015, despite the pressure on inversions from the U.S. Treasury, and some walking away by other companies from inversions,"" said Jeff Windau, an analyst with Edward Jones. ""The (tax law) changes from Treasury are making people re-look at deal terms, and deals are not as favorable now. That's what happened here, there had to be some tweaks."" Abbott plans to sell to Mylan its generics business in developed markets outside the United States. It plans to keep its generic brands in fast-growing emerging markets.Mylan said that the terms of the deal were changed to include better pricing terms for Mylan at Abbott units that will manufacture and supply products for Mylan. It also said that Mylan will issue 110 million shares in the newly formed company to Abbott, 5 million more than the original terms dictated. Mylan shareholders will own 78 percent of the company and Abbott will own 22 percent of the new company. Mylan said the deal would be accretive.Abbott has said it plans to quickly sell the shares after the closing of the deal.   (Reporting by Caroline Humer and Ransdell Pierson; Editing by Chizu Nomiyama)",2014-10-22,MYL,"Wed Oct 22, 2014 | 9:24am EDT","Abbott, Mylan back generics deal, tweak terms after tax rule change",http://www.reuters.com//article/abbott-ma-mylan-idUSL2N0SH0WL20141022?type=companyNews
63,"  A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.Pfizer filed the lawsuit in June 2010 after Mylan attempted to market a generic version of Sutent, patented until 2021.Sutent, which is approved for use in advanced kidney cancer, gastrointestinal and pancreatic tumors, raked in sales of about $578 million in the first half of this year.  The case is Pfizer Inc v. Mylan Pharmaceuticals Inc, U.S. District Court, District of Delaware, No. 10-cv-00528-GMS.   (Reporting by Natalie Grover in Bangalore; Editing by Don Sebastian)",2014-10-23,MYL,"Thu Oct 23, 2014 | 9:00am EDT",U.S. court upholds patents on Pfizer's cancer drug,http://www.reuters.com//article/us-pfizer-mylan-cancer-idUSKCN0IC1I520141023?type=companyNews
64,"  Oct 23 A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.Pfizer filed the lawsuit in June 2010 after Mylan attempted to market a generic version of Sutent, patented until 2021. Sutent, which is approved for use in advanced kidney cancer, gastrointestinal and pancreatic tumors, raked in sales of about $578 million in the first half of this year.  The case is Pfizer Inc v. Mylan Pharmaceuticals Inc, U.S. District Court, District of Delaware, No. 10-cv-00528-GMS.   (Reporting by Natalie Grover in Bangalore; Editing by Don Sebastian)",2014-10-23,MYL,"Thu Oct 23, 2014 | 8:57am EDT",U.S. court upholds patents on Pfizer's cancer drug,http://www.reuters.com//article/pfizer-mylan-cancer-idUSL3N0SI54R20141023?type=companyNews
65,"  Oct 27 A U.S. court ruled Mylan Inc  infringed the Medicines Co's patent on its blood-clot-inhibitor Angiomax, according to a court filing on Monday.The Medicines Co filed the lawsuit in February 2011 against Mylan's proposed bivalirudin drug, which Medicines said infringed its patent on Angiomax. Mylan had argued that several of Medicines Co's patent claims were invalid.The U.S. District Court for northern Illinois rejected Mylan's contention, saying it failed to provide ""clear and convincing"" evidence that Medicines Co's patent claims were invalid or unenforceable.""We are highly satisfied with the Illinois Court's ruling, which supports our ongoing conviction to defend these patents vigorously,"" Medicines Co Chief Executive Officer Clive Meanwell said in a statement. Mylan planned to manufacture and sell the generic version of Angiomax before the patent expires in January 2028. Angiomax, an injectable drug, was approved by U.S. Food and Drug Administration in December 2000 to be used as an anticoagulant in conjunction with aspirin for patients undergoing angioplasty.Angiomax accounted for 87 percent of the total revenue reported by Medicines Co for the quarter ending September 2014. Mylan officials were not immediately available for comment.The case is in the U.S. District Court Northern District of Illinois Eastern Division, The Medicines company vs Mylan Inc, Mylan Pharmaceuticals Inc and Bioniche Pharma USA,LLC, case no: 11-cv-1285   (Reporting by Anjali Rao Koppala in Bangalore; Editing by Cynthia Osterman)",2014-10-28,MYL,"Mon Oct 27, 2014 | 8:26pm EDT",Medicines Co wins patent infringement suit against Mylan,http://www.reuters.com//article/medicines-mylan-lawsuit-idUSL4N0SM6I620141028?type=companyNews
66,"   By Jan Strupczewski | BRUSSELS  BRUSSELS The European Commission approved on Wednesday the acquisition of Abbot Laboratories'  non-U.S. Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM) by the U.S. based producer of generic pharmaceuticals Mylan Inc, subject to conditions.Abbott EPD-DM is a Swiss-based manufacturer focused on distributing branded ex-originator products with expired patents. It has internal production capabilities in Europe, Canada and Japan. ""The decision is conditional upon the divestment of a number of Mylan's businesses in Germany, the United Kingdom, France, Ireland and Italy,"" the Commission, which is also the European Union's competition authority, said in a statement. ""The Commission had concerns that the transaction, as initially notified, would have reduced competition on the market for several medicines. The commitments offered by Mylan address these concerns,"" it said. Generic drugmaker Mylan Inc agreed in July to buy Abbott's  branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.",2015-01-28,MYL,"Wed Jan 28, 2015 | 3:34pm EST","EU approves Mylan purchase of Abbot generics, subject to conditions",http://www.reuters.com//article/abbott-mylan-eu-idUSL1N0V72DD20150128?type=companyNews
67,"  BRUSSELS Jan 28 The following are mergers under review by the European Commission and a brief guide to the EU merger process:APPROVALS AND WITHDRAWALS -- Generic drugmaker Mylan Inc to purchase Abbot Laboratories' specialty and branded generics business outside the United States (approved Jan. 28)-- Swiss drugmaker Novartis to acquire British peer GlaxoSmithKline's oncology products (approved Jan. 28)-- British drugmaker GlaxoSmithKline to acquire Novartis' vaccines business, excluding flu, and the setting up of a consumer healthcare joint venture (approved Jan. 28)NEW LISTINGS NoneEXTENSIONS AND OTHER CHANGES NoneFIRST-STAGE REVIEWS BY DEADLINE JAN 28 -- French chemicals producer Arkema to purchase Blu-Tack maker Bostik from French oil major Total  (notified Dec. 12/deadline Jan. 28)FEB 5 -- Belgian telecoms group Telenet to acquire 50 percent stake in Belgian broadcasting company De Vijver Media (notified Aug. 18/deadline extended for the second time to March 5 from Feb. 5)FEB 9 -- Proposed joint venture for 1 gigawatt ""Nemo"" power link between Belgium and Britain between Britain's National Grid  and Belgium's transmission system operator Elia  (notified Jan. 5/deadline Feb. 9/simplified)FEB 12 -- European private equity firm CVC Capital Partners   to buy Finnish insulation material maker Paroc  for enterprise value of some 700 million euros. (notified Jan. 8/deadline Feb. 12)FEB 13  -- German conglomerate Siemens to purchase U.S. oilfield equipment maker Dresser-Rand Group Inc  (notified Jan. 9/deadline Feb. 13)-- Japanese building materials and housing equipment group LIXIL Group Corp to take sole control of sanitory fittings group Grohe (notified Jan. 9/deadline Feb 13/simplified)FEB 16 -- Private equity firm Bain Capital to acquire British brickmaker Ibstock Group from Irish buidling supplies group CRH  (notified Jan. 12/deadline Feb. 16/simplified)FEB 17 -- Private equity firm Apax Partners to acquire Scandinavian IT services provider Evry (notified Jan. 13/deadline Feb. 17/simplified)FEB 18 -- Canadian asset manager Brookfield Infrastructure Fund  to acquire broadcasting and wireless telecom infrastructure platform operator TDF S.A.S.(notified Jan. 14/deadline Feb. 18/simplified)FEB 19 -- Swiss telecoms provider Swisscom and car leasing company Sixt to set up a joint venture (notified Jan. 15/deadline Feb. 19/simplified) FEB 20 -- French minerals company Imerys to acquire rival S&B Minerals (notified Jan. 15/deadline Feb. 20)FEB 23 -- U.S. conglomerate General Electric to acquire most of French engineering group Alstom's power equipment business (notified Jan. 19/deadline Feb. 23)-- Commodities trader Cargill to buy rival Archer Daniels Midland Co's global chocolate business (notified Jan. 19/deadline Feb. 23)-- German DIY retailer OBI to acquire a joint venture led by Brico Business Cooperation (notified Jan. 19/deadline Feb. 23/simplified)FEB 25 -- Asset manager The Carlyle Group and private equity firm Warburg Pincus to jointly acquire control of credit rating agency DBRS Holdings (notified Jan. 21/deadline Feb. 25/simplified)FEB 26 -- German car parts maker ZF Friedrichshafen to buy U.S. peer TRW Automotive Holdings Corp (notified Jan. 22/deadline Feb. 26) FEB 27 -- Canadian private equity firm Onex Corp to acquire aseptic filler machines maker SIG Combibloc Group AG  and SIG Holding USA (notified Jan. 23/deadline Feb. 27/simplified)MARCH 5 -- Belgian telecoms group Telenet, which is a subsidiary of U.S. cable group Liberty Global, to acquire 50 percent stake in Belgian broadcasting company De Vijver Media (notified Aug. 18/deadline extended for the second time to March 5 from Feb. 5/companies submitted concessions on Nov. 24)APRIL 22 -- SOCAR, Azerbaijan's state energy company, to buy stakes in Greek natural gas grid operator DESFA from Greek natural gas utility DEPA (notified Oct. 1/deadline extended for the second time to April 22 from March 23)APRIL 30 -- French telecoms operator Orange to acquire Spanish provider Jazztel (notified Oct. 16/deadline extended to April 30 from April 24 after the Commission resumed its scrutiny after a four-day halt)MAY 13 -- Mondelez International Inc and competitor D.E Master Blenders to merge their coffee businesses in new company called Jacobs Douwe Egberts (notified Oct. 27/deadline extended for the third time to May 13 from May 6)MAY 29 -- PRS for Music Ltd (PRSfM), Foreningen Svenska Tonsattares Internationella Mysikbyra (Stim) and Gesellschaft fr musikalische Auffhrungs- und mechanische Vervielfltigungsrechte (Gema) to set up a joint venture to administer mechanical and performing rights (notified Nov. 28/deadline extended to May 29 from Jan. 14 after the Commission opened an in-depth probe)SUSPENDED -- U.S. orthopaedic products maker Zimmer Holdings  to acquire rival Biomet Inc (notified Aug. 29/deadline suspended from Dec. 2, 2014)GUIDE TO EU MERGER PROCESS DEADLINES: The European Commission has 25 working days after a deal is  filed for a first-stage review. It may extend that by 10 working days to 35 working days, to consider either a company's proposed remedies or an EU member state's request to handle the case.Most mergers win approval but occasionally the Commission  opens a detailed second-stage investigation for up to 90  additional working days, which it may extend to 105 working  days.SIMPLIFIED: Under the simplified procedure, the Commission announces the clearance of uncontroversial first-stage mergers without giving any reason for its decision. Cases may be reclassified as non-simplified - that is, ordinary first-stage reviews - until they are approved.   (Editing by Foo Yun Chee)",2015-01-28,MYL,"Wed Jan 28, 2015 | 1:21pm EST",EU mergers and takeovers (Jan 28),http://www.reuters.com//article/eu-mergers-idUSL6N0V74WY20150128?type=companyNews
68,"  BRUSSELS The European Commission approved on Wednesday the acquisition of Abbot Laboratories' (ABT.N) non-U.S. Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM) by the U.S. based producer of generic pharmaceuticals Mylan Inc (MYL.O), subject to conditions.Abbott EPD-DM is a Swiss-based manufacturer focused on distributing branded ex-originator products with expired patents. It has internal production capabilities in Europe, Canada and Japan.""The decision is conditional upon the divestment of a number of Mylan's businesses in Germany, the United Kingdom, France, Ireland and Italy,"" the Commission, which is also the European Union's competition authority, said in a statement. ""The Commission had concerns that the transaction, as initially notified, would have reduced competition on the market for several medicines. The commitments offered by Mylan address these concerns,"" it said.  Generic drugmaker Mylan Inc agreed in July to buy Abbott's  branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.  (Reporting By Jan Strupczewski)",2015-01-28,MYL,"Wed Jan 28, 2015 | 11:37am EST","EU approves Mylan purchase of Abbot generics, subject to conditions",http://www.reuters.com//article/us-abbott-mylan-eu-idUSKBN0L120W20150128?type=companyNews
69,"  BRUSSELS Jan 28 The European Commission approved on Wednesday the acquisition of Abbot Laboratories'  non-U.S. Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM) by the U.S. based producer of generic pharmaceuticals Mylan Inc, subject to conditions.Abbott EPD-DM is a Swiss-based manufacturer focused on distributing branded ex-originator products with expired patents. It has internal production capabilities in Europe, Canada and Japan. ""The decision is conditional upon the divestment of a number of Mylan's businesses in Germany, the United Kingdom, France, Ireland and Italy,"" the Commission, which is also the European Union's competition authority, said in a statement. ""The Commission had concerns that the transaction, as initially notified, would have reduced competition on the market for several medicines. The commitments offered by Mylan address these concerns,"" it said. Generic drugmaker Mylan Inc agreed in July to buy Abbott's  branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.   (Reporting By Jan Strupczewski)",2015-01-28,MYL,"Wed Jan 28, 2015 | 11:30am EST","EU approves Mylan purchase of Abbot generics, subject to conditions",http://www.reuters.com//article/abbott-mylan-eu-idUSL6N0V749L20150128?type=companyNews
70,"  Mylan Inc (MYL.O) said it would buy Indian drugmaker Famy Care Ltd's female health businesses for about $750 million in cash and $50 million in contingent payments to expand its line of women's health products.Mumbai-based Famy Care is a leader in generic oral contraceptives. Monday's announcement marks Mylan's second deal with an Indian drugmaker after it bought Bangalore-based Strides Arcolab's injectable drugs unit for $1.6 billion in 2013.U.S.-based pharmaceutical giants have in recent years been trying to woo drugmakers in fast-growing emerging markets to reap the benefits of cheaper production facilities. Famy Care, which also makes intra-uterine devices and hormone-replacement therapy products, will spin off some businesses into a separate company, which will then be bought by Mylan, the companies said in a statement.The companies already have a partnership stretching back to 2008, under which Famy Care makes and supplies oral contraceptive pills that Mylan sells in the United States. Mylan said it expects the deal to close in the second half of 2015 and to complement its pending acquisition of Abbott Laboratories' (ABT.N) non-U.S. generics business.  (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza and Simon Jennings)",2015-02-02,MYL,"Mon Feb 2, 2015 | 7:53am EST",Mylan buys female health businesses from Indian drugmaker,http://www.reuters.com//article/us-mylan-famycare-m-a-idUSKBN0L612820150202?type=companyNews
71,"  (Adds details, background)Feb 2 Mylan Inc said it would buy Indian drugmaker Famy Care Ltd's female health businesses for about $750 million in cash and $50 million in contingent payments to expand its line of women's health products.Mumbai-based Famy Care is a leader in generic oral contraceptives. Monday's announcement marks Mylan's second deal with an Indian drugmaker after it bought Bangalore-based Strides Arcolab's injectable drugs unit for $1.6 billion in 2013. U.S.-based pharmaceutical giants have in recent years been trying to woo drugmakers in fast-growing emerging markets to reap the benefits of cheaper production facilities. Famy Care, which also makes intra-uterine devices and hormone-replacement therapy products, will spin off some businesses into a separate company, which will then be bought by Mylan, the companies said in a statement. The companies already have a partnership stretching back to 2008, under which Famy Care makes and supplies oral contraceptive pills that Mylan sells in the United States.Mylan said it expects the deal to close in the second half of 2015 and to complement its pending acquisition of Abbott Laboratories' non-U.S. generics business.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza and Simon Jennings)",2015-02-02,MYL,"Mon Feb 2, 2015 | 7:52am EST",UPDATE 1-Mylan buys female health businesses from Indian drugmaker,http://www.reuters.com//article/mylan-famycare-ma-idUSL4N0VC4I920150202?type=companyNews
72,"  Feb 2 Mylan Inc said it would buy Indian drugmaker Famy Care Ltd's female health businesses to expand its line of women's health products.The U.S. drugmaker will pay $750 million in cash and $50 million in contingent payments, the companies said in a statement.  Mylan expects the deal to add to its profits in 2015.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza) ",2015-02-02,MYL,"Mon Feb 2, 2015 | 6:59am EST",Mylan buys female health businesses from Indian drugmaker,http://www.reuters.com//article/mylan-famycare-ma-idUSL4N0VC4HH20150202?type=companyNews
73,"  Generic and specialty drugmaker Mylan Inc reported a rise in quarterly profit and revenue, driven mainly by strong demand for its generics in North America.Net profit attributable to the company's common shareholders rose to $189.2 million, or 47 cents per share, in the fourth quarter ended Dec. 31, from $180.2 million, or 45 cents per share, a year earlier.Revenue rose 15 percent to $2.08 billion. The company, last week, completed its acquisition of some of Abbott Laboratories' non-U.S. businesses, clearing the way for Mylan to cut its tax bill by shifting its tax base to the Netherlands.   (Reporting by Natalie Grover in Bengaluru; Editing by Simon Jennings)",2015-03-02,MYL,"Mon Mar 2, 2015 | 4:32pm EST",Drugmaker Mylan's fourth-quarter profit rises on strong demand in North America,http://www.reuters.com//article/us-mylan-results-idUSKBN0LY2EP20150302?type=companyNews
74,"  March 2 Generic and specialty drugmaker Mylan Inc reported a rise in quarterly profit and revenue, driven mainly by strong demand for its generics in North America.Net profit attributable to the company's common shareholders rose to $189.2 million, or 47 cents per share, in the fourth quarter ended Dec. 31, from $180.2 million, or 45 cents per share, a year earlier. Revenue rose 15 percent to $2.08 billion.  The company, last week, completed its acquisition of some of Abbott Laboratories' non-U.S. businesses, clearing the way for Mylan to cut its tax bill by shifting its tax base to the Netherlands.    (Reporting by Natalie Grover in Bengaluru; Editing by Simon Jennings)",2015-03-02,MYL,"Mon Mar 2, 2015 | 4:29pm EST",Drugmaker Mylan's 4th-qtr profit rises on strong demand in N. America,http://www.reuters.com//article/mylan-results-idUSL4N0W45PY20150302?type=companyNews
75,"  (Adds detail, background, CEO comment, shares)March 2 U.S. generic drug maker Mylan Inc  is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week.Chief Executive Heather Bresch, on a call after the company posted fourth-quarter results on Monday, raised the prospect of another ""material transaction"" by the end of 2015. She did not offer details.The company forecast 2015 revenue of $9.6 billion to $10.1 billion and adjusted earnings of $4 to $4.30 per share. Analysts on average expect revenue of $9.8 billion and a profit of $4.16 per share for the year.In February, Mylan, which also sells specialty products, said it would buy privately held Indian drugmaker Famy Care Ltd's female health businesses. The company said it still expects to launch a generic version of Teva Pharmaceutical Industries Ltd's  top-selling multiple sclerosis drug, Copaxone, in the second half of the year, despite a U.S. Supreme Court ruling in favor of Teva in January.Net profit attributable to the company's common shareholders rose to $189.2 million, or 47 cents per share, in the fourth quarter, from $180.2 million, or 45 cents per share, a year earlier. Excluding special items, the company earned $1.05 per share, matching the average analyst estimate, according to Thomson Reuters I/B/E/S.Revenue rose 15 percent to $2.08 billion, edging past the Wall Street estimate of about $2.06 billion. The Abbott deal, unveiled in July, allowed Mylan to purchase Abbott's specialty and generics business in developed markets outside the United States, as well as move its tax address to the Netherlands.Mylan's stock was marginally down at $56.80 on the Nasdaq in extended trade.(Reporting by Natalie Grover in Bengaluru; Editing by Simon Jennings and Steve Orlofdky)",2015-03-03,MYL,"Mon Mar 2, 2015 | 7:23pm EST","UPDATE 1-Mylan still on the prowl for deals, perhaps one by end 2015",http://www.reuters.com//article/mylan-results-idUSL4N0W46E720150303?type=companyNews
76,"   By Bill Berkrot  Generic drugmaker Mylan NV has offered to buy Perrigo Co Plc for about $29 billion in cash and stock, a deal that would make Mylan a major player in over-the-counter consumer products and extend its geographic reach.Mylan's disclosure on Wednesday set off fresh speculation in an already hot market for healthcare deals. Some industry watchers questioned whether Mylan sought to fend off unwanted takeover advances from larger rival Israel-based Teva Pharmaceutical Industries. Others said the offer could spur competing bids for Perrigo.   Mylan offered to buy the Ireland-based company for $205 per share. That represents more than a 25 percent premium over Perrigo's April 3 closing price, the last trading day before Mylan made its offer in an April 6 letter to Perrigo Chief Executive Joseph Papa.Perrigo shares initially jumped well above the offer price to $215.72, but closed up 18.4 percent at $195, indicating some investor skepticism that the deal will happen. Mylan shares rose 15 percent to $68.36, while Teva's U.S.-listed shares gained 3.5 percent.""People think that this is going to flush out a Teva bid for Mylan,"" said Stifel Nicolaus analyst Annabel Samimy. ""If that's the case, then this bid for Perrigo is not going to go through."" She noted that Mylan provided very few details of the offer, including how much would be cash and how much in stock.Mylan Executive Chairman Robert Coury said the two companies have held several discussions about a proposed merger. Perrigo confirmed that it had received an unsolicited offer from Mylan and said its board would meet to discuss the proposal.Perrigo, with a large and attractive portfolio of OTC consumer products, infant formulas and a line of generic topical pharmaceutical medicines, has long been seen as a takeover target. Combined, Perrigo and Mylan had sales of about $15.3 billion in 2014. ""What will be interesting to see is if we end up in a bidding war,"" said Morningstar analyst Michael Waterhouse. He suggested Teva, the world's largest maker of generic drugs, and serial acquirer Valeant Pharmaceuticals International as potential rival bidders for Perrigo.Samimy mentioned Novartis's Sandoz generic unit as a possible Perrigo bidder. ""They've said in the past that they need to get bigger or get out.""Teva, Novartis and Valeant all declined to comment on the speculation. BIGGEST DEAL OF THE YEAR? The proposed $29 billion deal would the largest in the healthcare sector announced this year, ahead of AbbVie Inc's nearly $21 billion deal for Pharmacyclics Inc and Pfizer Inc's planned $16.7 billion purchase of Hospira Inc, according to Thomson Reuters data. (For a graphic, see: link.reuters.com/waf54w)It is further evidence that the appetite for healthcare acquisitions continues unabated. Generic drugmakers are looking to get bigger and gain access to product lines with higher profit margins and pharmaceutical companies seek to bolster their development pipelines by acquiring potentially lucrative specialty medicines, such as for cancer and rare diseases. Medical device makers have also sought to expand product portfolios through acquisitions.  Several potential deals in which U.S. healthcare companies sought to buy overseas assets to benefit from lower tax rates were shelved in 2014 after the U.S. Treasury issued tougher rules on such purchases.         AbbVie, for example, scuttled a $55 billion purchase of Ireland's Shire Plc. But both companies have since pursued new deals. AbbVie won a three-way bidding war for Pharmacyclics and Shire bought NPS Pharmaceuticals for more than $5 billion.Mylan has been at the center of deal speculation as  Actavis, one of its main rivals, swallows up companies to expand beyond generic medicines, including a $67 billion purchase of Botox-maker Allergan last year. Just last month, Mylan CEO Heather Bresch raised the prospect of another ""material transaction"" by the end of 2015.""Assuming Mylan can get to the finish line with this, they'd be a heck of a lot bigger in Europe,"" said CRT Capital Group analyst Timothy Chiang. Perrigo recently bulked up with a $4.5 billion purchase of Belgium-based OTC drugmaker Omega Pharma.Both Mylan and Perrigo had previously undertaken so-called inversion deals to gain lower tax rates.Mylan's $5.3 billion acquisition of Abbott Laboratories' overseas generic drugs business allowed it to move its corporate headquarters to the Netherlands. In 2013, Perrigo bought Irish drugmaker Elan for $6.7 billion and rebased from Michigan to Ireland. (Additional reporting by Caroline Humer in New York and Ankur Banerjee in Bengaluru; Editing by Don Sebastian, Bernard Orr)",2015-04-08,MYL,"Wed Apr 8, 2015 | 5:01pm EDT",Generic drugmaker Mylan offers $29 billion for Perrigo,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-idUSKBN0MZ1OX20150408?type=companyNews
77,"  (Adds healthcare merger activity, Perrigo confirms offer, analyst comment)By Bill BerkrotApril 8 Generic drugmaker Mylan NV has offered to buy Perrigo Co Plc for about $29 billion in cash and stock, a deal that would make Mylan a major player in over-the-counter consumer products and extend its geographic reach.Mylan's disclosure on Wednesday set off fresh speculation in an already hot market for healthcare deals. Some industry watchers questioned whether Mylan sought to fend off unwanted takeover advances from larger rival Israel-based Teva Pharmaceutical Industries. Others said the offer could spur competing bids for Perrigo.Mylan offered to buy the Ireland-based company for $205 per share. That represents more than a 25 percent premium over Perrigo's April 3 closing price, the last trading day before Mylan made its offer in an April 6 letter to Perrigo Chief Executive Joseph Papa.Perrigo shares initially jumped well above the offer price to $215.72, but closed up 18.4 percent at $195, indicating some investor skepticism that the deal will happen. Mylan shares rose 15 percent to $68.36, while Teva's U.S.-listed shares gained 3.5 percent.""People think that this is going to flush out a Teva bid for Mylan,"" said Stifel Nicolaus analyst Annabel Samimy. ""If that's the case, then this bid for Perrigo is not going to go through.""She noted that Mylan provided very few details of the offer, including how much would be cash and how much in stock.Mylan Executive Chairman Robert Coury said the two companies have held several discussions about a proposed merger. Perrigo confirmed that it had received an unsolicited offer from Mylan and said its board would meet to discuss the proposal. Perrigo, with a large and attractive portfolio of OTC consumer products, infant formulas and a line of generic topical pharmaceutical medicines, has long been seen as a takeover target.Combined, Perrigo and Mylan had sales of about $15.3 billion in 2014.""What will be interesting to see is if we end up in a bidding war,"" said Morningstar analyst Michael Waterhouse. He suggested Teva, the world's largest maker of generic drugs, and serial acquirer Valeant Pharmaceuticals International  as potential rival bidders for Perrigo.Samimy mentioned Novartis's Sandoz generic unit as a possible Perrigo bidder. ""They've said in the past that they need to get bigger or get out."" Teva, Novartis and Valeant all declined to comment on the speculation.BIGGEST DEAL OF THE YEAR? The proposed $29 billion deal would the largest in the healthcare sector announced this year, ahead of AbbVie Inc's  nearly $21 billion deal for Pharmacyclics Inc  and Pfizer Inc's planned $16.7 billion purchase of Hospira Inc, according to Thomson Reuters data. (For a graphic, see: link.reuters.com/waf54w) It is further evidence that the appetite for healthcare acquisitions continues unabated. Generic drugmakers are looking to get bigger and gain access to product lines with higher profit margins and pharmaceutical companies seek to bolster their development pipelines by acquiring potentially lucrative specialty medicines, such as for cancer and rare diseases. Medical device makers have also sought to expand product portfolios through acquisitions.Several potential deals in which U.S. healthcare companies sought to buy overseas assets to benefit from lower tax rates were shelved in 2014 after the U.S. Treasury issued tougher rules on such purchases.AbbVie, for example, scuttled a $55 billion purchase of Ireland's Shire Plc. But both companies have since pursued new deals. AbbVie won a three-way bidding war for Pharmacyclics and Shire bought NPS Pharmaceuticals for more than $5 billion.Mylan has been at the center of deal speculation as  Actavis, one of its main rivals, swallows up companies to expand beyond generic medicines, including a $67 billion purchase of Botox-maker Allergan last year.Just last month, Mylan CEO Heather Bresch raised the prospect of another ""material transaction"" by the end of 2015.""Assuming Mylan can get to the finish line with this, they'd be a heck of a lot bigger in Europe,"" said CRT Capital Group analyst Timothy Chiang. Perrigo recently bulked up with a $4.5 billion purchase of Belgium-based OTC drugmaker Omega Pharma.Both Mylan and Perrigo had previously undertaken so-called inversion deals to gain lower tax rates.Mylan's $5.3 billion acquisition of Abbott Laboratories'  overseas generic drugs business allowed it to move its corporate headquarters to the Netherlands. In 2013, Perrigo bought Irish drugmaker Elan for $6.7 billion and rebased from Michigan to Ireland.   (Additional reporting by Caroline Humer in New York and Ankur Banerjee in Bengaluru; Editing by Don Sebastian, Bernard Orr)",2015-04-08,MYL,"Wed Apr 8, 2015 | 4:59pm EDT",UPDATE 3-Generic drugmaker Mylan offers $29 bln for Perrigo,http://www.reuters.com//article/perrigo-company-ma-mylan-idUSL4N0X54F520150408?type=companyNews
78,"  * Fed minutes indicate rate hike in 2015; members differ on month* Mylan jumps after offering to buy Perrigo for about $29 bln* Alcoa flat in extended trading after results* Indexes up: Dow 0.2 pct, S&P 0.3 pct, Nasdaq 0.8 pct   (Updates to market close, Alcoa results)By Ryan VlastelicaNEW YORK, April 8 U.S. stocks ended a volatile session with modest gains on Wednesday after minutes from a U.S. Federal Reserve meeting indicated that the central bank remained on track for a interest rate hike this year.Major indexes moved between negative territory and session highs after the news as traders parsed the minutes for clues as to when the first rise could occur. Some Fed participants went on record saying they expected upcoming economic data would warrant an initial rate increase in June, while others anticipated a hike later in 2015 due to recent strength in the U.S. dollar. Market participants had been expecting the first rate hike to come in September or later, with last week's much weaker-than-expected March payroll report pointing to slowing growth. The central bank has said it would only raise rates when data suggests the economy is strong enough to withstand it.""June would come as a surprise,"" said Alan Gayle, senior investment strategist and director of asset allocation at RidgeWorth Investments in Atlanta, Georgia. ""If the Fed moves monetary policy in an arbitrarily fast manner, that would be a detriment for stocks.""Fed officials acknowledged risks from overseas and a weak start to the year at their March meeting but remained confident in the strength of the recovery, the minutes showed. Markets were supported boosted by merger activity in the healthcare sector, though the energy sector was weak as crude oil plunged.Mylan jumped 14.8 percent to $68.36 after the generic drugmaker offered to buy Perrigo Co for about $29 billion in cash and stock. Perrigo jumped 18.4 percent to $195. The two companies were the biggest percentage gainers on the S&P 500.U.S. crude futures dropped 6.6 percent to settle at $50.42 a barrel after U.S. Energy Information Administration data showed the largest weekly build in oil inventories since March 2001. The news offset Royal Dutch Shell's  $70 billion bid for rival BG Group. The S&P Energy index fell 1 percent while Exxon Mobil lost 2 percent to $84.06 and Chevron Corp  shed 1.7 percent to $106.66.The Dow Jones industrial average rose 27.09 points, or 0.15 percent, to 17,902.51, the S&P 500 gained 5.57 points, or 0.27 percent, to 2,081.9 and the Nasdaq Composite  added 40.59 points, or 0.83 percent, to 4,950.82.After the market closed, Alcoa Inc reported first-quarter revenue that was below expectations. The stock, which is viewed as the unofficial kick-off to the earnings season, was flat in extended trading.Advancing issues outnumbered declining ones on the NYSE by 1,847 to 1,163, for a 1.59-to-1 ratio on the upside; on the Nasdaq, 1,739 issues rose and 979 fell for a 1.78-to-1 ratio favoring advancers.The benchmark S&P 500 index was posting 12 new 52-week highs and no new lows; the Nasdaq Composite was recording 79 new highs and 29 new lows.About 5.68 billion shares traded on all U.S. platforms, according to BATS exchange data, below the month-to-date average of 6.25 billion.   (Editing by Meredith Mazzilli)",2015-04-08,MYL,"Wed Apr 8, 2015 | 4:27pm EDT",US STOCKS-Wall St ends with modest gains after Fed minutes,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0X526C20150408?type=companyNews
79,"  (Adds Mylan, ICBPI, Coinsetter, OneBeacon Insurance Group, Apollo Global Management)April 8 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:** Royal Dutch Shell agreed to buy smaller rival BG Group for $70 billion in the first oil super-merger in more than a decade to close the gap with the world's largest oil firm U.S. ExxonMobil after a plunge in prices.** Generic drugmaker Mylan NV said on Wednesday it has offered to buy Perrigo Co Plc for about $29 billion in a deal that would make Mylan a major player in over-the-counter consumer products and extend its geographic reach.** Canon Inc said it was extending the offer period for its proposed $2.7 billion takeover of Swedish video-surveillance firm Axis AB after falling short of its ownership goals, but stressed it would not be raising its bid.** The owners of Italy's Istituto Centrale delle Banche Popolari (ICBPI) plan to enter exclusive talks in May with the preferred bidder for the 2-billion euro ($2.2 billion) banking services provider, two sources close to the matter said on Wednesday.** Coinsetter, a New York-based bitcoin exchange that targets institutional and professional traders, said on Wednesday it has acquired Canadian Virtual Exchange, a bitcoin trading platform which recently shut down due to security breaches.** OneBeacon Insurance Group Ltd, a specialty insurer controlled by White Mountains Insurance Group Ltd, is considering a sale, Bloomberg reported, citing people familiar with the matter. ** Apollo Global Management is in talks to expand its business into the Middle East for the first time through a joint venture with a local investment firm, three sources aware of the matter told Reuters on Wednesday.** Zep Inc, a maker of maintenance and cleaning chemicals, agreed to be taken private by New Mountain Capital for about $692 million, including net debt.** German ATM maker Wincor Nixdorf has asked investment banks to come up with ideas to secure the future of the group, including a potential sale to a private equity group, two people familiar with the matter said.** French media conglomerate Vivendi is looking at a possible acquisition of pay-TV group Sky as one of several options to expand the reach of its own TV group Canal Plus, three sources familiar with the matter said. ** Chinese authorities have lifted a sales blockage on most apartments built by Kaisa Group Holdings Ltd, removing a key hurdle to the proposed sale of the troubled developer to larger peer Sunac China Holdings Ltd.** The executive board of Austrian real estate group Immofinanz recommended that its shareholders reject a 2.80 euro per share offer that rival CA Immo and its partner O1 Group made for a stake in the company.** Canadian insurer Manulife Financial Corp is close to an about $1 billion deal to sell products through Singapore lender DBS Group Holdings Ltd's branch network across Asia, a person with direct knowledge of the matter said. ** Indian e-retailer Snapdeal.com said it had bought online mobile recharge firm Freecharge for an undisclosed amount in a bid to boost its reach in the fast-growing mobile transactions business.** Polish financial group Getin Holding agreed to sell 96 percent in its Russian unit Idea Bank Rosja to Russia's Forus Bank and three private investors for an equivalent of 3.4 million zlotys ($916,516), Getin said late on Tuesday.** Singapore Telecommunications, Southeast Asia's largest telecommunications operator by revenue, is buying U.S.-based cyber-security firm Trustwave for $810 million, marking its biggest acquisition outside the main telecoms sector.** South Korean steelmaker Hyundai Steel said it has decided to acquire sister company Hyundai Hysco  on July 1 ""to enhance management efficiency"".** Bahrain Kuwait Insurance Co, the kingdom's largest insurer, has raised its stake in local peer Takaful International to 40.9 percent, a move that could herald the start of wider consolidation in the sector.** Private equity firms Blackstone Group LP and Corsair Capital are in talks to acquire a major stake in First Eagle Investment Management, valuing the company at around $4 billion, including debt, according to people familiar with the matter.** Discovery Communications Inc and private equity firm Providence Equity Partners were among four U.S. bidders expressing interest in South Korean cable TV firm C&M Co, a newspaper reported on Wednesday.($1 = 3.7097 zlotys)   (Compiled by Avik Das and Lehar Maan in Bengaluru)",2015-04-08,MYL,"Wed Apr 8, 2015 | 4:01pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N0X536F20150408?type=companyNews
80,"   By Saqib Iqbal Ahmed | NEW YORK  NEW YORK Perrigo Co Plc's (PRGO.N) options attracted an unusually large bullish bet days ahead of an offer from generic drugmaker Mylan NV (MYL.O) to buy the company, options data shows.On Wednesday, Mylan said it made a proposal to acquire Perrigo for about $29 billion in cash and stock, sending the Dublin, Ireland company's shares up by more than 30 percent to an all-time high of $215.73. Mylan shares rose as much as 16 percent to a high of $69.45. Options activity has been known to spike before the public announcement of deals and the U.S. Securities and Exchange Commission has in the past announced enforcement action for alleged insider trading involving options trading. On March 24, the volume in Perrigo's options, which on average trade less than 600 contracts a day, jumped to more than 4,700 contracts, driven by a large options bet on Perrigo shares rising sharply before mid-May. ""They were positioning for an upside move and they had their eye on a catalyst. It could have been earnings or it could have been some kind of deal talk, said optionMonster.com lead analyst David Russell.A trader appears to have bought 2,000 calls and sold the same number of puts, for a net payout of about $400,000, said Fred Ruffy, options strategist at WhatsTrading.com. Calls convey the right to buy the stock at a certain price in the future and puts impart the right to sell the stock at a fixed price at a future date.    The options were set to expire in May 15 and would capture Perrigo's third-quarter results on May 4. On Wednesday, the value of these calls jumped, at one point to as much as $6.8 million, according to Thomson Reuters data.   A spokeswoman for the Financial Industry Regulatory Authority, which oversees securities firms, declined to comment on the options activity. The U.S. Securities and Exchange Commission did not immediately respond to a request for comment. (Reporting by Saqib Iqbal Ahmed; editing by Andrew Hay)",2015-04-08,MYL,"Wed Apr 8, 2015 | 3:58pm EDT",Perrigo options attracted large bullish bet ahead of Mylan offer,http://www.reuters.com//article/us-perrigocompany-m-a-mylan-options-idUSKBN0MZ25G20150408?type=companyNews
81,"  * Fed minutes indicate rate hike in 2015, but members differ on month* Mylan jumps after offering to buy Perrigo for about $29 bln* Indexes up: Dow 0.2 pct, S&P 0.3 pct, Nasdaq 0.8 pct   (Updates with Fed minutes, changes byline)By Ryan VlastelicaNEW YORK, April 8 U.S. stocks rose on Wednesday, but trading was volatile following the release of minutes from the U.S. Federal Reserve that indicated the central bank remained on track for a rate hike this year.Major indexes initially fell after the release, as several Fed participants went on record saying they expected upcoming economic data would warrant an initial rate increase in June, which would be sooner than currently expected. Other participants anticipate a hike later in 2015 due to recent strength in the U.S. dollar. Market participants had been expecting the first rate hike to come in September or later, with the March payroll report, which came in sharply under expectations last week, pointing to slowing growth. The central bank has said it would only raise rates when data suggests the economy is strong enough to withstand it.""Recent comments suggested that the Fed was moving more towards September or later, based off some softer economic reports. June would come as a surprise,"" said Alan Gayle, senior investment strategist and director of asset allocation at RidgeWorth Investments in Atlanta, Georgia. ""If the Fed moves monetary policy in an arbitrarily fast manner, that would be a detriment for stocks.""Fed officials acknowledged risks from overseas and a weak start to the year at their March meeting but remained confident in the strength of the recovery, the minutes showed. Markets had been positive prior to the minutes, boosted by merger activity in the healthcare sector, though the energy sector was weak as crude oil plunged.Mylan jumped 17 percent to $69.94 after the generic drugmaker offered to buy Perrigo Co for about $29 billion in cash and stock. Perrigo jumped 20 percent to $197.75.  The two companies were the biggest gainers on the S&P 500. U.S. crude futures dropped 6.3 percent after U.S. Energy Information Administration data showed the largest weekly build in oil inventories since March 2001. The news offset Royal Dutch Shell's $70 billion bid for rival BG Group.The S&P Energy index fell 0.7 percent while Exxon Mobil lost 1.5 percent to $84.44 and Chevron Corp  shed 1.5 percent to $106.86.The Dow Jones industrial average rose 34.2 points, or 0.19 percent, to 17,909.62, the S&P 500 gained 5.9 points, or 0.28 percent, to 2,082.23 and the Nasdaq Composite  added 37.68 points, or 0.77 percent, to 4,947.91.Advancing issues outnumbered declining ones on the NYSE by 1,888 to 1,093, for a 1.73-to-1 ratio on the upside; on the Nasdaq, 1,727 issues rose and 958 fell for a 1.80-to-1 ratio favoring advancers.The benchmark S&P 500 index was posting 12 new 52-week highs and no new lows; the Nasdaq Composite was recording 67 new highs and 25 new lows.     (Editing by Meredith Mazzilli)",2015-04-08,MYL,"Wed Apr 8, 2015 | 2:54pm EDT",US STOCKS-Wall St rises in volatile trading after Fed minutes,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0X51VX20150408?type=companyNews
82,"  * Fed's Dudley keeps June rate hike on the table depending on data* Mylan jumps after offering to buy Perrigo for about $29 bln* Fed minutes due at 1800 GMT* Indexes up: Dow 0.2 pct, S&P 0.29 pct, Nasdaq 0.77 pct   (Adds details on Mylan deal, comment, updates prices)By Tanya AgrawalNEW YORK, April 8 U.S. stocks rose on Wednesday on merger activity in the healthcare sector even as energy stocks sold off after a large buildup in crude stockpiles sent oil futures reeling. Traders are keeping an eye out for the release of minutes from the Federal Open Market Committee's March policy meeting, in which the Fed downgraded its economic growth and inflation projections while leaving the door open to raising rates in the near future. The minutes are due at 2 p.m. EDT (1800 GMT).Mylan shares jumped 14.4 percent to $68.15, boosting the Nasdaq and the S&P healthcare sector, on news it offered to buy Perrigo for about $29 billion in cash and stock. Perrigo shares jumped 21.7 percent to $200.50.Biotech and pharmaceuticals have seen more than $60 billion in deals so far this year, the highest volume since 2009. Brent crude slid 4.5 percent and U.S. crude  lost 5.6 percent after data from the U.S. Energy Information Administration showed the largest weekly build in oil inventories since March 2001.""Expect to see a lot more consolidation in the energy sector,"" said Brian Amidei, managing director and partner at HighTower Advisors in California, referring to the state of smaller players after the sharp decline in oil prices in the past year.Energy stocks, which had been supported by Royal Dutch Shell's $70 billion bid for rival BG Group, fell sharply after the EIA data. At 12:49 p.m. EDT (1649 GMT) the Dow Jones industrial average rose 38.67 points, or 0.22 percent, to 17,914.09, the S&P 500 gained 5.93 points, or 0.29 percent, to 2,082.26, and the Nasdaq Composite added 37.49 points, or 0.76 percent, to 4,947.72.New York Fed President William Dudley said a June rate hike remains on the table, reiterating the Fed mantra that any tightening is data dependent.As the reporting season gains momentum, first-quarter S&P 500 earnings are projected to show a decline of 2.8 percent from a year earlier, which would be the worst comparatives since the third quarter of 2009.Advancing issues outnumbered declining ones on the NYSE by 1,762 to 1,176, for a 1.50-to-1 ratio on the upside; on the Nasdaq, 1,680 issues rose and 946 fell, for a 1.78-to-1 ratio favoring advancers.The benchmark S&P 500 index was posting 11 new 52-week highs and no new lows; the Nasdaq Composite was recording 60 new highs and 21 new lows.     (Additional reporting by Rodrigo Campos and Chuck Mikolajczak; Editing by Ted Botha)",2015-04-08,MYL,"Wed Apr 8, 2015 | 1:12pm EDT",US STOCKS-Wall St ticks up on M&A but energy weighs as crude drops,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0X51EE20150408?type=companyNews
83,"  * Fed's Dudley keeps June rate hike on the table depending on data* Mylan jumps after JPMorgan note hints at deal* Fed minutes due at 1800 GMT* Indexes up: Dow 0.15 pct, S&P 0.13 pct, Nasdaq 0.5 pct   (Updates prices, adds comment)By Rodrigo CamposNEW YORK, April 8 U.S. stocks pared initial gains to trade slightly higher on Wednesday as energy stocks sold off after a large buildup in crude stockpiles sent oil futures reeling. Brent slid 3.3 percent and U.S. crude lost more than 4 percent after data from the U.S. Energy Information Administration showed the largest weekly build in oil inventories since March 2001.Energy stocks, which had been supported by Royal Dutch Shell's $70 billion bid for rival BG Group, fell sharply after the EIA data.""It's a huge build so how are we looking at it - is it a slowdown in the economy? Certainly the market is feeling that,"" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. At 11:07 a.m. (1507 GMT) the Dow Jones industrial average  rose 26.19 points, or 0.15 percent, to 17,901.61, the S&P 500 gained 2.74 points, or 0.13 percent, to 2,079.07 and the Nasdaq Composite added 24.69 points, or 0.5 percent, to 4,934.92.Mylan jumped 6 percent to $63.12, boosting the Nasdaq, after JPMorgan analysts said in a note the merits from a potential merger between Teva Pharmaceutical and Mylan would be ""hard to ignore."" U.S.-traded Teva shares gained 0.4 percent to $64.49.Traders were keeping an eye out for the release of minutes from the Federal Open Market Committee's March policy meeting, in which the Fed downgraded its economic growth and inflation projections while leaving the door open to kick-start its tightening path, expected at 2 p.m. EDT (1800 GMT). New York Fed President William Dudley said Wednesday a June rate hike remains on the table, reiterating the Fed mantra that any tightening is data dependent.As the reporting season gains momentum, first-quarter S&P 500 earnings are projected to show a decline of 2.8 percent from a year earlier, which would be the worst comparatives since the third quarter of 2009.""We are waiting on earnings and all signs are that it is not going to be a great quarter,"" Saluzzi said. ""Whether it is weather or the dollar, you are going to see excuses like that being built into company reports.""Advancing issues outnumbered declining ones on the NYSE by 1,650 to 1,206, for a 1.37-to-1 ratio on the upside; on the Nasdaq, 1,557 issues rose and 973 fell for a 1.60-to-1 ratio favoring advancers.The benchmark S&P 500 index was posting 9 new 52-week highs and no new lows; the Nasdaq Composite was recording 46 new highs and 18 new lows.     (Additioal reporting by Tanya Agrawal and Chuck Mikolajczak; Editing by Meredith Mazzilli)",2015-04-08,MYL,"Wed Apr 8, 2015 | 11:28am EDT",US STOCKS-Wall St ticks up but energy weighs after crude drop,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0X51AF20150408?type=companyNews
84,"   By Danielle Robinson  NEW YORK, April 10 (IFR) - Drugmaker Mylan is at risk of dropping back into junk territory if it doesn't strike a perfect balance between bond and equity to finance its proposed US$30bn acquisition of healthcare supplier Perrigo, analysts warned.The Baa3/BBB- pharma has offered to buy Perrigo for US$205 a share in transaction valued at US$30bn, including assumed debt, and it may need to raise up to US$9bn to complete the acquisition.Analysts and rating agencies have been spooked by Mylan's decision not to divulge exactly how much debt and equity it plans to issue for the acquisition and warn that, at best, the deal will leave it teetering on the edge of junk.Late this week S&P put Mylan's BBB- rating on CreditWatch with negative implications, threatening its investment grade rating amid concerns that the merger ""could significantly increase debt leverage"".Moody's also rates Mylan at its lowest investment-grade rating of Baa3, which the pharma company achieved in late 2012 after years of struggling with high leverage due to acquisitions. KEEPING THE GRADE Mylan won its investment-grade status back then by publicly articulating a 3.0-times debt/EBITDA target.Even if the Perrigo acquisition financing has a 70-75% equity component, the combined company's total debt to EBITDA would soar to around 4.5-times, according to analysts. ""The company has repeatedly stated its commitment to investment grade, but...the cash/stock consideration will have a material impact on the degree of credit deterioration and potential agency actions,"" said CreditSight pharma credit analyst, Eric Axon.Axon believes Mylan could use a 25% debt, 75% equity financing split to pay for the acquisition and keep its investment grade rating, but only if it aggressively delevers over an 18-month period.That would imply taking on an additional US$7.2bn in debt, bringing total debt to US$19.897bn or 4.5-times EBITDA for the combined company and net leverage to US$16.05bn or 3.6-times. Shubhomoy Mukherjee, credit strategist at Barclays, also believes that Mylan could issue between US$7.5bn-US$9bn and still maintain its BBB- rating, as long as it achieves about US$500m of synergies from the acquisition and rapidly delevers over 18-24 months.Under Mukherjee's calculations, that would imply a 70% equity mix in the financings. Despite the significant dilution implications of such a high equity component, Mukherjee believes Mylan can pull it off.""We think it could reduce the resulting equity dilution by financing a portion of the consideration with mandatorily convertible preferreds, which could get 100% equity credit from the rating agencies,"" said Mukherjee.For the time being, bond investors are sitting tight. Mylan's bonds have already been trading at a 7-12% discount to other low BBB healthcare credits like Actavis and Perrigo, in expectation that it would seek a major acquisition this year.""Given the possibility of Mylan's issuing US$7.5bn-US$9bn to fund this transaction and meaningfully increasing leverage, we expect Mylan bonds to re-price another 10bp wider,"" said Mukherjee.   (Reporting By Danielle Robinson; Editing Paul Kilby)",2015-04-10,MYL,"Fri Apr 10, 2015 | 4:03pm EDT",Perrigo acquisition could threaten Mylan's investment grade,http://www.reuters.com//article/markets-uscorpbonds-idUSL2N0X71LB20150410?type=companyNews
85,"   By Anjali Rao  Koppala  Drugmaker Mylan N.V said it settled a patent litigation with Pfizer Inc related to Viagra, paving the way for the launch of the drug's generic version in the United States once approved.Mylan said on Monday that the settlement would allow it to launch Sildenafil Citrate by December 2017, or sooner under certain conditions, subject to approval by the U.S. Food and Drug Administration. Pfizer's patent for Viagra, used to treat erectile dysfunction, expires in 2020.Mylan did not disclose other terms of the settlement, citing confidentiality, and added that the settlement and license agreement was subject to review by the U.S. Department of Justice and the Federal Trade Commission. Mylan said Viagra had U.S. sales of about $1.3 billion last year according to IMS Health. Mylan's Sildenafil Citrate is currently sold in 11 European countries.Pfizer's shares closed down marginally at $35.09, after touching an 11-year high on Monday. Mylan's shares closed down 2.4 percent at $68.56.",2015-04-13,MYL,"Mon Apr 13, 2015 | 5:04pm EDT",Mylan settles Viagra patent litigation with Pfizer,http://www.reuters.com//article/mylan-litigation-pfizer-idUSL2N0XA26J20150413?type=companyNews
86,"  Drugmaker Mylan N.V said it settled a patent litigation with Pfizer Inc related to Viagra, paving the way for the launch of the drug's generic version in the United States once approved.Mylan said on Monday that the settlement would allow it to launch Sildenafil Citrate by December 2017, or sooner under certain conditions, subject to approval by the U.S. Food and Drug Administration.Pfizer's patent for Viagra, used to treat erectile dysfunction, expires in 2020.Mylan did not disclose other terms of the settlement, citing confidentiality, and added that the settlement and license agreement was subject to review by the U.S. Department of Justice and the Federal Trade Commission. Mylan said Viagra had U.S. sales of about $1.3 billion last year according to IMS Health. Mylan's Sildenafil Citrate is currently sold in 11 European countries.Pfizer's shares closed down marginally at $35.09, after touching an 11-year high on Monday. Mylan's shares closed down 2.4 percent at $68.56.  (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Savio D'Souza)",2015-04-13,MYL,"Mon Apr 13, 2015 | 4:37pm EDT",Mylan settles Viagra patent litigation with Pfizer,http://www.reuters.com//article/us-mylan-litigation-pfizer-idUSKBN0N423K20150413?type=companyNews
87,"  (Adds details from statement, background on drug, shares)April 13 Drugmaker Mylan N.V said it settled a patent litigation with Pfizer Inc related to Viagra, paving the way for the launch of the drug's generic version in the United States once approved.Mylan said on Monday that the settlement would allow it to launch Sildenafil Citrate by December 2017, or sooner under certain conditions, subject to approval by the U.S. Food and Drug Administration. Pfizer's patent for Viagra, used to treat erectile dysfunction, expires in 2020.Mylan did not disclose other terms of the settlement, citing confidentiality, and added that the settlement and license agreement was subject to review by the U.S. Department of Justice and the Federal Trade Commission. Mylan said Viagra had U.S. sales of about $1.3 billion last year according to IMS Health. Mylan's Sildenafil Citrate is currently sold in 11 European countries.Pfizer's shares closed down marginally at $35.09, after touching an 11-year high on Monday. Mylan's shares closed down 2.4 percent at $68.56.   (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Savio D'Souza)",2015-04-13,MYL,"Mon Apr 13, 2015 | 4:37pm EDT",UPDATE 1-Mylan settles Viagra patent litigation with Pfizer,http://www.reuters.com//article/mylan-litigation-pfizer-idUSL4N0XA5EZ20150413?type=companyNews
88,"   By Bill Berkrot  Generic drugmaker Mylan NV moved quickly on Friday to pour cold water on published reports that Teva Pharmaceuticals Industries is considering a bid to acquire it.Mylan last week announced a $29 billion offer to buy Perrigo Co Plc in a move that some analysts suggested was a tactic to help fend off an acquisition by larger rival Teva.Mylan Executive Chairman and former Chief Executive Officer Robert Coury said the Perrigo plans remain on track.""Mylan is fully committed to its stand-alone strategy, including its proposal to acquire Perrigo, and today's speculation has no impact whatsoever on this strategy,"" Coury said in a statement. ""We have studied the potential combination of Mylan and Teva for some time and we believe it is clear that such a combination is without sound industrial logic or cultural fit. Further, there would be significant overlap in the companies' businesses and we believe that it is unlikely that any such combination could obtain antitrust regulatory clearances,"" Coury said.Teva spokeswoman Denise Bradley declined to comment on the rumor that the world's largest generic drugmaker was considering a bid for Mylan. The speculation was reported by Bloomberg and the Wall Street Journal.Teva has not made a formal approach to Mylan, Bloomberg reported. ""Of course, should any party make an actual offer to acquire Mylan, the board would carefully consider it in exercising its fiduciary duties in the best interests of the company, our stockholders and other stakeholders,"" Coury said.Israel-based Teva has a market value of about $64.4 billion and annual revenue of about $20 billion. Mylan, which moved its headquarters from Pittsburgh to the Netherlands in a so-called inversion deal to take advantage of lower taxes outside the United States, has a market value of about $32.7 billion and annual revenue of about $7.7 billion. A Mylan/Perrigo combination would have annual revenue of about $15 billion.Mylan shares were up 4.3 percent at $69.72 on a sharply down day for the broader markets, while Teva shares trading in New York were up 2 percent at $64.72. Shares of Perrigo were down 1.6 percent at $195.79. (Additional reporting by Reporting by Ankur Banerjee in Bengaluru; Editing by Savio D'Souza and Jonathan Oatis)",2015-04-17,MYL,"Fri Apr 17, 2015 | 3:32pm EDT",Mylan says merger with Teva would be bad fit,http://www.reuters.com//article/us-mylan-m-a-teva-pharm-ind-idUSKBN0N826E20150417?type=companyNews
89,"  (Recasts with Mylan comment, adds Teva declining to comment, background, share moves)By Bill BerkrotApril 17 Generic drugmaker Mylan NV  moved quickly on Friday to pour cold water on published reports that Teva Pharmaceuticals Industries is considering a bid to acquire it.Mylan last week announced a $29 billion offer to buy Perrigo Co Plc in a move that some analysts suggested was a tactic to help fend off an acquisition by larger rival Teva.Mylan Executive Chairman and former Chief Executive Officer Robert Coury said the Perrigo plans remain on track. ""Mylan is fully committed to its stand-alone strategy, including its proposal to acquire Perrigo, and today's speculation has no impact whatsoever on this strategy,"" Coury said in a statement.""We have studied the potential combination of Mylan and Teva for some time and we believe it is clear that such a combination is without sound industrial logic or cultural fit. Further, there would be significant overlap in the companies' businesses and we believe that it is unlikely that any such combination could obtain antitrust regulatory clearances,"" Coury said. Teva spokeswoman Denise Bradley declined to comment on the rumor that the world's largest generic drugmaker was considering a bid for Mylan. The speculation was reported by Bloomberg and the Wall Street Journal.Teva has not made a formal approach to Mylan, Bloomberg reported. ""Of course, should any party make an actual offer to acquire Mylan, the board would carefully consider it in exercising its fiduciary duties in the best interests of the company, our stockholders and other stakeholders,"" Coury said.Israel-based Teva has a market value of about $64.4 billion and annual revenue of about $20 billion.Mylan, which moved its headquarters from Pittsburgh to the Netherlands in a so-called inversion deal to take advantage of lower taxes outside the United States, has a market value of about $32.7 billion and annual revenue of about $7.7 billion. A Mylan/Perrigo combination would have annual revenue of about $15 billion.Mylan shares were up 4.3 percent at $69.72 on a sharply down day for the broader markets, while Teva shares trading in New York were up 2 percent at $64.72. Shares of Perrigo were down 1.6 percent at $195.79.   (Additional reporting by Reporting by Ankur Banerjee in Bengaluru; Editing by Savio D'Souza and Jonathan Oatis)",2015-04-17,MYL,"Fri Apr 17, 2015 | 3:31pm EDT",UPDATE 1-Mylan says merger with Teva would be bad fit,http://www.reuters.com//article/mylan-ma-teva-pharm-ind-idUSL4N0XE51620150417?type=companyNews
90,     ,2015-04-17,MYL,"Fri Apr 17, 2015 | 3:11pm EDT",Teva considering potential bid for Mylan - Bloomberg,http://www.reuters.com//article/mylan-ma-teva-pharm-ind-idUSL4N0XE4Z520150417?type=companyNews
91,"   By Olivia Oran and Nadia Damouni  Some of the top investors at Mylan NV, including Paulson & Co, are encouraging its board of directors to consider a takeover proposal from rival Teva Pharmaceutical Industries Inc, according to people familiar with the matter.A handful of these investors have expressed their support in recent weeks for the creation of the world's largest generic drug maker by sales, these people said, declining to be named because they were not authorized to speak to the media.Teva unveiled an unsolicited $40 billion takeover proposal on Tuesday for the Canonsburg, Pennsylvania-based company. Paulson, a New York-based hedge fund that owned roughly 14.9 million shares or 3 percent of Mylan as of Dec. 31, declined to comment. A representative for Mylan also declined to comment.Pressure has been growing on Jerusalem-based Teva for new revenue sources. Its biggest selling drug, multiple sclerosis injectable treatment Copaxone, faces competition from oral treatments and cheaper generics in the coming years.        Mylan, which makes the EpiPen product for severe allergies, is incorporated in the Netherlands and can take advantage of Dutch provisions that would make a hostile takeover difficult. In response to media speculation about a potential deal, Mylan Executive Chairman Robert Coury said last week that the company had studied a transaction with Teva and concluded that such a combination ""is without sound industrial logic or cultural fit,"" and would attract antitrust scrutiny.Mylan is pursuing its own $29 billion unsolicited bid for over-the-counter medicines maker Perrigo Co PLC. Perrigo's board rejected that offer earlier on Tuesday.  Teva said acquisition of Mylan would create an entity with more than $30 billion in annual revenue, add to earnings in the first year and eventually generate $2 billion in annual savings.The purchase of Mylan would also help Teva expand its offering of harder-to-produce medical products, such as soft-gel caps, topical and inhalant technologies and injectables, and increase its portfolio of specialty pharmaceuticals.    In March, Teva said it would acquire neurology company Auspex Pharmaceuticals Inc for $3.5 billion to boost its portfolio of treatments for the central nervous system. A Teva-Mylan deal would be the second-largest healthcare transaction in the last 12 months, following generic drugmaker Actavis Plc's $66 billion purchase of Botox maker Allergan. The wave of consolidation has also included AbbVie Inc's proposed $21 billion purchase of Pharmacyclics and Valeant Pharmaceuticals' $11 billion deal for Salix Pharmaceuticals Ltd.Mylan shares rose 8.9 percent to $74.04 in Nasdaq trading on Tuesday, while Teva gained 1.4 percent to $64.16 on the New York Stock Exchange. Perrigo fell 2.66 percent to $192.82. (Reporting by Olivia Oran and Nadia Damouni in New York; Editing by Alan Crosby and David Gregorio)",2015-04-21,MYL,"Tue Apr 21, 2015 | 6:50pm EDT",Top Mylan shareholders seek deal with Teva: sources,http://www.reuters.com//article/us-teva-mylan-investors-idUSKBN0NC2FS20150421?type=companyNews
92,"   By Tova Cohen and Caroline Humer | TEL AVIV/NEW YORK  TEL AVIV/NEW YORK Teva Pharmaceutical Industries Ltd on Tuesday made an unsolicited $40 billion offer for smaller rival Mylan NV, a bold bid for growth as its lucrative Copaxone drug faces generic competition. The offer followed weeks of speculation that Israel-based Teva, the world's largest generic drugmaker, would soon target Mylan. Shares of Mylan traded below the offer price of $82 in cash and stock, evidence of investor skepticism that Teva can win over the company, which has set up a defense that includes a poison pill.Analysts agreed that Teva would need to sweeten its bid to the $90-per-share range. S&P Capital IQ analyst Jeffrey Loo said a viable offer would be $92, about 22 times Mylan's 2015 expected earnings.""If they raise their bid, they will have more Mylan shareholders pressuring management to come to the table,"" Loo said. He suggested Teva would need to increase the cash component of the offer, which is now at 50 percent.Mylan has yet to respond publicly. The company is pursuing an unsolicited, $29 billion bid for Perrigo Co Plc, a major producer of over-the-counter medicines, in an apparent attempt to stave off interest from Teva. Perrigo has not yet responded to that offer, saying it would consult its board, but a source familiar with the matter said the company was set to reject Mylan's bid as soon as this week.Mylan Executive Chairman Robert Coury said last week that the company had studied the potential for a deal with Teva and concluded that such a combination ""is without sound industrial logic or cultural fit,"" and would attract antitrust scrutiny.Teva said its offer should be more attractive to Mylan shareholders than the proposed purchase of Perrigo, representing a 48 percent premium to the company's share price before speculation of a deal surfaced on March 10.  Pressure has been growing on Teva for new revenue sources as multiple sclerosis drug Copaxone starts to face generic competition this year. Teva said the purchase would help it to expand its offering of harder-to-produce medical products, such as soft-gel caps, topical and inhalant technologies and injectables, and increase its portfolio of specialty pharmaceuticals.The acquisition would create an entity with more than $30 billion in annual revenue, add to earnings in the first year and eventually generate $2 billion in annual savings, Teva said. It expects that a transaction could close by the end of 2015 and pledged a quick response, including selling assets if necessary, to ease any regulatory concerns.Mylan shares were up 8.9 percent at $74.12 in afternoon Nasdaq trading, while Teva rose 2.0 percent to $64.55 on the New York Stock Exchange. Perrigo fell 2.2 percent to $193.79. HEALTHCARE DEAL FRENZY A Teva-Mylan deal would be the second-largest healthcare transaction in the last 12 months, following generic drugmaker Actavis Plc's $66 billion purchase of Botox maker Allergan. The wave of consolidation has also included AbbVie Inc's proposed purchase of Pharmacyclics and Valeant Pharmaceuticals' deal for Salix.Generic drugmakers are looking to get bigger and gain access to product lines with higher profit margins, while traditional pharmaceutical companies have tried to add novel treatments for cancer and rare diseases.         Teva Chief Executive Officer Erez Vigodman said the companies should meet to address Mylan's concerns. In a letter to Coury, he said a deal would create ""an organization with the scale and reach to excel in the current environment, which I know you appreciate."" A turnaround specialist, Vigodman joined Teva last year, tasked with cutting costs and improving profits under pressure from rising competition. In February, he said the company was ready to return to making acquisitions. A Mylan purchase would be the largest deal in Israeli history.Mylan recently moved its headquarters from the United States to the Netherlands, where corporate taxes are lower and where it could take advantage of Dutch anti-takeover provisions that can dilute shares by granting a call option to a foundation set up for this purpose.   In early April, Mylan said it had entered into such a call option agreement.Sanford Bernstein analyst Aaron Gal said in a research note that Perrigo was likely to reject Mylan but might then start negotiating with the company. That would push Mylan to campaign to win shareholder support for its purchase.At the same time, Teva will start its own campaign to publicly convince Mylan shareholders of the merits of its offer. Mylan is likely to demand a higher price, shared management and maybe some employee job protection, he said.    Barclays and Greenhill & Co Inc are advising Teva, whose lawyers are Kirkland & Ellis LLP, Tulchinsky Stern Marciano Cohen Levitski & Co, De Brauw Blackstone Westbroek N.V. and Loyens & Loeff N.V.  (Additional reporting by Steven Scheer in Jerusalem)",2015-04-21,MYL,"Tue Apr 21, 2015 | 6:25pm EDT",Generic drugmaker Teva makes $40 billion offer for rival Mylan,http://www.reuters.com//article/us-mylan-m-a-teva-pharm-ind-idUSKBN0NC15W20150421?type=companyNews
93,"  Dublin-based Perrigo Company Plc said its board unanimously rejected a $205 per share offer from generic drugmaker Mylan NV, saying the bid substantially undervalued the company.Perrigo said Mylan's offer did not take into account Perrigo's 2.48 billion euros ($2.66 billion) acquisition of Omega Pharma and new products that are expected to generate about $1 billion in revenue. [ID:nPn9VLYVg] Earlier in the day, Reuters reported that Perrigo was set to reject the $29 billion offer from Mylan, as it tackles an unsolicited offer from Israeli drugmaker Teva Pharmaceutical Industries Ltd. [ID:nL1N0XI1OR]   (Reporting by Vidya L Nathan in Bengaluru; Editing by Sayantani Ghosh)",2015-04-21,MYL,"Tue Apr 21, 2015 | 4:30pm EDT",Perrigo rejects $205/share bid from Mylan,http://www.reuters.com//article/us-perrigo-m-a-mylan-idUSKBN0NC2DE20150421?type=companyNews
94,"  * Yahoo, Chipotle down after the bell following quarterly reports* Mylan shares up almost 9 pct after Teva bid* Dow ends down 0.47 pct, S&P down 0.15 pct, Nasdaq up 0.39 pct   (Updates to close)By Noel RandewichApril 21 U.S. stocks were a mixed bag on Tuesday, with the Dow ending lower after a handful of uninspiring earnings reports while the Nasdaq closed near a record high following a proposed biotech merger.Travelers, DuPont and IBM shares weighed on the Dow Jones industrial average. DuPont reported lower sales in all of its businesses and said a strong dollar would take a toll on its full-year earnings. IBM also mentioned currency effects when it reported a fall in revenue late on Monday.DuPont ended the session 2.95 percent lower at $70.69 and IBM fell 1.14 percent to $164.26. March-quarter earnings season is in full swing, with almost 73 percent of the S&P 500 components that have reported so far beating bottom-line expectations, but just 42.2 percent beating expectations for revenue.Investors struggled to gauge how much a strong dollar has hurt U.S. multinationals, including technology companies like Facebook, Google, Qualcomm, Microsoft  that sell many of their products and services overseas and are expected to report their earnings this week.""There's a lot of cross-current in the earnings picture. Are we at peak margins? Are we likely to hold, or might there be some downside?"" said Mark Foster, chief investment officer at Kirr Marbach & Co in Columbus, Indiana. ""People are pretty zeroed in on that.""The dollar has gained almost 9 percent since the beginning of the year against a basket of major currencies, hurting companies with large overseas operations. Travelers reported a drop in quarterly net profit and its shares ended down 4.01 percent.The Dow Jones industrial average fell 85.34 points, or 0.47 percent, to end at 17,949.59. The S&P 500 lost 3.11 points, or 0.15 percent, to 2,097.29 and the Nasdaq Composite added 19.50 points, or 0.39 percent, to 5,014.10.The Nasdaq ended the day less than 35 points away from its March 2000 all-time closing high. Mylan shares rose 8.85 percent to end at $74.07 after Israeli drugmaker Teva made an unsolicited offer of $82 per share, in what could be the drug industry's largest takeover this year. Teva rose 1.37 percent. The Nasdaq Biotech index ended up 1.87 percent.After the bell, Chipotle Mexican Grill and Yahoo  posted their quarterly results and their shares fell 4.5 percent and 1.19 percent, respectively.First-quarter earnings of S&P 500 companies are expected to dip 2.2 percent, while revenues are seen declining 3.1 percent, according to Thomson Reuters data which includes companies that already reported.Advancing issues outnumbered declining ones on the NYSE by 1,521 to 1,512, for a 1.01-to-1 ratio on the upside; on the Nasdaq, 1,381 issues fell and 1,346 advanced, for a 1.03-to-1 ratio favoring decliners.The S&P 500 posted 12 new 52-week highs and no new lows; the Nasdaq Composite, recorded 95 new highs and 27 new lows.About 5.8 billion shares changed hands on U.S. exchanges, below the 6.2 billion daily average for the month to date, according to BATS Global Markets.   (Additional reporting by Tanya Agrawal; Editing by Meredith Mazzilli and Nick Zieminski)",2015-04-21,MYL,"Tue Apr 21, 2015 | 4:27pm EDT",US STOCKS-Earnings cloud drags down Dow; Nasdaq gains on biotech M&A,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0XI21S20150421?type=companyNews
95,"  April 21 Dublin-based Perrigo Company Plc  said its board unanimously rejected a $205 per share offer from generic drugmaker Mylan NV, saying the bid substantially undervalued the company.Perrigo said Mylan's offer did not take into account Perrigo's 2.48 billion euros ($2.66 billion) acquisition of Omega Pharma and new products that are expected to generate about $1 billion in revenue.  Earlier in the day, Reuters reported that Perrigo was set to reject the $29 billion offer from Mylan, as it tackles an unsolicited offer from Israeli drugmaker Teva Pharmaceutical Industries Ltd.   ($1 = 0.9316 euros)   (Reporting by Vidya L Nathan in Bengaluru; Editing by Sayantani Ghosh) ",2015-04-21,MYL,"Tue Apr 21, 2015 | 4:26pm EDT",Perrigo rejects $205/share bid from Mylan,http://www.reuters.com//article/perrigo-ma-mylan-idUSL4N0XI5UW20150421?type=companyNews
96,"  (Adds link to video)By Tova Cohen and Caroline HumerTEL AVIV/NEW YORK, April 21 Teva Pharmaceutical Industries Ltd on Tuesday made an unsolicited $40 billion offer for smaller rival Mylan NV, a bold bid for growth as its lucrative Copaxone drug faces generic competition.The offer followed weeks of speculation that Israel-based Teva, the world's largest generic drugmaker, would soon target Mylan. Shares of Mylan traded below the offer price of $82 in cash and stock, evidence of investor skepticism that Teva can win over the company, which has set up a defense that includes a poison pill.Analysts agreed that Teva would need to sweeten its bid to the $90-per-share range. S&P Capital IQ analyst Jeffrey Loo said a viable offer would be $92, about 22 times Mylan's 2015 expected earnings.""If they raise their bid, they will have more Mylan shareholders pressuring management to come to the table,"" Loo said. He suggested Teva would need to increase the cash component of the offer, which is now at 50 percent.Mylan has yet to respond publicly. The company is pursuing an unsolicited, $29 billion bid for Perrigo Co Plc, a major producer of over-the-counter medicines, in an apparent attempt to stave off interest from Teva.Perrigo has not yet responded to that offer, saying it would consult its board, but a source familiar with the matter said the company was set to reject Mylan's bid as soon as this week.Mylan Executive Chairman Robert Coury said last week that the company had studied the potential for a deal with Teva and concluded that such a combination ""is without sound industrial logic or cultural fit,"" and would attract antitrust scrutiny. Teva said its offer should be more attractive to Mylan shareholders than the proposed purchase of Perrigo, representing a 48 percent premium to the company's share price before speculation of a deal surfaced on March 10.Pressure has been growing on Teva for new revenue sources as multiple sclerosis drug Copaxone starts to face generic competition this year.Teva said the purchase would help it to expand its offering of harder-to-produce medical products, such as soft-gel caps, topical and inhalant technologies and injectables, and increase its portfolio of specialty pharmaceuticals.The acquisition would create an entity with more than $30 billion in annual revenue, add to earnings in the first year and eventually generate $2 billion in annual savings, Teva said. It expects that a transaction could close by the end of 2015 and pledged a quick response, including selling assets if necessary, to ease any regulatory concerns. Mylan shares were up 8.9 percent at $74.12 in afternoon Nasdaq trading, while Teva rose 2.0 percent to $64.55 on the New York Stock Exchange. Perrigo fell 2.2 percent to $193.79.HEALTHCARE DEAL FRENZY A Teva-Mylan deal would be the second-largest healthcare transaction in the last 12 months, following generic drugmaker Actavis Plc's $66 billion purchase of Botox maker Allergan. The wave of consolidation has also included AbbVie Inc's proposed purchase of Pharmacyclics and Valeant Pharmaceuticals' deal for Salix. Generic drugmakers are looking to get bigger and gain access to product lines with higher profit margins, while traditional pharmaceutical companies have tried to add novel treatments for cancer and rare diseases.Teva Chief Executive Officer Erez Vigodman said the companies should meet to address Mylan's concerns. In a letter to Coury, he said a deal would create ""an organization with the scale and reach to excel in the current environment, which I know you appreciate.""A turnaround specialist, Vigodman joined Teva last year, tasked with cutting costs and improving profits under pressure from rising competition. In February, he said the company was ready to return to making acquisitions. A Mylan purchase would be the largest deal in Israeli history.Mylan recently moved its headquarters from the United States to the Netherlands, where corporate taxes are lower and where it could take advantage of Dutch anti-takeover provisions that can dilute shares by granting a call option to a foundation set up for this purpose.In early April, Mylan said it had entered into such a call option agreement.Sanford Bernstein analyst Aaron Gal said in a research note that Perrigo was likely to reject Mylan but might then start negotiating with the company. That would push Mylan to campaign to win shareholder support for its purchase.At the same time, Teva will start its own campaign to publicly convince Mylan shareholders of the merits of its offer. Mylan is likely to demand a higher price, shared management and maybe some employee job protection, he said.Barclays and Greenhill & Co Inc are advising Teva, whose lawyers are Kirkland & Ellis LLP, Tulchinsky Stern Marciano Cohen Levitski & Co, De Brauw Blackstone Westbroek N.V. and Loyens & Loeff N.V.    (Additional reporting by Steven Scheer in Jerusalem; Editing by Michele Gershberg, Alden Bentley and Lisa Von Ahn)",2015-04-21,MYL,"Tue Apr 21, 2015 | 3:45pm EDT",UPDATE 6-Generic drugmaker Teva makes $40 billion offer for rival Mylan,http://www.reuters.com//article/mylan-ma-teva-pharm-ind-idUSL5N0XI30O20150421?type=companyNews
97,"  * Yahoo, Chipotle, Yum to report after the close* Mylan shares up almost 10 pct after Teva bid* Dow off 0.45 pct, S&P down 0.1 pct, Nasdaq up 0.48 pct   (Updates to afternoon)By Noel RandewichApril 21 U.S. stocks were mixed on Tuesday, with the Dow industrials pulled down by a handful of uninspiring earnings reports, while the Nasdaq was pushed higher by a proposed biotech merger.Travelers, DuPont and IBM shares weighed on the Dow. DuPont reported lower sales in all of its businesses and said a strong dollar would take a toll on its full-year earnings. IBM also mentioned currency effects when it reported a fall in revenue late on Monday. DuPont was down 2.73 percent at $70.84 and IBM fell 1.14 percent.March-quarter earnings season is in full swing, with almost 73 percent of the S&P 500 components that have reported so far beating bottom-line expectations, but just 42.2 percent beating expectations for revenue.Investors are gauging how much a strong dollar has hurt U.S. multinationals, including technology companies like Facebook , Google, Qualcomm, Microsoft  that sell many of their products and services overseas and are expected to report their earnings this week. ""There's a lot of cross-current in the earnings picture. Are we at peak margins? Are we likely to hold, or might there be some downside?"" said Mark Foster, chief investment officer at Kirr Marbach & Co in Columbus, Indiana. ""People are pretty zeroed in on that.""The dollar has gained almost 9 percent since the beginning of the year against a basket of major currencies, hurting companies with large overseas operations.Travelers reported a drop in quarterly net profit and its shares fell 3.73 percent. At 3:04 p.m.. the Dow Jones industrial average fell 80.47 points, or 0.45 percent, to 17,954.46, the S&P 500  lost 2 points, or 0.1 percent, to 2,098.4 and the Nasdaq Composite added 23.74 points, or 0.48 percent, to 5,018.34.Mylan shares rose 9 percent to $74.23 after Israeli drugmaker Teva made an unsolicited offer of $82 per share, in what could be the drug industry's largest takeover this year. Teva rose 1.91 percent. The Nasdaq Biotech index  rose 2 percent.Chipotle, Yahoo and chipmaker Broadcom  were expected to report their quarterly results after the bell on Tuesday.Advancing issues outnumbered declining ones on the NYSE by 1,552 to 1,466, for a 1.06-to-1 ratio; on the Nasdaq, 1,363 issues fell and 1,338 advanced, for a 1.02-to-1 ratio favoring decliners.The S&P 500 was posting 12 new 52-week highs and no new lows; the Nasdaq Composite was recording 87 new highs and 24 new lows.     (Additional reporting by Tanya Agrawal; Editing by Meredith Mazzilli and Nick Zieminski)",2015-04-21,MYL,"Tue Apr 21, 2015 | 3:16pm EDT",US STOCKS-Wall St mixed as doubts about earnings offset biotech M&A bid,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0XI1SK20150421?type=companyNews
98,"   By Nadia Damouni and Olivia Oran  Perrigo Co Plc is set to reject a $29 billion unsolicited takeover offer from generic drugmaker Mylan NV as soon as this week, according to a source familiar with the matter.A rejection leaves Mylan with no immediate alternative to a takeover offer from Teva Pharmaceutical Industries Ltd which went public on Tuesday with a $40 billion unsolicited bid for its Canonsburg, Pennsylvania-based rival.Mylan, which makes the EpiPen product for severe allergies, now must decide whether to raise its offer for Perrigo, engage in talks with Teva, or take another route. Mylan has adopted a Dutch-style poison pill defense strategy which makes a hostile takeover less likely, and has said it is committed to remain independent. Teva said its offer for Mylan was contingent on the company's not completing an acquisition of Perrigo or any alternative transaction. Representatives from Perrigo and Mylan were not immediately available for comment.Perrigo shares fell as much as 2.9 percent to $192.35 following the Reuters report.  Earlier this month, Mylan offered to buy Perrigo for $205 per share in cash and stock.  Perrigo, which has a large and attractive portfolio of over-the-counter consumer products, infant formulas and a line of generic topical pharmaceutical medicines, has long been seen as a takeover target. Perrigo confirmed it had received Mylan's offer and said its board would meet to discuss the proposal.A tie-up between Perrigo and Mylan would be the latest in a string of recent multibillion-dollar pharmaceutical deals, including Valeant Pharmaceuticals International Ltd's $11 billion deal for Salix Pharmaceuticals Ltd and AbbVie Inc's $21 billion offer for Pharmacyclics Inc.  (Reporting by Nadia Damouni and Olivia Oran in New York; Editing by Andrew Hay, Cynthia Osterman and Lisa Von Ahn)",2015-04-21,MYL,"Tue Apr 21, 2015 | 3:04pm EDT",Exclusive: Perrigo expected to reject Mylan offer as soon as this week - source,http://www.reuters.com//article/us-perrigo-company-mylan-exclusive-idUSKBN0NC24620150421?type=companyNews
99,"  (Adds details on poison pill, next steps for Mylan)By Nadia Damouni and Olivia OranApril 21 Perrigo Co Plc is set to reject a $29 billion unsolicited takeover offer from generic drugmaker Mylan NV as soon as this week, according to a source familiar with the matter.A rejection leaves Mylan with no immediate alternative to a takeover offer from Teva Pharmaceutical Industries Ltd  which went public on Tuesday with a $40 billion unsolicited bid for its Canonsburg, Pennsylvania-based rival.Mylan, which makes the EpiPen product for severe allergies, now must decide whether to raise its offer for Perrigo, engage in talks with Teva, or take another route. Mylan has adopted a Dutch-style poison pill defense strategy which makes a hostile takeover less likely, and has said it is committed to remain independent. Teva said its offer for Mylan was contingent on the company's not completing an acquisition of Perrigo or any alternative transaction.Representatives from Perrigo and Mylan were not immediately available for comment. Perrigo shares fell as much as 2.9 percent to $192.35 following the Reuters report.Earlier this month, Mylan offered to buy Perrigo for $205 per share in cash and stock. Perrigo, which has a large and attractive portfolio of over-the-counter consumer products, infant formulas and a line of generic topical pharmaceutical medicines, has long been seen as a takeover target.Perrigo confirmed it had received Mylan's offer and said its board would meet to discuss the proposal.A tie-up between Perrigo and Mylan would be the latest in a string of recent multibillion-dollar pharmaceutical deals, including Valeant Pharmaceuticals International Ltd's  $11 billion deal for Salix Pharmaceuticals Ltd and AbbVie Inc's  $21 billion offer for Pharmacyclics Inc.    (Reporting by Nadia Damouni and Olivia Oran in New York; Editing by Andrew Hay, Cynthia Osterman and Lisa Von Ahn)",2015-04-21,MYL,"Tue Apr 21, 2015 | 3:01pm EDT",EXCLUSIVE-Perrigo expected to reject Mylan offer as soon as this week -source,http://www.reuters.com//article/perrigo-company-mylan-idUSL1N0XI1OR20150421?type=companyNews
100,"  (Adds company background)By Nadia Damouni and Olivia OranApril 21 Perrigo Company PLC is set to reject a $29 billion unsolicited takeover offer from generics drugmaker Mylan NV as soon as this week, according to a source familiar with the matter.A rejection leaves Mylan with no immediate alternative to a takeover offer from Teva Pharmaceutical Industries Ltd  which went public on Tuesday with a $40 billion unsolicited proposal for the Canonsburg, Pennsylvania-based rival. Mylan has adopted a poison pill defense, a shareholder rights plan that makes a hostile takeover less likely, and has said it is committed to a stand-alone strategy. Teva said that its offer for Mylan is contingent on the company not completing an acquisition of Perrigo or any alternative transaction.Representatives from Perrigo and Mylan were not immediately available for comment. Perrigo shares, which opened at $195.20, fell as low as $192.35 in afternoon trading following the Reuters report.Earlier this month, Mylan offered to buy Perrigo for $205 per share in cash and stock. Perrigo, with a large and attractive portfolio of OTC consumer products, infant formulas and a line of generic topical pharmaceutical medicines, has long been seen as a takeover target.Perrigo confirmed it had received Mylan's offer and said its board would meet to discuss the proposal.A tieup between Perrigo and Mylan would be the latest in a string of recent multibillion-dollar pharmaceutical deals, including Valeant Pharmaceuticals International Ltd's  $11 billion deal for Salix Pharmaceuticals Ltd and AbbVie Inc's  $21 billion offer for Pharmacyclics Inc.    (Reporting by Nadia Damouni and Olivia Oran in New York; Editing by Andrew Hay and Cynthia Osterman)",2015-04-21,MYL,"Tue Apr 21, 2015 | 2:25pm EDT",EXCLUSIVE-Perrigo expected to reject Mylan offer as soon as this week -source,http://www.reuters.com//article/perrigo-company-mylan-idUSL1N0XI1LY20150421?type=companyNews
101,"  Generic drugmaker Teva Pharmaceutical Industries Ltd (TEVA.N) (TEVA.TA) said it could ""promptly"" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV (MYL.O).Mylan, which has said a merger with Teva would be bad fit, plans to make a new offer for Perrigo Co Plc (PRGO.N) in the near term, CNBC reported on Wednesday. (cnb.cx/1EbtArn)Mylan earlier this month made a $29 billion offer for Perrigo, in a move that some analysts suggested was a tactic to help fend off Teva. But, Perrigo, a maker of over-the-counter medicines, rejected the offer on Tuesday. A Mylan spokesman declined to comment on the CNBC report.Teva plans to work with antitrust authorities and expects that the proposed transaction with Mylan can be completed by the end of 2015, it said on Wednesday, a day after going public with its bid for Mylan. Jerusalem, Israel-based Teva did not say which operations it could be ready to divest.Mylan has yet to publicly respond to Teva's offer, but last week Mylan Executive Chairman Robert Coury responded to reports of a potential deal by saying that such a combination would attract antitrust scrutiny and was ""without sound industrial logic or cultural fit"". However, some of Mylan's top investors, including Paulson and Co, are encouraging its board to consider Teva's proposal, Reuters has reported.Abbott Laboratories (ABT.N) said on Wednesday it intends to hold on to its 14.25 percent stake in Mylan for at least the short term. A Teva-Mylan deal would be the second-largest healthcare transaction in the last 12 months after Botox maker Allergan was bought for $66 billion by Actavis Plc ACT.N, also a generic drugmaker.Generic drugmakers are looking to get bigger and gain access to product lines with higher profit margins. (Reporting by Natalie Grover and Ankur Banerjee in Bengaluru; Editing by Savio D'Souza)",2015-04-22,MYL,"Wed Apr 22, 2015 | 1:02pm EDT",Teva ready to divest operations to win regulatory nod for Mylan buy,http://www.reuters.com//article/us-mylan-m-a-teva-pharm-ind-idUSKBN0ND1MD20150422?type=companyNews
102,"  (Adds details)April 22 Generic drugmaker Teva Pharmaceutical Industries Ltd  said it could ""promptly"" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV.Mylan, which has said a merger with Teva would be bad fit, plans to make a new offer for Perrigo Co Plc in the near term, CNBC reported on Wednesday. (cnb.cx/1EbtArn)Mylan earlier this month made a $29 billion offer for Perrigo, in a move that some analysts suggested was a tactic to help fend off Teva. But, Perrigo, a maker of over-the-counter medicines, rejected the offer on Tuesday.A Mylan spokesman declined to comment on the CNBC report. Teva plans to work with antitrust authorities and expects that the proposed transaction with Mylan can be completed by the end of 2015, it said on Wednesday, a day after going public with its bid for Mylan.Jerusalem, Israel-based Teva did not say which operations it could be ready to divest. Mylan has yet to publicly respond to Teva's offer, but last week Mylan Executive Chairman Robert Coury responded to reports of a potential deal by saying that such a combination would attract antitrust scrutiny and was ""without sound industrial logic or cultural fit"".However, some of Mylan's top investors, including Paulson and Co, are encouraging its board to consider Teva's proposal, Reuters has reported. Abbott Laboratories said on Wednesday it intends to hold on to its 14.25 percent stake in Mylan for at least the short term.A Teva-Mylan deal would be the second-largest healthcare transaction in the last 12 months after Botox maker Allergan was bought for $66 billion by Actavis Plc, also a generic drugmaker.Generic drugmakers are looking to get bigger and gain access to product lines with higher profit margins.   (Reporting by Natalie Grover and Ankur Banerjee in Bengaluru; Editing by Savio D'Souza)",2015-04-22,MYL,"Wed Apr 22, 2015 | 12:55pm EDT",UPDATE 1-Teva ready to divest operations to win regulatory nod for Mylan buy,http://www.reuters.com//article/mylan-ma-teva-pharm-ind-idUSL4N0XJ5C020150422?type=companyNews
103,"  Abbott Laboratories (ABT.N) on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan (MYL.O) of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.Under the deal, Abbott transferred generic and specialty drugs it had sold in Europe, Japan, Canada, Australia and New Zealand to a new publicly traded company in the Netherlands that also included Mylan's existing businesses.Abbott received 105 million shares of the combined company, renamed Mylan NV. It has since sold a third of the stock, reducing its stake in Mylan to about 15 percent from 21 percent.""What was a $5 billion value is now worth north of $7 billion,"" Abbott Chief Executive Miles White told analysts on Wednesday during a conference call to discuss first-quarter results.  ""It has been prudent to hold"" the stock, he said, adding that Abbott retained most of the shares and was in ""no hurry"" to sell them.Shares of Mylan have risen sharply in recent weeks on speculation that larger generic drugmaker Teva Pharmaceuticals Industries Ltd (TEVA.TA) would offer to buy the company. The speculation proved true on Tuesday, when Teva unveiled an unsolicited $40 billion bid for Mylan in an attempt to ease pressure for new revenue sources.  Abbott earlier on Wednesday reported a higher-than-expected first-quarter profit, helped in part by growing sales of generics it sells in emerging markets.        Shares of Abbott were up 1.8 percent at $47.99 in midday trading on the New York Stock Exchange. (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2015-04-22,MYL,"Wed Apr 22, 2015 | 12:11pm EDT",Abbott says its payoff from Mylan deal surged,http://www.reuters.com//article/us-abbott-mylan-idUSKBN0ND1SY20150422?type=companyNews
104,"  (Adds CEO quotes, background on Teva bid for Mylan)April 22 Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.Under the deal, Abbott transferred generic and specialty drugs it had sold in Europe, Japan, Canada, Australia and New Zealand to a new publicly traded company in the Netherlands that also included Mylan's existing businesses.Abbott received 105 million shares of the combined company, renamed Mylan NV. It has since sold a third of the stock, reducing its stake in Mylan to about 15 percent from 21 percent. ""What was a $5 billion value is now worth north of $7 billion,"" Abbott Chief Executive Miles White told analysts on Wednesday during a conference call to discuss first-quarter results. ""It has been prudent to hold"" the stock, he said, adding that Abbott retained most of the shares and was in ""no hurry"" to sell them.Shares of Mylan have risen sharply in recent weeks on speculation that larger generic drugmaker Teva Pharmaceuticals Industries Ltd would offer to buy the company. The speculation proved true on Tuesday, when Teva unveiled an unsolicited $40 billion bid for Mylan in an attempt to ease pressure for new revenue sources. Abbott earlier on Wednesday reported a higher-than-expected first-quarter profit, helped in part by growing sales of generics it sells in emerging markets.Shares of Abbott were up 1.8 percent at $47.99 in midday trading on the New York Stock Exchange.   (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2015-04-22,MYL,"Wed Apr 22, 2015 | 12:09pm EDT",UPDATE 1-Abbott says its payoff from Mylan deal surged,http://www.reuters.com//article/abbott-mylan-idUSL1N0XJ1EJ20150422?type=companyNews
105,"  (Corrects first paragraph to show $5.3 billion was proceeds, not a gain)April 22 Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal. Under the transaction, Abbott transfered generic and specialty drugs it had sold in Europe, Japan, Canada, Australia and New Zealand to a new publicly traded company in the Netherlands that also included Mylan's existing businesses.  Abbott received 105 million shares of the combined company, renamed Mylan NV, giving it an ownership stake of about 21 percent.   (Reporting by Ransdell Pierson)",2015-04-22,MYL,"Wed Apr 22, 2015 | 12:06pm EDT","CORRECTED-Abbott says payoff from Mylan deal surges, as Mylan shares leap",http://www.reuters.com//article/abbott-mylan-idUSL1N0XJ16Q20150422?type=companyNews
106,"  Generic drugmaker Mylan NV (MYL.O) plans to make a new offer for Perrigo Co Plc (PRGO.N) in the near term, CNBC reported on Wednesday, citing a source familiar with the matter.Dublin-based Perrigo rejected Mylan's $205 per share offer on Tuesday, saying the bid substantially undervalued the company. A new bid from Mylan will include firm financing commitments, CNBC reported. (cnb.cx/1EbtArn)   (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)",2015-04-22,MYL,"Wed Apr 22, 2015 | 10:07am EDT",Mylan plans to make new offer for Perrigo: CNBC,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-idUSKBN0ND1O720150422?type=companyNews
107,"  April 22 Generic drugmaker Mylan NV  plans to make a new offer for Perrigo Co Plc in the near term, CNBC reported on Wednesday, citing a source familiar with the matter.Dublin-based Perrigo rejected Mylan's $205 per share offer on Tuesday, saying the bid substantially undervalued the company.  A new bid from Mylan will include firm financing commitments, CNBC reported. (cnb.cx/1EbtArn)   (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila) ",2015-04-22,MYL,"Wed Apr 22, 2015 | 10:00am EDT",Mylan plans to make new offer for Perrigo - CNBC,http://www.reuters.com//article/perrigo-company-ma-mylan-idUSL4N0XJ52420150422?type=companyNews
108,"  April 22 Teva Pharmaceutical Industries Ltd   said on Wednesday it could ""promptly"" divest some operations if necessary to obtain regulatory clearance for its proposed takeover of smaller rival Mylan NV.Teva unveiled an unsolicited $40 billion bid on Tuesday for Mylan in an attempt to ease pressure for new revenue sources.Mylan has yet to publicly respond to Teva's bid, but last week Mylan Executive Chairman Robert Coury responded to reports of a potential deal by concluding that such a combination would attract antitrust scrutiny and was ""without sound industrial logic or cultural fit"". Teva plans to work with antitrust authorities and expects that the proposed transaction can be completed by the end of 2015, it said in a statement on Wednesday.Jerusalem, Israel-based Teva did not say which operations it could be ready to divest. Reuters has reported that some of Mylan's top investors, including Paulson and Co, are encouraging its board of directors to consider Teva's proposal. Meanwhile, Canonsburg, Pennsylvania-based Mylan is pursuing its own $29 billion unsolicited bid for Perrigo Co Plc, which the maker of over-the-counter medicines spurned on Tuesday.A Teva-Mylan deal would be the second-largest healthcare transaction in the last 12 months, following generic drugmaker Actavis Plc's $66 billion purchase of Botox maker Allergan.   (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)",2015-04-22,MYL,"Wed Apr 22, 2015 | 9:48am EDT",Teva ready to divest operations to win regulatory nod for Mylan buy,http://www.reuters.com//article/mylan-ma-teva-pharm-ind-idUSL4N0XJ50O20150422?type=companyNews
109,"  Teva Pharmaceutical Industries (TEVA.N) has offered to buy rival generic drugmaker Mylan (MYL.O) for $40 billion in what would be the largest acquisition in Israel's history, equivalent to nearly 15 percent of GDP.Below are major deals by Teva, Israel's largest company and the world's biggest maker of generic drugs. The company, which employs around 45,000 people, was founded in Jerusalem in 1901 as a wholesale drugs distributor:* In March 2015 it said it would buy U.S. neurology drug company Auspex Pharmaceuticals ASPX.O for an equity value of $3.5 billion, a move to boost its portfolio of treatments for the central nervous system.* In 2011, Teva bought U.S. specialty drugmaker Cephalon for $6.8 billion, acquiring pain, sleep and cancer drugs as well as 57 percent of Japan's Taiyo Pharmaceutical for $460 million. * In 2010, Teva acquired Germany's Ratiopharm for $5 billion, including debt, to become the largest generics drugmaker in Germany.* In 2008, Teva bought Barr Pharmaceuticals in the United States and its European subsidiary Pliva for $7.5 billion. The deal significantly enhanced Teva's leadership position in the U.S. generic drugs market and strengthened its position in key European markets. * Teva acquired U.S.-based IVAX Corp in 2006 for $7.4 billion, giving it a strong presence in Latin America and Central and Eastern Europe and complementary operations in North America and Europe. IVAX also had a significant respiratory business and a pipeline of generic and proprietary products in the areas of respiratory ailments and oncology.* Sicor became a wholly owned subsidiary of Teva in 2004. Teva paid $3.4 billion for Sicor, which had a leading generic injectable business as well as biogeneric capabilities. * In 2000, Teva bought privately held Novopharm, Canada's second-largest generic company, making Teva the largest generic drug company in North America.* In 1999, Teva bought Massachusetts-based Copley Pharmaceutical Inc, a maker of generic and branded drugs, for $220 million (Compiled by Steven Scheer; Editing by Elaine Hardcastle)",2015-04-22,MYL,"Wed Apr 22, 2015 | 9:10am EDT",Factbox: Teva Pharmaceutical's history of key acquisitions,http://www.reuters.com//article/us-teva-pharm-ind-acquisitions-idUSKBN0ND1JC20150422?type=companyNews
110,"   By Caroline Humer and Ransdell Pierson | NEW YORK  NEW YORK Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings.Both issues will factor into any antitrust review, they said.Teva, the worlds largest generic drugmaker, made its $40 billion offer public on Tuesday and quickly signaled it was ready to sell some overlapping assets to win antitrust approval for a deal. Mylan has not responded to the unsolicited bid but has said it wants to remain independent and that the overlap with Teva's products could scuttle a combination. It is also pursuing a hostile takeover of drugmaker Perrigo Co Plc.Most treatments used by the U.S. public are cheaper generic copies of brand-name medications. The percentage has grown as leading drugs lost patent protection in the last decade and health insurers sought ways to rein in costs. But manufacturing generics is a low-margin business, prompting companies to reduce production of some drugs over time.Previous industry mergers have also reduced capacity, and manufacturing lapses at some plants have delayed or shuttered production, leading to temporary shortages of cancer drugs, anesthesia and other medicines.Teva has already looked at the competitive overlap between its portfolio and Mylans, and started discussions with the Federal Trade Commission about the possible merger, sources familiar with the situation said. Mylan makes 360 generic products for the U.S. market, while Teva manufactures 375.The FTC has studied the potential impact of a pharmaceutical deal on drug shortages. In reviewing the 2012 merger of generics makers Actavis and Watson Pharmaceuticals, the agency said it ""evaluated whether the proposed transaction would exacerbate any of those (drug) shortages."" Typically, the FTC wants to be sure there are several competitors making a particular medicine so that production would continue even if one manufacturing source shuts down, sources familiar with the situation said. ""The FTC should be thinking about and not wanting to approve mergers that would worsen the conditions that would cause shortages,"" said an antitrust expert who requested anonymity because he wished to protect his business relationships. ""The fewer production facilities that there are, the greater susceptibility to price fluctuations.""Prices for generic drugs sometimes spike when supplies dry up. Last fall, Independent Senator Bernie Sanders and Democratic Representative Elijah Cummings opened an investigation into 14 drug companies about generic price increases. The office of the inspector general of the Department of Health and Human Services is also planning to a review.""All the manufacturing consolidation makes us nervous,"" said Dr. Beverly Philip, a professor of anesthesiology at Harvard Medical School. With some shortages, doctors have had to shift patients to medicines that may not work as well.If Teva buys Mylan and phases out some of its less-profitable sterile injectable drugs, both for anesthesia and other uses, she said, it would tighten the screw another notch. LOOKING AT COMPETITION Globally, Teva holds 12 percent of the global generic market, while Novartis AG, Actavis and Mylan each account for about 9 percent, according to UK market intelligence firm Evaluate Ltd.Their U.S. market shares are less clear because generic drug company reporting on product sales varies. Wells Fargo analyst Michael Faerm estimates a combined Teva-Mylan would account for 22 percent of U.S. prescriptions. Morningstar Research analyst Michael Waterhouse put the U.S. combined share at about 25 percent of the retail generic market, which is about $31 billion.But those numbers do not reflect the overlap between their businesses. Teva sells more than 50 percent of the U.S. generic products also sold by Mylan, said Louise Pearson, an analyst with GermanysBerenberg Bank, citing data from IMS Health. IMS Health was not immediately available to verify the figures.  In the case of overlapping products, antitrust regulators will want to see that they have at least three or four competitors. If not, the companies considering a merger may need to sell the product line to another party, the antitrust experts and two of the sources said. The FTC would also take into account whether new competitors are about to start production.The U.S Food and Drug Administration considers more than 70 drugs to be in short supply. At least three of them are made by both Teva and Mylan: doxorubicin injections for cancer patients, haloperidol lactate injections for psychiatric patients, and antibiotic injection tobramycin. Each has three or four other manufacturers listed on the FDA website.Separately, Mylan makes four medicines in short supply, while Teva accounts for another five scarce drugs.Pressure to divest assets may also hit some big drugs that are not in short supply. Tevas biggest product is multiple sclerosis treatment Copaxone, and Mylan's generic version is under FDA review. In addition, Teva's plans for a generic version of EpiPen, Mylan's best-selling treatment for severe allergic reactions, would probably need to go, industry experts said. ""In most deals you have to give up something,"" BMO Capital Markets analyst David Maris said, ""but these are two pipeline products that both companies have highlighted over and over as important for them."" (Additional reporting by Diane Bartz in Washington D.C.; Editing by Michele Gershberg and Lisa Von Ahn)",2015-04-24,MYL,"Fri Apr 24, 2015 | 4:58pm EDT","Drug overlaps, shortages may complicate Teva bid for Mylan",http://www.reuters.com//article/us-mylan-m-a-antitrust-idUSKBN0NF28R20150424?type=companyNews
111,"  (For more Reuters DEALTALKS, click on )By Caroline Humer and Ransdell PiersonNEW YORK, April 24 Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings.Both issues will factor into any antitrust review, they said.Teva , the world's largest generic drugmaker, made its $40 billion offer public on Tuesday and quickly signaled it was ready to sell some overlapping assets to win antitrust approval for a deal.Mylan has not responded to the unsolicited bid but has said it wants to remain independent and that the overlap with Teva's products could scuttle a combination. It is also pursuing a hostile takeover of drugmaker Perrigo Co Plc .Most treatments used by the U.S. public are cheaper generic copies of brand-name medications. The percentage has grown as leading drugs lost patent protection in the last decade and health insurers sought ways to rein in costs. But manufacturing generics is a low-margin business, prompting companies to reduce production of some drugs over time.Previous industry mergers have also reduced capacity, and manufacturing lapses at some plants have delayed or shuttered production, leading to temporary shortages of cancer drugs, anesthesia and other medicines.Teva has already looked at the competitive overlap between its portfolio and Mylan's, and started discussions with the Federal Trade Commission about the possible merger, sources familiar with the situation said. Mylan makes 360 generic products for the U.S. market, while Teva manufactures 375. The FTC has studied the potential impact of a pharmaceutical deal on drug shortages. In reviewing the 2012 merger of generics makers Actavis and Watson Pharmaceuticals, the agency said it ""evaluated whether the proposed transaction would exacerbate any of those (drug) shortages.""Typically, the FTC wants to be sure there are several competitors making a particular medicine so that production would continue even if one manufacturing source shuts down, sources familiar with the situation said.""The FTC should be thinking about and not wanting to approve mergers that would worsen the conditions that would cause shortages,"" said an antitrust expert who requested anonymity because he wished to protect his business relationships. ""The fewer production facilities that there are, the greater susceptibility to price fluctuations.""Prices for generic drugs sometimes spike when supplies dry up. Last fall, Independent Senator Bernie Sanders and Democratic Representative Elijah Cummings opened an investigation into 14 drug companies about generic price increases. The office of the inspector general of the Department of Health and Human Services is also planning to a review.""All the manufacturing consolidation makes us nervous,"" said Dr. Beverly Philip, a professor of anesthesiology at Harvard Medical School. With some shortages, doctors have had to shift patients to medicines that may not work as well. If Teva buys Mylan and phases out some of its less-profitable sterile injectable drugs, both for anesthesia and other uses, she said, it would tighten the screw another notch.LOOKING AT COMPETITION Globally, Teva holds 12 percent of the global generic market, while Novartis AG, Actavis and Mylan each account for about 9 percent, according to UK market intelligence firm Evaluate Ltd. Their U.S. market shares are less clear because generic drug company reporting on product sales varies.Wells Fargo analyst Michael Faerm estimates a combined Teva-Mylan would account for 22 percent of U.S. prescriptions. Morningstar Research analyst Michael Waterhouse put the U.S. combined share at about 25 percent of the retail generic market, which is about $31 billion. But those numbers do not reflect the overlap between their businesses. Teva sells more than 50 percent of the U.S. generic products also sold by Mylan, said Louise Pearson, an analyst with Germany's Berenberg Bank, citing data from IMS Health. IMS Health was not immediately available to verify the figures.In the case of overlapping products, antitrust regulators will want to see that they have at least three or four competitors. If not, the companies considering a merger may need to sell the product line to another party, the antitrust experts and two of the sources said. The FTC would also take into account whether new competitors are about to start production.The U.S Food and Drug Administration considers more than 70 drugs to be in short supply. At least three of them are made by both Teva and Mylan: doxorubicin injections for cancer patients, haloperidol lactate injections for psychiatric patients, and antibiotic injection tobramycin. Each has three or four other manufacturers listed on the FDA website.Separately, Mylan makes four medicines in short supply, while Teva accounts for another five scarce drugs.Pressure to divest assets may also hit some big drugs that are not in short supply. Teva's biggest product is multiple sclerosis treatment Copaxone, and Mylan's generic version is under FDA review.In addition, Teva's plans for a generic version of EpiPen, Mylan's best-selling treatment for severe allergic reactions, would probably need to go, industry experts said.""In most deals you have to give up something,"" BMO Capital Markets analyst David Maris said, ""but these are two pipeline products that both companies have highlighted over and over as important for them.""(Additional reporting by Diane Bartz in Washington D.C.; Editing by Michele Gershberg and Lisa Von Ahn)",2015-04-24,MYL,"Fri Apr 24, 2015 | 4:47pm EDT","DEALTALK-Drug overlaps, shortages may complicate Teva bid for Mylan",http://www.reuters.com//article/mylan-ma-antitrust-idUSL1N0XK2AU20150424?type=companyNews
112,"  (Adds Charter, Mylan, Total, Scholastic, ThyssenKrupp, Atlantia; updates Comcast)April 24 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:** Comcast Corp abandoned its $45 billion offer for Time Warner Cable Inc on Friday after U.S. regulators raised concerns that the deal would give Comcast an unfair advantage in the cable TV and Internet-based services market.** Charter Communications Inc representatives have reached out to Time Warner Cable to begin discussions on a potential merger, a person familiar with the matter said on Friday.** Generic drug maker Mylan NV said it would take its $31 billion offer for Perrigo Co Plc directly to shareholders, in what is set to be one of the most high-profile hostile takeover attempts of the year.** Total aims to sell its fuel distribution business in Turkey and has asked Societe Generale to lead the process, sources said, as the French oil producer looks to retreat from a highly competitive and regulated market.** The Italian unit of Sky Plc approached Italian broadcaster Mediaset to buy its unprofitable pay-TV business Mediaset Premium but was rebuffed, according to two sources close to the matter.** Swedish utility Vattenfall is facing delays in the planned sale of its brown coal assets in Germany, three people with direct knowledge of the matter said, pointing to concerns over a proposed coal levy that could threaten any deal. ** Mexico's America Movil said it was still reviewing alternatives to a sale of assets in Mexico in the wake of AT&T's entry into the market, adding that it did not want to sell infrastructure.** German industrial group ThyssenKrupp plans to invest more than 800 million euros ($865 million) in North America by 2020 to take advantage of the economy's reindustrialization.** Scholastic Corp said it would sell its educational technology and services business to publisher Houghton Mifflin Harcourt Co for $575 million in cash, as it focuses on its core children's book publishing business.** Britain has reduced its stake in Lloyds Banking Group  by a further 1 percent to below 21 percent, a further step towards returning the bank to full private ownership. ** Abu Dhabi sovereign fund is interested in buying a minority stake in Atlantia's airport business Aeroporti di Roma, the chief executive for the Italian motorway and airport operator said.** Cenovus Energy Inc, Canada's second-largest independent oil producer, has hired bankers to explore a sale or initial public offering of its royalty lands in Western Canada, a company spokesman told Reuters.** Europe's biggest defense contractor BAE Systems  has hired advisers to carry out a review of its U.S-based IT and analysis support businesses in a move that could lead to their sale. ** The holding company behind India's Crompton Greaves Ltd  has agreed to sell the group's consumer electricals unit for 20 billion rupees ($316 million) to Advent International Corp and a unit of Singapore's Temasek Holdings.** French fragrances group Interparfums, which is buying perfumes and fashion company Rochas, does not plan to make further acquisitions in the medium-term, its chief executive said on Friday.** Swedish utility Vattenfall is facing delays in the planned sale of its brown coal assets in Germany, three people with direct knowledge of the matter said, pointing to concerns over a proposed coal levy that could threaten any deal.** Russian homebuilder PIK Group said on Friday one of its shareholders, Mikail Shishkhanov, had reduced his stake in the company to 9.8 percent from 19.9 percent.** India's Mahindra and Mahindra Ltd has denied a media report that it plans to increase its stake in South Korean automaker Ssangyong Motor Co Ltd, a spokesman for Ssangyong Motor said on Friday.** British electricals and mobile phone retailer Dixons Carphone has agreed to dispose of most of its shares in The Phone House Netherlands, further streamlining its business to focus on markets where it has leading positions.** North Sea oil and gas company Ithaca Energy has agreed to sell its Norwegian business to Hungary's MOL  for $60 million, the companies said on Friday, marking the Hungarian company's entry into Norway's oil market.      ($1 = 0.92 euros)   (Compiled by Rohit T.K. and Kshitiz Goliya in Bengaluru)",2015-04-24,MYL,"Fri Apr 24, 2015 | 4:38pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N0XL4B420150424?type=companyNews
113,"   By Ankur Banerjee and Nadia Damouni  Generic drugmaker Mylan NV said on Friday it would take its $31 billion offer for Perrigo Co Plc directly to shareholders, in what is set to be one of the most high-profile hostile takeover attempts of the year.Mylan, which itself is the target of an unsolicited $40 billion bid from larger rival Teva Pharmaceutical Industries Ltd, said it would offer $60 in cash and 2.2 of its shares for each Perrigo share.The company's pursuit of Perrigo, a major producer of over-the-counter drugs, is widely seen as an attempt to fend off Teva, the world's biggest maker of generic drugs.The three-way chase is further evidence that the appetite for healthcare acquisitions continues unabated.M&A in the industry has hit $193.9 billion so far this year, double the amount in the same period last year. Mylan, which is legally based in the Netherlands, said on April 8 that it would make a cash-and-share bid that valued Dublin-based Perrigo at $205 per share but did not detail the breakdown between shares and cash to be offered.The offer announced on Friday works out to about $222 per share, based on Mylan's Thursday close, valuing Perrigo at about $31 billion, according to Thomson Reuters data. However, Perrigo said the offer valued it at $181.67 per share based on Mylan's unaffected price of $55.31 per share on March 10, the last day of trading before speculation emerged that Israel-based Teva was considering an offer for Mylan.Mylan's shares have risen by about a third since March 10.""Today's announcement from Mylan proposes a price that is lower than the previously rejected proposal,"" Perrigo said. Perrigo's shares were down 3 percent at $195 in early afternoon trading on Friday, while Mylan's stock was up 2.8 percent at $75.75.Mylan said its offer was fully financed and not conditional on due diligence.The cash portion will be financed by a new bridge credit facility arranged by Goldman Sachs, the company said.Teva said in an emailed statement that it remained fully committed to its Mylan offer.",2015-04-24,MYL,"Fri Apr 24, 2015 | 1:15pm EDT",Generic drugmaker Mylan goes hostile in bid for Perrigo,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-idUSKBN0NF1KS20150424?type=companyNews
114,"  * Mylan to offer $60 cash plus 2.2 of its own shares* Perrigo rejects offer again* Perrigo shares fall 3 pct, Mylan up 2.8 pct*    (Adds Perrigo rejection)April 24 Generic drugmaker Mylan NV said on Friday it would take its $31 billion offer for Perrigo Co Plc  directly to shareholders, in what is set to be one of the most high-profile hostile takeover attempts of the year.Mylan, which itself is the target of an unsolicited $40 billion bid from larger rival Teva Pharmaceutical Industries Ltd , said it would offer $60 in cash and 2.2 of its shares for each Perrigo share.The company's pursuit of Perrigo, a major producer of over-the-counter drugs, is widely seen as an attempt to fend off Teva, the world's biggest maker of generic drugs. The three-way chase is further evidence that the appetite for healthcare acquisitions continues unabated.M&A in the industry has hit $193.9 billion so far this year, double the amount in the same period last year.Mylan, which is legally based in the Netherlands, said on April 8 that it would make a cash-and-share bid that valued Dublin-based Perrigo at $205 per share but did not detail the breakdown between shares and cash to be offered. The offer announced on Friday works out to about $222 per share, based on Mylan's Thursday close, valuing Perrigo at about $31 billion, according to Thomson Reuters data.However, Perrigo said the offer valued it at $181.67 per share based on Mylan's unaffected price of $55.31 per share on March 10, the last day of trading before speculation emerged that Israel-based Teva was considering an offer for Mylan.Mylan's shares have risen by about a third since March 10. ""Today's announcement from Mylan proposes a price that is lower than the previously rejected proposal,"" Perrigo said.Perrigo's shares were down 3 percent at $195 in early afternoon trading on Friday, while Mylan's stock was up 2.8 percent at $75.75.Mylan said its offer was fully financed and not conditional on due diligence.The cash portion will be financed by a new bridge credit facility arranged by Goldman Sachs, the company said.Teva said in an emailed statement that it remained fully committed to its Mylan offer.   (Reporting by Ankur Banerjee in Bengaluru, Nadia Damouni in New York; Editing by Sriraj Kalluvila and Ted Kerr)",2015-04-24,MYL,"Fri Apr 24, 2015 | 12:57pm EDT",UPDATE 2-Generic drugmaker Mylan goes hostile in bid for Perrigo,http://www.reuters.com//article/perrigo-company-ma-mylan-idUSL4N0XL5LU20150424?type=companyNews
115,"  April 24 Generic drugmaker Mylan NV said on Friday it would commence a formal offer to acquire Perrigo Co Plc, three days after Perrigo rejected its unsolicited offer.Perrigo shareholders will receive $60 in cash and 2.2 Mylan ordinary shares for each Perrigo ordinary share, Mylan said.Perrigo unanimously rejected Mylan's $205 per share offer on Tuesday, saying the bid substantially undervalued the company. ""Mylan has today begun a legally-binding process under the Irish Takeover Rules to commence its offer for Perrigo ...,"" Executive Chairman Robert Coury said in a statement on Friday. Mylan received an unsolicited $40 billion offer from larger rival Teva Pharmaceutical Industries Ltd on Tuesday. (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)",2015-04-24,MYL,"Fri Apr 24, 2015 | 10:20am EDT",Mylan says to commence offer for Perrigo,http://www.reuters.com//article/perrigo-company-ma-mylan-idUSL4N0XL5IW20150424?type=companyNews
116,"  LONDON, April 24 Worldwide dealmaking in the healthcare sector has doubled this year compared with the same time in 2014, buoyed by Teva Pharmaceuticals Industries'  unsolicited $40 billion bid for smaller rival Mylan  this week, Thomson Reuters data shows.So far this year, deals worth $193.9 billion have been announced in healthcare, the data shows. Worldwide M&A is up 23 percent year-to-date versus the same period last year, with deals worth $1,186 trillion having been struck so far.  (For more weekly data click here: here%20Scorecard%20Template%20042315.pdf)   (Reporting By Anjuli Davies; Editing by Pravin Char)",2015-04-24,MYL,"Fri Apr 24, 2015 | 4:37am EDT",Global healthcare M&A doubles versus 2014,http://www.reuters.com//article/investment-banking-scorecard-idUSL5N0XL1LA20150424?type=companyNews
117,"  (Repeats story first published late on Friday)By Caroline Humer and Ransdell PiersonNEW YORK, April 24 Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings.Both issues will factor into any antitrust review, they said.Teva , the world's largest generic drugmaker, made its $40 billion offer public on Tuesday and quickly signaled it was ready to sell some overlapping assets to win antitrust approval for a deal.Mylan has not responded to the unsolicited bid but has said it wants to remain independent and that the overlap with Teva's products could scuttle a combination. It is also pursuing a hostile takeover of drugmaker Perrigo Co Plc .Most treatments used by the U.S. public are cheaper generic copies of brand-name medications. The percentage has grown as leading drugs lost patent protection in the last decade and health insurers sought ways to rein in costs. But manufacturing generics is a low-margin business, prompting companies to reduce production of some drugs over time.Previous industry mergers have also reduced capacity, and manufacturing lapses at some plants have delayed or shuttered production, leading to temporary shortages of cancer drugs, anesthesia and other medicines.Teva has already looked at the competitive overlap between its portfolio and Mylan's, and started discussions with the Federal Trade Commission about the possible merger, sources familiar with the situation said. Mylan makes 360 generic products for the U.S. market, while Teva manufactures 375. The FTC has studied the potential impact of a pharmaceutical deal on drug shortages. In reviewing the 2012 merger of generics makers Actavis and Watson Pharmaceuticals, the agency said it ""evaluated whether the proposed transaction would exacerbate any of those (drug) shortages.""Typically, the FTC wants to be sure there are several competitors making a particular medicine so that production would continue even if one manufacturing source shuts down, sources familiar with the situation said.""The FTC should be thinking about and not wanting to approve mergers that would worsen the conditions that would cause shortages,"" said an antitrust expert who requested anonymity because he wished to protect his business relationships. ""The fewer production facilities that there are, the greater susceptibility to price fluctuations.""Prices for generic drugs sometimes spike when supplies dry up. Last fall, Independent Senator Bernie Sanders and Democratic Representative Elijah Cummings opened an investigation into 14 drug companies about generic price increases. The office of the inspector general of the Department of Health and Human Services is also planning to a review.""All the manufacturing consolidation makes us nervous,"" said Dr. Beverly Philip, a professor of anesthesiology at Harvard Medical School. With some shortages, doctors have had to shift patients to medicines that may not work as well. If Teva buys Mylan and phases out some of its less-profitable sterile injectable drugs, both for anesthesia and other uses, she said, it would tighten the screw another notch.LOOKING AT COMPETITION Globally, Teva holds 12 percent of the global generic market, while Novartis AG, Actavis and Mylan each account for about 9 percent, according to UK market intelligence firm Evaluate Ltd. Their U.S. market shares are less clear because generic drug company reporting on product sales varies.Wells Fargo analyst Michael Faerm estimates a combined Teva-Mylan would account for 22 percent of U.S. prescriptions. Morningstar Research analyst Michael Waterhouse put the U.S. combined share at about 25 percent of the retail generic market, which is about $31 billion. But those numbers do not reflect the overlap between their businesses. Teva sells more than 50 percent of the U.S. generic products also sold by Mylan, said Louise Pearson, an analyst with Germany's Berenberg Bank, citing data from IMS Health. IMS Health was not immediately available to verify the figures.In the case of overlapping products, antitrust regulators will want to see that they have at least three or four competitors. If not, the companies considering a merger may need to sell the product line to another party, the antitrust experts and two of the sources said. The FTC would also take into account whether new competitors are about to start production.The U.S Food and Drug Administration considers more than 70 drugs to be in short supply. At least three of them are made by both Teva and Mylan: doxorubicin injections for cancer patients, haloperidol lactate injections for psychiatric patients, and antibiotic injection tobramycin. Each has three or four other manufacturers listed on the FDA website.Separately, Mylan makes four medicines in short supply, while Teva accounts for another five scarce drugs.Pressure to divest assets may also hit some big drugs that are not in short supply. Teva's biggest product is multiple sclerosis treatment Copaxone, and Mylan's generic version is under FDA review.In addition, Teva's plans for a generic version of EpiPen, Mylan's best-selling treatment for severe allergic reactions, would probably need to go, industry experts said.""In most deals you have to give up something,"" BMO Capital Markets analyst David Maris said, ""but these are two pipeline products that both companies have highlighted over and over as important for them.""(Additional reporting by Diane Bartz in Washington; Editing by Michele Gershberg and Lisa Von Ahn)",2015-04-26,MYL,"Sun Apr 26, 2015 | 8:00am EDT","RPT-DEALTALK-Drug overlaps, shortages may complicate Teva bid for Mylan",http://www.reuters.com//article/mylan-ma-antitrust-idUSL1N0XL2BI20150426?type=companyNews
118,"  (Adds Mylan, Caliber Midstream Partners, Dunnhumby, Centrica, Altera Corp and Dubal Holding; updates TORC Oil & Gas)April 27 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:** Mylan NV rejected Teva Pharmaceutical Industries Ltd's $40 billion takeover offer on Monday, saying in a scathing letter that it grossly undervalued the company and that Mylan had no interest in payment in what it termed ""high-risk"" Teva stock.** The Peugeot family plans to hold a meeting in June to iron out differences over the future of its 14.1 percent stake in the French carmaker, Les Echos newspaper reported on Monday.** Caliber Midstream Partners LP, the owner of an oil and gas pipeline network in North Dakota, is exploring a sale that it hopes could value it at as much as $1 billion, including debt, according to people familiar with the process.** Rare disease drugmaker Swedish Orphan Biovitrum  said a potential buyer had made a preliminary takeover proposal, the latest company to be sucked into a wave of deal-making in the healthcare sector.** Australian telecommunications firm M2 Group Ltd  said it proposed to buy Internet service provider iiNet Ltd  for A$1.6 billion ($1.3 billion), trumping an approach by rival TPG Telecom Ltd and raising the prospect of a bidding war.** U.S.-based Applied Materials Inc scrapped its $10 billion planned takeover of chip-making gear rival Tokyo Electron Ltd after the deal, a rare foreign bid for a Japanese firm, fell foul of U.S. anti-trust regulators.** Cap Gemini SA, a French information technology services company, said it will buy U.S.-based rival IGATE Corp  for $4 billion in a deal that would make North America into its biggest market and hand IGATE's founders a $1 billion windfall.** France's EDF wants to sell its minority stake in Austrian regional utility Energie Steiermark for 270 million to 340 million euros ($294-370 million), the Wirtschaftsblatt newspaper reported on Monday. ** Canadian intermediate producer TORC Oil & Gas Ltd  is buying light oil assets from Surge Energy Inc in the Canadian Bakken region of southeast Saskatchewan and Manitoba for C$430 million ($354 million), Surge said on Monday.** Dunnhumby, the customer data business which has been put up for sale by British retailer Tesco, said it was free to work with new clients in the United States, in a move which could make it more attractive to potential buyers.** Britain's largest energy supplier Centrica has made preparations in case it is approached with a takeover offer, the utility's chairman said at the company's annual shareholders' meeting in London.** TIG Advisors LLC, an investment firm that holds shares in Altera Corp, challenged a nomination to the company's board of directors on Monday over Altera's refusal to engage with Intel Corp about a potential merger.** Dubal Holding, the holding company for Dubai's stake in Emirates Global Aluminium and other assets, is considering possible acquisitions in local and international energy projects, it said on Monday. ** An investment management company is seeking to prevent French telecommunications company Orange SA shifting to a system where long-term investors get two votes per share rather than one, a move that has failed in other high-profile cases.** Royal Bank of Scotland has sold a further portfolio of North American loans to Mizuho, as it continues to sell off unwanted international assets to focus on domestic lending.** China will likely cut the number of its central government-owned conglomerates to 40 through massive mergers, as Beijing pushes forward a sweeping plan to overhaul the country's underperforming state sector, the state media reported on Monday.** Australian television broadcaster Ten Network Holdings Ltd on Monday said it was in talks with Rupert Murdoch's local cable TV operator Foxtel about a potential investment in the struggling free-to-air network. ** Britain's outgoing government has told BP Plc that it wanted the company to remain a British industrial champion and it would oppose any takeover of the oil producer, the Financial Times reported.** The Swiss family that controls chemicals business Sika  said it was seeking to overturn several decisions made at a recent investor meeting over a 2.75 billion Swiss franc ($2.88 billion) takeover by French rival Saint-Gobain.** HSBC, Europe's biggest bank, was weighing plans to spin off its British retail bank in a 20 billion-pound ($30.37 billion) deal, the Sunday Times reported.** Ratan Tata, chairman emeritus of the holding company of India's Tata conglomerate, has acquired a stake in Xiaomi Technology, a deal that is likely to bolster the Chinese phone maker's presence in the world's third-largest smartphone market.** UBI, Italy's fifth-biggest bank, does not rule out a tie-up with troubled Monte dei Paschi di Siena  but will not be pushed into an unwanted deal, its chief executive said on Saturday.** Czech energy group CEZ was less likely to buy a 66 percent stake in the main Slovak electricity producer from Italy's Enel due to opposition from the Slovak government controlling the minority, CEZ's CEO was quoted as saying.** Deutsche Bank will cut back investment banking, sell its Postbank retail chain via a public share offering and reduce costs, the group said late on Friday, in a restructuring plan designed to boost profits.** SunTrust Banks Inc, Apollo Global Management  and Ares Management LP are considering offers for buying General Electric Co's unit that lends to private-equity firms in the United States, Bloomberg reported, citing people with knowledge of the matter.** Japan's Inpex Corp became the first Asian oil company to get a stake in a new 40-year onshore oil concession in Abu Dhabi, joining France's Total in developing the United Arab Emirates' (UAE) biggest oilfields.   ($1 = C$1.21)      ($1 = 6.20 Chinese yuan renminbi)  ($1 = 0.92 euros)  ($1 = 1.28 Australian dollars)   (Compiled by Yashaswini Swamynathan and Manya Venkatesh in Bengaluru)",2015-04-27,MYL,"Mon Apr 27, 2015 | 4:00pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N0XO3TX20150427?type=companyNews
119,"   By Caroline Humer  Mylan NV (MYL.O) rejected Teva Pharmaceutical Industries Ltd's (TEVA.TA) $40 billion takeover offer on Monday, saying in a scathing letter that it grossly undervalued the company and that Mylan has no interest in payment in what it termed ""high-risk"" Teva stock.Teva, the world's biggest maker of generic drugs, quickly responded to Mylan's refusal with word that it was ""fully committed"" and would move forward with the $82 per share cash and stock offer. Teva said it had begun the regulatory approval process and that it expects to complete a deal by the end of 2015. The company will meet with Mylan shareholders this week, according to sources familiar with the situation. The Israeli company will need Mylan shareholders like Paulson & Co on its side if it wants to get past the poison pill defense, aimed at making a takeover prohibitively expensive, that Netherlands-based Mylan has put into place.Mylan's rejection was widely expected and sets up a three-way battle as it pursues its own hostile takeover of over-the-counter drugmaker Perrigo Co Plc (PRGO.N).Sanford Bernstein analyst Ronny Gal said Teva is not likely to walk away while its is meeting with Mylan investors to ask them to advocate the merits of a deal to the Mylan board. ""If they (Teva) feel the shareholders are willing sellers..., then they will probably push it,"" Gal said. ""If they feel there is no interest among shareholders in doing the deal at a price it can afford, then they will probably walk away.""Mylan shares fell 5.7 percent to $71.71 on Nasdaq, and Teva fell 3.8 percent to $61.93 on the New York Stock Exchange. 'High-Risk Currency'Mylan Executive Chairman Rob Coury said in a lengthy, critical letter to Teva released on Monday that Mylan's $82 per share offer was too low. Coury said the board of directors would not consider any discussions unless ""the starting point"" was ""significantly in excess of $100 per share.""Wall Street analysts had said Mylan might be looking for $90 to $95 per share and an increased cash component. Coury said in the letter, which described Teva's culture as  ""dysfunctional,"" that Teva's stock had underperformed its peers, including Mylan, over the last three years and was ""unacceptable.""""The Mylan board has no interest in considering an expression of interest that... requires Mylan shareholders to accept what we believe is low-quality and high-risk currency in the form of Teva shares,"" it said. In addition, it said its customers and partners did not support the possible combination. (Reporting by Caroline Humer, Bill Berkrot and Ransdell Pierson in New York and Ankur Banerjee in Bengaluru; Editing by Maju Samuel and Dan Grebler)",2015-04-27,MYL,"Mon Apr 27, 2015 | 2:25pm EDT","Mylan says Teva offer too low; criticizes stock, growth prospects",http://www.reuters.com//article/us-mylan-m-a-teva-pharm-ind-idUSKBN0NI1DE20150427?type=companyNews
120,"  (Recasts with details, context; adds analyst comment)By Caroline HumerApril 27 Mylan NV rejected Teva Pharmaceutical Industries Ltd's $40 billion takeover offer on Monday, saying in a scathing letter that it grossly undervalued the company and that Mylan has no interest in payment in what it termed ""high-risk"" Teva stock.Teva, the world's biggest maker of generic drugs, quickly responded to Mylan's refusal with word that it was ""fully committed"" and would move forward with the $82 per share cash and stock offer.Teva said it had begun the regulatory approval process and that it expects to complete a deal by the end of 2015. The company will meet with Mylan shareholders this week, according to sources familiar with the situation.The Israeli company will need Mylan shareholders like Paulson & Co on its side if it wants to get past the poison pill defense, aimed at making a takeover prohibitively expensive, that Netherlands-based Mylan has put into place. Mylan's rejection was widely expected and sets up a three-way battle as it pursues its own hostile takeover of over-the-counter drugmaker Perrigo Co Plc.Sanford Bernstein analyst Ronny Gal said Teva is not likely to walk away while its is meeting with Mylan investors to ask them to advocate the merits of a deal to the Mylan board.""If they (Teva) feel the shareholders are willing sellers..., then they will probably push it,"" Gal said. ""If they feel there is no interest among shareholders in doing the deal at a price it can afford, then they will probably walk away."" Mylan shares fell 5.7 percent to $71.71 on Nasdaq, and Teva fell 3.8 percent to $61.93 on the New York Stock Exchange.'High-Risk Currency' Mylan Executive Chairman Rob Coury said in a lengthy, critical letter to Teva released on Monday that Mylan's $82 per share offer was too low. Coury said the board of directors would not consider any discussions unless ""the starting point"" was ""significantly in excess of $100 per share.""Wall Street analysts had said Mylan might be looking for $90 to $95 per share and an increased cash component.Coury said in the letter, which described Teva's culture as  ""dysfunctional,"" that Teva's stock had underperformed its peers, including Mylan, over the last three years and was ""unacceptable.""""The Mylan board has no interest in considering an expression of interest that... requires Mylan shareholders to accept what we believe is low-quality and high-risk currency in the form of Teva shares,"" it said.In addition, it said its customers and partners did not support the possible combination.      (Reporting by Caroline Humer, Bill Berkrot and Ransdell Pierson in New York and Ankur Banerjee in Bengaluru; Editing by Maju Samuel and Dan Grebler)",2015-04-27,MYL,"Mon Apr 27, 2015 | 2:24pm EDT","UPDATE 4-Mylan says Teva offer too low; criticizes stock, growth prospects",http://www.reuters.com//article/mylan-ma-teva-pharm-ind-idUSL4N0XO5DJ20150427?type=companyNews
121,"  April 27 Mylan NV rejected Teva Pharmaceutical Industries Ltd's unsolicited $40 billion takeover offer, saying it ""grossly undervalues"" the company. The offer, announced last week, will expose Mylan to a ""problematic culture and leadership with poor record of delivering shareholder value,"" Mylan said on Monday.      (Reporting by Ankur Banerjee in Bengaluru; Editing by Maju Samuel)  ",2015-04-27,MYL,"Mon Apr 27, 2015 | 9:31am EDT",Mylan rejects Teva's $40 bln offer,http://www.reuters.com//article/mylan-ma-teva-pharm-ind-idUSL4N0XO5CC20150427?type=companyNews
122,"   By Bill Berkrot and Ankur Banerjee  Perrigo Co Ltd (PRGO.N) on Wednesday rejected a sweetened takeover offer from Mylan NV (MYL.O), while Teva Pharmaceutical Industries Ltd (TEVA.TA) said it remains committed to acquiring Mylan, in a high stakes battle of major generic drugmakers.Mylan's pursuit of Perrigo, which also sells over-the-counter consumer products, is widely seen as an attempt to fend off Teva, the world's biggest maker of generic drugs.Mylan's latest offer, worth $34.1 billion, comprised $75 in cash and 2.3 of its shares for each Perrigo share, up from a previous $60 in cash and 2.2 shares. With Mylan raising its bid for Perrigo, it appeared more likely that Teva would increase the size of the cash component of its rejected bid for Mylan, Leerink analyst Jason Gerberry said.Based on Mylan's Tuesday close, the raised offer valued  Perrigo at $242 per share. The previous offer was about $220 per share. Perrigo said it viewed Mylan's latest offer to be worth $202.20, based on Mylan's March 10 share price of $55.31, before speculation over Teva's interest in Mylan pushed up the stock.""Today's announcement from Mylan continues to propose a price lower than the previously rejected proposal,"" Perrigo said.Mylan summarily rejected Teva's $40 billion offer on Monday, saying it grossly undervalued the company, and made public a scathing letter to Teva management from Executive Chairman Robert Coury, who took several shots at the Israel-based company. Coury said Mylan did not want to be paid with Teva's ""high-risk"" stock and he raised antitrust issues. Teva Chief Executive Erez Vigodman responded on Wednesday in a letter to Coury that took exception to the tone of Coury's response and attempted to rebut Mylan's lengthy list of objections to a deal.Vigodman said Coury painted ""a fundamentally distorted picture of Teva"" and that stakeholders of the two companies do not ""benefit from mudslinging, mischaracterization, rehashing of history or selective presentation of facts.""Teva said its $82-per-share cash and stock offer was now worth $43 billion and was ""more attractive"" for Mylan shareholders than any alternative. It also said it did not see significant antitrust hurdles, adding that any potential divestitures would be manageable. ""We certainly hope that the Mylan board of directors chooses to engage constructively with us as soon as possible in order to reach agreement on a combination that offers an unparalleled opportunity for value-creation and many other benefits for our respective stockholders, customers, patients and employees. This is a message we are hearing from more and more stockholders of Teva and Mylan,"" Vigodman concluded in his letter.Mylan, which is legally based in the Netherlands, said last week it would take its offer for Perrigo directly to shareholders after being rejected.Dublin-based Perrigo's shares closed down 0.9 percent at $184.74 on the New York Stock Exchange, while Mylan's shares closed up 2.5 percent at $74.50 on the Nasdaq. Teva shares trading in New York closed up 1.3 percent at $62.08. (Reporting by Ankur Banerjee in Bengaluru and Bill Berkrot and Nadia Damouni in New York; Editing by Saumyadeb Chakrabarty, Savio D'Souza and Steve Orlofsky)",2015-04-29,MYL,"Wed Apr 29, 2015 | 6:47pm EDT",Perrigo rejects raised Mylan bid; Teva recommits to Mylan buy,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-nl-idUSKBN0NK1K520150429?type=companyNews
123,"  * Mylan offers $75 and 2.3 Mylan shares per Perrigo share* Perrigo rejects Mylan's offer again* Teva responds to Mylan rejection   (Adds details from Teva letter to Mylan, updates shares)By Bill Berkrot and Ankur BanerjeeApril 29 Perrigo Co Ltd on Wednesday rejected a sweetened takeover offer from Mylan NV, while Teva Pharmaceutical Industries Ltd said it remains committed to acquiring Mylan, in a high stakes battle of major generic drugmakers.Mylan's pursuit of Perrigo, which also sells over-the-counter consumer products, is widely seen as an attempt to fend off Teva, the world's biggest maker of generic drugs.Mylan's latest offer, worth $34.1 billion, comprised $75 in cash and 2.3 of its shares for each Perrigo share, up from a previous $60 in cash and 2.2 shares. With Mylan raising its bid for Perrigo, it appeared more likely that Teva would increase the size of the cash component of its rejected bid for Mylan, Leerink analyst Jason Gerberry said.Based on Mylan's Tuesday close, the raised offer valued  Perrigo at $242 per share. The previous offer was about $220 per share.Perrigo said it viewed Mylan's latest offer to be worth $202.20, based on Mylan's March 10 share price of $55.31, before speculation over Teva's interest in Mylan pushed up the stock. ""Today's announcement from Mylan continues to propose a price lower than the previously rejected proposal,"" Perrigo said.Mylan summarily rejected Teva's $40 billion offer on Monday, saying it grossly undervalued the company, and made public a scathing letter to Teva management from Executive Chairman Robert Coury, who took several shots at the Israel-based company. Coury said Mylan did not want to be paid with Teva's ""high-risk"" stock and he raised antitrust issues.Teva Chief Executive Erez Vigodman responded on Wednesday in a letter to Coury that took exception to the tone of Coury's response and attempted to rebut Mylan's lengthy list of objections to a deal. Vigodman said Coury painted ""a fundamentally distorted picture of Teva"" and that stakeholders of the two companies do not ""benefit from mudslinging, mischaracterization, rehashing of history or selective presentation of facts.""Teva said its $82-per-share cash and stock offer was now worth $43 billion and was ""more attractive"" for Mylan shareholders than any alternative. It also said it did not see significant antitrust hurdles, adding that any potential divestitures would be manageable.""We certainly hope that the Mylan board of directors chooses to engage constructively with us as soon as possible in order to reach agreement on a combination that offers an unparalleled opportunity for value-creation and many other benefits for our respective stockholders, customers, patients and employees. This is a message we are hearing from more and more stockholders of Teva and Mylan,"" Vigodman concluded in his letter.Mylan, which is legally based in the Netherlands, said last week it would take its offer for Perrigo directly to shareholders after being rejected.Dublin-based Perrigo's shares closed down 0.9 percent at $184.74 on the New York Stock Exchange, while Mylan's shares closed up 2.5 percent at $74.50 on the Nasdaq. Teva shares trading in New York closed up 1.3 percent at $62.08.     (Reporting by Ankur Banerjee in Bengaluru and Bill Berkrot and Nadia Damouni in New York; Editing by Saumyadeb Chakrabarty, Savio D'Souza and Steve Orlofsky)",2015-04-29,MYL,"Wed Apr 29, 2015 | 6:42pm EDT",UPDATE 4-Perrigo rejects raised Mylan bid; Teva recommits to Mylan buy,http://www.reuters.com//article/perrigo-company-ma-mylan-nl-idUSL4N0XQ4ML20150429?type=companyNews
124,"  (Adds Perrigo, Turk Telekom, Ophir Energy, Bombardier and Cenovus Energy)April 29 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:** Mylan NV boosted its cash-and-stock offer to buy Perrigo Co Plc to $34.10 billion, a bid that was swiftly rejected.** XPO Logistics Inc has agreed to buy France's Norbert Dentressangle SA for $3.53 billion, including debt, in a deal it says will make it one of the top 10 logistics company in the world.** Egypt's Mobinil said it had sold its stake in an Egyptian mobile tower services firm to a subsidiary of telecommunications tower firm Eaton Towers in a deal worth about 1 billion Egyptian pounds ($131.06 million).** Volkswagen's finance chief said the carmaker has no merger or acquisition plans beyond ongoing discussions with its Chinese joint venture partner FAW that may result in its increasing its stake.** Israel's planned sale of one of its largest defense contractors has received interest from more than 20 Israeli and foreign entities, the country's privatization chief said. A decade after its last privatization program, the government aims to sell all or part of eight companies and two ports by 2017, raising around $4 billion.** Fixed-line operator Turk Telekom said on Wednesday that it agreed to buy the remaining 10 percent stake in wireless company Avea from lender IS Bank for 875 million lira ($330 million).** Poland's richest man, Jan Kulczyk, has put his 8 percent stake worth around 92 million pounds ($142 million) in oil company Ophir Energy on the market, bookrunner JP Morgan Securities said in a statement. ** China's top two trainmakers have been in discussions with Bombardier Inc about possibly buying a controlling stake in the Canadian company's railway unit, two sources with direct knowledge of the matter said.** Cenovus Energy Inc will sell or spin off its wholly-owned oil and gas lands when it believes market value for the properties meet its expectations, Chief Executive Brian Ferguson said on Wednesday.** Slovakia will talk with Enel on raising the government's stake in utility Slovenske Elektrarne to a majority, pushing the Italian group to change a plan to sell its entire 66 percent share to a private investor.** Dubai Investments said it plans to enter new markets in Africa and the Gulf region. ""Several new investment proposals are currently under evaluation, with some of them in advanced stages of negotiations,"" Khalid bin Kalban, the firm's chief executive said. ** Consumer products company Spectrum Brands Holdings Inc  agreed to buy Armored AutoGroup Parent Inc, a maker of car care products, for $1.4 billion from private equity firm Avista Capital Partners.** China's top two trainmakers have been in discussions with Bombardier Inc about possibly buying a controlling stake in the Canadian company's railway unit, two sources with direct knowledge of the matter said.** Barrick Gold Corp is targeting the sale of up to a 50 percent stake in its Zaldivar copper mine in Chile but would consider selling a bigger stake if it got a ""knock-out"" offer, company co-president Kelvin Dushnisky said.** Aer Lingus is ""hopeful"" that talks between its suitor British Airways-owner IAG and the Irish government, one of its biggest shareholders, will conclude in the short term, its executive counsel said on Wednesday. ** China Minsheng Banking Corp (CMBC) , the country's biggest private lender, said late on Tuesday it's in talks to invest as much as $970 million for a controlling stake in Hong Kong-based securities firm Quam Ltd.** Creditors of Asiana Airlines' parent Kumho Industrial Co Ltd 002990.KS have rejected a 600.7 billion won ($561.88 million) bid for a controlling stake in Kumho as the price was too low, a spokesman for the lead creditor said on Wednesday.** Slovak Prime Minister Robert Fico said on Wednesday his government would start talks with Enel to raise the state's stake in utility Slovenske Elektrarne, possibly thwarting the Italian group's current plan to sell its entire 66 percent stake to a private bidder.** NMC Health, the London-listed and United Arab Emirates-based healthcare provider, has bought two healthcare service providers in the Gulf Arab state for an enterprise value of $100 million, NMC said on Wednesday.** PT Cakra Mineral TbK slightly raised a bid for Cokal Ltd to A$75.5 million ($60.4 million), winning the backing of its Australian target which owns a coal project in Indonesia.**  French sugar maker Tereos has agreed to buy sugar distributor Napier Brown Sugar Ltd, a unit of Real Good Food, for 34 million pounds ($52.27 million) plus working capital in cash on completion of the sale, Real Good Food said in a statement on Wednesday.** Bank Islami Pakistan, the country's second-largest full-fledged Islamic bank, said it would submit plans on Wednesday to buy troubled lender KASB Bank Ltd  for a nominal fee.($1 = 1,069.08 won)  ($1 = 1.25 Australian dollars)  ($1 = 101.65 Pakistani rupees)  ($1 = 0.65 pounds)  ($1 = 7.63 Egyptian pounds)  ($1 = 2.65 liras)   (Compiled by Yashaswini Swamynathan, Rosmi Shaji and Manya Venkatesh in Bengaluru)",2015-04-29,MYL,"Wed Apr 29, 2015 | 4:00pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N0XQ4JV20150429?type=companyNews
125,"   By Nadia Damouni and Olivia Oran  Generic drugmaker Perrigo Company Plc (PRGO.N)> is expected to reject the latest offer made on Wednesday by Mylan NV (MYL.O), according to a person familiar with the matter.Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share under Mylan's latest offer. Perrigo sees this offer to be worth only $202.21 based on Mylan's unaffected March 10 share price of $55.31, before speculation over Teva Pharmaceuticals Ltd's (TEVA.TA) interest in Mylan intensified, according to the source.The source asked not to be identified because the deliberations are confidential. Perrigo and Mylan spokespeople did not immediately respond to requests for comment.Mylan last week raised its original offer to $60 in cash and 2.2 Mylan shares, valuing Perrigo at $222 a share. Perrigo said that offer valued it at $181.67 per share, based on the Mylan's March 10 share price.  Mylan, which makes the EpiPen product for severe allergies, is pursuing an offer for Perrigo as it fends off an unsolicited takeover from larger rival Teva Pharmaceuticals Industries Ltd (TEVA.TA). Mylan on Tuesday rejected Teva's $40 billion offer, saying it ""grossly undervalues"" the company. Teva said it is ""fully committed"" and will move forward with the offer.Teva has also said its offer for Mylan is contingent on the company's not completing an acquisition of Perrigo or any alternative transaction. Perrigo, which has a large portfolio of over-the-counter consumer products, infant formulas and a line of generic topical pharmaceutical medicines, has long been seen as a takeover target.A tie-up between Perrigo and Mylan would be the latest in a string of recent multibillion-dollar pharmaceutical deals, including Valeant Pharmaceuticals International Ltd's (VRX.TO) $11 billion deal for Salix Pharmaceuticals Ltd and AbbVie Inc's (ABBV.N) $21 billion offer for Pharmacyclics Inc PCYC.O.  (Reporting by Nadia Damouni and Olivia Oran in New York; Editing by Chris Reese and Meredith Mazzilli)",2015-04-29,MYL,"Wed Apr 29, 2015 | 10:43am EDT",Perrigo expected to reject Mylan's latest offer: source,http://www.reuters.com//article/us-perrigo-m-a-mylan-idUSKBN0NK1OW20150429?type=companyNews
126,"  (Adds Dow Chemical, Roberto Cavalli, Audience Inc, WuXi PharmaTech Cayman, United Finance Co; updates OmniVision Technologies)April 30 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:** Perrigo Co Ltd rejected a sweetened takeover offer from Mylan NV, while Teva Pharmaceutical Industries Ltd said it remains committed to acquiring Mylan, in a high stakes battle of major generic drugmakers.** Royal Dutch Shell is still looking for targets after agreeing to buy rival BG for $70 billion but has not got the resources to perform another mega-deal, Chief Financial Officer Simon Henry said.** Bermuda-based Axis Capital Holdings said it continued to believe a merger with reinsurer PartnerRe  was in the best interests of its shareholders. In January, the two companies agreed on an $11 billion deal meant to close in the second half of this year.** OmniVision Technologies Inc, a maker of chips for smartphone and tablet cameras, agreed to be taken private by a group of Chinese investors for about $1.9 billion in cash.** Dow Chemical Co said it would sell its AgroFresh unit, which makes chemicals that keep farm produce fresh, for $860 million as part of a plan to divest less-lucrative units.** Italian private equity fund Clessidra acquired control of fashion house Roberto Cavalli on Thursday for an undisclosed sum, concluding one of the longest running courtships in the luxury goods industry.** Audio-chip maker Audience Inc, which has struggled since losing Apple Inc as its No. 1 customer in 2012, agreed to a distress sale to hearing-aid component maker Knowles Corp in a cash-and-stock deal valued at $85 million.** WuXi PharmaTech Cayman Inc, a contract R&D services provider, said it had received a proposal to be taken private by a consortium led by its chief executive and Ally Bridge Group Capital Partners. The offer values the China-based company at about $3.23 billion and represents a 16.5 percent premium to its closing price on Wednesday, according to Thomson Reuters calculations.** National Bank of Oman has offered to buy fellow domestic lender United Finance Co, challenging a potential merger with Bank Nizwa in the country's cluttered banking sector.** An investor in John Menzies has called on the Scottish company to consider splitting up, believing its distribution and aviation services businesses would be worth more apart. ** Cloud software company Salesforce.com Inc is working with financial advisers to help it field takeover offers after being approached by a potential acquirer, Bloomberg said, citing people with knowledge of the matter.** Eurocement Holding AG, Holcim Ltd's  second-largest shareholder, said it supports the Swiss cement maker's planned merger with France's Lafarge SA.** Abu Dhabi Investment Authority (ADIA) has agreed to buy a 50 percent stake in three Hong Kong hotels from a group led by New World Development Co Ltd in a HK$18.5 billion ($2.4 billion) deal, the sovereign wealth fund's biggest Asian property investment.** The bidding for a controlling stake in Hewlett-Packard Co's data-networking business in China, worth more than $2 billion, has thrown up a rare tussle between two Chinese state-backed firms who are wrangling over which has Beijing's backing.** Australian telecommunications firm iiNet Ltd gave prospective buyer TPG Telecom Ltd three days to lift an indicative takeover bid after another rival, M2 Group Ltd , launched a A$1.6 billion ($1.28 billion) counteroffer. ** ClickSoftware Technologies said it signed a deal to be bought by private funds managed by Francisco Partners Management for $438 million in cash.** Titanium miner Kenmare Resources Plc   received a watered-down share offer from Australia's Iluka Resources Ltd, valuing the Irish company at about 189 million pounds ($292.5 million), and said that it was talking to Iluka.** Newmont Mining Corp said it has tentatively agreed to sell its Waihi gold mining operation in New Zealand to OceanaGold Corp for about $106 million plus a 1 percent net smelter royalty on a recent discovery near the mine.** Tencent Holdings Ltd, the dominant social networking and online entertainment company in China, has agreed to buy 14.6 percent of mobile game developer Glu Mobile Inc  for $126 million to expand in the U.S. gaming market.** Russia's Eurasia Drilling said it had agreed to extend a deadline on a proposed deal to sell a stake to international oilfield services firm Schlumberger from to April 30 to May 31. ** British property search website Zoopla said it was buying price comparison service uSwitch for 160 million pounds ($247 million), to offer deals on home energy to the millions of customers that visit its websites and mobile apps.** Bank of Cyprus said it had disposed of its holding in Marfin Diversified Strategy Fund to Dorchester Capital Secondaries Offshore III, for approximately $92 million.** Swiss firm Kaba and Germany's Dorma Holding said they plan to merge to form a top-three player in the building security and ""access products"" market, a category including door locks and keys.** PostNL, the Netherlands-based postal company, said it had ended talks with LDC on expanding PostNL's ""Whistl"" subsidiary in Britain to include broader ""end-to-end"" services.** Ukrainian miner Ferrexpo is considering a potential sale of its entire stake in Brazilian iron ore production company Ferrous Resources.** Japan Tobacco said it had agreed to buy Florida-based e-cigarette maker Logic Technology Development LLC as it aims to become a global leader in the nascent, but fast-growing, market.** China's Yangzijiang Shipbuilding Holdings Ltd  is considering a possible investment in troubled peer China Huarong Energy Co Ltd, formerly known as China Rongsheng, its executive chairman said.** Brazilian homebuilder Gafisa SA said in a securities filing that it had been approached by groups of investors interested in taking a stake in one or two of the company's divisions.** Greece's government is considering selling stakes in its two largest ports as a concession to reach an agreement with its lenders and unlock bailout funds, a government official said.($1 = 1.2519 Australian dollars)  ($1 = 6.1989 Chinese yuan)  ($1 = 7.7504 Hong Kong dollars)  ($1 = 0.6482 pounds)   (Compiled by Yashaswini Swamynathan and Manya Venkatesh in Bengaluru)",2015-04-30,MYL,"Thu Apr 30, 2015 | 4:02pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N0XR4WX20150430?type=companyNews
127,"   By Tova Cohen | TEL AVIV  TEL AVIV Teva Pharmaceutical Industries (TEVA.N) raised its 2015 earnings forecast after beating first-quarter estimates, and said it would devote ""all necessary resources"" to its $40 billion-plus bid for rival Mylan Inc (MYL.O).In an attempt to increase its share of the generic drug market, Teva has offered $82 a share in cash and stock for Mylan, but the U.S. company has rejected this as too low.""From all perspectives this deal is compelling. It makes sense for Teva, it makes sense for Mylan,"" Teva Chief Executive Erez Vigodman told a conference call of analysts on Thursday.He said Teva would devote ""all necessary resources"" to the bid, which it values at $43 billion on a fully diluted basis.  Analysts have speculated Teva will have to sweeten its offer to win Mylan shareholders over, but Vigodman declined to comment.Teva (TEVA.TA), the world's biggest generic drugmaker, posted first-quarter earnings of $1.36 per diluted share excluding one-time items, compared with $1.23 a year earlier. Revenue was unchanged at $5.0 billion.That beat forecasts for underlying earnings of $1.25 and revenue of $4.84 billion, according to Thomson Reuters I/B/E/S. Teva shares were down 1.2 percent at $61.32 in early New York trade.Revenue from generic drugs rose 9 percent to $2.6 billion, including a 37 percent jump in the United States, mainly due to the launch of a generic version of AstraZeneca's (AZN.L) gastrointestinal drug Nexium.Global sales of Teva's best-selling multiple sclerosis (MS) drug Copaxone, which accounts for about 50 percent of profit, fell 14 percent to $924 million. Wells Fargo analyst Michael Faerm said revenues from branded drugs were weaker than expected, with the biggest shortfalls coming from Copaxone and Treanda.Two weeks ago, U.S. regulators approved the first generic version of Copaxone, developed by Sandoz, a unit of Swiss drugmaker Novartis NOVN.VX and Momenta Pharmaceuticals Inc (MNTA.O). It is not yet known when they will launch their 20 mg drug Glatopa due to ongoing patent litigation.Trying to minimize the damage, Teva has been shifting MS patients from a daily 20 mg dose to a three times a week 40 mg formulation. Though the patent of the higher dose expires in 2030, investors fear it will be challenged and possibly nullified as early as 2017. Teva officials said they felt ""very good"" about their ability to defend the 40 mg patent.Teva raised its 2015 estimate for underlying earnings per share to $5.05-$5.35 from $5.00-$5.30. It kept its revenue estimate at $19.0-$19.4 billion and said that assumed a mid-year launch of generic Copaxone.    It declared a quarterly dividend of 34 cents a share. (Additional reporting by Steven Scheer; Editing by Mark Potter)",2015-04-30,MYL,"Thu Apr 30, 2015 | 10:22am EDT",Teva lifts 2015 earnings forecast as pursues Mylan bid,http://www.reuters.com//article/us-teva-pharm-ind-results-idUSKBN0NL1DS20150430?type=companyNews
128,"  * Q1 adjusted EPS $1.36 vs $1.25 forecast* Q1 revenue $5.0 billion vs $4.84 bln forecast* Raises 2015 adjusted EPS forecast to $5.05-$5.35* Prepared to devote all resources to complete Mylan deal* Teva shares down 1.2 pct in New York   (Adds comments on Mylan, Copaxone, analyst, shares)By Tova CohenTEL AVIV, April 30 Teva Pharmaceutical Industries raised its 2015 earnings forecast after beating first-quarter estimates, and said it would devote ""all necessary resources"" to its $40 billion-plus bid for rival Mylan Inc.In an attempt to increase its share of the generic drug market, Teva has offered $82 a share in cash and stock for Mylan, but the U.S. company has rejected this as too low. ""From all perspectives this deal is compelling. It makes sense for Teva, it makes sense for Mylan,"" Teva Chief Executive Erez Vigodman told a conference call of analysts on Thursday.He said Teva would devote ""all necessary resources"" to the bid, which it values at $43 billion on a fully diluted basis.  Analysts have speculated Teva will have to sweeten its offer to win Mylan shareholders over, but Vigodman declined to comment.Teva, the world's biggest generic drugmaker, posted first-quarter earnings of $1.36 per diluted share excluding one-time items, compared with $1.23 a year earlier. Revenue was unchanged at $5.0 billion. That beat forecasts for underlying earnings of $1.25 and revenue of $4.84 billion, according to Thomson Reuters I/B/E/S.Teva shares were down 1.2 percent at $61.32 in early New York trade.Revenue from generic drugs rose 9 percent to $2.6 billion, including a 37 percent jump in the United States, mainly due to the launch of a generic version of AstraZeneca's  gastrointestinal drug Nexium.Global sales of Teva's best-selling multiple sclerosis (MS) drug Copaxone, which accounts for about 50 percent of profit, fell 14 percent to $924 million. Wells Fargo analyst Michael Faerm said revenues from branded drugs were weaker than expected, with the biggest shortfalls coming from Copaxone and Treanda.Two weeks ago, U.S. regulators approved the first generic version of Copaxone, developed by Sandoz, a unit of Swiss drugmaker Novartis and Momenta Pharmaceuticals Inc . It is not yet known when they will launch their 20 mg drug Glatopa due to ongoing patent litigation.Trying to minimise the damage, Teva has been shifting MS patients from a daily 20 mg dose to a three times a week 40 mg formulation. Though the patent of the higher dose expires in 2030, investors fear it will be challenged and possibly nullified as early as 2017.Teva officials said they felt ""very good"" about their ability to defend the 40 mg patent.Teva raised its 2015 estimate for underlying earnings per share to $5.05-$5.35 from $5.00-$5.30. It kept its revenue estimate at $19.0-$19.4 billion and said that assumed a mid-year launch of generic Copaxone.It declared a quarterly dividend of 34 cents a share.   (Additional reporting by Steven Scheer; Editing by Mark Potter)",2015-04-30,MYL,"Thu Apr 30, 2015 | 10:14am EDT",UPDATE 2-Teva lifts 2015 earnings forecast as pursues Mylan bid,http://www.reuters.com//article/teva-pharm-ind-results-idUSL5N0XR3UG20150430?type=companyNews
129,  April 30 Teva Pharmaceutical Industries  TEVA.N> CEO Erez Vigodman says:* Intends to devote all necessary resources to complete acquisition of Mylan  * Won't comment further on proposed Mylan deal during Q1 results conference call   Further company coverage: [ TEVA.TA MYL.O]   (Reporting By Tova Cohen and Steven Scheer) ,2015-04-30,MYL,"Thu Apr 30, 2015 | 8:13am EDT",BRIEF-Teva CEO on Mylan bid,http://www.reuters.com//article/mylan-nl-teva-pharm-ind-ceo-idUSL5N0XR42O20150430?type=companyNews
130,"   By Bill Berkrot  Generic drugmaker Mylan NV (MYL.O), at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland-based Perrigo Co (PRGO.N) and believes it can complete the deal by year end.Mylan, on a conference call with analysts, said it is legally committed to take its offer directly to Perrigo shareholders under Irish takeover rules. As proposed, the deal would give current Perrigo shareholders 39 percent of the combined company.Mylan also reported slightly higher-than-expected first-quarter profit.""We remain steadfast in our legally binding commitment to acquire Perrigo and have taken numerous concrete steps to lay out a clear and certain path towards completion,"" Mylan Chief Executive Heather Bresch said in a statement.In making its case for a combination with Perrigo, Mylan said the merger would give it massive global manufacturing and supply chain presence, add to earnings, and make it a ""stronger, larger and more diverse business"" with ""significant free cash flow.""Mylan also said it would expect to realize at least $800 million in cost savings by the end of year four after completion of the deal. ""I don't think we will disappoint on what we deliver on a short-term, mid-term and long-term basis,"" Bresch said.Perrigo, which would give Mylan over-the-counter consumer and nutritional products and a line of generic topical medicines, last week rejected a sweetened $34 billion offer from Mylan.At the same time, Mylan is attempting to fend off a takeover by Israel-based Teva Pharmaceutical Industries (TEVA.TA), the world's largest generic drugmaker, which earlier on Tuesday said it was moving ahead with plans to acquire Mylan contingent on the Perrigo deal not being completed. Teva proposed to acquire Mylan for $82 per share, or about $43 billion, in cash and stock. Mylan, in rejecting the offer, said it ""grossly undervalued"" the company. Mylan, on its call, said it would not discuss board matters or the Teva approach or answer questions related to Teva.Excluding items, such as acquisition costs for a deal with Abbott Laboratories (ABT.N) that enabled it to redomicile in Europe, Mylan earned 70 cents per share, topping analysts' average expectations by a penny, according to Thomson Reuters I/B/E/S.Mylan maintained its full-year forecast of adjusted earnings of $4 to $4.30 per share and revenue of $9.6 billion to $10.1 billion. It forecast second-quarter adjusted earnings of 86 cents to 90 cents per share. Revenue of $1.87 billion for the quarter fell short of Wall Street estimates of $2.06 billion. The company said foreign exchange rates resulting from the impact of a strong dollar on overseas sales clipped revenue by $93 million. The former Pittsburgh-based company, now headquartered in the Netherlands, posted a net profit of $56.6 million, or 13 cents per share, compared with $115.9 million, or 29 cents a share, a year ago.Mylan shares slipped to $72.60 in extended trading from a Nasdaq close at $72.89. (Reporting by Bill Berkrot; Editing by Steve Orlofsky)",2015-05-05,MYL,"Tue May 5, 2015 | 6:24pm EDT","Mylan says can close Perrigo deal by year end, reports profit",http://www.reuters.com//article/us-mylan-results-idUSKBN0NQ28L20150505?type=companyNews
131,"  (Add company comment from conference call, Q2 EPS forecast, share price)By Bill BerkrotMay 5 Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland-based Perrigo Co and believes it can complete the deal by year end.Mylan, on a conference call with analysts, said it is legally committed to take its offer directly to Perrigo shareholders under Irish takeover rules. As proposed, the deal would give current Perrigo shareholders 39 percent of the combined company.Mylan also reported slightly higher-than-expected first-quarter profit.""We remain steadfast in our legally binding commitment to acquire Perrigo and have taken numerous concrete steps to lay out a clear and certain path towards completion,"" Mylan Chief Executive Heather Bresch said in a statement.In making its case for a combination with Perrigo, Mylan said the merger would give it massive global manufacturing and supply chain presence, add to earnings, and make it a ""stronger, larger and more diverse business"" with ""significant free cash flow."" Mylan also said it would expect to realize at least $800 million in cost savings by the end of year four after completion of the deal.""I don't think we will disappoint on what we deliver on a short-term, mid-term and long-term basis,"" Bresch said.Perrigo, which would give Mylan over-the-counter consumer and nutritional products and a line of generic topical medicines, last week rejected a sweetened $34 billion offer from Mylan. At the same time, Mylan is attempting to fend off a takeover by Israel-based Teva Pharmaceutical Industries, the world's largest generic drugmaker, which earlier on Tuesday said it was moving ahead with plans to acquire Mylan contingent on the Perrigo deal not being completed.Teva proposed to acquire Mylan for $82 per share, or about $43 billion, in cash and stock. Mylan, in rejecting the offer, said it ""grossly undervalued"" the company.Mylan, on its call, said it would not discuss board matters or the Teva approach or answer questions related to Teva. Excluding items, such as acquisition costs for a deal with Abbott Laboratories that enabled it to redomicile in Europe, Mylan earned 70 cents per share, topping analysts' average expectations by a penny, according to Thomson Reuters I/B/E/S.Mylan maintained its full-year forecast of adjusted earnings of $4 to $4.30 per share and revenue of $9.6 billion to $10.1 billion. It forecast second-quarter adjusted earnings of 86 cents to 90 cents per share.Revenue of $1.87 billion for the quarter fell short of Wall Street estimates of $2.06 billion. The company said foreign exchange rates resulting from the impact of a strong dollar on overseas sales clipped revenue by $93 million.The former Pittsburgh-based company, now headquartered in the Netherlands, posted a net profit of $56.6 million, or 13 cents per share, compared with $115.9 million, or 29 cents a share, a year ago.Mylan shares slipped to $72.60 in extended trading from a Nasdaq close at $72.89.     (Reporting by Bill Berkrot; Editing by Steve Orlofsky)",2015-05-05,MYL,"Tue May 5, 2015 | 6:22pm EDT","UPDATE 2-Mylan says can close Perrigo deal by year end, reports profit",http://www.reuters.com//article/mylan-results-idUSL1N0XW2XR20150505?type=companyNews
132,  May 5   Mylan Sees q2 adjusted eps $0.86 to $0.90* Mylan says perrigo acquisition would create $800 million in synergies by year 4 after closing * Says Mylan and Perrigo are highly complementary businesses  * Mylan says confident it can close perrigo deal by year end   Further company coverage:    (Reporting By Bill Berkrot),2015-05-05,MYL,"Tue May 5, 2015 | 5:51pm EDT",BRIEF-Mylan confident it can close Perrigo deal by year end,http://www.reuters.com//article/idUSL1N0XW34920150505?type=companyNews
133,"  May 5 Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, on Tuesday reported slightly higher-than-expected first-quarter profit and said it was ""steadfast"" in its commitment to acquire Ireland-based Perrigo Co.Excluding items, such as acquisition costs for a deal with Abbott Laboratories that enabled it to redomicile in Europe, Mylan earned 70 cents per share. Analysts on average expected 69 cents, according to Thomson Reuters I/B/E/S.The former Pittsburgh-based company, now headquartered in the Netherlands, posted a net profit of $56.6 million, or 13 cents per share, compared with a net profit of $115.9 million, or 29 cents a share, a year ago. Perrigo last week rejected a sweetened $34 billion offer from Mylan. At the same time, Mylan is attempting to fend off a takeover by Israel-based Teva Pharmaceutical Industries , the world's largest generic drugmaker, which earlier on Tuesday said it was moving ahead with plans to acquire Mylan contingent on the Perrigo deal not being completed.  (Reporting by Bill Berkrot; Editing by Steve Orlofsky)",2015-05-05,MYL,"Tue May 5, 2015 | 4:25pm EDT","Mylan reports profit, maintains commitment to acquire Perrigo",http://www.reuters.com//article/mylan-results-idUSL1N0XV2YM20150505?type=companyNews
134,  May 7 Stada CEO in conference call* Says expects Russia business to bottom out in Q4 at the latest * Says Teva-Mylan merger could create antitrust-related asset sales that we will look into  * Says targeting Russia sales growth of 17-20 percent in 2015 when adjusted for currency effects  Further company coverage:,2015-05-07,MYL,"Thu May 7, 2015 | 6:37am EDT",BRIEF-Stada targets forex-adj Russia sales growth of 17-20 pct,http://www.reuters.com//article/idUSL5N0XY3FM20150507?type=companyNews
135,"   By Olivia Oran and Caroline Humer  Generics drugmaker Mylan NV, which is in the middle of a three-way takeover battle, has said it is unwilling to sell itself to Israeli rival Teva Pharmaceuticals Industries Ltd, but would consider buying that company down the road, Mylan Executive Chairman Robert Coury told investors this week.The company has been steadfast in its refusal to combine with Teva and is instead encouraging shareholders to support its own $34 billion unsolicited offer for over-the-counter drugmaker Perrigo Co Plc.Teva made an unsolicited $40 billion bid for Mylan last month, and it was rejected. Teva said on Tuesday it will move ahead with its plans to acquire Mylan if the Perrigo deal is not completed.Mylan's Coury said in a statement in April the company has studied a possible combination with Teva for some time. Mylan concluded a deal would be ""without sound industrial logic or cultural fit"" and would attract antitrust scrutiny.Mylan said in April it would not engage with Teva until the company was willing to offer more than $100 per share. Speaking privately to investors this week, however, Coury was more willing to consider a deal with Teva after the Perrigo transaction is completed, as long as Mylan is the buyer, sources told Reuters.Mylan Chief Executive Officer Heather Bresch explained to Reuters in an interview the logic behind Coury's comments. Mylan has a better management team and integrated global supply chain, as well as a superior track record with acquisitions. That would make it more capable than Teva to lead the potential combined company, she said. A deal could make sense following a Mylan-Perrigo combination and more time for Teva's management to ""clean up"" the company.""We were just saying in a hypothetical situation, if it ever were to happen after all these other things, the only way it could happen is with us,"" Bresch said. She added antitrust concerns would still exist.The investor sources declined to be named because they are not authorized to speak with the media. A Teva spokesman said the company remains deeply committed to a deal with Mylan and that there is strong strategic and cultural fit in combining the two companies.Mylan management is meeting privately with top investors this week in New York and Boston to drum up support for its bid for Perrigo. Perrigo last week rejected Mylan's latest offer worth $75 and 2.3 Mylan shares per Perigo share, up from a previous $60 in cash and 2.2 shares.Mylan, which makes the EpiPen product for severe allergies, is incorporated in the Netherlands and can take advantage of Dutch provisions that would make a hostile takeover difficult.Pressure has been growing on Jerusalem-based Teva for new revenue sources. Its biggest selling drug, multiple sclerosis injectable treatment Copaxone, faces competition from oral treatments and cheaper generics in the coming years.",2015-05-08,MYL,"Fri May 8, 2015 | 4:56pm EDT",Mylan chairman tells investors he would consider buying Teva,http://www.reuters.com//article/mylan-teva-idUSL1N0XZ2IR20150508?type=companyNews
136,"   By Olivia Oran and Caroline Humer  Generics drugmaker Mylan NV (MYL.O), which is in the middle of a three-way takeover battle, has said it is unwilling to sell itself to Israeli rival Teva Pharmaceuticals Industries Ltd (TEVA.TA), but would consider buying that company down the road, Mylan Executive Chairman Robert Coury told investors this week.The company has been steadfast in its refusal to combine with Teva and is instead encouraging shareholders to support its own $34 billion unsolicited offer for over-the-counter drugmaker Perrigo Co Plc (PRGO.N). Teva made an unsolicited $40 billion bid for Mylan last month, and it was rejected. Teva said on Tuesday it will move ahead with its plans to acquire Mylan if the Perrigo deal is not completed. Mylan's Coury said in a statement in April the company has studied a possible combination with Teva for some time. Mylan concluded a deal would be ""without sound industrial logic or cultural fit"" and would attract antitrust scrutiny.Mylan said in April it would not engage with Teva until the company was willing to offer more than $100 per share.  Speaking privately to investors this week, however, Coury was more willing to consider a deal with Teva after the Perrigo transaction is completed, as long as Mylan is the buyer, sources told Reuters. Mylan Chief Executive Officer Heather Bresch explained to Reuters in an interview the logic behind Coury's comments. Mylan has a better management team and integrated global supply chain, as well as a superior track record with acquisitions. That would make it more capable than Teva to lead the potential combined company, she said. A deal could make sense following a Mylan-Perrigo combination and more time for Teva's management to ""clean up"" the company.   ""We were just saying in a hypothetical situation, if it ever were to happen after all these other things, the only way it could happen is with us,"" Bresch said. She added antitrust concerns would still exist. The investor sources declined to be named because they are not authorized to speak with the media. A Teva spokesman said the company remains deeply committed to a deal with Mylan and that there is strong strategic and cultural fit in combining the two companies.  Mylan management is meeting privately with top investors this week in New York and Boston to drum up support for its bid for Perrigo.Perrigo last week rejected Mylan's latest offer worth $75 and 2.3 Mylan shares per Perigo share, up from a previous $60 in cash and 2.2 shares. Mylan, which makes the EpiPen product for severe allergies, is incorporated in the Netherlands and can take advantage of Dutch provisions that would make a hostile takeover difficult. Pressure has been growing on Jerusalem-based Teva for new revenue sources. Its biggest selling drug, multiple sclerosis injectable treatment Copaxone, faces competition from oral treatments and cheaper generics in the coming years. (Reporting by Olivia Oran and Caroline Humer in New York; Editing by Ted Botha and Andre Grenon)",2015-05-08,MYL,"Fri May 8, 2015 | 4:38pm EDT",Exclusive: Mylan chairman tells investors he would consider buying Teva,http://www.reuters.com//article/us-mylan-teva-idUSKBN0NT28F20150508?type=companyNews
137,"  Mylan NV's Chairman Robert Coury said he may sweeten the company's offer for Perrigo Co Plc by adding terms that will reduce risk to Perrigo's shareholders, sources told Bloomberg on Monday.People familiar with the matter said that Coury laid out scenarios that could play out in the future and had even suggested that a Mylan-Perrigo combination could be an attractive target for Pfizer Inc, Bloomberg said.   This comes after Reuters reported comments from Coury last week on how Mylan would consider buying Israeli pharma firm Teva Pharmaceutical Industries down the line.Mylan is attempting to buy over-the-counter drugmaker Perrigo for $34 billion in an unsolicited offer that is expected to turn into a hostile one. Teva, meanwhile, made an unsolicited $40 billion bid for Mylan last month, which the latter rejected. Teva said last week it will move ahead with its plans to acquire Mylan if the Perrigo deal is not completed.At the meetings, Coury also brought up the idea that Mylan could make a deal with Novartis AG's generic business unit, Sandoz, people told Bloomberg. Mylan and Novartis could not be reached outside of regular business hours.  (Reporting by Amrutha Penumudi in Bengaluru; Editing by Lisa Shumaker)",2015-05-12,MYL,"Mon May 11, 2015 | 9:48pm EDT",Mylan chairman said to consider Perrigo sweeteners to make deal: Bloomberg,http://www.reuters.com//article/us-mylan-nl-m-a-perrigo-company-idUSKBN0NX04C20150512?type=companyNews
138,"  May 11 Mylan NV's Chairman Robert Coury said he may sweeten the company's offer for Perrigo Co Plc  by adding terms that will reduce risk to Perrigo's shareholders, sources told Bloomberg on Monday.People familiar with the matter said that Coury laid out scenarios that could play out in the future and had even suggested that a Mylan-Perrigo combination could be an attractive target for Pfizer Inc, Bloomberg said.       (bloom.bg/1PD2z1S)This comes after Reuters reported comments from Coury last week on how Mylan would consider buying Israeli pharma firm Teva Pharmaceutical Industries down the line. Mylan is attempting to buy over-the-counter drugmaker Perrigo for $34 billion in an unsolicited offer that is expected to turn into a hostile one. Teva, meanwhile, made an unsolicited $40 billion bid for Mylan last month, which the latter rejected. Teva said last week it will move ahead with its plans to acquire Mylan if the Perrigo deal is not completed. At the meetings, Coury also brought up the idea that Mylan could make a deal with Novartis AG's generic business unit, Sandoz, people told Bloomberg.Mylan and Novartis could not be reached outside of regular business hours.    (Reporting by Amrutha Penumudi in Bengaluru; Editing by Lisa Shumaker)",2015-05-12,MYL,"Mon May 11, 2015 | 9:47pm EDT",Mylan chairman said to consider Perrigo sweeteners to make deal -Bloomberg,http://www.reuters.com//article/mylan-nl-ma-perrigo-company-idUSL1N0Y303920150512?type=companyNews
139,"  May 27 Teva Pharmaceutical Industries Ltd   disclosed a 1.35 percent interest in Mylan NV , saying the purchase underscored its commitment to buy Mylan as soon as possible.The company said it was ready to meet with Mylan and its advisers to discuss the deal. Teva proposed to buy Mylan for $82 per share, or about $43 billion, in cash and stock last month.  Mylan rejected the offer saying it ""grossly undervalued"" the company, setting up a three-way battle as it pursues its own hostile takeover of over-the-counter drugmaker Perrigo Co Plc .   (Reporting by Shailesh Kuber; Editing by Don Sebastian)",2015-05-27,MYL,"Wed May 27, 2015 | 4:42pm EDT",Teva discloses 1.35 pct stake in target Mylan,http://www.reuters.com//article/mylan-teva-idUSL3N0YI5H420150527?type=companyNews
140,"   By Olivia Oran  Teva Pharmaceutical Industries Ltd (TEVA.TA) is looking to buy more shares in Mylan NV (MYL.O), positioning itself for a possible legal challenge to the generics drugmaker that has spurned its takeover bid, people familiar with the matter said.The strategy is a sign of Teva's commitment to its $40 billion bid for Mylan, as the latter presses on with its own $34 billion hostile bid for over-the-counter drug company Perrigo Company Plc (PRGO.N).Teva last week disclosed a 1.8 percent stake in Mylan, which blasted the move as breaching U.S. antitrust laws because of the stake's size. U.S antitrust laws bar companies from acquiring stakes worth more than $76.3 million in rivals without first obtaining regulatory approval. Teva's stake in Mylan far exceeds that threshold.The dispute boils down to where Mylan, which is incorporated in the Netherlands, has its ""principal"" offices. Mylan argues these are located within the United States for the purposes of the U.S. Federal Trade Commission, thereby affording it antitrust protection, even as it lists its principal executives offices in Britain in filings with the U.S. Securities and Exchange Commission. Despite this issue, Teva may increase its stake in Mylan to around 4.6 percent, the people said. Such a stake would allow Teva to have standing in Dutch court to potentially challenge Mylan, which has so far refused to engage with its Israeli rival, the people added.   Teva may seek to reach this ownership threshold ahead of Mylan's record date, or the date in which a shareholder must officially own shares to be entitled to vote on the tender offer for Perrigo, they said. This would raise pressure on Mylan's management ahead of the vote, the people added.  A tender offer for Mylan is likely to come after Teva raises its stake, the people said. The sources asked not to be identified because Teva's deliberations are not public. Representatives for Teva and Mylan declined to comment.  Mylan, which makes the EpiPen product for severe allergies, can take advantage of Dutch provisions that would make a hostile takeover difficult because of its incorporation in the Netherlands.Hedge fund Paulson & Co LP in April raised its stake in Mylan to around 4.6 percent, including derivatives, to put pressure on Mylan management to pursue a tie-up with Teva. The hedge fund has been privately encouraging Mylan's board to consider Teva's takeover proposal, people previously told Reuters.  (Additional reporting by Greg Roumeliotis in New York)",2015-06-02,MYL,"Tue Jun 2, 2015 | 6:22pm EDT",Exclusive: Teva poised to raise its stake in Mylan - sources,http://www.reuters.com//article/us-mylan-teva-idUSKBN0OI2OO20150602?type=companyNews
141,"   By Olivia Oran  Teva Pharmaceutical Industries Ltd is looking to buy more shares in Mylan NV, positioning itself for a possible legal challenge to the generics drugmaker that has spurned its takeover bid, people familiar with the matter said.The strategy is a sign of Teva's commitment to its $40 billion bid for Mylan, as the latter presses on with its own $34 billion hostile bid for over-the-counter drug company Perrigo Company Plc.Teva last week disclosed a 1.8 percent stake in Mylan, which blasted the move as breaching U.S. antitrust laws because of the stake's size. U.S antitrust laws bar companies from acquiring stakes worth more than $76.3 million in rivals without first obtaining regulatory approval. Teva's stake in Mylan far exceeds that threshold. The dispute boils down to where Mylan, which is incorporated in the Netherlands, has its ""principal"" offices. Mylan argues these are located within the United States for the purposes of the U.S. Federal Trade Commission, thereby affording it antitrust protection, even as it lists its principal executives offices in Britain in filings with the U.S. Securities and Exchange Commission.Despite this issue, Teva may increase its stake in Mylan to around 4.6 percent, the people said. Such a stake would allow Teva to have standing in Dutch court to potentially challenge Mylan, which has so far refused to engage with its Israeli rival, the people added. Teva may seek to reach this ownership threshold ahead of Mylan's record date, or the date in which a shareholder must officially own shares to be entitled to vote on the tender offer for Perrigo, they said. This would raise pressure on Mylan's management ahead of the vote, the people added.A tender offer for Mylan is likely to come after Teva raises its stake, the people said. The sources asked not to be identified because Teva's deliberations are not public. Representatives for Teva and Mylan declined to comment.Mylan, which makes the EpiPen product for severe allergies, can take advantage of Dutch provisions that would make a hostile takeover difficult because of its incorporation in the Netherlands.Hedge fund Paulson & Co LP in April raised its stake in Mylan to around 4.6 percent, including derivatives, to put pressure on Mylan management to pursue a tie-up with Teva. The hedge fund has been privately encouraging Mylan's board to consider Teva's takeover proposal, people previously told Reuters.    (Additional reporting by Greg Roumeliotis in New York)",2015-06-02,MYL,"Tue Jun 2, 2015 | 6:14pm EDT",Teva poised to raise its stake in Mylan -sources,http://www.reuters.com//article/mylan-teva-idUSL1N0YO2VP20150602?type=companyNews
142,"  (Adds Petrobras, BASF, Telecom Italia, TAP, Areva, Mobinil, Ita Unibanco Holding, Volvo, UniCredit Bank Austria; updates Wendy's)June 3 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:** Teva Pharmaceutical Industries Ltd is looking to buy more shares in Mylan NV, positioning itself for a possible legal challenge to the generics drugmaker that has spurned its takeover bid, people familiar with the matter said.The strategy is a sign of Teva's commitment to its $40 billion bid for Mylan, as the latter presses on with its own $34 billion hostile bid for over-the-counter drug company Perrigo Co Plc.** Software maker Synchronoss Technologies Inc is working with financial adviser Qatalyst Partners LP on a possible sale that could be valued at more than $2 billion, The Wall Street Journal reported on Tuesday, citing people familiar with the matter.** Indebted Brazilian oil company Petrobras has brought in Bank of America Merrill Lynch to help manage a multi-billion dollar divestment plan and has already contacted major oil companies who might be interested buyers, three sources familiar with the matter said.** German chemicals group BASF SE is considering a potential offer for Syngenta AG, its Swiss rival which has received a $45 billion takeover offer from Monsanto Co , people familiar with the matter said.** Stock Building Supply Holdings Inc and fellow construction materials supplier Building Materials Holding Corp (BMC) said they would combine to expand in the fast-growing south and west regions in the United States.BMC's shareholders will receive 0.5231 new shares of Stock Building Supply for each share held and own about 60 percent of the merged entity, which would have an enterprise value of $1.5 billion.** Telecom Italia could raise up to 936 million euros ($1 billion) from the listing of a minority stake in its broadcasting tower unit INWIT, the company said.** Italian holding company Exor has filed a lawsuit to force PartnerRe to release information about its shareholders, it said on Wednesday, as it moves ahead in a battle to take over the Bermuda-based reinsurer. ** The Portuguese government vowed to press ahead with the sale of airline TAP despite a court ruling on Wednesday to suspend the privatisation.** The French government said it would recapitalise state-owned nuclear group Areva as it gave its backing for power company EDF's plan to take over its nuclear reactor business.**  Investment firm Cinven said its bid for Slovenia's largest telecoms provider, state-owned Telekom Slovenia, is only valid until June 10.Cinven is the only bidder for Telekom Slovenia and has offered up to 130 euros per share, according to Reuters sources, which would value the company at 850 million euros ($945 million).** Billionaire investor William Ackman's hedge fund has taken a position in Nomad Foods Limited, a young company created to make acquisitions in the food industry, according to a release made by the London Stock Exchange on Tuesday. ** Telecoms operator Orange aims to sell shares in its Egyptian unit Mobinil to bring in new investors and increase its stake in its Moroccan subsidiary, as part of expansion plans in North Africa, its CEO said.** Nomad Foods Ltd is in exclusive early talks with private equity-owned frozen food maker Findus Group  about buying its continental European business and the Findus brand, it said on Wednesday.** Hamburger chain Wendy's Co will buy back $1.4 billion of shares, including $211 million from Nelson Peltz's Trian Group, its largest shareholder, in its biggest repurchase program.** Ita Unibanco Holding SA and Chile's CorpBanca SA agreed to modify terms of an agreement to merge some of their Chilean operations, seeking to win shareholder approval ahead of a June 26 meeting. The changes aim to speed up the completion of the merger. ** Tech giant Samsung Electronics Co Ltd said on Wednesday it has no plans to merge with affiliate Samsung SDS Co Ltd, in an attempt to quell speculation that such a deal is in the works to help Samsung Group's succession process.** Japanese telecoms group SoftBank Corp is investing $1 billion in South Korean online retailer Coupang as part of a plan to step up its overseas expansion and as it struggles to turn around U.S. carrier Sprint which it bought in 2013.** Sweden's Volvo AB is selling 1 million shares in Indian auto firm Eicher Motors in a deal valued at $278 million, according to a term sheet seen by IFR.** Lukoil, Russia's second largest oil producer, has signed a sale-and-purchase contract with Aqua Marina to sell 100 percent of Lukoil Eesti AS, which owns 37 gas filling stations in Estonia, the company said.** South Korea's SK Innovation Co Ltd has signed a contract to sell its 11.1 percent stake in Peruvian natural gas transporter Transportadora de Gas del Peru for $251 million, the company said in a statement.** UniCredit Bank Austria has bought a 45 percent stake in UniCredit Tiriac Bank from Tiriac Holdings Ltd, boosting its stake in the Romanian lender to 95.6 percent, it said.** Cocoaland Holdings Bhd, a Malaysian snack and candy company, said on Tuesday it had received a takeover offer from new suitor Hong Kong-listed First Pacific Co Ltd  that values it at 463.3 million ringgit ($125 million).** Israel's Clal Industries is in talks to sell its entire 59.1 percent stake in Hadera Paper Ltd to the FIMI Opportunity Funds, the country's largest private equity fund.($1 = 0.90 euros)      ($1 = 3.68 ringgit)   (Compiled by Manya Venkatesh in Bengaluru)",2015-06-03,MYL,"Wed Jun 3, 2015 | 4:13pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0YP3JM20150603?type=companyNews
143,  June 4 Ab-Biotics SA :* Signs deal with Mylan EPD for exclusive marketing of its probiotic AB-LIFE in Australia and New Zealand * The product was approved as a drug for cholesterol control by the Australian authorities in Jan. and has been marketed since April under the brand Mylan Enliva  Source text: bit.ly/1eQIlXa  Further company coverage:    (Gdynia Newsroom),2015-06-04,MYL,"Thu Jun 4, 2015 | 3:07am EDT",BRIEF-Ab-Biotics signs deal for exclusive marketing of its probiotic in Australia and New Zealand,http://www.reuters.com//article/idUSFWN0YQ00O20150604?type=companyNews
144,"   By Olivia Oran  Teva Pharmaceutical Industries Ltd (TEVA.TA) has increased its stake in Mylan NV (MYL.O) to nearly 2.2 percent as it presses on with an unsolicited bid for its generic drug-making rival, a regulatory filing showed on Friday.The strategy is another sign of Teva's commitment to its $40 billion takeover proposal for Mylan, as the latter continues to pursue its own hostile bid for over-the-counter drug company Perrigo Company PLC (PRGO.N).Teva had accumulated around 10.5 million shares in Mylan as of June 4, according to the filing.Teva last week disclosed a 1.8 percent stake in Mylan, which on Monday said in a letter addressed to Teva Chief Executive Officer Erez Vigodman that the move breached antitrust laws because of the stake's size.  U.S. antitrust laws bar companies from acquiring stakes worth more than $76.3 million in rivals without first obtaining regulatory approval. Teva's stake exceeds this amount. Companies found guilty of FTC violations could face multimillion-dollar fines for every day in the market they purchase shares. Mylan, which is incorporated in the Netherlands, argues that it is entitled to antitrust protection because its principal offices are located within the United States for U.S. Federal Trade Commission purposes, even as it lists its principal executives offices in Britain in filings with the U.S. Securities and Exchange Commission. The Federal Trade Commission has refused to comment on whether it is investigating Teva in connection to its stake-building in Mylan. Following Mylan's letter, Teva did not purchase shares in Mylan from June 1 to June 3. It resumed buying on June 4.  Teva is looking to increase its stake in Mylan to around 4.6 percent, Reuters previously reported. A stake of this size would allow Teva to have standing in Dutch court to potentially challenge Mylan, which so far has refused to engage in tie-up talks. Teva has not yet submitted a formal offer to buy Mylan but will likely do so after it completes accumulating shares, Reuters reported. (Reporting by Olivia Oran in New York; Editing by James Dalgleish)",2015-06-05,MYL,"Fri Jun 5, 2015 | 1:25pm EDT",Teva raises its stake in acquisition target Mylan,http://www.reuters.com//article/us-mylan-m-a-teva-idUSKBN0OL1YU20150605?type=companyNews
145,"   By Olivia Oran | June 5  June 5 Teva Pharmaceutical Industries Ltd  has increased its stake in Mylan NV to nearly 2.2 percent as it presses on with an unsolicited bid for its generic drug-making rival, a regulatory filing showed on Friday.The strategy is another sign of Teva's commitment to its $40 billion takeover proposal for Mylan, as the latter continues to pursue its own hostile bid for over-the-counter drug company Perrigo Company PLC.Teva had accumulated around 10.5 million shares in Mylan as of June 4, according to the filing. Teva last week disclosed a 1.8 percent stake in Mylan, which on Monday said in a letter addressed to Teva Chief Executive Officer Erez Vigodman that the move breached antitrust laws because of the stake's size.U.S. antitrust laws bar companies from acquiring stakes worth more than $76.3 million in rivals without first obtaining regulatory approval. Teva's stake exceeds this amount. Companies found guilty of FTC violations could face multimillion-dollar fines for every day in the market they purchase shares. Mylan, which is incorporated in the Netherlands, argues that it is entitled to antitrust protection because its principal offices are located within the United States for U.S. Federal Trade Commission purposes, even as it lists its principal executives offices in Britain in filings with the U.S. Securities and Exchange Commission.The Federal Trade Commission has refused to comment on whether it is investigating Teva in connection to its stake-building in Mylan. Following Mylan's letter, Teva did not purchase shares in Mylan from June 1 to June 3. It resumed buying on June 4.Teva is looking to increase its stake in Mylan to around 4.6 percent, Reuters previously reported. A stake of this size would allow Teva to have standing in Dutch court to potentially challenge Mylan, which so far has refused to engage in tie-up talks.Teva has not yet submitted a formal offer to buy Mylan but will likely do so after it completes accumulating shares, Reuters reported.   (Reporting by Olivia Oran in New York; Editing by James Dalgleish)",2015-06-05,MYL,"Fri Jun 5, 2015 | 1:22pm EDT",Teva raises its stake in acquisition target Mylan,http://www.reuters.com//article/mylan-ma-teva-idUSL5N0YQ49S20150605?type=companyNews
146,"   By Toby Sterling | AMSTERDAM  AMSTERDAM Executives at Israeli drugmaker Teva (TEVA.TA) sent an open letter to takeover target Mylan (MYL.O) on Monday, saying they remain committed to a deal and reiterated that Teva's $40 billion takeover proposal would benefit shareholders of both firms.In the letter, addressed to Mylan executive founder Robert Coury, Teva CEO Erez Vigodman and Chairman Yitzhak Peterburg repeated that a combination would add value to both companies.The letter said Mylan had made ""made grossly incorrect statements to mislead your stockholders and other stakeholders about us"".Mylan responded later on Monday, saying Teva's statements continue to leave it and its stakeholders with ""great uncertainty"" regarding the Israeli drugmaker's intentions.In a letter addressed to Vigodman, Coury asked for ""straightforward"" answers to two questions. (1.usa.gov/1BUOEhm)The first is whether Teva was planning a legally binding exchange offer for Mylan. The second is whether any such offer would contain a ""hell or high water provision"" under which Teva would agree to whatever the U.S. Federal Trade Commission requires to clear the transaction.The letters are the latest in a series of unusually combative communications between the two companies.Teva began an unsolicited pursuit of Mylan NV in April but has yet to make a formal offer as it awaits antitrust approval in the United States. Coury has since sent two open letters criticising Teva as a poor fit for Mylan, most recently on June 1.Spurning Teva's advances, Mylan has begun pursuing its own unsolicited $32.7 billion bid for Perrigo of Ireland.Coury has previously said that Teva ""has engaged in a pattern of making noncommittal, unclear, inaccurate and non specific statements to shareholders ... regarding its intentions with respect to Mylan."" Teva has built a 2.2 percent stake in Mylan ahead of making a formal offer.Mylan has its operational headquarters in Canonsburg, Pennsylvania, but is incorporated in the Netherlands. (Additional reporting by Natalie Grover; Editing by Pravin Char, David Evans and Simon Jennings)",2015-06-08,MYL,"Mon Jun 8, 2015 | 4:33pm EDT","Teva bosses issue riposte to Mylan, praise takeover plan",http://www.reuters.com//article/us-mylan-m-a-teva-idUSKBN0OO1O320150608?type=companyNews
147,"  (Adds Mylan's response)By Toby SterlingAMSTERDAM, June 8 Executives at Israeli drugmaker Teva sent an open letter to takeover target Mylan on Monday, saying they remain committed to a deal and reiterated that Teva's $40 billion takeover proposal would benefit shareholders of both firms.In the letter, addressed to Mylan executive founder Robert Coury, Teva CEO Erez Vigodman and Chairman Yitzhak Peterburg repeated that a combination would add value to both companies.The letter said Mylan had made ""made grossly incorrect statements to mislead your stockholders and other stakeholders about us"".Mylan responded later on Monday, saying Teva's statements continue to leave it and its stakeholders with ""great uncertainty"" regarding the Israeli drugmaker's intentions. In a letter addressed to Vigodman, Coury asked for ""straightforward"" answers to two questions. (1.usa.gov/1BUOEhm)The first is whether Teva was planning a legally binding exchange offer for Mylan.The second is whether any such offer would contain a ""hell or high water provision"" under which Teva would agree to whatever the U.S. Federal Trade Commission requires to clear the transaction. The letters are the latest in a series of unusually combative communications between the two companies.Teva began an unsolicited pursuit of Mylan NV in April but has yet to make a formal offer as it awaits antitrust approval in the United States.Coury has since sent two open letters criticising Teva as a poor fit for Mylan, most recently on June 1. Spurning Teva's advances, Mylan has begun pursuing its own unsolicited $32.7 billion bid for Perrigo of Ireland.Coury has previously said that Teva ""has engaged in a pattern of making noncommittal, unclear, inaccurate and non specific statements to shareholders ... regarding its intentions with respect to Mylan.""Teva has built a 2.2 percent stake in Mylan ahead of making a formal offer.Mylan has its operational headquarters in Canonsburg, Pennsylvania, but is incorporated in the Netherlands.(Additional reporting by Natalie Grover; Editing by Pravin Char, David Evans and Simon Jennings)",2015-06-08,MYL,"Mon Jun 8, 2015 | 4:30pm EDT","UPDATE 2-Teva bosses issue riposte to Mylan, praise takeover plan",http://www.reuters.com//article/mylan-ma-teva-idUSL5N0YU39J20150608?type=companyNews
148,"  AMSTERDAM, June 8 Top executives at Israeli drugmaker Teva sent an open letter to takeover target Mylan on Monday, saying they remained committed to striking a deal and reasserting that Teva's $82-per-share offer would benefit shareholders of both firms.In a letter addressed to Mylan executive founder Robert Coury, Teva CEO Erez Vidgodman and Chairman Yitzhak Peterburg repeated that a combination of the two companies would add value to both.  The letter accused Mylan of having ""made grossly incorrect statements to mislead your stockholders and other stakeholders about us"". The letter went on to list the reasons why Teva's offer was favourable.   (Reporting By Toby Sterling; Editing by Pravin Char) ",2015-06-08,MYL,"Mon Jun 8, 2015 | 10:33am EDT",Teva bosses say remain committed to Mylan takeover,http://www.reuters.com//article/mylan-ma-teva-idUSL5N0YU32520150608?type=companyNews
149,"   By Olivia Oran  Teva Pharmaceutical Industries Ltd has changed the law firm it had tapped for advice on its $40 billion attempt to take over smaller rival Mylan NV after a court sided with the latter's bid to seek a preliminary injunction against the previous law firm.Teva is now working with Sullivan & Cromwell LLP as legal counsel in its proposal to acquire Mylan, the Israeli drugmaker said late on Tuesday. It was previously working with another law firm, Kirkland & Ellis LLP.A U.S. federal court had earlier on Tuesday recommended that a preliminary injunction be issued to disqualify Kirkland from advising Teva because that law firm already had an existing relationship with Mylan.""Teva will continue to take the steps necessary to deliver the compelling benefits inherent in a combination to both companies' stockholders and other stakeholders,"" the company said in the statement, without commenting specifically on Kirkland. Kirkland stepped aside to avoid potential distractions, according to a person briefed on the matter who was not authorized to discuss the relationship between the law firm and Teva publicly.The U.S. District Court for the Western District of Pennsylvania, in Pittsburgh, said the relationship between Kirkland and Mylan, which dates back to January 2013, made it impermissible for the law firm to represent Teva as it could harm Mylan's interests.Mylan, which is headquartered outside Pittsburgh, filed a complaint against Kirkland in May saying the law firm had ""wide-ranging access"" to its business and its portfolio of current and unlaunched products. ""We strongly disagree with the recommendation made by the Magistrate Judge, and we reject any suggestion that Kirkland & Ellis' representation of Teva in its proposed acquisition of Mylan presents a conflict of interest,"" Kirkland said in a statement.The injunction also seeks to prohibit Kirkland from using, relying on or disclosing any information it learned from its representation of Mylan to other clients and requires it to retrieve all work product provided by Kirkland to Teva. Kirkland said the scope of its legal work for certain Mylan subsidiaries is narrowly limited to discrete Food and Drug Administration administrative law issues, and that it has never represented the parent company.The law firm said it will file an objection with the U.S. District Court chief judge.Mylan declined to comment. Sullivan & Cromwell did not immediately respond to a request for comment.Teva made the unsolicited offer for Mylan in April, in a bid for growth as its lucrative Copaxone drug faces competition from generic alternatives.    (Additional reporting by Shivam Srivastava in Bangalore and Greg Roumeliotis in New York)",2015-06-10,MYL,"Wed Jun 10, 2015 | 7:14am EDT",Teva switches legal counsel after Mylan challenge,http://www.reuters.com//article/mylan-nl-teva-pharm-ind-kirkland-update-idUSL1N0YW0H820150610?type=companyNews
150,"   By Olivia Oran  Teva Pharmaceutical Industries Ltd (TEVA.TA) has changed the law firm it had tapped for advice on its $40 billion attempt to take over smaller rival Mylan NV (MYL.O) after a court sided with the latter's bid to seek a preliminary injunction against the previous law firm.Teva is now working with Sullivan & Cromwell LLP as legal counsel in its proposal to acquire Mylan, the Israeli drugmaker said late on Tuesday. It was previously working with another law firm, Kirkland & Ellis LLP.A U.S. federal court had earlier on Tuesday recommended that a preliminary injunction be issued to disqualify Kirkland from advising Teva because that law firm already had an existing relationship with Mylan. ""Teva will continue to take the steps necessary to deliver the compelling benefits inherent in a combination to both companies stockholders and other stakeholders,"" the company said in the statement, without commenting specifically on Kirkland.Kirkland stepped aside to avoid potential distractions, according to a person briefed on the matter who was not authorized to discuss the relationship between the law firm and Teva publicly. The U.S. District Court for the Western District of Pennsylvania, in Pittsburgh, said the relationship between Kirkland and Mylan, which dates back to January 2013, made it impermissible for the law firm to represent Teva as it could harm Mylan's interests.Mylan, which is headquartered outside Pittsburgh, filed a complaint against Kirkland in May saying the law firm had ""wide-ranging access"" to its business and its portfolio of current and unlaunched products.""We strongly disagree with the recommendation made by the Magistrate Judge, and we reject any suggestion that Kirkland & Ellis' representation of Teva in its proposed acquisition of Mylan presents a conflict of interest,"" Kirkland said in a statement. The injunction also seeks to prohibit Kirkland from using, relying on or disclosing any information it learned from its representation of Mylan to other clients and requires it to retrieve all work product provided by Kirkland to Teva.Kirkland said the scope of its legal work for certain Mylan subsidiaries is narrowly limited to discrete Food and Drug Administration administrative law issues, and that it has never represented the parent company.The law firm said it will file an objection with the U.S. District Court chief judge. Mylan declined to comment. Sullivan & Cromwell did not immediately respond to a request for comment.Teva made the unsolicited offer for Mylan in April, in a bid for growth as its lucrative Copaxone drug faces competition from generic alternatives.(The story corrects paragraphs two and three to show Teva's statement and court's recommendation came on Tuesday, not Monday) (Additional reporting by Shivam Srivastava in Bangalore and Greg Roumeliotis in New York; Editing by Leslie Adler and Muralikumar Anantharaman)",2015-06-10,MYL,"Wed Jun 10, 2015 | 2:22am EDT",Teva switches legal counsel after Mylan challenge,http://www.reuters.com//article/us-mylan-nl-teva-pharm-ind-kirkland-idUSKBN0OQ02Q20150610?type=companyNews
151,"  (Corrects paragraphs two and three to show Teva's statement and  court's recommendation came on Tuesday, not Monday)By Olivia OranJune 9 Teva Pharmaceutical Industries Ltd  has changed the law firm it had tapped for advice on its $40 billion attempt to take over smaller rival Mylan NV  after a court sided with the latter's bid to seek a preliminary injunction against the previous law firm.Teva is now working with Sullivan & Cromwell LLP as legal counsel in its proposal to acquire Mylan, the Israeli drugmaker said late on Tuesday. It was previously working with another law firm, Kirkland & Ellis LLP.A U.S. federal court had earlier on Tuesday recommended that a preliminary injunction be issued to disqualify Kirkland from advising Teva because that law firm already had an existing relationship with Mylan.""Teva will continue to take the steps necessary to deliver the compelling benefits inherent in a combination to both companies' stockholders and other stakeholders,"" the company said in the statement, without commenting specifically on Kirkland. Kirkland stepped aside to avoid potential distractions, according to a person briefed on the matter who was not authorized to discuss the relationship between the law firm and Teva publicly.The U.S. District Court for the Western District of Pennsylvania, in Pittsburgh, said the relationship between Kirkland and Mylan, which dates back to January 2013, made it impermissible for the law firm to represent Teva as it could harm Mylan's interests. Mylan, which is headquartered outside Pittsburgh, filed a complaint against Kirkland in May saying the law firm had ""wide-ranging access"" to its business and its portfolio of current and unlaunched products.""We strongly disagree with the recommendation made by the Magistrate Judge, and we reject any suggestion that Kirkland & Ellis' representation of Teva in its proposed acquisition of Mylan presents a conflict of interest,"" Kirkland said in a statement.The injunction also seeks to prohibit Kirkland from using, relying on or disclosing any information it learned from its representation of Mylan to other clients and requires it to retrieve all work product provided by Kirkland to Teva. Kirkland said the scope of its legal work for certain Mylan subsidiaries is narrowly limited to discrete Food and Drug Administration administrative law issues, and that it has never represented the parent company.The law firm said it will file an objection with the U.S. District Court chief judge.Mylan declined to comment. Sullivan & Cromwell did not immediately respond to a request for comment.Teva made the unsolicited offer for Mylan in April, in a bid for growth as its lucrative Copaxone drug faces competition from generic alternatives.    (Additional reporting by Shivam Srivastava in Bangalore and Greg Roumeliotis in New York; Editing by Leslie Adler and Muralikumar Anantharaman)",2015-06-10,MYL,"Wed Jun 10, 2015 | 2:07am EDT",REFILE-UPDATE 1-Teva switches legal counsel after Mylan challenge,http://www.reuters.com//article/mylan-nl-teva-pharm-ind-kirkland-update-idUSL1N0YW05C20150610?type=companyNews
152,"  (Corrects to recommendation, not issuance, of injuction in headline and paragraph 1)June 9 A U.S. federal court has recommended that a preliminary injunction be issued to disqualify law firm Kirkland & Ellis LLP from advising Teva Pharmaceutical in its $40 billion attempt to take over smaller rival Mylan NV.The U.S. District Court for the Western District of Pennsylvania, in Pittsburgh, said the relationship between Kirkland and Mylan, which dates back to January 2013, made it impermissible for the law firm to represent Teva as it could harm Mylan's interests.Mylan, which is headquartered outside Pittsburgh, filed a complaint against Kirkland in May saying the law firm had ""wide-ranging access"" to its business and its portfolio of current and unlaunched products. ""We strongly disagree with the recommendation made by the Magistrate Judge, and we reject any suggestion that Kirkland & Ellis' representation of Teva in its proposed acquisition of Mylan presents a conflict of interest,"" Kirkland said in a statement.The injunction also seeks to prohibit Kirkland from using, relying on or disclosing any information it learned from its representation of Mylan to other clients and requires it to retrieve all work product provided by Kirkland to Teva. Kirkland said the scope of its legal work for certain Mylan subsidiaries is narrowly limited to discrete Food and Drug Administration administrative law issues, and that it has never represented the parent company. The law firm said it will file an objection with the U.S. District Court chief judge.Mylan and Teva declined to comment.Israeli drugmaker Teva made the unsolicited offer for Mylan in April, in a bid for growth as its lucrative Copaxone drug faces competition from generic alternatives.    (Reporting by Shivam Srivastava in Bengaluru, and Gregory Roumeliotis and Olivia Oran in New York; Editing by Leslie Adler)",2015-06-10,MYL,"Tue Jun 9, 2015 | 11:39pm EDT",CORRECTED- Judge recommends injunction to Kirkland from representing Teva,http://www.reuters.com//article/mylan-nl-teva-pharm-ind-kirkland-idUSL3N0YW04G20150610?type=companyNews
153,"  Mylan NV's (MYL.O) largest stakeholder, Abbott Laboratories (ABT.N), said it would back Mylan's proposed acquisition of Perrigo Co Plc (PRGO.N), potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd (TEVA.TA).Abbott, which has a 14.5 percent stake in Mylan, said on Tuesday that it supported Mylan's ""standalone strategy"" and believed acquiring Perrigo would add value for shareholders.Mylan's latest offer for Perrigo, worth $34.1 billion, is widely seen as an attempt to fend off Teva, the world's biggest maker of generic drugs.Perrigo rejected Mylan's sweetened offer in late April, around the same time Mylan rejected an offer of $40 billion from Teva, saying it grossly undervalued the company. Last year, Mylan said it would buy Abbott's branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that would bolster its product line and cut its tax bill.The deal gave Mylan an array of Abbott brands with sales of almost $2 billion, while Abbott received 105 million shares of the combined company, renamed Mylan NV. Mylan's shares were down 2.1 percent at $72 in early trading. Perrigo's shares were up about 3 percent at $188.62, while Teva's stock was little changed. (Corrects to ""off"" from ""of"" in first paragraph) (Reporting by Amrutha Penumudi in Bengaluru; Editing by Joyjeet Das and Simon Jennings)",2015-06-16,MYL,"Tue Jun 16, 2015 | 5:12pm EDT",Abbott to vote for Mylan's acquisition of Perrigo,http://www.reuters.com//article/us-perrigo-m-a-mylanabbott-idUSKBN0OW1OG20150616?type=companyNews
154,"  (Adds Blackstone Group, Vivendi, Mylan, Daimler)June 16 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:** BG Group Plc said it had received anti-trust regulatory clearance from the U.S. Federal Trade Commission for Royal Dutch Shell's proposed $70 billion acquisition.** A 13 billion pound ($20 billion) mortgage portfolio put up for sale by UK Asset Resolution, the ""bad bank"" charged with winding down the assets of two failed British lenders, has lured interest from several possible bidders, the group's boss said.** Blackstone Group LP and Carlyle Group LP  are making a joint bid for NCR Corp in a leveraged buyout worth more than $10 billion, including debt, making it this year's biggest, according to people familiar with the matter.** French media group Vivendi plans to increase its stake in Telecom Italia to between 10-15 percent, cementing influence over the group once its current big shareholders exit, said people familiar with the matter. ** Mylan NV's largest stakeholder, Abbott Laboratories, said it would back Mylan's proposed acquisition of Perrigo Co Plc, potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd** German carmaker Daimler is poised to agree a deal to sell its eastern German Mercedes dealerships to China's Lei Shing Hong (LSH), Stuttgarter Zeitung reported, citing several people familiar with the matter.** Details of U.S. cosmetic company Coty Inc's  acquisition of Proctor & Gamble Co's beauty assets for as much as $12 billion could take at least two weeks to be finalised, sources close to the matter said. ** Cinven is still interested in buying Telekom Slovenia, the UK investment firm said on Tuesday, a day after Slovenia rejected its bid.** German property firm Alstria Office REIT AG  announced plans to make an all-share takeover offer for peer DO Deutsche Office AG, valuing the company at close to 800 million euros ($901.5 million). ** Malaysia's Felda Global Ventures Holdings Bhd  would consider taking control of Indonesia's PT Eagle High Plantations Tbk after first buying 37 percent for $680 million, Chief Executive Mohd Emir Mavani Abdullah said.** Westpac Banking Corp, Australia's No.2 lender by market value, said it plans to cut part of its stake in its wealth management arm, helping it raise up to A$700 million ($544 million) in an effort to boost its capital ratios.** Warren Buffett's Berkshire Hathaway Inc has bought a 3.7 percent stake in Insurance Australia Group Ltd  for A$500 million ($388 million), as part of a partnership that IAG said would reduce its capital requirements and support its return on equity targets.** Brenntag AG, the world's largest chemicals distributor, is conducting due diligence on takeover targets worth more than 250 million euros ($281 million), with a focus on North America and Asia-Pacific, its chief executive said.** Defence firm Samsung Techwin Co Ltd said it would sign an agreement giving it an option to buy Thales SA's  50 percent stake in their unlisted South Korean joint venture, valued at about $190 million.($1 = C$1.23)  ($1 = A$1.29)  ($1 = 0.88 euros)  ($1 = 0.64 pounds)   (Compiled by Rosmi Shaji and Anet Josline Pinto in Bengaluru)",2015-06-16,MYL,"Tue Jun 16, 2015 | 4:05pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0Z254V20150616?type=companyNews
155,"  (Corrects to ""off"" from ""of"" in first paragraph)June 16 Mylan NV's largest stakeholder, Abbott Laboratories, said it would back Mylan's proposed acquisition of Perrigo Co Plc, potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd .Abbott, which has a 14.5 percent stake in Mylan, said on Tuesday that it supported Mylan's ""standalone strategy"" and believed acquiring Perrigo would add value for shareholders.Mylan's latest offer for Perrigo, worth $34.1 billion, is widely seen as an attempt to fend off Teva, the world's biggest maker of generic drugs. Perrigo rejected Mylan's sweetened offer in late April, around the same time Mylan rejected an offer of $40 billion from Teva, saying it grossly undervalued the company. Last year, Mylan said it would buy Abbott's branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that would bolster its product line and cut its tax bill.The deal gave Mylan an array of Abbott brands with sales of almost $2 billion, while Abbott received 105 million shares of the combined company, renamed Mylan NV. Mylan's shares were down 2.1 percent at $72 in early trading. Perrigo's shares were up about 3 percent at $188.62, while Teva's stock was little changed.(Reporting by Amrutha Penumudi in Bengaluru; Editing by Joyjeet Das and Simon Jennings)",2015-06-16,MYL,"Tue Jun 16, 2015 | 11:28am EDT",REFILE-UPDATE 1-Abbott to vote for Mylan's acquisition of Perrigo,http://www.reuters.com//article/perrigo-ma-mylanabbott-idUSL3N0Z249D20150616?type=companyNews
156,"  Israel's Teva Pharmaceutical Industries Ltd (TEVA.TA) has raised its stake in Mylan N.V. (MYL.O) to the 4.61 percent needed for it to legally challenge Mylan's rejection of Teva's hostile takeover offer under Dutch law.Mylan rebuffed a $40 billion bid from Teva in April, saying it grossly undervalued the company, and pressed on with its own $34 billion hostile bid for Perrigo Co Plc (PRGO.N) in an attempt to fend off Teva's interest.Mylan reincorporated in the Netherlands last year, where it set up a legal structure called a stichting  Dutch for ""foundation"".The structure can be used as a kind of poison-pill defense against hostile takeovers. Under Dutch law, Teva's acquisition of a 4.61 pct stake makes it eligible to stand before the Dutch Enterprise Chamber and legally challenge Mylan, the Israeli company said.Mylan's top shareholder, Abbott Laboratories (ABT.N), has already come out in support of the company's rejection of Teva by backing Mylan's proposed acquisition of Perrigo. Abbott holds a 14.5 percent stake in Mylan. Teva also said on Friday that it would limit its stake to less than 5 percent before Mylan's extraordinary general meeting (EGM) on the Perrigo transaction if Mylan held the EGM before September. (Reporting By Samantha Kareen Nair in Bengaluru; Editing by Simon Jennigs)",2015-06-19,MYL,"Fri Jun 19, 2015 | 11:19am EDT",Teva raises stake in Mylan as three-way takeover battle heats up,http://www.reuters.com//article/us-mylan-nl-m-a-teva-pharm-ind-idUSKBN0OZ1UI20150619?type=companyNews
157,"  June 19 Israel's Teva Pharmaceutical Industries Ltd has raised its stake in Mylan N.V. to the 4.61 percent needed for it to legally challenge Mylan's rejection of Teva's hostile takeover offer under Dutch law.Mylan rebuffed a $40 billion bid from Teva in April, saying it grossly undervalued the company, and pressed on with its own $34 billion hostile bid for Perrigo Co Plc in an attempt to fend off Teva's interest.Mylan reincorporated in the Netherlands last year, where it set up a legal structure called a stichting - Dutch for ""foundation"". The structure can be used as a kind of poison-pill defense against hostile takeovers.Under Dutch law, Teva's acquisition of a 4.61 pct stake makes it eligible to stand before the Dutch Enterprise Chamber and legally challenge Mylan, the Israeli company said. Mylan's top shareholder, Abbott Laboratories, has already come out in support of the company's rejection of Teva by backing Mylan's proposed acquisition of Perrigo. Abbott holds a 14.5 percent stake in Mylan.Teva also said on Friday that it would limit its stake to less than 5 percent before Mylan's extraordinary general meeting (EGM) on the Perrigo transaction if Mylan held the EGM before September.   (Reporting By Samantha Kareen Nair in Bengaluru; Editing by Simon Jennigs)",2015-06-19,MYL,"Fri Jun 19, 2015 | 10:59am EDT",Teva raises stake in Mylan as three-way takeover battle heats up,http://www.reuters.com//article/mylan-nl-ma-teva-pharm-ind-idUSL3N0Z546M20150619?type=companyNews
158,"  TEL AVIV, June 23 Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co, an industry source said.Mylan has offered to acquire Perrigo for $34 billion in an attempt to fend off a bid from Israel's Teva Pharmaceutical Industries, the world's biggest generic drugmaker. Perrigo has rejected Mylan's offer.Perrigo's shares are listed on the Tel Aviv Stock Exchange since it acquired Israeli drugmaker Agis Industries in 2005.The source, who asked not to be named, said on Tuesday Mylan's shares would replace Perrigo in Tel Aviv just as Perrigo's shares replaced Agis when it was acquired.In addition to a meeting with Yossi Beinart, the chief executive of the stock exchange, Sheehan may also meet with institutional investors in Israel who own shares in Perrigo. A spokeswoman for Mylan in Israel declined to comment, while a spokeswoman for the bourse also declined to comment.The Tel Aviv Stock Exchange, which is seeking to stem falling trading volumes in recent years, is eager to ensure it does not lose Perrigo, which is one of the most active shares on the Israeli bourse. Teva last week raised its stake in Mylan to the 4.61 percent needed for it to legally challenge Mylan's rejection of Teva's hostile takeover offer under Dutch law.Mylan rebuffed a $40 billion bid from Teva in April, saying it grossly undervalued the company. Mylan reincorporated in the Netherlands last year, where it set up a legal structure called a stichting -- Dutch for ""foundation"",  which can be used as a kind of poison-pill defence against hostile takeovers.Mylan's top shareholder, Abbott Laboratories, has already come out in support of the company's rejection of Teva by backing Mylan's proposed acquisition of Perrigo. Abbott holds a 14.5 percent stake in Mylan.Teva said on Friday it would limit its stake to less than 5 percent before Mylan's extraordinary general meeting (EGM) on the Perrigo transaction if Mylan held the EGM before September.       (Reporting by Tova Cohen; Editing by Luke Baker and Mark Potter)",2015-06-23,MYL,"Tue Jun 23, 2015 | 8:16am EDT",Mylan CFO to meet Tel Aviv bourse chief to discuss listing - source,http://www.reuters.com//article/mylan-nl-perrigo-company-israel-idUSL8N0Z926E20150623?type=companyNews
159,"  TEL AVIV Drugmaker Mylan NV's (MYL.O) chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange (TASE) if it succeeds in buying Perrigo Co (PRGO.N).Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. This is widely seen as an attempt to protect itself from a bid from Israel's Teva Pharmaceutical Industries (TEVA.TA), the world's biggest generic drugmaker.Sheehan was in Israel to meet Yossi Beinart, chief executive of the stock exchange. ""Mylan believes that the Israeli market is important to Mylan and the pharmaceutical industry generally and would therefore be pleased to join TASE as one of the largest publicly traded companies following the consummation of the Perrigo acquisition,"" he said in a statement after the meeting.Perrigo's shares have been listed on TASE since it acquired Israeli drugmaker Agis Industries in 2005.  TASE is seeking to stem falling trading volumes in recent years. Sheehan's comments could reassure the exchange, which is eager to ensure it does not lose Perrigo, the second-biggest company by market value on the bourse behind Teva.  (Reporting by Tova Cohen; Editing by Steven Scheer and Pravin Char)",2015-06-24,MYL,"Wed Jun 24, 2015 | 9:21am EDT",Mylan eyes Tel Aviv listing if Perrigo deal goes ahead,http://www.reuters.com//article/us-mylan-nl-perrigo-company-israel-idUSKBN0P41M420150624?type=companyNews
160,"  (Adds context on TASE)TEL AVIV, June 24 Drugmaker Mylan NV's  chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange (TASE) if it succeeds in buying Perrigo Co.Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. This is widely seen as an attempt to protect itself from a bid from Israel's Teva Pharmaceutical Industries, the world's biggest generic drugmaker.Sheehan was in Israel to meet Yossi Beinart, chief executive of the stock exchange. ""Mylan believes that the Israeli market is important to Mylan and the pharmaceutical industry generally and would therefore be pleased to join TASE as one of the largest publicly traded companies following the consummation of the Perrigo acquisition,"" he said in a statement after the meeting. Perrigo's shares have been listed on TASE since it acquired Israeli drugmaker Agis Industries in 2005.TASE is seeking to stem falling trading volumes in recent years. Sheehan's comments could reassure the exchange, which is eager to ensure it does not lose Perrigo, the second-biggest company by market value on the bourse behind Teva. (Reporting by Tova Cohen; Editing by Steven Scheer and Pravin Char)",2015-06-24,MYL,"Wed Jun 24, 2015 | 9:20am EDT",UPDATE 1-Mylan eyes Tel Aviv listing if Perrigo deal goes ahead,http://www.reuters.com//article/mylan-nl-perrigo-company-israel-idUSL8N0ZA2YY20150624?type=companyNews
161,"  TEL AVIV, June 24 Drugmaker Mylan NV's  chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange (TASE) if it succeeds in buying Perrigo Co.Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. This is widely seen as an attempt to protect itself from a bid from Israel's Teva Pharmaceutical Industries, the world's biggest generic drugmaker. Sheehan was in Israel to meet Yossi Beinart, chief executive of the stock exchange.  ""Mylan believes that the Israeli market is important to Mylan and the pharmaceutical industry generally and would therefore be pleased to join TASE as one of the largest publicly traded companies following the consummation of the Perrigo acquisition,"" he said in a statement after the meeting.    (Reporting by Tova Cohen; Editing by Steven Scheer and Pravin Char)",2015-06-24,MYL,"Wed Jun 24, 2015 | 9:07am EDT",Mylan eyes Tel Aviv listing if Perrigo deal goes ahead,http://www.reuters.com//article/mylan-nl-perrigo-company-israel-idUSL8N0ZA2DN20150624?type=companyNews
162,"  (Adds Altice, Aetna, Cinven, Daimler, Johnson Matthey, Mylan, Penn Virginia, Societe Generale, Total, Potash Corporation of Saskatchewan, Bezeq Israel Telecom)June 25 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:** European telecoms group Altice SA defended its bid for Bouygues Telecom and confirmed it valued France's no.3 mobile operator at ""a minimum of 10 billion euros"" ($11.2 billion).** The bidding war for Integrated Silicon Solution Inc  intensified with rival chipmaker Cypress Semiconductor Corp further sweetening its offer to $22.60 per share.Cypress's latest offer values the company at about $718 million, compared with $730.5 million offered by Uphill on June 23, based on shares outstanding as of May 1.** The owner of the Miami Dolphins football team is joining forces with Qatar to buy a controlling stake in Formula One in a deal that could be worth up to $8 billion and inject new leadership into a sport facing falling TV audiences and ticket sales.**  U.S. health insurer Aetna Inc is close to buying rival Humana Inc and a deal could be signed as early as this weekend, Bloomberg reported, citing people familiar with the matter.** Buyout group Cinven has agreed to acquire German laboratory operator Synlab from BC Partners  for 1.7-1.8 billion euros ($1.9-2.0 billion) including debt, three sources familiar with the deal said on Thursday.** Daimler, the world's largest truck maker, bought a minority stake in Seattle-based telematics provider Zonar Systems Inc on Thursday, the latest step by established vehicle manufacturers to gain know-how in the area of connectivity.** Specialty chemicals firm Johnson Matthey Plc  said it would sell its research chemicals unit to Thermo Fisher Scientific Inc for 256 million pounds ($403 million) in cash.** Private equity funds CVC and KKR are studying a bid for a ""meaningful"" stake in Endesa, the Spanish subsidiary of Italy energy group Enel, sources with knowledge of the matter said.Enel declined to comment but sources close to the company said it had no interest in selling part or all of its 70 percent stake in Endesa, which is currently valued at around 13 billion euros ($14.5 billion). Endesa also declined to comment. ** European Union competition regulators will decide by July 29 whether U.S. drugmaker Mylan should be allowed to go ahead with its $34-billion hostile bid for Perrigo, the European Commission said.** Oil and natural gas producer Magnum Hunter Resources Corp  said it expected to raise $600-$700 million by selling its 45.53 percent stake in its natural gas gathering subsidiary, Eureka Hunter Holdings.** French bank Societe Generale said on Thursday it had sold a 7.04 percent stake in business consultants Sopra Steria for around 111 million euros.** British Airways-owner IAG has offered concessions in an attempt to win European Union regulatory approval for its plan to acquire a 25 percent stake in Irish rival Aer Lingus, the European Commission said on Thursday.** Penn Virginia Corp's shares rose as much as 23 percent on Thursday following a report that BP Plc had offered to buy the U.S. oil and gas producer for $8 per share. ** China's three largest airline cargo carriers, Air China Cargo, China Cargo Airlines and China Southern Cargo, will merge to form Asia's largest freight transport company, a senior official at the Civil Aviation Administration of China was quoted as saying in media reports. The reports did not provide a timeline or valuation for the deal.** South Africa's second-biggest private education firm Advtech Ltd said it had received an ""unsolicited proposal"" from a third party that its board was obliged to consider.** French oil major Total is in talks to sell its gas pipeline in the UK's North Sea to ArcLight Capital partners, a U.S.-based private equity firm focused on energy infrastructure, Bloomberg reported citing people familiar with the matter.** Potash Corporation of Saskatchewan Inc is eyeing German peer K+S for a possible takeover bid, German newspaper Handelsblatt reported on Thursday, citing financial sources.** Hillhouse Capital Group, the hedge fund headed by Chinese billionaire Zhang Lei, is in talks with existing Xiaoju Kuaizhi investors to increase its stake in the Chinese ride-sharing firm, according to a person familiar with the matter. ** DS Smith Plc agreed to buy Spanish company Grupo Lantero's corrugated products business, a move that would help the recycled packaging maker significantly expand its market share in Spain.The 190-million-euro ($213 million) purchase, including assumed debt, would deliver a return on invested capital in the second year of ownership, DS Smith said.** Snack manufacturer Orion Corp has submitted a preliminary bid for British retailer Tesco's South Korean unit Homeplus, the maker of ""Choco Pie"" said in a regulatory filing on Thursday.** Private equity firms Affinity Equity Partners, Carlyle Group and CVC Capital Partners were among seven to eight preliminary bidders for Tesco's South Korean unit, a Korean newspaper reported on Thursday.** South African iron ore producer Assore said on Thursday it had bought out African Rainbow Minerals' (ARM)  50 percent stake in the country's Dwarsrivier chrome mine for 450 million rand ($37 million) to take full ownership.** Two Samsung Group firms are looking at options to boost shareholder returns on completion of their proposed $8 billion merger, people familiar with the matter said, as the companies seek to overcome opposition from a U.S. hedge fund.** France's Vivendi does not rule out increasing its stake in Telecom Italia after becoming the group's biggest investor with 14.9 percent, CEO Arnaud de Puyfontaine told daily Corriere della Sera in an interview on Thursday.** Indonesia's Rajawali Group said on Thursday it would want to hold at least 21 percent of Felda Global Ventures Holdings Bhd if the Malaysian firm decides to seek a controlling stake in Rajawali unit PT Eagle High Plantations Tbk .** Bezeq Israel Telecom, Israel's largest telecoms group, has completed a deal to take full control of its satellite TV unit YES after the communications regulator determined it would not harm competition in the multi-channel TV market.($1 = 0.8925 euros)($1 = 12.1177 rand)($1 = 3.7735 shekels)   (Compiled by Manya Venkatesh and Yashaswini Swamynathan in Bengaluru)",2015-06-25,MYL,"Thu Jun 25, 2015 | 4:01pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0ZB3DV20150625?type=companyNews
163,"  BRUSSELS, June 25 European Union competition regulators will decide by July 29 whether U.S. drugmaker Mylan  should be allowed to go ahead with its $34-billion hostile bid for Perrigo, the European Commission said.Mylan's offer is seen as a move to head off world No. 1 generic drugmaker Teva Pharmaceutical Industries in a high-profile takeover battle. The Commission said Mylan requested EU clearance for its Perrigo bid on Tuesday. The EU antitrust enforcer can either clear the deal, extend its deadline if concessions are offered or open an extensive investigation.  Perrigo sells over-the-counter consumer products. The deal has the backing of Mylan's top shareholder Abbott Laboratories .    (Reporting by Foo Yun Chee; Editing by Elaine Hardcastle)",2015-06-25,MYL,"Thu Jun 25, 2015 | 12:00pm EDT",EU regulators to rule on Mylan bid for Perrigo by July 29,http://www.reuters.com//article/perrigo-company-ma-mylan-nl-eu-idUSL8N0ZB40E20150625?type=companyNews
164,"  Teva Pharmaceutical Industries Ltd (TEVA.TA) is preparing to raise its bid for rival drugmaker Mylan NV (MYL.O) by as much as $2 billion, to $43 billion, Bloomberg reported on Monday, citing people familiar with the matter.The improved proposal could be announced as soon as this week, Bloomberg said.Teva may offer $86 to $88 per share for Mylan, up from the $82 per share it bid in April, Bloomberg reported. Mylan rebuffed Teva's $40 billion bid in April, saying it grossly undervalued the company, and pressed on with its own $34 billion hostile bid for Perrigo Co Plc (PRGO.N) in an attempt to fend off Teva's interest.Mylan's market value stood at $34.36 billion as of Thursday's close, according to Thomson Reuters calculations. Mylan was not immediately available for comment and Teva declined to comment.  (Reporting by Ankur Banerjee in Bengaluru; Editing by Simon Jennings)",2015-07-06,MYL,"Mon Jul 6, 2015 | 12:56pm EDT",Teva plans to raise Mylan bid by as much as $2 billion: Bloomberg,http://www.reuters.com//article/us-mylan-nl-m-a-teva-pharm-ind-idUSKCN0PG1XD20150706?type=companyNews
165,"  July 6 Teva Pharmaceutical Industries Ltd  is preparing to raise its bid for rival drugmaker Mylan NV by as much as $2 billion, to $43 billion, Bloomberg reported on Monday, citing people familiar with the matter.The improved proposal could be announced as soon as this week, Bloomberg said. (bloom.bg/1S36gz5)Teva may offer $86 to $88 per share for Mylan, up from the $82 per share it bid in April, Bloomberg reported. Mylan rebuffed Teva's $40 billion bid in April, saying it grossly undervalued the company, and pressed on with its own $34 billion hostile bid for Perrigo Co Plc in an attempt to fend off Teva's interest. Mylan's market value stood at $34.36 billion as of Thursday's close, according to Thomson Reuters calculations. Mylan was not immediately available for comment and Teva declined to comment.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Simon Jennings)",2015-07-06,MYL,"Mon Jul 6, 2015 | 12:53pm EDT",Teva plans to raise Mylan bid by as much as $2 bln - Bloomberg,http://www.reuters.com//article/mylan-nl-ma-teva-pharm-ind-idUSL3N0ZM4YD20150706?type=companyNews
166,"   By Tova Cohen | TEL AVIV  TEL AVIV As Israel's biggest company Teva strives to get even bigger by swallowing up rival Mylan for more than $40 billion, further down the food chain a raft of upstart life science firms are struggling to climb onto the global ladder.Now the government is starting to take notice, urged on by influential advocates, including Teva Pharmaceutical Industries' own boss, who says the country's economic future depends on replicating his company's success.Israel has a burgeoning life science industry comprising around 1,380 mostly very small companies. Some 51 biotech, biopharma and medical devices firm are listed on the Tel Aviv Stock Exchange, making it the largest single sector. But few of them go on to build up their businesses, with most promising ideas snapped up by foreign heavyweights. Novartis, Johnson & Johnson and Merck Serono have all opened research centers in Israel, usually by acquiring small companies. Merck Serono's best-selling drug, Rebif, which treats multiple sclerosis (MS), was developed in Israel.That frustrates many in the Israeli industry, who believe the country is letting wealth and expertise drain overseas.  ""Start-up nation is not a sustainable model for Israel. What Israel needs is more large companies,"" Teva CEO Erez Vigodman said at the launch of a joint venture with Philips to invest in Israeli medical device and digital health start-ups.Teva, the world's largest generic drugmaker with annual sales of $20 billion, used its fortune from copycat drugs to move into the costlier innovative sector. Today, around half its profit is from one branded drug, MS treatment Copaxone.That is not an easy model to replicate.The biggest problem for Israeli firms, according to Claudio Yarza, head of life sciences at consultants PricewaterhouseCoopers (PwC) Israel, is a lack of funding -- from university level to capital markets, There are some signs, however, that is starting to change.  Israeli life science firms raised more than $2 billion from various resources in 2014, a record year, according to the Israel Advanced Technology Industries (IATI) association.What's more, start-ups raised $801 million, according to the Israel Venture Capital Research Center, up 55 percent on 2013.That's almost twice the rate of growth in the United States, although start-ups there raised a much larger $8.6 billion, according to PwC and the National Venture Capital Association. Also, of 73 biotech companies that went public on Nasdaq last year, seven were Israeli. ""Maybe now that some companies have raised nice sums on Nasdaq they will be able to take their drugs all the way,"" said  PwC Israel's Yarza.GOVERNMENT ACTION Israeli firms also complain about red tape, and the lack of manufacturing in Israel which means they have to turn to foreign companies for help developing drugs. ""We don't have enough drug development and manufacturing experience and infrastructure in Israel,"" Compugen CEO Anat Cohen-Dayag told Reuters. Compugen, which discovers drugs mainly in cancer immunotherapy using computational technology, has partnerships with Merck Serono and Bayer.  However, the Israeli government is now helping firms set up their own plants by offering funds for equipment, according to Ora Dar, head of life sciences in the chief scientist's office. In addition, ""we are talking to CMOs (contract manufacturing organizations) to see what it will take to convince them to build facilities in Israel,"" she said.Dar said the government was tackling another common complaint among life science executives -- a lack of experience in taking drugs through the regulatory process to market.The government is increasing funding for the health regulator to help speed approval for clinical trials in Israel, she said.There's a long way to go.While individual Israeli companies such as Protalix, whose plant-based enzyme was approved to treat Gaucher disease, may succeed, ""most will either license their products to larger corporations or be acquired,"" said IATI co-chairman Benny Zeevi.But Compugen's Cohen-Dayag was cautiously optimistic.""A small company that would like to take drugs to the market cannot establish the infrastructure in Israel on its own,"" she said. ""I think the government recognises this now and is trying to build bridges to address these gaps, but it will take time.""  (Editing by Mark Potter)",2015-07-08,MYL,"Wed Jul 8, 2015 | 11:06am EDT",Israeli life science firms seek help to follow Teva's lead,http://www.reuters.com//article/us-israel-lifesciences-idUSKCN0PI1SF20150708?type=companyNews
167,"   By Mike Stone | July 14  July 14 Hedge fund Paulson & Co has taken a stake in Syngenta AG,, and could push for the board of directors of the Swiss pesticide maker to accept a takeover offer from U.S. seed company Monsanto Co, people familiar with the matter said on Tuesday.Monsanto, the world's largest seed company, made a $45 billion bid for Syngenta that the Swiss company rejected. The U.S. company is still working on a deal and could decide to increase its bid. Paulson & Co, headed by billionaire John Paulson, became famous after betting that the U.S. housing bubble would burst.   The people familiar with the matter asked not to be named because they were not authorized to speak publicly. Paulson has purchased shares of potential acquisition targets in the past in contested mergers such as that of drug companies Mylan NV and Teva Pharmaceutical Industries Inc.. Paulson & Co was said to have began amassing its stake in June one of the people said.Bloomberg LP reported Paulson's stake earlier today.   (Reporting By Mike Stone; Editing by David Gregorio)",2015-07-14,MYL,"Tue Jul 14, 2015 | 6:15pm EDT",Paulson's hedge fund takes stake in Syngenta -sources,http://www.reuters.com//article/syngenta-ma-monsanto-paulson-stake-idUSL2N0ZU2OA20150714?type=companyNews
168,"   By Thomas Escritt | AMSTERDAM  AMSTERDAM An independent Dutch foundation linked to generic drugs manufacturer Mylan (MYL.O) used a poison pill to try and block a $40 billion takeover bid by Israeli rival Teva (TEVA.TA), citing potential job losses.Stichting Preferred Shares Mylan said on Thursday it had exercised a call option allowing it to buy 50 percent of Mylan's total issued and outstanding capital, giving it temporary control of half the company.The foundation - which can exercise the call option to safeguard the company's ""stakeholder interests"" - said a Teva takeover would likely lead to redundancies at Mylan and reduce access to cheap generic medicines in emerging markets.""Mylan follows a strategy of using financial leverage and retained profits to fuel further growth, whereas Teva has implemented a strategy of regular dividend payouts, a focus on cost control and product portfolio rationalization,"" it said.Teva said in a statement it had the power to challenge the foundation's action in court, and that it would ""take the necessary actions at the appropriate time"". Previous legal moves against Dutch preference share foundations - designed to block unsolicited takeover attempts - have had mixed success. Mylan has been rebuffing Teva's takeover bids, including one in April for $40 billion. Meanwhile, Mylan has pressed on with a $34 billion hostile bid for Perrigo Co Plc (PRGO.N).Teva, which has acquired a 4.6 percent stake in Mylan, also wants to use its stake to oppose Mylan's bid for Perrigo.The foundation said on Thursday it would vote ""to create a level playing field"" in the Perrigo takeover battle. In a note, analysts at RBC questioned the foundation's rationale for blocking the bid and said they believed Teva's bid for Mylan was more likely to succeed than Mylan's for Perrigo.Mylan, whose management is based in the United States, moved its domicile to the Netherlands last year to help reduce the company's U.S. tax liability. Independent foundations - common in the Netherlands - are typically endowed with a call option allowing them to temporarily issue enough shares to take control of a company to block unwelcome bids.Earlier this year, a judge overruled an attempt by marine engineer Boskalis to dismantle its rival Fugro's anti-takeover protections, while a foundation helped Dutch telecoms firm KPN fend off a bid by Carlos Slim's America Movil two years ago.Shares in Mylan fell almost 2 percent to $66.56 on the New York Stock Exchange on Thursday, while Teva closed down 1.03 percent in Tel Aviv. (Reporting By Thomas Escritt; Editing by Pravin Char and Susan Thomas)",2015-07-23,MYL,"Thu Jul 23, 2015 | 7:12pm EDT",Mylan foundation tries to block Teva takeover bid with poison pill,http://www.reuters.com//article/us-mylan-teva-idUSKCN0PX1JB20150723?type=companyNews
169,"  (Adds Breakingviews link, updates Mylan share price)* Exercises call option, allows it to control half of Mylan* Says takeover by Teva could mean job losses* Teva says has power to challenge action in courtBy Thomas EscrittAMSTERDAM, July 23 An independent Dutch foundation linked to generic drugs manufacturer Mylan  used a poison pill to try and block a $40 billion takeover bid by Israeli rival Teva, citing potential job losses.Stichting Preferred Shares Mylan said on Thursday it had exercised a call option allowing it to buy 50 percent of Mylan's total issued and outstanding capital, giving it temporary control of half the company. The foundation - which can exercise the call option to safeguard the company's ""stakeholder interests"" - said a Teva takeover would likely lead to redundancies at Mylan and reduce access to cheap generic medicines in emerging markets.""Mylan follows a strategy of using financial leverage and retained profits to fuel further growth, whereas Teva has implemented a strategy of regular dividend payouts, a focus on cost control and product portfolio rationalisation,"" it said.Teva said in a statement it had the power to challenge the foundation's action in court, and that it would ""take the necessary actions at the appropriate time"". Previous legal moves against Dutch preference share foundations - designed to block unsolicited takeover attempts - have had mixed success. Mylan has been rebuffing Teva's takeover bids, including one in April for $40 billion. Meanwhile, Mylan has pressed on with a $34 billion hostile bid for Perrigo Co Plc.Teva, which has acquired a 4.6 percent stake in Mylan, also wants to use its stake to oppose Mylan's bid for Perrigo.The foundation said on Thursday it would vote ""to create a level playing field"" in the Perrigo takeover battle. In a note, analysts at RBC questioned the foundation's rationale for blocking the bid and said they believed Teva's bid for Mylan was more likely to succeed than Mylan's for Perrigo.Mylan, whose management is based in the United States, moved its domicile to the Netherlands last year to help reduce the company's U.S. tax liability.Independent foundations - common in the Netherlands - are typically endowed with a call option allowing them to temporarily issue enough shares to take control of a company to block unwelcome bids.Earlier this year, a judge overruled an attempt by marine engineer Boskalis to dismantle its rival Fugro's anti-takeover protections, while a foundation helped Dutch telecoms firm KPN fend off a bid by Carlos Slim's America Movil two years ago.Shares in Mylan fell almost 2 percent to $66.56 on the New York Stock Exchange on Thursday, while Teva closed down 1.03 percent in Tel Aviv.(Reporting By Thomas Escritt; Editing by Pravin Char and Susan Thomas)",2015-07-23,MYL,"Thu Jul 23, 2015 | 7:09pm EDT",UPDATE 3-Mylan foundation tries to block Teva takeover bid with poison pill,http://www.reuters.com//article/mylan-nl-ma-teva-pharm-ind-idUSL1N1033VI20150723?type=companyNews
170,"  * Exercises call option, allows it to control half of Mylan* Says takeover by Teva could mean job losses* Teva says has power to challenge action in court   (Adds Breakingviews link, updates Mylan share price)By Thomas EscrittAMSTERDAM, July 23 An independent Dutch foundation linked to generic drugs manufacturer Mylan  used a poison pill to try and block a $40 billion takeover bid by Israeli rival Teva, citing potential job losses.Stichting Preferred Shares Mylan said on Thursday it had exercised a call option allowing it to buy 50 percent of Mylan's total issued and outstanding capital, giving it temporary control of half the company.The foundation - which can exercise the call option to safeguard the company's ""stakeholder interests"" - said a Teva takeover would likely lead to redundancies at Mylan and reduce access to cheap generic medicines in emerging markets. ""Mylan follows a strategy of using financial leverage and retained profits to fuel further growth, whereas Teva has implemented a strategy of regular dividend payouts, a focus on cost control and product portfolio rationalisation,"" it said.Teva said in a statement it had the power to challenge the foundation's action in court, and that it would ""take the necessary actions at the appropriate time"". Previous legal moves against Dutch preference share foundations - designed to block unsolicited takeover attempts - have had mixed success.Mylan has been rebuffing Teva's takeover bids, including one in April for $40 billion. Meanwhile, Mylan has pressed on with a $34 billion hostile bid for Perrigo Co Plc. Teva, which has acquired a 4.6 percent stake in Mylan, also wants to use its stake to oppose Mylan's bid for Perrigo.The foundation said on Thursday it would vote ""to create a level playing field"" in the Perrigo takeover battle.In a note, analysts at RBC questioned the foundation's rationale for blocking the bid and said they believed Teva's bid for Mylan was more likely to succeed than Mylan's for Perrigo. Mylan, whose management is based in the United States, moved its domicile to the Netherlands last year to help reduce the company's U.S. tax liability.Independent foundations - common in the Netherlands - are typically endowed with a call option allowing them to temporarily issue enough shares to take control of a company to block unwelcome bids.Earlier this year, a judge overruled an attempt by marine engineer Boskalis to dismantle its rival Fugro's anti-takeover protections, while a foundation helped Dutch telecoms firm KPN fend off a bid by Carlos Slim's America Movil two years ago.Shares in Mylan fell almost 2 percent to $66.56 on the New York Stock Exchange on Thursday, while Teva closed down 1.03 percent in Tel Aviv.(Reporting By Thomas Escritt; Editing by Pravin Char and Susan Thomas)",2015-07-23,MYL,"Thu Jul 23, 2015 | 7:08pm EDT",UPDATE 3-Mylan foundation tries to block Teva takeover bid with poison pill,http://www.reuters.com//article/mylan-nl-ma-teva-pharm-ind-idUSL5N1033QA20150723?type=companyNews
171,"  BRUSSELS, July 24 The following are mergers under review by the European Commission and a brief guide to the EU merger process:APPROVALS AND WITHDRAWALS -- Finnish telecoms equipment maker Nokia to acquire French peer Alcatel-Lucent (approved July 24)NEW LISTINGS -- Oilfield services provider Halliburton to buy rival Baker Hughes in a stock and cash transaction (notified July 23/deadline Aug. 27)EXTENSIONS AND OTHER CHANGES FIRST-STAGE REVIEWS BY DEADLINE JULY 29 -- U.S. drugmaker Mylan to acquire U.S. peer Perrigo  (notified June 23/deadline July 29)JULY 31 -- Talanx Asset Management GmbH and Norddeutsche Landesbank Girozentrale (Nord LB) to acquire joint control of alternative asset investment management company Caplantic GmbH (notified June 25/deadline July 31/simplified)AUG 4 -- U.S. drugmaker Pfizer to acquire U.S. peer Hospira (notified June 15/deadline extended to Aug. 4 from July 20 after Pfizer offered concessions)-- Private equity firm Cinven Capital Management to acquire biological testing services company Labco (notified June 29/deadline Aug. 4/simplified)AUG 5 -- Asset manager BlackRock and private equity firm First Reserve Management to acquire joint control of a joint venture building a gas pipeline in Mexico, in which GDF Suez holds a stake (notified June 30/deadline Aug. 5/simplified)-- Spanish cars part maker Grupo Antolin to acquire auto parts maker Magna Interiors from Canadian car parts maker Magna International Inc (notified June 30/deadline Aug. 5)AUG 6 -- U.S. healthcare company Danaher Corp to acquire air and water filter maker Pall Corp (notified July 1/deadline Aug. 6/simplified)-- Swiss travel retailer Dufry to acquire Italian peer World Duty Free (notified July 1/deadline Aug 6)AUG 7  -- Private equity firm CVC Capital Partners to acquire beauty products retailer Douglas Group (notified July 2/deadline Aug. 7/simplified)-- German insurer Axa Konzern and Compugroup Medical Mobile DTL to set up a joint venture (notified July 2/deadline Aug. 7/simplified)AUG 10 -- Private equity firm Lone Star Fund IX to acquire textile floor coverings producer Balta (notified July 3/deadline Aug. 10/simplified)AUG 11 -- Investment fund Apollo Management L.P. to acquire Saint-Gobain Emballage, Saint Gobain Vicasa S.A., Saint Gobain Vidros and Obale, with the group known as Verallia (notified July 6/deadline Aug. 11/simplified)AUG 13 -- Swiss bakery products maker Aryzta to acquire 49 percent of frozen food retailer Picard Groupe (notified July 8/deadline Aug. 13)AUG 14 -- NH Hotel Group SA and HNA Hospitality Group Co Ltd to set up a joint venture which will operate mainly in China (notified July 9/deadline Aug. 14/simplified) AUG 17 -- Investment fund Canada Pension Plan Investment Board (CPPIB) and real estate investment trust Intu Holding S.a.r.l. to indirectly acquire a joint controlling stake in Spanish shopping mall Puerto Venecia Investments SOCIMI S.A. (notified July 10/deadline Aug. 17/simplified)-- Private equity firm CVC to acquire theatre producer Stage Entertainment (notified July 10/deadline Aug. 17/simplified)-- Spanish energy company Repsol and Mexican industrial group Grupo Kuo to expand their joint venture Dynasol (notified July 10/deadline Aug. 17/simplified)-- Investment bank Goldman Sachs and Altor to jointly acquire soy-based protein solutions maker Hamlet Protein (notified July 10/deadline Aug. 17)AUG 18 -- U.S. staffing company ManpowerGroup Inc to acquire German peer 7S Group (notified July 13/deadline Aug. 18/simplified)AUG 19 -- French companies Groupe In Vivo and Groupe Scael to set up a joint venture (notified July 14/deadline Aug. 19/simplified)-- Fuel supplier World Fuel Services Corp to acquire businesses divested by BP Plc (notified July 14/deadline Aug. 19/simplified)AUG 20 -- Dutch building materials distributor PontMeyer, which is part of Deli Building Supplies B.V., to acquire Dutch holding company DBS (notified July 15/deadline Aug. 20) AUG 24 -- Funds advised by Apax Partners LLP to acquire online retailer RFS (notified July 17/deadline Aug. 24/simplified)-- Real estate services firm CBRE Group Inc to buy Johnson Controls Inc's workplace solutions business (notified July 17/deadline Aug. 24/simplified)-- Magyar Telekom, 59 percent owned by Deutsche Telekom, to form a joint venture with Swiss-based energy sales and trading group MET Holding AG (notified July 17/deadline Aug. 24)AUG 26 -- Italy's Ferrero Rocher to purchase Thornstons for 112 million pounds. (notified July 22/deadline Aug. 26/simplified)-- Perrigo to buy portfolio of over-the-counter brands form GlaxoSmithKline (notified July 22/deadline Aug. 26)-- Varo Energy, a joint venture between the world's top oil trader Vitol and private equity firm Carlyle Group , is expanding its reach in Europe through a merger with Dutch-based storage and trading company Argos (notified July 22/ deadline Aug. 26)SEPT 2 -- Norwegian telecoms company Telenor and Swedish peer TeliaSonera to combine their Danish mobile businesses (notified Feb. 27/deadline extended to Sept. 2 from Aug. 19 after the companies asked for more time)SEPT 11 -- U.S. conglomerate General Electric to acquire most of French engineering group Alstom's power equipment business (notified Jan. 19/deadline extended for third time to Sept. 11 from Aug. 21)NOV 25 -- U.S. drinks can maker Ball Corp to acquire British rival Rexam Plc (notified June 15/deadline extended to Nov. 25 from July 20 after Commission opened in-depth investigation)SUSPENDED -- SOCAR, Azerbaijan's state energy company, to buy stakes in Greek natural gas grid operator DESFA from Greek natural gas utility DEPA (notified Oct. 1/deadline suspended on Jan. 21)GUIDE TO EU MERGER PROCESS DEADLINES: The European Commission has 25 working days after a deal is  filed for a first-stage review. It may extend that by 10 working days to 35 working days, to consider either a company's proposed remedies or an EU member state's request to handle the case.Most mergers win approval but occasionally the Commission  opens a detailed second-stage investigation for up to 90  additional working days, which it may extend to 105 working  days.SIMPLIFIED: Under the simplified procedure, the Commission announces the clearance of uncontroversial first-stage mergers without giving any reason for its decision. Cases may be reclassified as non-simplified - that is, ordinary first-stage reviews - until they are approved.   (Compiled by Foo Yun Chee)",2015-07-24,MYL,"Fri Jul 24, 2015 | 12:39pm EDT",EU mergers and takeovers (July 24),http://www.reuters.com//article/eu-mergers-idUSL5N1040ZU20150724?type=companyNews
172,"   By Tova Cohen and Ari Rabinovitch | TEL AVIV, July 26  TEL AVIV, July 26 After months of sparring in a hostile takeover bid for rival Mylan NV, Teva Pharmaceutical's move to buy Allergan Plc's  generic drug business instead could be a smoother ride that will bring bigger returns, faster.Israel-based Teva, the world's largest generic drugmaker, is in advanced talks to buy Allergan's generic drugs unit for between $40-45 billion dollars, according to a person familiar with the matter.News of the deal broke on Saturday after Teva's $40 billion bid for Mylan hit a snag when a Dutch foundation linked to Mylan bought temporary control of half the company in an attempt to block the takeover.A Teva spokesman declined to comment on possible talks with Allergan.Though the Teva-Mylan feud has hogged the industry spotlight since April, Allergan' generics business may actually have been Teva's first choice. Teva CEO Erez Vigodman is believed to have approached Allergan last year, which was called Actavis prior to a March merger.In June 2014, just a few months after joining the company himself, Vigodman hired the former head of Actavis' generic drug business, Sigurdur Olafsson, to fill a similar role at Teva. ""There was previously a preference for Actavis over Mylan but for some reason it didn't materialise,"" said Bank of Jerusalem analyst Jonathan Kreizman.Should the deal with Dublin-based Allergan now go through, there will be two big upsides for Teva, he said.First, there is less overlap than with Mylan. Teva has been planning a generic version of Mylan's EpiPen, a billion-dollar product, while Mylan has been working on a generic version of Teva's best-selling multiple sclerosis drug Copaxone. In the short term, Teva would benefit from removing the uncertainty over the outcome of the Mylan deal that has weighed on its stock.Since hitting a year high of $68.74 in New York on April 9, just before speculation on a possible Mylan bid had surfaced, Teva shares are down more than 10 percent, closing on Friday at $61.85.Kreizman said he assumes the size of the deal would be similar in scope to Mylan, noting Allergan has about 8 percent of the U.S. drugs market, compared with 9 percent for Mylan and 14 percent for Teva. ""Assuming the entity is more or less the same size, valuation is less of an issue,"" he said.The Mylan deal is hard for the market to digest, he said, while ""any friendly transaction ... would have better impact.""Allergan's generics operations has about $7 billion in sales, said Umer Raffat, an analyst with investment research firm ISI Group.""Theoretically, a Teva/Allergan generics business combo offers Teva the opportunity to get what it was looking for without having to go through Dutch courts,"" he said.This includes boosting its scale and getting access to complex generics like injectables as well as biosimilar drugs through Allergan's partnership with Amgen on oncology biologic drugs, he said.   (Editing by William Hardy)",2015-07-26,MYL,"Sun Jul 26, 2015 | 6:51am EDT",Allergan bid may be healthier for Teva than battle with Mylan,http://www.reuters.com//article/teva-pharm-ind-allergan-idUSL5N10604B20150726?type=companyNews
173,"  (Updates sourcing, adds details)By Greg RoumeliotisJuly 25 Teva Pharmaceutical Industries Ltd  is in advanced talks to buy Allergan Plc's  generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV, according to a person familiar with the matter.Jerusalem-based Teva, which has offered to buy Mylan for $40 billion, is now close to an agreement to acquire Dublin-based Allergan's generic drugs unit for between $40 billion and $45 billion, the person said on Saturday.A deal could be announced as early as next week, the person said, cautioning that negotiations had not yet been completed and asking not to be identified because the discussions are confidential. Teva and Allergan representatives did not respond to requests for comment. Large drug makers are trying to realign their operations to focus on a small number of leading businesses, while smaller specialty and generic producers are seeking larger scale. Allergan's branded drugs business makes products such as Botox and Alzheimer's drug Namenda. Its generics business makes up about a third of the company's total revenue.A successful deal with Allergan would give Teva, which has a market capitalization of $60 billion, a much bigger footprint in the generic drugs sector. It would also offer opportunities for significant cost synergies and tax savings. Last year, Actavis Plc outbid Canadian drugmaker Valeant Pharmaceuticals International Inc and activist investor William Ackman to merge with Allergan and adopt its name. Allergan now has a market capitalization of $121 billion.Teva's bid for Mylan took a hit earlier this week when the latter's independent Dutch foundation exercised a call option allowing it to buy 50 percent of Mylan's total issued and outstanding capital, giving it temporary control of half the company. The foundation, known as Stichting, opposes Teva's bid, arguing that a Teva takeover would likely lead to job losses at Mylan and reduce access to cheap generic medicines in emerging markets.Mylan for its part is pressing on with a $34 billion hostile bid for Perrigo Co Plc. Were Teva to clinch a deal with Allergan for its generic drug business and drop its bid for Mylan, this would likely strengthen the hand of Mylan's management in its campaign to buy Perrigo.The Wall Street Journal first reported that Teva was in advanced talks to acquire Allergan's generic drug unit.   (Reporting by Greg Roumeliotis in New York; Editing by Steve Orlofsky)",2015-07-26,MYL,"Sat Jul 25, 2015 | 9:06pm EDT",UPDATE 1-Teva nears deal for Allergan's generic drugs unit -source,http://www.reuters.com//article/teva-allergan-idUSL1N1050K820150726?type=companyNews
174,"   By Tova Cohen and Steven Scheer | TEL AVIV  TEL AVIV Israel's Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan's generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential ""transformational"" acquisitions.The deal, the largest in Israel's corporate history, allows Teva stronger economies of scale, crucial in the low-margin generic drugs business. Teva , which dropped its hostile pursuit of Mylan, will likely have to sell off some drugs to allay antitrust concerns.""Allergan's business is more high-end (than Mylan). It's a more interesting business ... a profitable business and it's well managed,"" said Gilad Alper, an analyst at brokerage Excellence Nessuah.Allergan, known for its Botox anti-wrinkle treatment, became the third-largest generic drugmaker in the United States after combining with Actavis in March. It is seen as a better fit than Mylan because it will improve Teva's distribution channels and access to profitable injectable drugs.Pressure has been growing on Teva Chief Executive Erez Vigodman to find new revenue sources to combat generic competition for its branded multiple sclerosis drug Copaxone. Copaxone accounts for about half of Teva's profit.Allergan Chief Executive Brent Saunders, who led Actavis' purchase of Forest Laboratories and then Allergan, said the company will use the $36 billion in net proceeds from the generics sale to help fund further large acquisitions.""We can accelerate our timing on transformational M&A,"" Saunders said during a conference call. He cited aesthetics, eye care, central nervous system disorders and gastrointestinal therapies as areas for potential future deals. Wall Street analysts speculated that possible targets include Biogen Inc , Amgen Inc and AbbVie Inc.The healthcare sector has seen an unprecedented wave of deals since early 2014, from large drugmakers buying up smaller rivals, to consolidation among makers of generic medicines and tie-ups between insurers.Global healthcare M&A reached $398.5 billion as of July 23, up 80 percent on a year ago, according to Thomson Reuters data. HIGHLY COMPETITIVE Teva shares, which had been weighed down by the Mylan uncertainty, rose 16.4 percent in New York on Monday. Allergan shares gained about 6.1 percent and Mylan shares slid 14.5 percent.Mylan had used a poison pill-style defence to fight a $40 billion takeover by Teva, arguing that a deal was ""without sound industrial logic or cultural fit"" and would face regulatory hurdles. The company said on Monday it would continue efforts to buy Perrigo Company PLC, whose shares were up 3.8 percent.Teva may need to sell a large number of assets to satisfy antitrust authorities about the Allergan transaction, according to two antitrust attorneys who handle pharmaceutical deals. ""But if you look at the total size of the deal, that's going to be a tiny fraction,"" one of the lawyers said.It may also be harder to find buyers for those drugs given the consolidation already seen in the generics sector, they said. The U.S. Federal Trade Commission requires buyers for proposed divestitures before it will approve a deal.Teva said it has identified asset sales needed for the deal to pass muster with U.S. and UK antitrust regulators, and that the number was less than what had been anticipated in a combination with Mylan.CULTURAL FIT  Teva said it had approached Allergan a year ago but did not generate interest. It then went after Mylan, which repeatedly rebuffed its offers, and only turned its attention back to Allergan earlier this month. In June 2014, Vigodman hired Sigurdur Olafsson, former head of Actavis's generic drug business, to fill a similar role at Teva.""My sense always was that Mylan was Teva's Plan B,"" said Benny Landa, an industrialist who led an investor bid last year to shake up Teva's board, calling the deal ""brilliant.""Teva will pay $33.75 billion in cash and $6.75 billion in shares, representing a 10 percent stake in the Israel-based company, Teva said. It expects the deal to close in the first quarter of 2016.Vigodman said the combined company will have proforma revenue of $26 billion and earnings before interest, tax, depreciation and amortization of $9.5 billion in 2016.""This acquisition reinforces our strategy, accelerates growth and diversifies revenues both by product and geographically, supporting our new business model,"" he said.Teva, which will gain a portfolio of more than 1,000 products, forecast a double-digit boost to adjusted earnings per share in 2016 and a more than 20 percent benefit in years two and three after closing the deal.It expects cost synergies and tax savings of $1.4 billion annually by the third anniversary from efficiencies in operations, manufacturing, and sales and marketing.It also expects the acquisition to generate free cash flow of $6.5 billion in 2016 and increased free cash flow in subsequent years. This means Teva will be able to pursue acquisitions to expand its portfolio in both speciality pharmaceuticals and generics.J.P. Morgan is acting as financial advisor to Allergan and Latham & Watkins LLP is serving as Allergan's lead legal advisor. Barclays and Greenhill & Co are serving as financial advisors to Teva. Sullivan & Cromwell LLP and Tulchinsky Stern Marciano Cohen Levitski & Co are serving as legal counsel to Teva.   (Additional reporting by Caroline Humer and Bill Berkrot in New York, Diane Bartz in Washington, Ben Hirschler in London)",2015-07-27,MYL,"Mon Jul 27, 2015 | 6:43pm EDT","Teva to buy Allergan generic business for $40.5 bln, drops Mylan bid",http://www.reuters.com//article/allergan-ma-teva-idUSL1N1070Y320150727?type=companyNews
175,"   By Tova Cohen and Steven Scheer | TEL AVIV  TEL AVIV Israels Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergans generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential ""transformational"" acquisitions. The deal, the largest in Israel's corporate history, allows Teva stronger economies of scale, crucial in the low-margin generic drugs business. Teva, which dropped its hostile pursuit of Mylan, will likely have to sell off some drugs to allay antitrust concerns.""Allergan's business is more high-end (than Mylan). It's a more interesting business ... a profitable business and it's well managed,"" said Gilad Alper, an analyst at brokerage Excellence Nessuah.Allergan, known for its Botox anti-wrinkle treatment, became the third-largest generic drugmaker in the United States after combining with Actavis in March. It is seen as a better fit than Mylan because it will improve Teva's distribution channels and access to profitable injectable drugs.Pressure has been growing on Teva Chief Executive Erez Vigodman to find new revenue sources to combat generic competition for its branded multiple sclerosis drug Copaxone. Copaxone accounts for about half of Teva's profit.Allergan Chief Executive Brent Saunders, who led Actavis' purchase of Forest Laboratories and then Allergan, said the company will use the $36 billion in net proceeds from the generics sale to help fund further large acquisitions.""We can accelerate our timing on transformational M&A,"" Saunders said during a conference call. He cited aesthetics, eye care, central nervous system disorders and gastrointestinal therapies as areas for potential future deals. Wall Street analysts speculated that possible targets include Biogen Inc, Amgen Inc and AbbVie Inc.The healthcare sector has seen an unprecedented wave of deals since early 2014, from large drugmakers buying up smaller rivals, to consolidation among makers of generic medicines and tie-ups between insurers. Global healthcare M&A reached $398.5 billion as of July 23, up 80 percent on a year ago, according to Thomson Reuters data. HIGHLY COMPETITIVE  Teva shares, which had been weighed down by the Mylan uncertainty, rose 16.4 percent in New York on Monday. Allergan shares gained about 6.1 percent and Mylan shares slid 14.5 percent.     Mylan had used a poison pill-style defense to fight a $40 billion takeover by Teva, arguing that a deal was ""without sound industrial logic or cultural fit"" and would face regulatory hurdles. The company said on Monday it would continue efforts to buy Perrigo Company PLC, whose shares were up 3.8 percent.Teva may need to sell a large number of assets to satisfy antitrust authorities about the Allergan transaction, according to two antitrust attorneys who handle pharmaceutical deals. ""But if you look at the total size of the deal, that's going to be a tiny fraction,"" one of the lawyers said.  It may also be harder to find buyers for those drugs given the consolidation already seen in the generics sector, they said. The U.S. Federal Trade Commission requires buyers for proposed divestitures before it will approve a deal.Teva said it has identified asset sales needed for the deal to pass muster with U.S. and UK antitrust regulators, and that the number was less than what had been anticipated in a combination with Mylan.CULTURAL FIT  Teva said it had approached Allergan a year ago but did not generate interest. It then went after Mylan, which repeatedly rebuffed its offers, and only turned its attention back to Allergan earlier this month. In June 2014, Vigodman hired Sigurdur Olafsson, former head of Actavis's generic drug business, to fill a similar role at Teva. ""My sense always was that Mylan was Teva's Plan B,"" said Benny Landa, an industrialist who led an investor bid last year to shake up Teva's board, calling the deal ""brilliant.""Teva will pay $33.75 billion in cash and $6.75 billion in shares, representing a 10 percent stake in the Israel-based company, Teva said. It expects the deal to close in the first quarter of 2016.Vigodman said the combined company will have proforma revenue of $26 billion and earnings before interest, tax, depreciation and amortization of $9.5 billion in 2016.""This acquisition reinforces our strategy, accelerates growth and diversifies revenues both by product and geographically, supporting our new business model,"" he said.Teva, which will gain a portfolio of more than 1,000 products, forecast a double-digit boost to adjusted earnings per share in 2016 and a more than 20 percent benefit in years two and three after closing the deal.It expects cost synergies and tax savings of $1.4 billion annually by the third anniversary from efficiencies in operations, manufacturing, and sales and marketing.It also expects the acquisition to generate free cash flow of $6.5 billion in 2016 and increased free cash flow in subsequent years. This means Teva will be able to pursue acquisitions to expand its portfolio in both specialty pharmaceuticals and generics.J.P. Morgan is acting as financial advisor to Allergan and Latham & Watkins LLP is serving as Allergan's lead legal advisor. Barclays and Greenhill & Co are serving as financial advisors to Teva. Sullivan & Cromwell LLP and Tulchinsky Stern Marciano Cohen Levitski & Co are serving as legal counsel to Teva. (Additional reporting by Caroline Humer and Bill Berkrot in New York, Diane Bartz in Washington, Ben Hirschler in London; Editing by David Holmes and Nick Zieminski)",2015-07-27,MYL,"Mon Jul 27, 2015 | 6:13pm EDT","Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid",http://www.reuters.com//article/us-allergan-m-a-teva-pharm-ind-idUSKCN0Q10QE20150727?type=companyNews
176,"  * To pay $33.75 billion in cash, 10 pct of Teva's shares* Combined entity to have proforma revenue of $26 bln in 2016* Teva and Allergan shares jump; Mylan shares sink   (Adds Breakingviews link, updates share prices)By Tova Cohen and Steven ScheerTEL AVIV, July 27 Israel's Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan's generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential ""transformational"" acquisitions.The deal, the largest in Israel's corporate history, allows Teva stronger economies of scale, crucial in the low-margin generic drugs business. Teva , which dropped its hostile pursuit of Mylan, will likely have to sell off some drugs to allay antitrust concerns.""Allergan's business is more high-end (than Mylan). It's a more interesting business ... a profitable business and it's well managed,"" said Gilad Alper, an analyst at brokerage Excellence Nessuah.Allergan, known for its Botox anti-wrinkle treatment, became the third-largest generic drugmaker in the United States after combining with Actavis in March. It is seen as a better fit than Mylan because it will improve Teva's distribution channels and access to profitable injectable drugs.Pressure has been growing on Teva Chief Executive Erez Vigodman to find new revenue sources to combat generic competition for its branded multiple sclerosis drug Copaxone. Copaxone accounts for about half of Teva's profit.Allergan Chief Executive Brent Saunders, who led Actavis' purchase of Forest Laboratories and then Allergan, said the company will use the $36 billion in net proceeds from the generics sale to help fund further large acquisitions.""We can accelerate our timing on transformational M&A,"" Saunders said during a conference call. He cited aesthetics, eye care, central nervous system disorders and gastrointestinal therapies as areas for potential future deals. Wall Street analysts speculated that possible targets include Biogen Inc , Amgen Inc and AbbVie Inc. The healthcare sector has seen an unprecedented wave of deals since early 2014, from large drugmakers buying up smaller rivals, to consolidation among makers of generic medicines and tie-ups between insurers.Global healthcare M&A reached $398.5 billion as of July 23, up 80 percent on a year ago, according to Thomson Reuters data.HIGHLY COMPETITIVE Teva shares, which had been weighed down by the Mylan uncertainty, rose 16.4 percent in New York on Monday. Allergan shares gained about 6.1 percent and Mylan shares slid 14.5 percent.Mylan had used a poison pill-style defence to fight a $40 billion takeover by Teva, arguing that a deal was ""without sound industrial logic or cultural fit"" and would face regulatory hurdles. The company said on Monday it would continue efforts to buy Perrigo Company PLC, whose shares were up 3.8 percent. Teva may need to sell a large number of assets to satisfy antitrust authorities about the Allergan transaction, according to two antitrust attorneys who handle pharmaceutical deals.""But if you look at the total size of the deal, that's going to be a tiny fraction,"" one of the lawyers said.It may also be harder to find buyers for those drugs given the consolidation already seen in the generics sector, they said. The U.S. Federal Trade Commission requires buyers for proposed divestitures before it will approve a deal.Teva said it has identified asset sales needed for the deal to pass muster with U.S. and UK antitrust regulators, and that the number was less than what had been anticipated in a combination with Mylan. CULTURAL FIT Teva said it had approached Allergan a year ago but did not generate interest. It then went after Mylan, which repeatedly rebuffed its offers, and only turned its attention back to Allergan earlier this month. In June 2014, Vigodman hired Sigurdur Olafsson, former head of Actavis's generic drug business, to fill a similar role at Teva.""My sense always was that Mylan was Teva's Plan B,"" said Benny Landa, an industrialist who led an investor bid last year to shake up Teva's board, calling the deal ""brilliant.""Teva will pay $33.75 billion in cash and $6.75 billion in shares, representing a 10 percent stake in the Israel-based company, Teva said. It expects the deal to close in the first quarter of 2016.Vigodman said the combined company will have proforma revenue of $26 billion and earnings before interest, tax, depreciation and amortization of $9.5 billion in 2016.""This acquisition reinforces our strategy, accelerates growth and diversifies revenues both by product and geographically, supporting our new business model,"" he said.Teva, which will gain a portfolio of more than 1,000 products, forecast a double-digit boost to adjusted earnings per share in 2016 and a more than 20 percent benefit in years two and three after closing the deal.It expects cost synergies and tax savings of $1.4 billion annually by the third anniversary from efficiencies in operations, manufacturing, and sales and marketing.It also expects the acquisition to generate free cash flow of $6.5 billion in 2016 and increased free cash flow in subsequent years. This means Teva will be able to pursue acquisitions to expand its portfolio in both speciality pharmaceuticals and generics.J.P. Morgan is acting as financial advisor to Allergan and Latham & Watkins LLP is serving as Allergan's lead legal advisor. Barclays and Greenhill & Co are serving as financial advisors to Teva. Sullivan & Cromwell LLP and Tulchinsky Stern Marciano Cohen Levitski & Co are serving as legal counsel to Teva.   (Additional reporting by Caroline Humer and Bill Berkrot in New York, Diane Bartz in Washington, Ben Hirschler in London; Editing by David Holmes and Nick Zieminski)",2015-07-27,MYL,"Mon Jul 27, 2015 | 5:27pm EDT","UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bid",http://www.reuters.com//article/allergan-ma-teva-idUSL5N10717820150727?type=companyNews
177,"  BRUSSELS, July 29 The European Commission said on Wednesday it had cleared generic drug maker Mylan's  planned takeover of Ireland-based Perrigo Co.The Commission said in a statement that the proposed acquisition would not raise competition concerns, because the parties' activities are largely complementary, Mylan being one of the main European producers of prescribed generic drugs and Perrigo specialised in selling over-the-counter drugs. Mylan had been at the centre of a three-way takeover battle, with Perrigo having rejected a sweetened $34 billion offer, and Mylan seeking to fend off a takeover by Israel-based Teva Pharmaceutical Industries, the world's largest generic drugmaker.  However, Teva agreed this week to pay $40.5 billion in cash and stock for Allergan's generic drugs business and dropped its hostile pursuit.     (Reporting By Philip Blenkinsop)",2015-07-29,MYL,"Wed Jul 29, 2015 | 6:16am EDT",EU clears acquisition of Perrigo by Mylan,http://www.reuters.com//article/perrigo-company-ma-mylan-nl-eu-idUSB5N0ZA01B20150729?type=companyNews
178,"  BRUSSELS, July 30 The following are mergers under review by the European Commission and a brief guide to the EU merger process:APPROVALS AND WITHDRAWALS -- Investment fund Apollo Management L.P. to acquire Saint-Gobain Emballage, Saint Gobain Vicasa S.A., Saint Gobain Vidros and Obale, with the group known as Verallia (approved July 30)-- U.S. drugmaker Mylan to acquire U.S. peer Perrigo  (approved July 29)NEW LISTINGS -- Anglo-Dutch oil major Royal Dutch Shell to acquire BG Group (notified July 29/deadline Sept. 2)-- South African paper maker Mondi  to acquire some assets from portfolio company Walki (notified July 29/deadline Sept. 2)-- British engineering company GKN to acquire Dutch company Fokker Technologies (notified July 28/deadline Sept. 1/simplified)-- British support services provider DCC Group to acquire French gas company Butagaz from Anglo Dutch oil company Royal Dutch Shell (notified July 28/deadline Sept. 1/simplified)-- Archer Daniels Midland Co to acquire starch producer Eaststarch (notified July 28/deadline Sept. 1/simplified)EXTENSIONS AND OTHER CHANGES NoneFIRST-STAGE REVIEWS BY DEADLINE AUG 4 -- U.S. drugmaker Pfizer to acquire U.S. peer Hospira (notified June 15/deadline extended to Aug. 4 from July 20 after Pfizer offered concessions)AUG 5 -- Asset manager BlackRock and private equity firm First Reserve Management to acquire joint control of a joint venture building a gas pipeline in Mexico, in which GDF Suez holds a stake (notified June 30/deadline Aug. 5/simplified)-- Spanish cars part maker Grupo Antolin to acquire auto parts maker Magna Interiors from Canadian car parts maker Magna International Inc (notified June 30/deadline Aug. 5)AUG 6 -- Swiss travel retailer Dufry to acquire Italian peer World Duty Free (notified July 1/deadline Aug 6)AUG 7 -- Private equity firm CVC Capital Partners to acquire beauty products retailer Douglas Group (notified July 2/deadline Aug. 7/simplified)-- German insurer Axa Konzern and Compugroup Medical Mobile DTL to set up a joint venture (notified July 2/deadline Aug. 7/simplified) AUG 10 -- Private equity firm Lone Star Fund IX to acquire textile floor coverings producer Balta (notified July 3/deadline Aug. 10/simplified)AUG 13 -- Swiss bakery products maker Aryzta to acquire 49 percent of frozen food retailer Picard Groupe (notified July 8/deadline Aug. 13)AUG 14 -- NH Hotel Group SA and HNA Hospitality Group Co Ltd to set up a joint venture which will operate mainly in China (notified July 9/deadline Aug. 14/simplified)AUG 17 -- Investment fund Canada Pension Plan Investment Board (CPPIB) and real estate investment trust Intu Holding S.a.r.l. to indirectly acquire a joint controlling stake in Spanish shopping mall Puerto Venecia Investments SOCIMI S.A. (notified July 10/deadline Aug. 17/simplified)-- Private equity firm CVC to acquire theatre producer Stage Entertainment (notified July 10/deadline Aug. 17/simplified)-- Spanish energy company Repsol and Mexican industrial group Grupo Kuo to expand their joint venture Dynasol (notified July 10/deadline Aug. 17/simplified)-- Investment bank Goldman Sachs and Altor to jointly acquire soy-based protein solutions maker Hamlet Protein (notified July 10/deadline Aug. 17) AUG 18 -- U.S. staffing company ManpowerGroup Inc to acquire German peer 7S Group (notified July 13/deadline Aug. 18/simplified)AUG 19 -- French companies Groupe In Vivo and Groupe Scael to set up a joint venture (notified July 14/deadline Aug. 19/simplified)-- Fuel supplier World Fuel Services Corp to acquire businesses divested by BP Plc (notified July 14/deadline Aug. 19/simplified)AUG 20 -- Dutch building materials distributor PontMeyer, which is part of Deli Building Supplies B.V., to acquire Dutch holding company DBS (notified July 15/deadline Aug. 20)AUG 24 -- Volkswagen Financial Services, which is part of German carmaker Volkswagen, and Spanish lender Banco Bilbao Vizcaya Argentaria to set up a joint venture called Volkswagen Credit Compania Financiera (notified July 17/deadliine Aug. 24/simplified)-- Funds advised by Apax Partners LLP to acquire online retailer RFS (notified July 17/deadline Aug. 24/simplified)-- Real estate services firm CBRE Group Inc to buy Johnson Controls Inc's workplace solutions business (notified July 17/deadline Aug. 24/simplified)-- Magyar Telekom, 59 percent owned by Deutsche Telekom, to form a joint venture with Swiss-based energy sales and trading group MET Holding AG (notified July 17/deadline Aug. 24)AUG 26  -- Italian confectionery maker Ferrero to purchase British chocolate retailer Thornstons  (notified July 22/deadline Aug. 26/simplified)-- U.S. drugmaker Perrigo to buy portfolio of over-the-counter brands form British peer GlaxoSmithKline  (notified July 22/deadline Aug. 26)-- Varo Energy, a joint venture between the world's top oil trader Vitol and private equity firm Carlyle Group , is expanding its reach in Europe through a merger with Dutch-based storage and trading company Argos (notified July 22/ deadline Aug. 26)AUG 27 -- Oilfield services provider Halliburton to buy rival Baker Hughes in a stock and cash transaction (notified July 23/deadline Aug. 27)AUG 28 -- U.S. real estate services provider DTZ to acquire U.S. peer Cushman & Wakefield (notified July 24/deadline Aug. 28)SEPT 2 -- Norwegian telecoms company Telenor and Swedish peer TeliaSonera to combine their Danish mobile businesses (notified Feb. 27/deadline extended to Sept. 2 from Aug. 19 after the companies asked for more time)SEPT 11 -- U.S. conglomerate General Electric to acquire most of French engineering group Alstom's power equipment business (notified Jan. 19/deadline extended for third time to Sept. 11 from Aug. 21)NOV 25 -- U.S. drinks can maker Ball Corp to acquire British rival Rexam Plc (notified June 15/deadline extended to Nov. 25 from July 20 after Commission opened in-depth investigation)SUSPENDED -- SOCAR, Azerbaijan's state energy company, to buy stakes in Greek natural gas grid operator DESFA from Greek natural gas utility DEPA (notified Oct. 1/deadline suspended on Jan. 21)GUIDE TO EU MERGER PROCESS DEADLINES: The European Commission has 25 working days after a deal is  filed for a first-stage review. It may extend that by 10 working days to 35 working days, to consider either a company's proposed remedies or an EU member state's request to handle the case.Most mergers win approval but occasionally the Commission  opens a detailed second-stage investigation for up to 90  additional working days, which it may extend to 105 working  days.SIMPLIFIED: Under the simplified procedure, the Commission announces the clearance of uncontroversial first-stage mergers without giving any reason for its decision. Cases may be reclassified as non-simplified - that is, ordinary first-stage reviews - until they are approved.   (Compiled by Foo Yun Chee)",2015-07-30,MYL,"Thu Jul 30, 2015 | 2:01pm EDT",EU mergers and takeovers (July 30),http://www.reuters.com//article/eu-mergers-idUSL5N10A69Q20150730?type=companyNews
179,"   By Bill Berkrot  Perrigo Co Plc (PRGO.N) on Wednesday made a fresh case for rejecting a $34 billion offer from generic drugmaker Mylan NV (MYL.O) and said Mylan's recent share price plunge reinforces Perrigo's intention to remain independent.Perrigo Chief Executive Joseph Papa, in his first comments on the unsolicited acquisition attempt since Israel's Teva Pharmaceutical Industries (TEVA.TA) dropped its pursuit of Mylan in favor of another deal, reiterated that the $205 per share offer substantially undervalues Perrigo.On a call to discuss quarterly results Papa said the Perrigo board's rejection of Mylan was unanimous and had nothing to do with Teva walking away from its attempt to buy Mylan in favor of a $40.5 billion deal for Allergan's (AGN.N) generics business.However, Papa said, ""the market movement following Teva's announcement last week only reinforced our conviction about the Mylan offer.""Mylan's shares fell 14.5 percent after the Teva announcement. At $54.48, they are nearly 30 percent off where they were trading in April around the time of Teva's initial approach. Perrigo shares were down 32 cents at $190.32.  Mylan shareholders are set to vote on whether to move ahead with the takeover attempt Aug. 28.""I make no prediction on how the Mylan shareholders will vote but I want to remind everyone, including the Mylan shareholders, that if they proceed with a tender offer for Perrigo this will not be the easy path that some are painting it to be,"" Papa said. ""The bar for success in a tender offer process is a very high 80 percent of all outstanding Perrigo shares."" Mylan declined to address Papa's comments, but said it has discretion to lower the acceptance condition of a tender offer from 80 percent to greater than 50 percent of Perrigo shares.Papa said shareholders he has met with expressed confidence in the company's standalone strategy.The maker of over-the-counter consumer products, generic topical medicines, and animal health treatments, said it expects to launch more than $1 billion worth of new products over the next three years, and will use its significant cash flow for small, bolt-on acquisitions. ""If Mylan does win their shareholder vote and initiate a tender process, we'll make a strategic decision with the board about what's the right thing to do for the company,"" Papa said. ""Based on the current offer, if we ever get to a tender process, I intend to vote no to the Mylan unsolicited offer for Perrigo."" (Reporting by Bill Berkrot; Editing by Andrew Hay)",2015-08-05,MYL,"Wed Aug 5, 2015 | 1:44pm EDT",Perrigo CEO says no easy path for Mylan to acquire company,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-nl-idUSKCN0QA22Y20150805?type=companyNews
180,"   By Bill Berkrot  Aug 5 Perrigo Co Plc on Wednesday made a fresh case for rejecting a $34 billion offer from generic drugmaker Mylan NV and said Mylan's recent share price plunge reinforces Perrigo's intention to remain independent.Perrigo Chief Executive Joseph Papa, in his first comments on the unsolicited acquisition attempt since Israel's Teva Pharmaceutical Industries dropped its pursuit of Mylan in favor of another deal, reiterated that the $205 per share offer substantially undervalues Perrigo.On a call to discuss quarterly results Papa said the Perrigo board's rejection of Mylan was unanimous and had nothing to do with Teva walking away from its attempt to buy Mylan in favor of a $40.5 billion deal for Allergan's generics business.However, Papa said, ""the market movement following Teva's announcement last week only reinforced our conviction about the Mylan offer."" Mylan's shares fell 14.5 percent after the Teva announcement. At $54.48, they are nearly 30 percent off where they were trading in April around the time of Teva's initial approach. Perrigo shares were down 32 cents at $190.32.Mylan shareholders are set to vote on whether to move ahead with the takeover attempt Aug. 28. ""I make no prediction on how the Mylan shareholders will vote but I want to remind everyone, including the Mylan shareholders, that if they proceed with a tender offer for Perrigo this will not be the easy path that some are painting it to be,"" Papa said. ""The bar for success in a tender offer process is a very high 80 percent of all outstanding Perrigo shares.""Mylan declined to address Papa's comments, but said it has discretion to lower the acceptance condition of a tender offer from 80 percent to greater than 50 percent of Perrigo shares. Papa said shareholders he has met with expressed confidence in the company's standalone strategy.The maker of over-the-counter consumer products, generic topical medicines, and animal health treatments, said it expects to launch more than $1 billion worth of new products over the next three years, and will use its significant cash flow for small, bolt-on acquisitions.""If Mylan does win their shareholder vote and initiate a tender process, we'll make a strategic decision with the board about what's the right thing to do for the company,"" Papa said.""Based on the current offer, if we ever get to a tender process, I intend to vote no to the Mylan unsolicited offer for Perrigo.""   (Reporting by Bill Berkrot; Editing by Andrew Hay)",2015-08-05,MYL,"Wed Aug 5, 2015 | 1:21pm EDT",Perrigo CEO says no easy path for Mylan to acquire company,http://www.reuters.com//article/perrigo-company-ma-mylan-nl-idUSL1N10G24I20150805?type=companyNews
181,"  Drugmaker Mylan Inc reported a better-than-expected quarterly profit as it sold more generic drugs in North America, and said it remained committed to its acquisition of Perrigo Co Plc.Mylan, which also raised its full-year earnings forecast, has been pursuing Perrigo since April in an attempt to boost its over-the-counter drug business and extend its geographic reach.Mylan's generic sales in North America rose 27 percent to $937.4 million, contributing about 40 percent to its total revenue. The increase was driven by sale of new drugs.Mylan now expects full-year earnings between $4.15 and $4.35 per share. Analysts were expecting profit of $4.12 per share for the year, according to Thomson Reuters I/B/E/S. Net profit attributable to shareholders rose to $167.8 million in the second quarter ended June 30 from $125.2 million a year earlier.However, earnings per share were flat at 32 cents due to higher number of shares outstanding in the latest quarter. Excluding items, Mylan earned 91 cents per share, above average analyst estimate of 89 cents per share.Revenue rose to $2.37 billion from $1.84 billion, but fell shy of analysts' expectations of $2.39 billion. On Wednesday, Perrigo made a fresh case for rejecting Mylan's $34 billion offer, citing Mylan's recent share price drop after Teva Pharmaceutical Industries Ltd dropped its bid for Mylan in favor of another deal. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)",2015-08-06,MYL,"Thu Aug 6, 2015 | 8:26am EDT",North America generic sales help Mylan's profit beat,http://www.reuters.com//article/us-mylan-results-idUSKCN0QB1F220150806?type=companyNews
182,"  (Adds details)Aug 6 Drugmaker Mylan Inc reported a better-than-expected quarterly profit as it sold more generic drugs in North America, and said it remained committed to its acquisition of Perrigo Co Plc.Mylan, which also raised its full-year earnings forecast, has been pursuing Perrigo since April in an attempt to boost its over-the-counter drug business and extend its geographic reach.Mylan's generic sales in North America rose 27 percent to $937.4 million, contributing about 40 percent to its total revenue. The increase was driven by sale of new drugs. Mylan now expects full-year earnings between $4.15 and $4.35 per share. Analysts were expecting profit of $4.12 per share for the year, according to Thomson Reuters I/B/E/S.Net profit attributable to shareholders rose to $167.8 million in the second quarter ended June 30 from $125.2 million a year earlier. However, earnings per share were flat at 32 cents due to higher number of shares outstanding in the latest quarter. Excluding items, Mylan earned 91 cents per share, above average analyst estimate of 89 cents per share.Revenue rose to $2.37 billion from $1.84 billion, but fell shy of analysts' expectations of $2.39 billion.On Wednesday, Perrigo made a fresh case for rejecting Mylan's $34 billion offer, citing Mylan's recent share price drop after Teva Pharmaceutical Industries Ltd dropped its bid for Mylan in favor of another deal.    (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)",2015-08-06,MYL,"Thu Aug 6, 2015 | 8:14am EDT",UPDATE 1-North America generic sales help Mylan's profit beat,http://www.reuters.com//article/mylan-results-idUSL3N10H47720150806?type=companyNews
183,"  (Adds X5, CSN, Greece privatisation; updates Mylan)Aug 13 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:** Buyout firm TPG Capital LP is in advanced talks to acquire Ellucian Company LP, in a deal that could value the U.S. provider of software to universities and colleges at $3.5 billion, including debt, people familiar with the matter said.** India's government has hired five banks to manage a stake sale valued at up to $1.5 billion in state-run Indian Oil Corp , IFR reported on Thursday, citing people familiar with the deal.** German salt and fertilizer company K+S does not oppose a takeover in principle, but it affirmed the current proposal by Canada's Potash Corp of Saskatchewan is inadequate in its view.** Mexican retail group Femsa is close to sealing an agreement to buy privately owned Chilean pharmacy chain Cruz Verde for about $1 billion, Chilean newspaper Pulso reported on Thursday.** Nomad Foods Ltd is close to acquiring the continental European business operations of frozen food maker Findus Group Ltd in a deal valued at just over 500 million pounds ($780.6 million), the Financial Times reported, citing people familiar with the matter.** Mylan NV, which is trying to buy drugmaker Perrigo Co through a hostile tender offer, lowered on Thursday the level of support it requires from Perrigo shareholders to push through the takeover. ** Roche is buying U.S. diagnostics firm GeneWEAVE BioSciences for up to $425 million, expanding the Swiss group's commitment to fighting so-called ""superbugs"" as the threat from drug-resistant microbes grows.** Baxalta wants Shire to improve on its $30 billion bid significantly before it will engage in talks, while its Dublin-based rival could sweeten its offer if it gets to see the U.S. biotech company's books, according to sources on both sides.** America Movil is still sniffing out deals in Europe, which could become twice as important for the Mexican telecom company's revenue base within five years, its chief financial officer said on Wednesday. ** India's top state-run refiner Indian Oil Corp  has awarded to BG Group a tender to buy a liquefied natural gas (LNG) cargo for delivery on Aug. 27, a company executive said.** Chinese curtainmaker Jangho Group Co Ltd said it planned to buy Australian eye surgery group Vision Eye Institute Ltd for A$198 million ($145.5 million), trumping a lower offer from another Australian firm, Pulse Health Ltd.** Japanese telecoms group SoftBank Group Corp, the majority owner of U.S. wireless carrier Sprint Corp, said it bought an additional 22.9 million shares in Sprint at a weighted average price of $3.80.** Tougher regulation and deteriorating market conditions are the main factors that could influence RWE in deciding in favor of spinning off its ailing power generation unit, Chief Executive Peter Terium told analysts during a call. ** Shunfeng International Clean Energy Ltd said it would take a majority stake in U.S. solar panel manufacturer Suniva to gain a foothold in the fast-growing U.S. solar market.** Poland's state airline LOT said on Thursday that it signed a co-operation deal with Turkish Airlines, which may lead to a joint-venture between the two.** Germany's United Internet is on the look-out for acquisitions to expand its fibre-optic network and the business applications unit that it may list separately on the stock exchange, its chief executive told Reuters on Thursday.** Russia's No.2 food retailer X5 said it plans to make at least one more acquisition this year, taking advantage of attractively priced assets in a difficult environment to expand market share.** Brazilian steel maker CSN has begun efforts to sell off non-core assets to ease its heavy debt burden and has hired banks to assist in the process, company executives said on a Thursday conference call with analysts.** Greece's privatisations agency on Thursday announced deadlines for bids on tenders for the country's two largest ports and state railways Trainose, assets Athens has agreed to sell as part of a new three-year bailout by its international lenders.    (Compiled by Shubhankar Chakravorty in Bengaluru)",2015-08-13,MYL,"Thu Aug 13, 2015 | 3:53pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N10O3KP20150813?type=companyNews
184,"   By Caroline Humer | NEW YORK  NEW YORK Mylan NV (MYL.O), which is trying to buy drugmaker Perrigo Co  (PRGO.N) through a $34 billion hostile tender offer, on Thursday lowered the percentage of Perrigo shares it needs to control the company to just over 50 percent.Generic drugmaker Mylan had been seeking more than 80 percent of Perrigo's shares through the tender offer.Perrigo Chief Executive Joseph Papa, who has rejected the bid saying it undervalues the company, on Thursday called the move ""reckless"" and a ""sign of desperation,"" adding it would create credit and equity risks for both companies. Analysts and investors have also suggested the deal has a limited chance of closing, saying Mylan's offer price of $205 is too low. Perrigo shares rose 3.4 percent, or $6.32, to $192.60 on Thursday while Mylan fell less than 1 percent to $54.89.""I don't think very many Perrigo shareholders are going to tender at this price,"" said Jeff Jonas, portfolio manager at Gabelli Funds, which owns Mylan shares and some Perrigo shares.  Sanford C. Bernstein analyst Ronny Gal said in a research note earlier this week that odds of the transaction closing were less than 20 percent.Mylan CEO Heather Bresch told investors last week on a conference call that the company will not change its offer, saying that while it was committed to the deal, it is not a ""must"". Mylan also said last week it was considering cutting the threshold. Jonas said the lower threshold would drag things out by 6 to 9 months. ""That just creates a very messy situation if they get over 50 percent but not full control,"" he said.The proposed takeover is part of an industry-wide consolidation among generic drugmakers. Teva Pharmaceutical (TEVA.TA) had been pursuing Mylan but walked away to buy Allergan's (AGN.N) generic business.Mylan said it will start the tender offer after shareholders vote at its Aug. 28 meeting. On Tuesday, two proxy advisory firms recommended that Mylan shareholders vote for the takeover.  In Ireland, where Perrigo is based, takeover rules allow acquiring companies to take control of targets through a direct tender to shareholders. If Mylan gets more than 50 percent of Perrigo shares through the offer, it can take control of the company's board and then raise its stake to the 80 percent it needs to consolidate the operations.That two-part process could delay deal synergies, extend bridge financing fees, and result in a higher offer price down the road, Gal said in the research note. (Reporting by Caroline Humer; Editing by W Simon, Bernard Orr and Alan Crosby)",2015-08-13,MYL,"Thu Aug 13, 2015 | 2:20pm EDT",Mylan pursues minimum of Perrigo shareholder support for takeover,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-idUSKCN0QI1J020150813?type=companyNews
185,"  (Adds Perrigo comment)By Caroline HumerNEW YORK Aug 13 Mylan NV, which is trying to buy drugmaker Perrigo Co  through a $34 billion hostile tender offer, on Thursday lowered the percentage of Perrigo shares it needs to control the company to just over 50 percent.Generic drugmaker Mylan had been seeking more than 80 percent of Perrigo's shares through the tender offer.Perrigo Chief Executive Joseph Papa, who has rejected the bid saying it undervalues the company, on Thursday called the move ""reckless"" and a ""sign of desperation,"" adding it would create credit and equity risks for both companies. Analysts and investors have also suggested the deal has a limited chance of closing, saying Mylan's offer price of $205 is too low. Perrigo shares rose 3.4 percent, or $6.32, to $192.60 on Thursday while Mylan fell less than 1 percent to $54.89.""I don't think very many Perrigo shareholders are going to tender at this price,"" said Jeff Jonas, portfolio manager at Gabelli Funds, which owns Mylan shares and some Perrigo shares.Sanford C. Bernstein analyst Ronny Gal said in a research note earlier this week that odds of the transaction closing were less than 20 percent. Mylan CEO Heather Bresch told investors last week on a conference call that the company will not change its offer, saying that while it was committed to the deal, it is not a ""must"". Mylan also said last week it was considering cutting the threshold.Jonas said the lower threshold would drag things out by 6 to 9 months. ""That just creates a very messy situation if they get over 50 percent but not full control,"" he said. The proposed takeover is part of an industry-wide consolidation among generic drugmakers. Teva Pharmaceutical  had been pursuing Mylan but walked away to buy Allergan's generic business.Mylan said it will start the tender offer after shareholders vote at its Aug. 28 meeting. On Tuesday, two proxy advisory firms recommended that Mylan shareholders vote for the takeover.In Ireland, where Perrigo is based, takeover rules allow acquiring companies to take control of targets through a direct tender to shareholders. If Mylan gets more than 50 percent of Perrigo shares through the offer, it can take control of the company's board and then raise its stake to the 80 percent it needs to consolidate the operations.That two-part process could delay deal synergies, extend bridge financing fees, and result in a higher offer price down the road, Gal said in the research note.   (Reporting by Caroline Humer; Editing by W Simon, Bernard Orr and Alan Crosby)",2015-08-13,MYL,"Thu Aug 13, 2015 | 2:19pm EDT",UPDATE 3-Mylan pursues minimum of Perrigo shareholder support for takeover,http://www.reuters.com//article/perrigo-company-ma-mylan-idUSL1N10O0RB20150813?type=companyNews
186,"  NEW YORK Aug 13 Mylan NV, which is trying to buy drugmaker Perrigo Co  through a hostile tender offer, on Thursday lowered the  level of support it requires from Perrigo shareholders to push through the takeover.Mylan had been seeking support from more than 80 percent of Perrigo's shareholders but last week said that it might lower that threshold to more than 50 percent and that its financing banks had agreed to the move. Perrigo has steadfastly resisted the takeover proposal from Mylan, which itself had been the target of a hostile overture from Israeli drugmaker Teva Pharmaceutical. Teva recently walked away from Mylan to buy Allergan's  generic business.  Mylan said it will move forward with the tender offer after its own shareholders vote on the deal.   (Reporting by Caroline Humer, Editing by Franklin Paul)",2015-08-13,MYL,"Thu Aug 13, 2015 | 7:40am EDT",Mylan pursues Perrigo with lower shareholder support for takeover,http://www.reuters.com//article/perrigo-company-ma-mylan-idUSL1N10O0OF20150813?type=companyNews
187,"   By Caroline Humer | NEW YORK  NEW YORK ISS Proxy Advisory Services recommended on Friday that its clients vote against Mylan NV's (MYL.O) $30 billion hostile takeover of Perrigo Co (PRGO.N), even as Mylan's largest hedge fund investor put its money behind the combination.Paulson & Co, which owns a 4.6 percent stake in Mylan, said it voted for the generic drugmaker to pursue its tender offer for Perrigo shares. Paulson said that Perrigo would add to Mylan earnings based on cost savings alone and that combining generic drugs and over-the-counter medicines would create growth.In its client note, ISS criticized the combination as dilutive and said it would likely take years for these benefits to materialize. Paulson also disclosed on Friday that the firm had purchased about 2.1 million Perrigo shares in a range of $188.24 to $192.08 on Thursday.Two other proxy advisory firms earlier this week advised Mylan shareholders to vote for the deal, which is up for approval at Mylan's Aug. 28 shareholder meeting. Institutional shareholders typically follow proxy firm recommendations. Mylan's biggest shareholder, Abbott Laboratories (ABT.N), said in June it would vote with Mylan. Mylan made a cash and stock offer now worth about $200 per share in April, saying the Dublin-based generic and over-the-counter drugmaker would be a strategic fit. Perrigo has repeatedly rejected the offer, saying it can do better on its own.Mylan has stuck to its pursuit and on Thursday lowered the bar to move forward on a takeover to receiving just over 50 percent of Perrigo shares in the tender offer. That size stake would allow control of Perrigo's board, and after that Mylan would need to increase its stake to more than 80 percent in order to consolidate operations.ISS said in the note that the offer was ""not a compelling acquisition strategy."" In order to approve the proposal, shareholders must believe that the deal has synergies beyond what Mylan has revealed and that the acquisition will occur at the current price despite lack of support among Perrigo shareholders, it said. ISS said that since the acquisition would dilute shares, that the deal is not expected to add to earnings until 2019 and that Mylan does not have the leverage it needs to increase its stake above 80 percent, the proposal is not warranted. Mylan Executive Chairman Robert Coury said the ISS report misunderstands or underestimates key aspects of the transaction such as the opportunity for value creation and synergies. Mylan shares were up slightly at $54.28 on Friday afternoon while Perrigo shares were up 1.1 percent at $194.70. (Additional reporting by Mike Stone and Greg Roumeliotis in New York; Editing by Matthew Lewis)",2015-08-14,MYL,"Fri Aug 14, 2015 | 2:57pm EDT",Proxy firm urges Mylan investors vote 'no'; Paulson backs deal,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-nl-idUSKCN0QJ1D320150814?type=companyNews
188,"  (Recasts first sentence with hedge fund Paulson backing the deal, adds company background, updates share prices)By Caroline HumerNEW YORK Aug 14 ISS Proxy Advisory Services recommended on Friday that its clients vote against Mylan NV's  $30 billion hostile takeover of Perrigo Co, even as Mylan's largest hedge fund investor put its money behind the combination.Paulson & Co, which owns a 4.6 percent stake in Mylan, said it voted for the generic drugmaker to pursue its tender offer for Perrigo shares.Paulson said that Perrigo would add to Mylan earnings based on cost savings alone and that combining generic drugs and over-the-counter medicines would create growth.In its client note, ISS criticized the combination as dilutive and said it would likely take years for these benefits to materialize. Paulson also disclosed on Friday that the firm had purchased about 2.1 million Perrigo shares in a range of $188.24 to $192.08 on Thursday.Two other proxy advisory firms earlier this week advised Mylan shareholders to vote for the deal, which is up for approval at Mylan's Aug. 28 shareholder meeting. Institutional shareholders typically follow proxy firm recommendations.Mylan's biggest shareholder, Abbott Laboratories, said in June it would vote with Mylan. Mylan made a cash and stock offer now worth about $200 per share in April, saying the Dublin-based generic and over-the-counter drugmaker would be a strategic fit. Perrigo has repeatedly rejected the offer, saying it can do better on its own.Mylan has stuck to its pursuit and on Thursday lowered the bar to move forward on a takeover to receiving just over 50 percent of Perrigo shares in the tender offer.That size stake would allow control of Perrigo's board, and after that Mylan would need to increase its stake to more than 80 percent in order to consolidate operations. ISS said in the note that the offer was ""not a compelling acquisition strategy."" In order to approve the proposal, shareholders must believe that the deal has synergies beyond what Mylan has revealed and that the acquisition will occur at the current price despite lack of support among Perrigo shareholders, it said.ISS said that since the acquisition would dilute shares, that the deal is not expected to add to earnings until 2019 and that Mylan does not have the leverage it needs to increase its stake above 80 percent, the proposal is not warranted.Mylan Executive Chairman Robert Coury said the ISS report misunderstands or underestimates key aspects of the transaction such as the opportunity for value creation and synergies.Mylan shares were up slightly at $54.28 on Friday afternoon while Perrigo shares were up 1.1 percent at $194.70.(Additional reporting by Mike Stone and Greg Roumeliotis in New York; Editing by Matthew Lewis)",2015-08-14,MYL,"Fri Aug 14, 2015 | 2:30pm EDT",UPDATE 2-Proxy firm urges Mylan investors vote 'no'; Paulson backs deal,http://www.reuters.com//article/perrigo-company-ma-mylan-nl-idUSL1N10P0XE20150814?type=companyNews
189,"  NEW YORK Aug 14 ISS Proxy Advisory Services on Friday recommended that its institutional investor clients vote against Mylan NV's $34 billion hostile takeover offer of Perrigo Co saying that it would result in significant dilution.ISS's recommendation veered in the opposite direction from two other proxy advisory firms which earlier this week advised clients to vote for the deal.Mylan shareholders will vote at an Aug. 28 meeting on whether to pursue a tender offer for Perrigo shares. Mylan said on Thursday that it would go forward with the deal if it received more than 50 percent of shares through the tender offer. That would give the company control of Perrigo's board, and after that it would need to increase its stake to more than 80 percent in order to consolidate the company. Given that the acquisition would dilute shares, that the deal is not expected to add to earnings until 2019 and that Mylan does not have the leverage it needs to increase its stake above 80 percent, ISS said the proposal is not warranted. (Reporting by Caroline Humer)",2015-08-14,MYL,"Fri Aug 14, 2015 | 8:57am EDT",Proxy firm ISS advises Mylan investors to vote no on Perrigo buy,http://www.reuters.com//article/perrigo-company-ma-mylan-nl-idUSL1N10P0P420150814?type=companyNews
190,"  BRUSSELS Aug 19 The following are mergers under review by the European Commission and a brief guide to the EU merger process:APPROVALS AND WITHDRAWALS -- Dutch building materials distributor PontMeyer, which is part of Deli Building Supplies B.V., to acquire Dutch holding company DBS (notified July 15/approved Aug. 20)--Irish pharmaceutical company Perrigo, which is to be acquired by Dutch pharmaceutical firm Mylan, to acquire a number of consumer health products belonging to British pharmaceutical company GSK (notified July 22/approved Aug. 21)NEW LISTINGS -- British private equity firm Equistone Partners Europe to acquire German apparel retailer TriStyle Mode (notified Aug. 20/deadline Sep. 24/simplified)EXTENSIONS AND OTHER CHANGES -- U.S. drinks can maker Ball Corp to acquire British rival Rexam Plc (notified June 15/deadline extended to Dec. 9 from Nov. 25)FIRST-STAGE REVIEWS BY DEADLINE AUG 26 -- Varo Energy, a joint venture between the world's top oil trader Vitol and private equity firm Carlyle Group , is expanding its reach in Europe through a merger with Dutch-based storage and trading company Argos (notified July 22/ deadline Aug. 26)AUG 28 -- U.S. real estate services provider DTZ to acquire U.S. peer Cushman & Wakefield (notified July 24/deadline Aug. 28)SEPT 1 -- British engineering company GKN to acquire Dutch company Fokker Technologies (notified July 28/deadline Sept. 1/simplified)-- British support services provider DCC Group to acquire French gas company Butagaz from Anglo Dutch oil company Royal Dutch Shell (notified July 28/deadline Sept. 1/simplified)-- U.S. grains company Archer Daniels Midland Co to acquire starch producer Eaststarch (notified July 28/deadline Sept. 1/simplified)SEPT 2 -- Anglo-Dutch oil major Royal Dutch Shell to acquire BG Group (notified July 29/deadline Sept. 2)-- South African paper maker Mondi  to acquire some assets from portfolio company Walki (notified July 29/deadline Sept. 2)SEPT 4 -- Private equity firms 3i Group and AMP Capital Investors to acquire joint control of offshore emergency and rescue services provider Esvagt (notified July 31/deadline Sept. 4/simplified) SEPT 7 -- Austrian bank Raiffeisen Zentralbank Osterreich  to acquire sole control of Austrian pension fund Valida Holding (notified Aug. 3/deadline Sept. 7/simplified)-- Mahindra World City Developers and Japan's Sumitomo Corp to set up a joint venture (notified Aug. 3/deadline Sept. 7/simplified)SEPT 8 -- Evo Payments International, Raiffeisen Bank Polska  and Czech lender Raiffeisenbank to jointly control two new subsidiaries with merchant acquiring and acquiring processing services transferred from the two banks (notified Aug. 4/deadline Sept. 8/simplified)SEPT 9 -- U.S. grain trader Archer Daniel Midland to acquire Belgian vegetable oil distributor AOR NV (notified Aug. 5/deadline Sept. 9)-- German retailer REWE to acquire some travel units from Swiss travel operator Kuoni Reisen (notified Aug. 5/deadline Sept. 9/simplified)SEPT 10 -- Buyout group KKR to acquire majority stake in German fibre-optic network operator Deutsche Glasfaser (notified Aug. 6/deadline Sept. 10/simplified) SEPT 11 -- U.S. investment firm Apollo Global Management to acquire majority control of Slovenian bank Nova KBM (notified Aug. 7/deadline Sept. 11/simplified)-- U.S. conglomerate General Electric to acquire most of French engineering group Alstom's power equipment business (notified Jan. 19/deadline extended for third time to Sept. 11 from Aug. 21)SEPT 14 -- Singapore-listed palm oil processor Wilmar International  and Italian oil products company Fox Petrolifera Italiana SpA to set up a joint venture (notified Aug. 10/deadline Sept. 14/simplified)-- BPIFrance and Springwater Capital LLC to acquire joint control of French paper producer Delion France (notified Aug. 10/deadline Sept. 14/simplified)-- Naxicap Partners and Fonds Avenir Automobile to acquire joint control of French car parts maker Defta Group (notified Aug. 10/deadline Sept. 14/simplified)SEPT 16 -- Norwegian telecoms company Telenor and Swedish peer TeliaSonera to combine their Danish mobile businesses (notified Feb. 27/deadline extended to Oct. 7 from Sept. 16 after the companies offered commitments)-- Private equity firm CVC Capital Partners to acquire energy company PKP Energetyka (notified Aug. 12/deadline Sept. 16/simplified)-- Private equity firms Advent International, Bain Capital and Clessidra to jointly acquire Italian banking services company ICBPI (notified Aug. 12/deadline Sept. 16)-- Chinese state-owned food firms Bright Food Group Co Ltd to acquire Spanish holding company Invermik SA (notified Aug. 12/deadline Sept. 16/simplified) SEPT 17 -- Kuwait Investment Authority (KIA) and Spanish energy group Gas Natural to acquire joint control of Global Power Generation (notified Aug. 13/deadline Sept. 17/simplified)-- Buyout group KKR to acquire German cutlery and coffee-machine maker WMF together with Austrian holding company FIBA (notified Aug.13/deadline Sept. 17)SEPT 18 -- U.S. distressed investment fund Apollo to acquire majority stake in steel trader Stemcor (notified Aug. 14/deadline Sept. 18/simplified)-- Japanese insurer Tokio Marine Holdings Inc to buy U.S. specialty insurer HCC Insurance Holdings Inc  (notified Aug. 14/deadline Sept. 18/simplified)-- Groupe Acticall to acquire customer relationship management company Sitel (notified Aug. 14/deadline Sept. 18/simplified)-- Dutch chipmaker NXP to acquire U.S. peer Freescale (notified July 31, deadline extended to Sept. 18 from Sept. 4 after NXP offered concessions)SEPT 21 -- Pfizer to acquire British drugmaker GlaxoSmithKline's menACWY meningitis vaccine business (notified Aug. 17/deadline Sept. 21)-- Cable telecoms company Liberty Global's Belgian subsidiary Telenet to buy mobile network operator Base from Dutch group KPN (notified Aug. 17/deadline Sept. 21)-- European private equity group Cinven to buy majority stake in German laboratory operator Synlab from BC Partners (notified Aug. 17/deadline Sept. 21/simplified)JAN 13 -- U.S. packages delivery company FedEx to acquire Dutch peer TNT (notified July /deadline extended to Jan. 13 from Dec. 8 after the companies asked for more time)SUSPENDED -- Oilfield services provider Halliburton to buy rival Baker Hughes in a stock and cash transaction (notified July 23/deadline suspended after the companies provided insufficient information)-- SOCAR, Azerbaijan's state energy company, to buy stakes in Greek natural gas grid operator DESFA from Greek natural gas utility DEPA (notified Oct. 1/deadline suspended on Jan. 21)GUIDE TO EU MERGER PROCESS DEADLINES: The European Commission has 25 working days after a deal is  filed for a first-stage review. It may extend that by 10 working days to 35 working days, to consider either a company's proposed remedies or an EU member state's request to handle the case.Most mergers win approval but occasionally the Commission  opens a detailed second-stage investigation for up to 90  additional working days, which it may extend to 105 working  days.SIMPLIFIED: Under the simplified procedure, the Commission announces the clearance of uncontroversial first-stage mergers without giving any reason for its decision. Cases may be reclassified as non-simplified - that is, ordinary first-stage reviews - until they are approved.   (Compiled by Foo Yun Chee)",2015-08-21,MYL,"Fri Aug 21, 2015 | 8:22am EDT",EU mergers and takeovers (Aug 21),http://www.reuters.com//article/eu-mergers-idUSL5N10U21O20150821?type=companyNews
191,"   By Bill Berkrot and Caroline Humer | NEW YORK  NEW YORK Perrigo Co Plc's (PRGO.N) chief executive expressed confidence on Tuesday that his company's shareholders will reject rival generic drugmaker Mylan NV's hostile takeover attempt, and said the offer is not close to what it would take to get a deal done.Mylan (MYL.O) shareholders are set to vote on Friday on whether the company should move forward with the Perrigo bid, whose value has declined with the recent market sell-off. If more than half vote ""yes,"" Mylan plans to take its cash and stock offer directly to Perrigo shareholders. Mylan has said that if just over 50 percent of Perrigo shareholders tender their shares, it will take control of the Dublin-based company. It had aimed for 80 percent of shareholders but lowered that to the bare minimum of just over 50 percent to gain control, an option under Irish takeover laws.""Based on what I've heard from shareholders they are not going to get 80 percent of Perrigo shareholders to tender their shares and they are not going to get 50 percent of Perrigo shareholders tendering their shares. I do not believe they are going to get to either threshold,"" Perrigo CEO Joseph Papa said in a telephone interview.He shrugged off the Aug. 28 vote by Mylan shareholders. ""If they get their vote, they get their vote.""  It is unclear if more than 50 percent of Mylan shareholders will back the deal. Abbott Laboratories (ABT.N), Mylan's largest shareholder with a stake of more than 14 percent, and hedge fund Paulson & Co, which owns just under 5 percent, have said they back the deal. Influential proxy advisory firm ISS weighed in against it.Mylan, whose shares closed at $49.11 on Tuesday, said in a press release on Tuesday that it believes its deal will gain   approval from both its shareholders and Perrigo shareholders.  With the recent plunge in world markets, shares of both Perrigo and Netherlands-based Mylan have suffered, lowering the overall value of the offer for Perrigo to about $192 per share from about $205. ""That's not even close,"" Papa said, referring to what it would take for the Perrigo board to recommend the deal it has unanimously rejected. ""I have no problem to use words substantially undervaluing us as a company, said Papa, whose company's shares closed at $178 on the New York Stock Exchange on Tuesday. ""There's no logical reason to go forward here. It will reduce the price to earnings multiple of Perrigo. Our PE multiple is substantially higher than the PE multiple of the Mylan company.""Earlier this month, Mylan CEO Heather Bresch called its offer ""fair and compelling"" and said it was not looking to alter the terms. Papa said he does not believe the recent sell-off in the Chinese and other markets will hurt Perrigo's business. The company sells over-the-counter (OTC) consumer products, generic topical medicines, and animal health products.""OTC drugs, where we have about 75 percent of our sales, are going to do extraordinarily well despite what happens with economies of China or Asia or anywhere else in the world,"" Papa said.Asked if the market correction might make small acquisitions more attractive, Papa said, ""I do think there will be more opportunities."" (Editing by Matthew Lewis)",2015-08-25,MYL,"Tue Aug 25, 2015 | 5:13pm EDT",Perrigo CEO expects shareholders to reject Mylan bid,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-nl-idUSKCN0QU2HF20150825?type=companyNews
192,"  Aug 25 Irish Takeover Panel* Ruled Perrigo's Aug 13 statement ""Mylan already proposed a dilutive deal that substantially undervalues Perrigo"" breached rule  * Perrigo's statement breached rule 19.3(a) as it was unclear that term ""dilutive"" described effect on Mylan shareholders  Source text for Eikon: ",2015-08-25,MYL,"Tue Aug 25, 2015 | 11:12am EDT",BRIEF-Irish Takeover Panel says Perrigo's Aug 13 statement breached rule,http://www.reuters.com//article/idUSFWN11001S20150825?type=companyNews
193,"   By Caroline Humer | NEW YORK  NEW YORK Mylan NV (MYL.O) shareholders on Friday backed the drugmaker's hostile bid for Perrigo Co (PRGO.N), allowing it to launch a tender offer for the company's shares in the next few weeks.Mylan said that it had the support from investors representing a majority of shares, passing the threshold it needed to go directly to Perrigo shareholders. The company is now looking for holders of more than 50 percent of Perrigo's shares to take part in the tender offer.Mylan, a generic drugmaker, offered to buy Perrigo in April for cash and stock then worth $205 per share. Perrigo, which makes over-the-counter and generic medicines, has consistently rejected the offer as too low and says that it will do better on its own.Perrigo, based in Dublin, Ireland, said on Friday that it is confident that fewer than 50 percent of its shares will be tendered to Mylan. That Mylan investors backed the deal does not necessarily mean that enough Perrigo shareholders will do so, said Erik Gordon, a business professor at the University of Michigan.""The Perrigo acquisition makes sense for Mylan. The Perrigo resistance is the hard part. The benefits to its stockholders are less obvious,"" Gordon said. The offer is now worth about $193 per share, or $28 billion, based on Mylan's latest share price of $51.49. Perrigo shares closed on Thursday at $188.19.The vote was held at a shareholder meeting in the Netherlands, where Mylan is based. Mylan said that of votes cast at the meeting, about two-thirds backed the deal. Proxy advisory firm ISS had advised Mylan investors to vote against the deal, while two of ISS's competitors recommended the deal for Mylan shareholders. Two large Mylan shareholders representing about 20 percent of the shares, Abbott Laboratories Inc (ABT.N) and Paulson & Co, backed Mylan. ""We continue to think that a deal here is far from likely though largely priced into both stocks,"" RBC Capital Markets analyst Randall Stanicky said in a research note. (Reporting by Caroline Humer; Editing by Steve Orlofsky)",2015-08-28,MYL,"Fri Aug 28, 2015 | 9:37am EDT","Mylan shareholders back Perrigo takeover, tender offer up next",http://www.reuters.com//article/us-perrigo-company-m-a-mylan-idUSKCN0QX1C520150828?type=companyNews
194,"  (Adds outside reaction)By Caroline HumerNEW YORK Aug 28 Mylan NV shareholders on Friday backed the drugmaker's hostile bid for Perrigo Co , allowing it to launch a tender offer for the company's shares in the next few weeks.Mylan said that it had the support from investors representing a majority of shares, passing the threshold it needed to go directly to Perrigo shareholders. The company is now looking for holders of more than 50 percent of Perrigo's shares to take part in the tender offer.Mylan, a generic drugmaker, offered to buy Perrigo in April for cash and stock then worth $205 per share. Perrigo, which makes over-the-counter and generic medicines, has consistently rejected the offer as too low and says that it will do better on its own. Perrigo, based in Dublin, Ireland, said on Friday that it is confident that fewer than 50 percent of its shares will be tendered to Mylan.That Mylan investors backed the deal does not necessarily mean that enough Perrigo shareholders will do so, said Erik Gordon, a business professor at the University of Michigan. ""The Perrigo acquisition makes sense for Mylan. The Perrigo resistance is the hard part. The benefits to its stockholders are less obvious,"" Gordon said.The offer is now worth about $193 per share, or $28 billion, based on Mylan's latest share price of $51.49. Perrigo shares closed on Thursday at $188.19. The vote was held at a shareholder meeting in the Netherlands, where Mylan is based. Mylan said that of votes cast at the meeting, about two-thirds backed the deal.Proxy advisory firm ISS had advised Mylan investors to vote against the deal, while two of ISS's competitors recommended the deal for Mylan shareholders. Two large Mylan shareholders representing about 20 percent of the shares, Abbott Laboratories Inc and Paulson & Co, backed Mylan.""We continue to think that a deal here is far from likely though largely priced into both stocks,"" RBC Capital Markets analyst Randall Stanicky said in a research note.   (Reporting by Caroline Humer; Editing by Steve Orlofsky)",2015-08-28,MYL,"Fri Aug 28, 2015 | 9:34am EDT","UPDATE 2-Mylan shareholders back Perrigo takeover, tender offer up next",http://www.reuters.com//article/perrigo-company-ma-mylan-idUSL1N1130GD20150828?type=companyNews
195,"  NEW YORK Aug 28 Mylan NV shareholders on Friday backed the drugmaker's hostile bid for Perrigo Co , allowing it to launch a tender offer for the company's shares in the next few weeks. Mylan said that more than two-thirds of shareholders had backed the vote. It needed more than half of them to do so in order to pursue the takeover.   (Reporting by Caroline Humer)  ",2015-08-28,MYL,"Fri Aug 28, 2015 | 7:42am EDT",Mylan says shareholders back Perrigo takeover,http://www.reuters.com//article/perrigo-company-ma-mylan-idUSL1N1130FV20150828?type=companyNews
196,"   By Thomas Escritt | AMSTERDAM  AMSTERDAM The Dutch public employees' pension fund, the world's third largest, has sold all its shares in pharmaceuticals maker Mylan after it emerged that one of the company's products is in stock at a U.S. prison where death sentences are carried out.The move comes amid increasing pressure from European countries over continuing use of capital punishment in the United States.European companies are barred from selling drugs for use in executions, forcing states that still impose the death penalty to scrabble for alternative substances, some of which have led to widely publicized and gruesome botched executions.The move by ABP, which had $416 billion in assets in 2014 according to consultancy Towers Watson, is thought to have been followed by other Dutch pension funds. The Netherlands has the world's largest pool of pension assets per capita, worth $1.2 trillion in 2012.Harmen Geers, a spokesman for ABP, said the decision came after a nine-month dialogue with the company failed to achieve a satisfactory result. ""As the Dutch government and Dutch society as a whole renounced the death penalty a long time ago, we do not want Dutch pension money to be involved in that,"" he said.The U.S-based but Dutch-registered company has a declaration on its website saying its products are not designed or intended for use in executions, but Geers said Mylan could do more to police their use. The U.S. state of Virginia confirmed in response to a freedom of information request in July that it held stocks of Rocuronium Bromide, a Mylan-made drug that can be used to kill people.Geers said it was this information that led to the decision to sell its Mylan holdings in full. ""We thought we have only one step left to show our disapproval,"" he said.ABP, the largest Dutch pension fund, held 9 million euros ($10 million) in the company before the divestment, down from 25 million euros last year when it first approached Mylan with its concerns. Calls to Mylan were not immediately returned. (Reporting by Thomas Escritt; Editing by Dale Hudson)",2015-08-29,MYL,"Sat Aug 29, 2015 | 5:02am EDT",Largest Dutch pension fund exits Mylan over death penalty concerns,http://www.reuters.com//article/us-mylan-abp-deathpenalty-idUSKCN0QY06D20150829?type=companyNews
197,"  (Adds details, context)By Thomas EscrittAMSTERDAM Aug 29 The Dutch public employees' pension fund, the world's third largest, has sold all its shares in pharmaceuticals maker Mylan after it emerged that one of the company's products is in stock at a U.S. prison where death sentences are carried out.The move comes amid increasing pressure from European countries over continuing use of capital punishment in the United States.European companies are barred from selling drugs for use in executions, forcing states that still impose the death penalty to scrabble for alternative substances, some of which have led to widely publicised and gruesome botched executions. The move by ABP, which had $416 billion in assets in 2014 according to consultancy Towers Watson, is thought to have been followed by other Dutch pension funds. The Netherlands has the world's largest pool of pension assets per capita, worth $1.2 trillion in 2012.Harmen Geers, a spokesman for ABP, said the decision came after a nine-month dialogue with the company failed to achieve a satisfactory result. ""As the Dutch government and Dutch society as a whole renounced the death penalty a long time ago, we do not want Dutch pension money to be involved in that,"" he said.The U.S-based but Dutch-registered company has a declaration on its website saying its products are not designed or intended for use in executions, but Geers said Mylan could do more to police their use. The U.S. state of Virginia confirmed in response to a freedom of information request in July that it held stocks of Rocuronium Bromide, a Mylan-made drug that can be used to kill people.Geers said it was this information that led to the decision to sell its Mylan holdings in full. ""We thought we have only one step left to show our disapproval,"" he said.ABP, the largest Dutch pension fund, held 9 million euros ($10 million) in the company before the divestment, down from 25 million euros last year when it first approached Mylan with its concerns.Calls to Mylan were not immediately returned. ($1 = 0.8946 euros)   (Reporting by Thomas Escritt; Editing by Dale Hudson)",2015-08-29,MYL,"Sat Aug 29, 2015 | 5:00am EDT",UPDATE 1-Largest Dutch pension fund exits Mylan over death penalty concerns,http://www.reuters.com//article/mylan-abp-deathpenalty-idUSL5N11404O20150829?type=companyNews
198,"  AMSTERDAM Aug 29 The Dutch public employees' pension fund, the world's third largest, has sold all its shares in pharmaceuticals maker Mylan after it emerged that one of its products is in stock at a United States prison where death sentences are carried out.The U.S. state of Virginia confirmed in response to a freedom of information request in July that it held stocks of Rocuronium Bromide, a Mylan-made drug that can be used to kill people. Harmen Geers, spokesman for the ABP pension fund, said on Saturday that while it welcomed Mylan's decision to declare publicly that its products were not to be used in executions, it was clear that Mylan was not doing enough to police their use. ""As the Dutch government and Dutch society as a whole renounced the death penalty a long time ago, we do not want Dutch pension money to be involved in that,"" he said. The fund held 9 million euros ($10.06 million) in the company before the divestment. Other Dutch pension funds are believed to have taken similar steps. ($1 = 0.8946 euros)   (Reporting by Thomas Escritt; Editing by Dale Hudson)",2015-08-29,MYL,"Sat Aug 29, 2015 | 4:25am EDT",Largest Dutch pension fund exits Mylan over death penalty concerns,http://www.reuters.com//article/mylan-abp-deathpenalty-idUSL5N11404320150829?type=companyNews
199,"  (Adds Legumex Walker; Updates Mylan)Sept 14 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:** Mylan NV said it launched a tender offer to acquire fellow generic drugmaker Perrigo Co Plc for about $27 billion - an offer Perrigo has rejected so far.** Oil Search Ltd rebuffed an $8 billion takeover proposal from Australia's biggest energy company Woodside Petroleum Ltd as far too cheap, although it left the door open to higher offers.** Solera Holdings Inc, which provides technology services to insurance companies, said it agreed to be acquired by an affiliate of private-equity firm Vista Equity Partners for $3.74 billion in cash.** China Railway Group Ltd  said it would absorb the assets of subsidiary China Railway Erju Co Ltd  as part of wider efforts to streamline the government's sprawling railway sector. ** Spanish bank Sabadell SA is considering making a bid for an 18 billion euro ($20.4 billion) mortgage portfolio held by British nationalized banks Northern Rock and Bradford & Bingley, a source familiar with the process said.** Trinity Mirror Plc, publisher of the Daily Mirror and Sunday Mirror, said it was in talks to buy out the shares it does not already own in rival Local World Holdings Ltd.** Canada's Legumex Walker Inc said it had agreed to sell its legume crop processing plants and expects to sell its U.S. canola-crushing facility, allowing it to wind down the company. ** Raiffeisen Bank International AG's Czech unit has agreed to buy Citibank's local credit-card and retail banking businesses, the banks said.** Poland's No.3 power group Enea SA offered 1.48 billion zlotys ($398.3 million) to buy a majority of its main coal supplier Bogdanka, as part of a strategy envisaging 17 billion zloty investments by 2020. ** South African fashion retailer Truworths International Ltd said it was in talks with closely held British shoe chain Office.** Tele Columbus AG Germany's third-largest cable network operator, said on Sunday it has agreed to buy rival pepcom GmbH to create a combined company reaching 3.7 million homes, in a deal valued at 608 million euros ($689 million), including debt.** Credit Suisse Group AG intends to sell its U.S. private bank and slash its prime brokerage business under a strategy being developed by new Chief Executive Tidjane Thiam, Swiss newspaper Schweiz am Sonntag reported on Sunday.** India's JK Tyre & Industries Ltd has agreed to buy Kesoram Industries Ltd's tyre manufacturing unit in northern India for 22 billion rupees ($332.2 million), according to an exchange filing.($1 = 0.6470 pounds)  ($1 = 0.8821 euros)  ($1 = 66.2310 Indian rupees)  ($1 = 3.7159 zlotys)   (Compiled by Anet Josline Pinto in Bengaluru)",2015-09-14,MYL,"Mon Sep 14, 2015 | 4:02pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N11K3GY20150914?type=companyNews
200,"  Mylan NV (MYL.O) said it launched a tender offer on Monday to acquire fellow generic drugmaker Perrigo Co Plc (PRGO.N) for about $27 billion - an offer Perrigo has rejected so far.Mylan Chief Executive Robert Coury said he was confident a majority of Perrigo shareholders would support the offer of $75 in cash and 2.3 Mylan shares for each share held.Perrigo urged shareholders to take no action, pending a board review.The board will assess Netherlands-based Mylan's offer and advise shareholders within 10 days, Perrigo said in a statement.  Perrigo is domiciled in Ireland. Under Irish law, an owner needs 80 percent of votes to squeeze out minority investors. Perrigo shareholders would own about 40 percent of the combined company upon completion of the transaction.Perrigo and Mylan's shares were little changed in early trading.  (Reporting by Amrutha Penumudi in Bengaluru; Editing by Anil D'Silva)",2015-09-14,MYL,"Mon Sep 14, 2015 | 10:18am EDT",Mylan launches tender offer for Perrigo,http://www.reuters.com//article/us-perrigo-company-m-a-idUSKCN0RE1E520150914?type=companyNews
201,"  (Adds Perrigo's response)Sept 14 Mylan NV said it launched a tender offer on Monday to acquire fellow generic drugmaker Perrigo Co Plc for about $27 billion - an offer Perrigo has rejected so far.Mylan Chief Executive Robert Coury said he was confident a majority of Perrigo shareholders would support the offer of $75 in cash and 2.3 Mylan shares for each share held. Perrigo urged shareholders to take no action, pending a board review.The board will assess Netherlands-based Mylan's offer and advise shareholders within 10 days, Perrigo said in a statement. Perrigo is domiciled in Ireland. Under Irish law, an owner needs 80 percent of votes to squeeze out minority investors. Perrigo shareholders would own about 40 percent of the combined company upon completion of the transaction.Perrigo and Mylan's shares were little changed in early trading.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Anil D'Silva)",2015-09-14,MYL,"Mon Sep 14, 2015 | 10:18am EDT",UPDATE 1-Mylan launches tender offer for Perrigo,http://www.reuters.com//article/perrigo-company-ma-idUSL4N11K4DM20150914?type=companyNews
202,"  Sept 14 Mylan NV said it launched a tender offer to acquire fellow generic drugmaker Perrigo Co Plc  for about $27 billion - an offer Perrigo has rejected.Perrigo shareholders will receive $75 in cash and 2.3 Mylan shares for each share held.Mylan Chief Executive Robert Coury said the company was confident a majority of Perrigo shareholders would support the offer. Perrigo CEO Joseph Papa wrote to Coury last week, again rejecting the deal and saying he was confident that shareholders would not accept the offer from Mylan, which is based in the Netherlands. Perrigo is domiciled in Ireland. Under Irish law, an owner needs 80 percent of votes to squeeze out minority investors. Perrigo shareholders would own about 40 percent of the combined company upon completion of the transaction.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Anil D'Silva)",2015-09-14,MYL,"Mon Sep 14, 2015 | 9:06am EDT",Mylan launches tender offer for Perrigo,http://www.reuters.com//article/perrigo-company-ma-idUSL4N11K48820150914?type=companyNews
203,"   By Caroline Humer  Generic and over-the-counter drugmaker Perrigo Co on Thursday urged its shareholders to reject Mylan NV's unsolicited $27 billion tender offer, saying it substantially undervalued the company.Mylan first proposed to buy Perrigo in April and, after being repeatedly rebuffed, launched a tender offer on Monday.It has said it would take control if more than 50 percent of Perrigo shares are tendered in the offer. That strategy is possible under takeover law in Ireland, where Perrigo has been incorporated since buying Irish drugmaker Elan in 2013.Perrigo also filed a lawsuit against Mylan in Manhattan federal court, seeking an injunction to block the closing of any tender offer unless Mylan corrects its alleged misleading statements to Perrigo shareholders about a potential merger. The lawsuit said Mylan overstated potential synergies, and falsely claimed power to delist Perrigo shares in an effort to strong-arm Perrigo shareholders into accepting the tender offer.Mylan, in a statement, said the lawsuit had no merit and was ""an attempt by Perrigo to further frustrate the tender process and to prevent their shareholders from tendering to Mylan in support of this compelling, value creating transaction.""Netherlands-based Mylan has offered $75 in cash and 2.3 of its shares for each Perrigo share, a combination now worth $188.55 based on Mylan's Thursday closing price of $49.37. Perrigo shares closed down $1.31 at $181.08. Joseph Papa, Perrigo's chief executive, said in an interview that he does not believe his company's shareholders will agree to swap their shares for Mylan shares, and that the deal premium of 13 percent was lower than in other pharmaceutical takeovers.""I canceled vacations this summer and I plan to spend more times with shareholders over the next 60 or so days to make sure they understand this is a bad deal,"" Papa said. Perrigo shareholders have until Nov. 13 to take part in the tender offer.Shareholders often wait until near the closing date before deciding to participate, so it is unclear if Mylan will succeed.Buying Perrigo would give Mylan over-the-counter consumer and nutritional products and a line of generic topical medicines.A takeover would be the latest in a string of recent multibillion-dollar pharmaceutical deals, including Valeant Pharmaceuticals International Ltd's $11 billion acquisition of Salix Pharmaceuticals Ltd and AbbVie Inc's  $21 billion offer for Pharmacyclics Inc.   (Additional reporting by Jonathan Stempel in New York and Amrutha Penumudi in Bengaluru)",2015-09-17,MYL,"Thu Sep 17, 2015 | 6:26pm EDT",Perrigo recommends shareholders reject Mylan's tender offer,http://www.reuters.com//article/perrigo-company-ma-mylan-idUSL1N11N2KR20150917?type=companyNews
204,"   By Caroline Humer  Generic and over-the-counter drugmaker Perrigo Co on Thursday urged its shareholders to reject Mylan NV's unsolicited $27 billion tender offer, saying it substantially undervalued the company. Mylan first proposed to buy Perrigo in April and, after being repeatedly rebuffed, launched a tender offer on Monday. It has said it would take control if more than 50 percent of Perrigo shares are tendered in the offer. That strategy is possible under takeover law in Ireland, where Perrigo has been incorporated since buying Irish drugmaker Elan in 2013.Perrigo also filed a lawsuit against Mylan in Manhattan federal court, seeking an injunction to block the closing of any tender offer unless Mylan corrects its alleged misleading statements to Perrigo shareholders about a potential merger.The lawsuit said Mylan overstated potential synergies, and falsely claimed power to delist Perrigo shares in an effort to strong-arm Perrigo shareholders into accepting the tender offer. Mylan, in a statement, said the lawsuit had no merit and was ""an attempt by Perrigo to further frustrate the tender process and to prevent their shareholders from tendering to Mylan in support of this compelling, value creating transaction.""Netherlands-based Mylan has offered $75 in cash and 2.3 of its shares for each Perrigo share, a combination now worth $188.55 based on Mylan's Thursday closing price of $49.37. Perrigo shares closed down $1.31 at $181.08.Joseph Papa, Perrigo's chief executive, said in an interview that he does not believe his company's shareholders will agree to swap their shares for Mylan shares, and that the deal premium of 13 percent was lower than in other pharmaceutical takeovers. ""I canceled vacations this summer and I plan to spend more times with shareholders over the next 60 or so days to make sure they understand this is a bad deal,"" Papa said.Perrigo shareholders have until Nov. 13 to take part in the tender offer. Shareholders often wait until near the closing date before deciding to participate, so it is unclear if Mylan will succeed.Buying Perrigo would give Mylan over-the-counter consumer and nutritional products and a line of generic topical medicines.A takeover would be the latest in a string of recent multibillion-dollar pharmaceutical deals, including Valeant Pharmaceuticals International Ltd's $11 billion acquisition of Salix Pharmaceuticals Ltd and AbbVie Inc's $21 billion offer for Pharmacyclics Inc. (Additional reporting by Jonathan Stempel in New York and Amrutha Penumudi in Bengaluru; Editing by Meredith Mazzilli and Grant McCool)",2015-09-17,MYL,"Thu Sep 17, 2015 | 6:19pm EDT",Perrigo recommends shareholders reject Mylan's tender offer,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-idUSKCN0RH1DA20150917?type=companyNews
205,"  (Adds Perrigo lawsuit against Mylan, closing stock prices)By Caroline HumerSept 17 Generic and over-the-counter drugmaker Perrigo Co on Thursday urged its shareholders to reject Mylan NV's unsolicited $27 billion tender offer, saying it substantially undervalued the company.Mylan first proposed to buy Perrigo in April and, after being repeatedly rebuffed, launched a tender offer on Monday.It has said it would take control if more than 50 percent of Perrigo shares are tendered in the offer. That strategy is possible under takeover law in Ireland, where Perrigo has been incorporated since buying Irish drugmaker Elan in 2013.Perrigo also filed a lawsuit against Mylan in Manhattan federal court, seeking an injunction to block the closing of any tender offer unless Mylan corrects its alleged misleading statements to Perrigo shareholders about a potential merger. The lawsuit said Mylan overstated potential synergies, and falsely claimed power to delist Perrigo shares in an effort to strong-arm Perrigo shareholders into accepting the tender offer.Mylan, in a statement, said the lawsuit had no merit and was ""an attempt by Perrigo to further frustrate the tender process and to prevent their shareholders from tendering to Mylan in support of this compelling, value creating transaction."" Netherlands-based Mylan has offered $75 in cash and 2.3 of its shares for each Perrigo share, a combination now worth $188.55 based on Mylan's Thursday closing price of $49.37. Perrigo shares closed down $1.31 at $181.08.Joseph Papa, Perrigo's chief executive, said in an interview that he does not believe his company's shareholders will agree to swap their shares for Mylan shares, and that the deal premium of 13 percent was lower than in other pharmaceutical takeovers.""I canceled vacations this summer and I plan to spend more times with shareholders over the next 60 or so days to make sure they understand this is a bad deal,"" Papa said. Perrigo shareholders have until Nov. 13 to take part in the tender offer.Shareholders often wait until near the closing date before deciding to participate, so it is unclear if Mylan will succeed.Buying Perrigo would give Mylan over-the-counter consumer and nutritional products and a line of generic topical medicines.A takeover would be the latest in a string of recent multibillion-dollar pharmaceutical deals, including Valeant Pharmaceuticals International Ltd's $11 billion acquisition of Salix Pharmaceuticals Ltd and AbbVie Inc's  $21 billion offer for Pharmacyclics Inc.   (Additional reporting by Jonathan Stempel in New York and Amrutha Penumudi in Bengaluru; Editing by Meredith Mazzilli and Grant McCool)",2015-09-17,MYL,"Thu Sep 17, 2015 | 6:09pm EDT",UPDATE 3-Perrigo recommends shareholders reject Mylan's tender offer,http://www.reuters.com//article/perrigo-company-ma-mylan-idUSL4N11N3N420150917?type=companyNews
206,"  (Adds Colony Capital; updates Perrigo, Altice, Biostime)Sept 17 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:** Anheuser-Busch InBev SA, the world's largest brewer, has approached rival SABMiller Plc about a takeover that would form a colossus producing a third of the world's beer. The merged group would have a market value of about $275 billion at current prices.** Generic and over-the-counter drugmaker Perrigo Co Plc  advised its shareholders to reject Mylan NV's  unsolicited $27 billion tender offer, saying it substantially undervalued the company.** European telecoms group Altice will become a major force in the lucrative U.S. cable market after it agreed to buy fourth-largest operator Cablevision for a mix of cash and shares in a deal worth $17.7 billion including debt.** Suzuki Motor Corp said it had bought back a 19.9 percent stake previously held by Volkswagen AG for 460.28 billion yen ($3.82 billion), ending a partnership that soured soon after it was formed.** Hong Kong-listed dietary supplements company Biostime International Holdings Ltd has agreed to buy Australian vitamin maker Swisse Wellness Pty Ltd for more than A$1.5 billion ($1.08 billion), Australian media reported.** Phoenix Group Holdings, Britain's largest owner of life assurance funds closed to new customers, is in talks to buy Guardian Financial Services, it said on Thursday, although analysts say uncertainty over new capital requirements for European insurers could delay any agreement. ** Port operator China Merchants Holdings (International) Co Ltd said a consortium it was leading had agreed to buy stake in a container terminal in Turkey for $940 million as it seeks to expand its business globally.** Boeing Co said it had rejected an unsolicited bid from Aerojet Rocketdyne Holdings Inc for United Launch Alliance, a 50-50 rocket launch venture of Boeing and Lockheed Martin Corp.** U.S. investment fund Colony Capital is in talks to buy French auto servicing chain Feu Vert, two people with knowledge of the discussions told Reuters. ** Glencore Plc is in talks with Franco-Nevada Corp , Silver Wheaton Corp, Royal Gold Inc  and two other companies to sell portions of the future production of three South American copper mines, two sources with knowledge of the talks said.** Boston-based private equity company Advent International said it had agreed to buy 13 percent of Brazilian medical diagnostics company Fleury SA as it moves ahead with plans to expand investments in the country.** India's Hero Cycles Ltd said it had bought Delhi-based Firefox Bikes for an undisclosed sum to expand its presence in the country's premium cycle market.** French utility Engie SA said it is buying the 80 percent in Australian air conditioning and heating company TSC which it does not already own. ** Black River Asset Management LLC, Cargill Inc's   global asset management firm, is in ""advanced negotiations"" to buy two Brazilian sugar cane mills from Grupo Ruette for around 700 million reais ($179 million), newspaper Valor Economico said on Thursday.** New Zealand's government unexpectedly blocked the NZ$88 million ($56 million) purchase of a local farm by China's Shanghai Pengxin amid public concerns about foreign land ownership.** German publisher Axel Springer SE may want to increase its current 7 percent stake in U.S. news website Business Insider, German Manager Magazin reported on Thursday.** Qatar National Bank SAQ (QNB), the largest bank in the Gulf Arab region, is in preliminary talks to buy Kuwait Finance House KSCP's (KFH) Malaysia unit, the Qatari lender said.** Turkcell, Turkey's largest mobile operator, said it was considering acquiring some of the Eurasian assets of its shareholder TeliaSonera AB, after the Nordic telecom operator said it was looking at leaving seven markets.** British engineering supply group Premier Farnell Plc  unveiled a slew of measures on Thursday, including cutting its dividend and the sale of a non-core unit, to fight slowing sales growth.($1 = 120.5200 yen)  ($1=A$1.39)   (Compiled by Anet Josline Pinto and Shubhankar Chakravorty in Bengaluru)",2015-09-17,MYL,"Thu Sep 17, 2015 | 4:04pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N11N39W20150917?type=companyNews
207,"  Sept 17 Perrigo Co Plc rejected Mylan NV's unsolicited $27 billion tender offer, saying it substantially undervalued the company and did not adequately compensate shareholders.Dublin-based Perrigo said shareholders should ""just say no"" by taking no action. Netherlands-based Mylan launched its tender offer on Monday.  Morgan Stanley is Perrigo's financial adviser.      (Reporting by Amrutha Penumudi in Bengaluru; Editing by Ted Kerr)",2015-09-17,MYL,"Thu Sep 17, 2015 | 6:41am EDT",Perrigo rejects Mylan's tender offer,http://www.reuters.com//article/perrigo-company-ma-mylan-idUSL4N11N3LT20150917?type=companyNews
208,"   By Nate Raymond | NEW YORK  NEW YORK Mylan NV countersued Perrigo Co on Tuesday over ""serious misstatements"" it made as part of its defense against an unsolicited $27 billion tender offer by the generic and over-the-counter drugmaker.In a filing in Manhattan federal court, Mylan sought an order requiring Perrigo to correct ""false and misleading statements"" it made as part of an effort to prevent any merger.The counterclaims were filed after Perrigo last Thursday sought an injunction to block the closing of any tender offer unless Mylan corrected its own alleged misleading statements to Perrigo shareholders about a potential merger.Perrigo's lawsuit said Mylan overstated potential synergies, and falsely claimed power to delist Perrigo shares in an effort to strong-arm acceptance of the tender offer.But in Tuesday's filing, Mylan said Perrigo management including CEO Joseph Papa, sought to mislead its own shareholders into rejecting an offer ""that is, in fact, in their best interest.""Mylan said Papa for six weeks made public statements against the proposed deal without disclosing that he had in March made a ""conflicting purchase"" of more than $220,000 in Mylan stock. He then ""inundated"" shareholders with false statements about the proposed deal through an investor presentation and in media interviews, Mylan said.Mylan filed its counterclaims after earlier in the day saying that at the request of the Irish Takeover Panel, it would qualify a Sept. 8 statement that could itself be misleading and violate Irish takeover rules.Mylan had in that statement said that Perrigo's stock had been ""protected from the recent sell-off in the markets, solely as a result of our offer."" A spokesman for Perrigo did not immediately respond to a request for comment. A spokeswoman for Mylan had no immediate comment.Netherlands-based Mylan has offered $75 in cash and 2.3 of its shares for each Perrigo share, a combination now worth $182.30 based on Mylan's Tuesday closing price of $46.65. Perrigo shares closed down $2.86 at $171.97.Perrigo shareholders have until Nov. 13 to take part in the tender offer. Shareholders often wait until near the closing date before deciding to participate, so it is unclear if Mylan will succeed.Buying Perrigo would give Mylan over-the-counter consumer and nutritional products and a line of generic topical medicines.A takeover would be the latest in a string of recent multibillion-dollar pharmaceutical deals, including Valeant Pharmaceuticals International Ltd's $11 billion acquisition of Salix Pharmaceuticals Ltd and AbbVie Inc's ABBV.N $21 billion offer for Pharmacyclics Inc. (Reporting by Nate Raymond; Editing by Lisa Shumaker and Christian Plumb)",2015-09-22,MYL,"Tue Sep 22, 2015 | 7:06pm EDT",Mylan countersues Perrigo over 'misstatements' about tender offer,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-nl-idUSKCN0RM2QV20150922?type=companyNews
209,"  (Adds further details on lawsuit and deal)By Nate RaymondNEW YORK, Sept 22 Mylan NV countersued Perrigo Co on Tuesday over ""serious misstatements"" it made as part of its defense against an unsolicited $27 billion tender offer by the generic and over-the-counter drugmaker.In a filing in Manhattan federal court, Mylan sought an order requiring Perrigo to correct ""false and misleading statements"" it made as part of an effort to prevent any merger.The counterclaims were filed after Perrigo last Thursday sought an injunction to block the closing of any tender offer unless Mylan corrected its own alleged misleading statements to Perrigo shareholders about a potential merger.Perrigo's lawsuit said Mylan overstated potential synergies, and falsely claimed power to delist Perrigo shares in an effort to strong-arm acceptance of the tender offer. But in Tuesday's filing, Mylan said Perrigo management including CEO Joseph Papa, sought to mislead its own shareholders into rejecting an offer ""that is, in fact, in their best interest.""Mylan said Papa for six weeks made public statements against the proposed deal without disclosing that he had in March made a ""conflicting purchase"" of more than $220,000 in Mylan stock.He then ""inundated"" shareholders with false statements about the proposed deal through an investor presentation and in media interviews, Mylan said. Mylan filed its counterclaims after earlier in the day saying that at the request of the Irish Takeover Panel, it would qualify a Sept. 8 statement that could itself be misleading and violate Irish takeover rules.Mylan had in that statement said that Perrigo's stock had been ""protected from the recent sell-off in the markets, solely as a result of our offer.""A spokesman for Perrigo did not immediately respond to a request for comment. A spokeswoman for Mylan had no immediate comment. Netherlands-based Mylan has offered $75 in cash and 2.3 of its shares for each Perrigo share, a combination now worth $182.30 based on Mylan's Tuesday closing price of $46.65. Perrigo shares closed down $2.86 at $171.97.Perrigo shareholders have until Nov. 13 to take part in the tender offer.Shareholders often wait until near the closing date before deciding to participate, so it is unclear if Mylan will succeed.Buying Perrigo would give Mylan over-the-counter consumer and nutritional products and a line of generic topical medicines.A takeover would be the latest in a string of recent multibillion-dollar pharmaceutical deals, including Valeant Pharmaceuticals International Ltd's $11 billion acquisition of Salix Pharmaceuticals Ltd and AbbVie Inc's ABBV.N  $21 billion offer for Pharmacyclics Inc.   (Reporting by Nate Raymond; Editing by Lisa Shumaker and Christian Plumb)",2015-09-22,MYL,"Tue Sep 22, 2015 | 7:03pm EDT",UPDATE 1-Mylan countersues Perrigo over 'misstatements' about tender offer,http://www.reuters.com//article/perrigo-company-ma-mylan-nl-idUSL1N11S2T320150922?type=companyNews
210,"  NEW YORK, Sept 22 Mylan NV countersued Perrigo Company Plc on Tuesday over ""serious misstatements"" it made related to the generic and over-the-counter drugmaker's unsolicited $27 billion tender offer.In a filing in Manhattan federal court, Mylan sought a court order requiring Perrigo to correct ""false and misleading statements"" it made as part of an effort to prevent any merger.  The counterclaims were in a lawsuit that Perrigo filed last Thursday, which sought an injunction to block the closing of any tender offer unless Mylan corrected its alleged misleading statements to Perrigo shareholders about a potential merger.    (Reporting by Nate Raymond; Editing by Lisa Shumaker) ",2015-09-22,MYL,"Tue Sep 22, 2015 | 6:12pm EDT",Mylan countersues Perrigo over 'misstatements' about tender offer,http://www.reuters.com//article/perrigo-company-ma-mylan-nl-idUSL1N11S2R920150922?type=companyNews
211,"  The Irish Takeover Panel said on Tuesday that it had rejected generic drugmaker Perrigo Company Plc's request to declare Mylan NV's unsolicited tender offer lapsed.The offer from Mylan remains ""lawful and valid and fully capable of acceptance"" by all Perrigo shareholders including Israeli ones, the takeover panel said.Netherlands-based Mylan has offered $75 in cash and 2.3 Mylan shares for each Perrigo share, a combination now worth $173.67 based on Mylan's closing price of $42.90 on Monday.Perrigo and Mylan did not immediately respond to emails seeking comments. Perrigo had rejected Mylan's offer in April following which Mylan took the offer directly to Perrigo shareholders. Perrigo's board recommended shareholders not to tender their shares to Mylan, but is restricted by Irish law from blocking the offer.Dublin-based Perrigo has since made a string of submissions to the panel asking for the offer to be declared lapsed, as it tries to rebuff Mylan's advances.  (Reporting by Esha Vaish and Ankur Banerjee in Bengaluru; Editing by Gopakumar Warrier)",2015-10-13,MYL,"Tue Oct 13, 2015 | 6:28am EDT",Irish takeover panel rejects Perrigo's request over Mylan offer,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-nl-idUSKCN0S715V20151013?type=companyNews
212,"  (Adds details, background)     Oct 13 The Irish Takeover Panel said on Tuesday that it had rejected generic drugmaker Perrigo Company Plc's  request to declare Mylan NV's unsolicited tender offer lapsed.     The offer from Mylan remains ""lawful and valid and fully capable of acceptance"" by all Perrigo shareholders including Israeli ones, the takeover panel said.      Netherlands-based Mylan has offered $75 in cash and 2.3 Mylan shares for each Perrigo share, a combination now worth $173.67 based on Mylan's closing price of $42.90 on Monday.     Perrigo and Mylan did not immediately respond to emails seeking comments.     Perrigo had rejected Mylan's offer in April following which Mylan took the offer directly to Perrigo shareholders.        Perrigo's board recommended shareholders not to tender their shares to Mylan, but is restricted by Irish law from blocking the offer.     Dublin-based Perrigo has since made a string of submissions to the panel asking for the offer to be declared lapsed, as it tries to rebuff Mylan's advances.   (Reporting by Esha Vaish and Ankur Banerjee in Bengaluru; Editing by Gopakumar Warrier)   ",2015-10-13,MYL,"Tue Oct 13, 2015 | 6:24am EDT",UPDATE 1-Irish takeover panel rejects Perrigo's request over Mylan offer,http://www.reuters.com//article/perrigo-company-ma-mylan-nl-idUSL3N12D3K220151013?type=companyNews
213,"  Oct 13 The Irish Takeover Panel said on Tuesday that it had rejected Perrigo Company Plc's request to declare Mylan NV's unsolicited tender offer lapsed.The offer from Mylan remains lawful and valid and fully capable of acceptance by all Perrigo shareholders including Israeli ones, the takeover panel said.  Perrigo, headquartered in the Republic of Ireland, had earlier sought a ruling from the panel saying that Mylan had breached Irish Securities Law by allegedly failing to make a valid offer to Perrigo's Israel shareholders by Sept. 14.   (Reporting by Esha Vaish in Bengaluru; Editing by Gopakumar Warrier) ",2015-10-13,MYL,"Tue Oct 13, 2015 | 5:44am EDT",Irish takeover panel rejects Perrigo's request over Mylan offer,http://www.reuters.com//article/perrigo-company-ma-mylan-nl-idUSL3N12D3FS20151013?type=companyNews
214,"  Oct 13 Irish Takeover Panel* Perrigo recently made an application to Panel requesting Panel to declare Mylan's offer of Sept. 14, 2015 lapsed * Ruled that Mylan's offer remains lawful, valid, fully capable of acceptance by all perrigo shareholders including Israeli shareholders  * Accordingly the panel rejected Perrigo's application  Source text for Eikon:  Further company coverage:     (Bengaluru Newsroom: +91 806 749 1136)",2015-10-13,MYL,"Tue Oct 13, 2015 | 5:20am EDT",BRIEF-Irish Takeover Panel rejects Perrigo application to declare Mylan offer lapsed,http://www.reuters.com//article/idUSFWN12C01R20151013?type=companyNews
215,"   By Brendan Pierson  A lawyer for Perrigo Co on Wednesday urged a federal judge in Manhattan to stop Mylan NV from moving forward with its unsolicited offer to buy the Michigan-based drugmaker until it corrects what he called misleading statements to Perrigo shareholders.Attorney Bradley Wilson's argument to U.S. District Judge Naomi Reice Buchwald focused on Mylan's promise that the deal would yield $800 million per year in synergies, and Mylan would de-list Perrigo from the New York Stock Exchange.Wilson argued that the $800 million projection was based on Mylan's original plan to get full ownership of Perrigo, but that it stuck to that number even after saying it would settle for majority ownership.Opening the door to majority ownership ""completely changed the ballgame,"" he said, because Perrigo would remain a separate company whose interests could be opposed to Mylan's.Mylan's attorney, Sandra Goldstein, said the $800 million estimate was ""conservative"" and Mylan expected to realize it no matter what. She also said the relationship between Mylan and a majority-owned Perrigo would not be hostile. ""Perrigo is going to be Mylan's greatest asset,"" she added. ""The notion that we would try to pick it apart makes no sense.""The argument then turned to Mylan's pledge that it would de-list Perrigo, which Wilson called an empty threat meant to pressure Perrigo's shareholders to sell. In fact, Wilson said, Mylan would not be able to de-list Perrigo, because it would have no legitimate business grounds and would go against the interests of minority shareholders.""They want shareholders to be scared of being stuck behind,"" he said.Goldstein said there was ""absolutely no evidence"" Mylan meant to threaten Perrigo shareholders. It was only disclosing its intentions to comply with securities law, she said. Buchwald did not signal when she would rule.Netherlands-based Mylan has offered $75 in cash and 2.3 of its shares for each Perrigo share, a combination worth $172.86 based on Mylan's Tuesday closing price of $42.55. Perrigo ended Tuesday trading at $162.61.Perrigo shareholders have until Nov. 13 to accept the tender offer. Under the law of Ireland, where Perrigo is incorporated, 80 percent of its shareholders must agree to sell for Mylan to win full ownership.If Mylan succeeds, the merger would make it one of the largest sellers of generic and over-the-counter drugs, with about $15 billion in annual revenue.",2015-10-21,MYL,"Wed Oct 21, 2015 | 2:05pm EDT",Perrigo urges judge to put Mylan offer on hold,http://www.reuters.com//article/perrigo-company-ma-mylan-nv-idUSL1N12L1ZV20151021?type=companyNews
216,"   By Brendan Pierson  A lawyer for Perrigo Co (PRGO.N) on Wednesday urged a federal judge in Manhattan to stop Mylan NV(MYL.O) from moving forward with its unsolicited offer to buy the Michigan-based drugmaker until it corrects what he called misleading statements to Perrigo shareholders.Attorney Bradley Wilson's argument to U.S. District Judge Naomi Reice Buchwald focused on Mylan's promise that the deal would yield $800 million per year in synergies, and Mylan would de-list Perrigo from the New York Stock Exchange.Wilson argued that the $800 million projection was based on Mylan's original plan to get full ownership of Perrigo, but that it stuck to that number even after saying it would settle for majority ownership.Opening the door to majority ownership ""completely changed the ballgame,"" he said, because Perrigo would remain a separate company whose interests could be opposed to Mylan's.Mylan's attorney, Sandra Goldstein, said the $800 million estimate was ""conservative"" and Mylan expected to realize it no matter what. She also said the relationship between Mylan and a majority-owned Perrigo would not be hostile. ""Perrigo is going to be Mylan's greatest asset,"" she added. ""The notion that we would try to pick it apart makes no sense.""The argument then turned to Mylan's pledge that it would de-list Perrigo, which Wilson called an empty threat meant to pressure Perrigo's shareholders to sell.In fact, Wilson said, Mylan would not be able to de-list Perrigo, because it would have no legitimate business grounds and would go against the interests of minority shareholders. ""They want shareholders to be scared of being stuck behind,"" he said.Goldstein said there was ""absolutely no evidence"" Mylan meant to threaten Perrigo shareholders. It was only disclosing its intentions to comply with securities law, she said.Buchwald did not signal when she would rule. Netherlands-based Mylan has offered $75 in cash and 2.3 of its shares for each Perrigo share, a combination worth $172.86 based on Mylan's Tuesday closing price of $42.55. Perrigo ended Tuesday trading at $162.61.Perrigo shareholders have until Nov. 13 to accept the tender offer. Under the law of Ireland, where Perrigo is incorporated, 80 percent of its shareholders must agree to sell for Mylan to win full ownership.If Mylan succeeds, the merger would make it one of the largest sellers of generic and over-the-counter drugs, with about $15 billion in annual revenue. (Reporting By Brendan Pierson in New York; Editing by Bernard Orr)",2015-10-21,MYL,"Wed Oct 21, 2015 | 2:00pm EDT",Perrigo urges judge to put Mylan offer on hold,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-nv-idUSKCN0SF2LT20151021?type=companyNews
217,"   By Brendan Pierson  Oct 21 A lawyer for Perrigo Co on Wednesday urged a federal judge in Manhattan to stop Mylan NV from moving forward with its unsolicited offer to buy the Michigan-based drugmaker until it corrects what he called misleading statements to Perrigo shareholders.Attorney Bradley Wilson's argument to U.S. District Judge Naomi Reice Buchwald focused on Mylan's promise that the deal would yield $800 million per year in synergies, and Mylan would de-list Perrigo from the New York Stock Exchange.Wilson argued that the $800 million projection was based on Mylan's original plan to get full ownership of Perrigo, but that it stuck to that number even after saying it would settle for majority ownership.Opening the door to majority ownership ""completely changed the ballgame,"" he said, because Perrigo would remain a separate company whose interests could be opposed to Mylan's.Mylan's attorney, Sandra Goldstein, said the $800 million estimate was ""conservative"" and Mylan expected to realize it no matter what. She also said the relationship between Mylan and a majority-owned Perrigo would not be hostile. ""Perrigo is going to be Mylan's greatest asset,"" she added. ""The notion that we would try to pick it apart makes no sense.""The argument then turned to Mylan's pledge that it would de-list Perrigo, which Wilson called an empty threat meant to pressure Perrigo's shareholders to sell. In fact, Wilson said, Mylan would not be able to de-list Perrigo, because it would have no legitimate business grounds and would go against the interests of minority shareholders.""They want shareholders to be scared of being stuck behind,"" he said.Goldstein said there was ""absolutely no evidence"" Mylan meant to threaten Perrigo shareholders. It was only disclosing its intentions to comply with securities law, she said. Buchwald did not signal when she would rule.Netherlands-based Mylan has offered $75 in cash and 2.3 of its shares for each Perrigo share, a combination worth $172.86 based on Mylan's Tuesday closing price of $42.55. Perrigo ended Tuesday trading at $162.61.Perrigo shareholders have until Nov. 13 to accept the tender offer. Under the law of Ireland, where Perrigo is incorporated, 80 percent of its shareholders must agree to sell for Mylan to win full ownership.If Mylan succeeds, the merger would make it one of the largest sellers of generic and over-the-counter drugs, with about $15 billion in annual revenue.   (Reporting By Brendan Pierson in New York; Editing by Bernard Orr)",2015-10-21,MYL,"Wed Oct 21, 2015 | 1:59pm EDT",Perrigo urges judge to put Mylan offer on hold,http://www.reuters.com//article/perrigo-company-ma-mylan-nv-idUSL1N12K22W20151021?type=companyNews
218,"   By Ankur Banerjee and Bill Berkrot  Perrigo Co Plc (PRGO.N) said it would lay off 6 percent of its global workforce and buy back shares worth $2 billion to boost earnings, as the generic drug maker looks to convince investors to rebuff Mylan NV's (MYL.O) hostile bid.Mylan, which first made a bid for Perrigo in April, went hostile in September, offering $75 in cash and 2.3 of its shares for each Perrigo share held. This translates into $169.05 per share as of Mylan's Wednesday close. Ireland-based Perrigo's shares fell as much as 8 percent to a year-low of $142.67 on Thursday, reversing course. Mylan's shares declined as much as 7.6 percent to an over two-year low of $37.78.Under Irish laws, Mylan has to secure at least 80 percent of Perrigo shares for the deal to go through. Perrigo shareholders have until Nov. 13 to accept Mylan's offer.Perrigo Chief Executive Joseph Papa said the company was not against deals and was willing to consider opportunities. ""We just happen to think the deal in front of us today is a bad deal,"" Papa told Reuters. ""If someone came in with a cash offer or an appropriate premium to our standalone price, we'd certainly be open to that."" Perrigo's board, which is restricted by Irish laws from blocking the deal, has repeatedly urged shareholders not to accept Netherlands-based Mylan's offer. Perrigo's actions on Thursday found favor with Guggenheim analysts, who said they believed the drugmaker's shareholders were better off owning its stock rather than Mylan's stock.  ""Stronger earnings platform supports our view that (Perrigo) could deliver better value as a standalone company,"" they wrote in a note. Perrigo, which also reported a better-than-expected profit for the third quarter, said it would cut about 800 jobs.  The company said it expected the layoffs and share buyback to boost its earnings to about $9.45 per share in 2016. Analysts on average were expecting $8.89 per share, according to Thomson Reuters I/B/E/S. A lawyer for Perrigo urged a U.S. federal judge on Wednesday to stop Mylan from moving forward with its bid until it corrects what he called misleading statements to Perrigo shareholders, mainly claims that the deal would yield $800 million in annual synergies.    (Reporting by Ankur Banerjee, Vidya L Nathan in Bengaluru and Bill Berkrot in New York; Editing by Robin Paxton, Anil D'Silva and Kirti Pandey)",2015-10-22,MYL,"Thu Oct 22, 2015 | 2:12pm EDT","Perrigo plans job cuts, share buyback as Mylan deadline looms",http://www.reuters.com//article/us-perrigo-company-restructuring-idUSKCN0SG13W20151022?type=companyNews
219,"  * Perrigo to cut 800 jobs, or 6 pct of workforce* Mylan's tender offer expires on Nov. 13* Perrigo shares fall as much as 8 pct   (Adds CEO, analyst comments; updates shares)By Ankur Banerjee and Bill BerkrotOct 22 Perrigo Co Plc said it would lay off 6 percent of its global workforce and buy back shares worth $2 billion to boost earnings, as the generic drug maker looks to convince investors to rebuff Mylan NV's hostile bid.Mylan, which first made a bid for Perrigo in April, went hostile in September, offering $75 in cash and 2.3 of its shares for each Perrigo share held. This translates into $169.05 per share as of Mylan's Wednesday close. Ireland-based Perrigo's shares fell as much as 8 percent to a year-low of $142.67 on Thursday, reversing course. Mylan's shares declined as much as 7.6 percent to an over two-year low of $37.78.Under Irish laws, Mylan has to secure at least 80 percent of Perrigo shares for the deal to go through. Perrigo shareholders have until Nov. 13 to accept Mylan's offer.Perrigo Chief Executive Joseph Papa said the company was not against deals and was willing to consider opportunities. ""We just happen to think the deal in front of us today is a bad deal,"" Papa told Reuters. ""If someone came in with a cash offer or an appropriate premium to our standalone price, we'd certainly be open to that.""Perrigo's board, which is restricted by Irish laws from blocking the deal, has repeatedly urged shareholders not to accept Netherlands-based Mylan's offer. Perrigo's actions on Thursday found favor with Guggenheim analysts, who said they believed the drugmaker's shareholders were better off owning its stock rather than Mylan's stock.""Stronger earnings platform supports our view that (Perrigo) could deliver better value as a standalone company,"" they wrote in a note.Perrigo, which also reported a better-than-expected profit for the third quarter, said it would cut about 800 jobs. (bit.ly/1kuvhd5)The company said it expected the layoffs and share buyback to boost its earnings to about $9.45 per share in 2016. Analysts on average were expecting $8.89 per share, according to Thomson Reuters I/B/E/S.A lawyer for Perrigo urged a U.S. federal judge on Wednesday to stop Mylan from moving forward with its bid until it corrects what he called misleading statements to Perrigo shareholders, mainly claims that the deal would yield $800 million in annual synergies.      (Reporting by Ankur Banerjee, Vidya L Nathan in Bengaluru and Bill Berkrot in New York; Editing by Robin Paxton, Anil D'Silva and Kirti Pandey)",2015-10-22,MYL,"Thu Oct 22, 2015 | 2:11pm EDT","UPDATE 4-Perrigo plans job cuts, share buyback as Mylan deadline looms",http://www.reuters.com//article/perrigo-company-restructuring-idUSL3N12M3K120151022?type=companyNews
220,"  Oct 22 Drugmaker Perrigo Co Plc said it would cut about 800 jobs and buy back $2 billion worth of common shares as it looks to stave off a hostile bid from Mylan NV .The company said the actions are expected to help it earn about $9.45 per share in 2016, including the benefit of buying back $500 million in shares in the fourth quarter. (bit.ly/1kuvhd5)  Net sales rose 41 percent to $1.34 billion in the third quarter, due to contribution from its branded consumer healthcare unit.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Anil D'Silva) ",2015-10-22,MYL,"Thu Oct 22, 2015 | 6:21am EDT","Perrigo to cut 800 jobs, buy back $2 bln in shares",http://www.reuters.com//article/perrigo-company-restructuring-idUSL3N12M3I620151022?type=companyNews
221,"   By Tova Cohen | TEL AVIV  TEL AVIV The chief executive of Irish-based generic drugmaker Perrigo Co (PRGO.N) on Tuesday urged shareholders not to accept rival Mylan NV's (MYL.O) $25 billion hostile bid for the company.Netherlands-based Mylan, which first made a bid for Perrigo in April, went hostile in September, and Perrigo shareholders have until Nov. 13 to accept its tender offer.Under Irish law, Mylan needs to secure 80 percent of shareholders' votes to take control of Perrigo. It says it will run Perrigo as a separate entity if it receives more than 50 percent, but less than 80 percent.Chief Executive Joseph Papa, speaking to reporters at the Tel Aviv Stock Exchange where Perrigo shares have traded since 2005, said he did not believe Mylan will secure 50 percent of shareholders' votes.""But if they do get to 50 to 80 percent it would be a very chaotic process,"" he said. ""The chaos that would occur ... is that all of the long-term Perrigo employees would be in a state of uncertainty that what Mylan would probably seek to do is change the board of directors of Perrigo and also the management team."" That uncertainty would last at least six to eight weeks, delaying the time it takes to achieve synergies.""If shareholders really think about that, it would give them all the more reason not to tender because Mylan to this date has never addressed the situation of negative synergies,"" he said.  Mylan has offered $75 in cash and 2.3 of its shares for each Perrigo share held. That translates into $171.26 per share as of Mylan's Monday close. Perrigo shares closed at $154.27 on Monday after hitting a year low of $142.67 on Thursday. Buying Perrigo would give Mylan over-the-counter consumer and nutritional products and generic topical medicines.Perrigo last week announced plans to lay off 6 percent of its workforce and buy back shares worth $2 billion to boost earnings, as it looks to convince investors to rebuff Mylan's bid.Papa noted there is a mandatory 14-day extension beyond Nov. 13 if Mylan secures more than 50 but less than 80 percent of Perrigo shares. ""If you are concerned about the chaos that could occur in that 50 to 80 percent you don't need to worry about that,"" Papa said. ""You can then during that 14 days tender your shares, you get the same price. There is no need to tender simply out of fear.""Papa reiterated Perrigo was willing to consider offers from other companies but he believes Mylan's bid was a ""bad deal"".He said Mylan would be interested in pursuing more acquisitions once the Mylan tender was done with. (Editing by Susan Fenton)",2015-10-27,MYL,"Tue Oct 27, 2015 | 9:50am EDT",Perrigo CEO doesn't believe Mylan's hostile bid will succeed,http://www.reuters.com//article/us-perrigo-company-ceo-idUSKCN0SL1UU20151027?type=companyNews
222,"   By Tova Cohen | TEL AVIV  TEL AVIV Oct 27 The chief executive of Irish-based generic drugmaker Perrigo Co on Tuesday urged shareholders not to accept rival Mylan NV's $25 billion hostile bid for the company.Netherlands-based Mylan, which first made a bid for Perrigo in April, went hostile in September, and Perrigo shareholders have until Nov. 13 to accept its tender offer.Under Irish law, Mylan needs to secure 80 percent of shareholders' votes to take control of Perrigo. It says it will run Perrigo as a separate entity if it receives more than 50 percent, but less than 80 percent.Chief Executive Joseph Papa, speaking to reporters at the Tel Aviv Stock Exchange where Perrigo shares have traded since 2005, said he did not believe Mylan will secure 50 percent of shareholders' votes.""But if they do get to 50 to 80 percent it would be a very chaotic process,"" he said. ""The chaos that would occur ... is that all of the long-term Perrigo employees would be in a state of uncertainty that what Mylan would probably seek to do is change the board of directors of Perrigo and also the management team."" That uncertainty would last at least six to eight weeks, delaying the time it takes to achieve synergies.""If shareholders really think about that, it would give them all the more reason not to tender because Mylan to this date has never addressed the situation of negative synergies,"" he said. Mylan has offered $75 in cash and 2.3 of its shares for each Perrigo share held. That translates into $171.26 per share as of Mylan's Monday close. Perrigo shares closed at $154.27 on Monday after hitting a year low of $142.67 on Thursday.Buying Perrigo would give Mylan over-the-counter consumer and nutritional products and generic topical medicines.Perrigo last week announced plans to lay off 6 percent of its workforce and buy back shares worth $2 billion to boost earnings, as it looks to convince investors to rebuff Mylan's bid. Papa noted there is a mandatory 14-day extension beyond Nov. 13 if Mylan secures more than 50 but less than 80 percent of Perrigo shares.""If you are concerned about the chaos that could occur in that 50 to 80 percent you don't need to worry about that,"" Papa said. ""You can then during that 14 days tender your shares, you get the same price. There is no need to tender simply out of fear.""Papa reiterated Perrigo was willing to consider offers from other companies but he believes Mylan's bid was a ""bad deal"".He said Mylan would be interested in pursuing more acquisitions once the Mylan tender was done with.   (Editing by Susan Fenton)",2015-10-27,MYL,"Tue Oct 27, 2015 | 9:44am EDT",Perrigo CEO doesn't believe Mylan's hostile bid will succeed,http://www.reuters.com//article/perrigo-company-ceo-idUSL8N12R2NP20151027?type=companyNews
223,"  Oct 28 Mylan NV said an Israeli district court has ruled against target Perrigo Company Plc's  attempt to block Mylan's listing on the Tel Aviv Stock Exchange.A Tel Aviv listing will strengthen Netherlands-based Mylan's efforts to get Perrigo shareholders on its side.Perrigo has repeatedly urged its shareholders not to accept Mylan's $25 billion hostile bid. Mylan, which first made a bid for Perrigo in April, went hostile in September. Perrigo shareholders have until Nov. 13 to accept the tender offer. ""We are very pleased by the court's ruling, clearing the way for the TASE to approve our listing and for Perrigo's Israeli shareholders to participate in our highly compelling offer,"" Mylan Chairman Robert Coury said. Mylan had said in June that the company would like to join the Tel Aviv Stock Exchange if it succeeds in buying Perrigo.Shares of Mylan closed at $44.89 on the Nasdaq on Wednesday.   (Reporting By Samantha Kareen Nair in Bengaluru; Editing by Anil D'Silva)",2015-10-28,MYL,"Wed Oct 28, 2015 | 4:05pm EDT",Israeli court rules in favour of Mylan's Tel Aviv stock listing,http://www.reuters.com//article/mylan-nl-perrigo-company-idUSL3N12S5IX20151028?type=companyNews
224,"   By Ramkumar Iyer and Natalie Grover  Vertex Pharmaceuticals Inc said it received a subpoena from the U.S. Department of Justice in the third quarter, seeking documents related primarily to its ""good laboratory practices"" in a bioanalytical lab.Good laboratory practices are rules that govern non-clinical safety studies, ensuring quality, integrity and reliability of data. Shares of the cystic fibrosis drugmaker, which said it was in the process of responding to the subpoena, fell about 2 percent after-hours.Separately, drugmaker Mylan NV and drugstore chain CVS Health Corp said in their quarterly filings that they had also received subpoenas from federal agencies. CVS said the Drug Enforcement Administration in September sought documents related to controlled substance policies, procedures, and practices at eight pharmacy locations since May 2012. Mylan said the U.S. Securities and Exchange Commission was seeking documents with regard to certain ""related party matters"".CVS and Mylan's shares were little changed after the bell.",2015-10-30,MYL,"Fri Oct 30, 2015 | 6:04pm EDT","Vertex, Mylan, CVS subpoenaed by federal agencies",http://www.reuters.com//article/healthcare-subpeona-idUSL1N12U31520151030?type=companyNews
225,"  Vertex Pharmaceuticals Inc said it received a subpoena from the U.S. Department of Justice in the third quarter, seeking documents related primarily to its ""good laboratory practices"" in a bioanalytical lab.Good laboratory practices are rules that govern non-clinical safety studies, ensuring quality, integrity and reliability of data. Shares of the cystic fibrosis drugmaker, which said it was in the process of responding to the subpoena, fell about 2 percent after-hours. Separately, drugmaker Mylan NV and drugstore chain CVS Health Corp said in their quarterly filings that they had also received subpoenas from federal agencies. CVS said the Drug Enforcement Administration in September sought documents related to controlled substance policies, procedures, and practices at eight pharmacy locations since May 2012. Mylan said the U.S. Securities and Exchange Commission was seeking documents with regard to certain ""related party matters"".CVS and Mylan's shares were little changed after the bell.  (Reporting by Natalie Grover and Ramkumar Iyer in Bengaluru; Editing by Anil D'Silva)",2015-10-30,MYL,"Fri Oct 30, 2015 | 6:01pm EDT","Vertex, Mylan, CVS subpoenaed by federal agencies",http://www.reuters.com//article/us-healthcare-subpeona-idUSKCN0SO2SS20151030?type=companyNews
226,"  Oct 30 Vertex Pharmaceuticals Inc said it received a subpoena from the U.S. Department of Justice in the third quarter, seeking documents related primarily to its ""good laboratory practices"" in a bioanalytical lab.Good laboratory practices are rules that govern non-clinical safety studies, ensuring quality, integrity and reliability of data.Shares of the cystic fibrosis drugmaker, which said it was in the process of responding to the subpoena, fell about 2 percent after-hours. Separately, drugmaker Mylan NV and drugstore chain CVS Health Corp said in their quarterly filings that they had also received subpoenas from federal agencies. CVS said the Drug Enforcement Administration in September sought documents related to controlled substance policies, procedures, and practices at eight pharmacy locations since May 2012. Mylan said the U.S. Securities and Exchange Commission was seeking documents with regard to certain ""related party matters"".CVS and Mylan's shares were little changed after the bell.   (Reporting by Natalie Grover and Ramkumar Iyer in Bengaluru; Editing by Anil D'Silva)",2015-10-30,MYL,"Fri Oct 30, 2015 | 6:00pm EDT","Vertex, Mylan, CVS subpoenaed by federal agencies",http://www.reuters.com//article/healthcare-subpeona-idUSL3N12U6IX20151030?type=companyNews
227,"  Mylan NV (MYL.O), embroiled in an increasingly bitter takeover attempt for fellow drugmaker Perrigo Co Plc (PRGO.N), posted a better-than-expected quarterly profit on Friday as sales of its generic drugs increased in North America and Europe.Mylan also said it expected to achieve the high end of its profit forecast of $4.15-$4.35 per share for the year.The company, which has been pursuing Perrigo to boost its over-the-counter drug business and extend its geographic reach, did not comment on the hostile bid in its earnings statement.Dublin-based Mylan offered to buy Perrigo in April in a cash-and-stock deal valued then at $29 billion.Perrigo, which is also based in Ireland, promptly rejected the offer, as well as a later one, and mud-slinging and court cases ensued.Mylan said on Friday that U.S. District Judge Naomi Reice Buchwald in New York had denied Perrigo's motion for a preliminary injunction to block the closing of any tender offer related to its bid. The company has also won court approval in Ireland and Israel validating its tender offer for Perrigo. Mylan has set a Nov. 13 deadline for Perrigo's shareholders to tender their shares. Mylan's generic drug sales in North America jumped 28 percent to $1.08 billion in the third quarter ended Sept. 30, contributing about 40 percent of total revenue. European generic drug sales surged 79 percent to $629 million.Net income attributable to shareholders fell to $428.6 million, or 83 cents per share, from $499.1 million, or $1.26 per share, due to higher operating costs and an income tax provision. The per-share figure was affected by a near-30 percent rise in outstanding shares in period.Excluding special items, Mylan earned $1.43 per share, beating the average analyst estimate of $1.38 per share, according to Thomson Reuters I/B/E/S. Revenue rose 29 percent to $2.70 billion, but fell short of the average forecast of $2.79 billion.Mylan's shares were little changed at $45.74 in light premarket trading on Friday.  (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza and Ted Kerr)",2015-10-30,MYL,"Fri Oct 30, 2015 | 9:07am EDT",Mylan profit beats as generic sales jump in North America and Europe,http://www.reuters.com//article/us-mylan-results-idUSKCN0SO1DA20151030?type=companyNews
228,"  * Q3 profit $1.43/shr vs. est. $1.38* N.America generic sales rise 28 pct, Europe 79 pct* Says expects to hit high end of 2015 profit forecast* Court denies Perrigo motion for injunction on tender offer* Shares little changed in light premarket trading   (Adds forecast, details; updates shares)Oct 30 Mylan NV, embroiled in an increasingly bitter takeover attempt for fellow drugmaker Perrigo Co Plc, posted a better-than-expected quarterly profit on Friday as sales of its generic drugs increased in North America and Europe.Mylan also said it expected to achieve the high end of its profit forecast of $4.15-$4.35 per share for the year. The company, which has been pursuing Perrigo to boost its over-the-counter drug business and extend its geographic reach, did not comment on the hostile bid in its earnings statement.Dublin-based Mylan offered to buy Perrigo in April in a cash-and-stock deal valued then at $29 billion.Perrigo, which is also based in Ireland, promptly rejected the offer, as well as a later one, and mud-slinging and court cases ensued. Mylan said on Friday that U.S. District Judge Naomi Reice Buchwald in New York had denied Perrigo's motion for a preliminary injunction to block the closing of any tender offer related to its bid.The company has also won court approval in Ireland and Israel validating its tender offer for Perrigo.Mylan has set a Nov. 13 deadline for Perrigo's shareholders to tender their shares. Mylan's generic drug sales in North America jumped 28 percent to $1.08 billion in the third quarter ended Sept. 30, contributing about 40 percent of total revenue. European generic drug sales surged 79 percent to $629 million.Net income attributable to shareholders fell to $428.6 million, or 83 cents per share, from $499.1 million, or $1.26 per share, due to higher operating costs and an income tax provision. The per-share figure was affected by a near-30 percent rise in outstanding shares in period.Excluding special items, Mylan earned $1.43 per share, beating the average analyst estimate of $1.38 per share, according to Thomson Reuters I/B/E/S.Revenue rose 29 percent to $2.70 billion, but fell short of the average forecast of $2.79 billion.Mylan's shares were little changed at $45.74 in light premarket trading on Friday.    (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza and Ted Kerr)",2015-10-30,MYL,"Fri Oct 30, 2015 | 9:06am EDT",UPDATE 2-Mylan profit beats as generic sales jump in N.America and Europe,http://www.reuters.com//article/mylan-results-idUSL3N12U4SL20151030?type=companyNews
229,"  Oct 30 Mylan NV, which has made a hostile bid for Perrigo Co Plc, posted a 29 percent rise in quarterly revenue as demand for its generic drugs increased in North America and Europe.Dublin-based Mylan's revenue rose to $2.70 billion in the third quarter ended Sept. 30 from $2.08 billion a year earlier. Net income attributable to shareholders fell to $428.6 million, or 83 cents per share, from $499.1 million, or $1.26 per share, due to an increase in the number of shares outstanding.  The company also said a U.S. district court had denied Perrigo's motion for a preliminary injunction to block the closing of any tender offer.    (Reporting by Vidya L Nathan in Bengaluru; Editing by Saumyadeb Chakrabarty)",2015-10-30,MYL,"Fri Oct 30, 2015 | 7:10am EDT",Mylan revenue rises 29 percent,http://www.reuters.com//article/mylan-results-idUSL3N12U4QQ20151030?type=companyNews
230,"  TEL AVIV Nov 2 Shares in Mylan will begin trading in Tel Aviv on Nov. 4, the Tel Aviv Stock Exchange (TASE) said on Monday, as the generic drugmaker seeks to strengthen its hand in its hostile bid for rival Perrigo Co Plc , which is also listed on the bourse.Mylan, whose shares already trade on the Nasdaq, last week said that an Israeli district court had ruled against Perrigo's attempt to block Mylan's listing on TASE.  Perrigo has repeatedly urged its shareholders not to accept Mylan's $25 billion hostile bid. Perrigo shareholders have until Nov. 13 to accept the offer.   (Reporting by Tova Cohen; editing by Jason Neely) ",2015-11-02,MYL,"Mon Nov 2, 2015 | 5:19am EST",Mylan shares to begin trading in Tel Aviv on Nov. 4,http://www.reuters.com//article/perrigo-company-ma-mylan-nl-listing-idUSL8N12X1T320151102?type=companyNews
231,"  WASHINGTON Mylan (MYL.O) received U.S. antitrust approval for its hostile bid for Irish-based generic drugmaker Perrigo Co (PRGO.N), the Federal Trade Commission said on Tuesday. Netherlands-based Mylan made an offer for Perrigo in April, which was rejected, and went hostile in September. Perrigo shareholders have until Nov. 13 to accept its tender offer. Under Irish law, Mylan needs 80 percent of shareholders' votes to take control of Perrigo.In a letter to shareholders on Tuesday, Perrigo Chief Executive Joseph Papa reiterated his opposition to a deal with Mylan, calling its offer ""grossly inadequate"" and accusing Mylan of ""poor corporate governance practices.""But Mylan Executive Chairman Robert Coury said on Tuesday that he was ""very confident"" that Perrigo shareholders would side with Mylan.  ""We are delighted to have received FTC clearance, making our offer for Perrigo now unconditional other than the one final step, which now rests solely in the hands of Perrigoshareholders,"" he said. If the deal goes forward as Mylan envisions, Mylan has agreed to sell seven drugs to Alvogen Group Inc, the FTC said in a statement.  They are bromocriptine mesylate (diabetes and Parkinsons disease), clindamycin phosphate/benzoyl peroxide (acne), liothyronine sodium (thyroid ailments) polyethylene glycol 3350 (a laxative), acyclovir (herpes), hydromorphone hydrochloride (pain), scopolamine (nausea). (Reporting by Diane Bartz; Editing by Peter Cooney and Sandra Maler)",2015-11-03,MYL,"Tue Nov 3, 2015 | 4:14pm EST",FTC approves Mylan's hostile bid for Perrigo with conditions,http://www.reuters.com//article/us-perrigo-mylan-ftc-idUSKCN0SS2JH20151103?type=companyNews
232,"  (Adds details on divestitures, background on Perrigo still fighting proposed deal)WASHINGTON Nov 3 Mylan received U.S. antitrust approval for its hostile bid for Irish-based generic drugmaker Perrigo Co, the Federal Trade Commission said on Tuesday.Netherlands-based Mylan made an offer for Perrigo in April, which was rejected, and went hostile in September. Perrigo shareholders have until Nov. 13 to accept its tender offer. Under Irish law, Mylan needs 80 percent of shareholders' votes to take control of Perrigo. In a letter to shareholders on Tuesday, Perrigo Chief Executive Joseph Papa reiterated his opposition to a deal with Mylan, calling its offer ""grossly inadequate"" and accusing Mylan of ""poor corporate governance practices.""But Mylan Executive Chairman Robert Coury said on Tuesday that he was ""very confident"" that Perrigo shareholders would side with Mylan. ""We are delighted to have received FTC clearance, making our offer for Perrigo now unconditional other than the one final step, which now rests solely in the hands of Perrigo shareholders,"" he said. If the deal goes forward as Mylan envisions, Mylan has agreed to sell seven drugs to Alvogen Group Inc, the FTC said in a statement.They are bromocriptine mesylate (diabetes and Parkinson's disease), clindamycin phosphate/benzoyl peroxide (acne), liothyronine sodium (thyroid ailments) polyethylene glycol 3350 (a laxative), acyclovir (herpes), hydromorphone hydrochloride (pain), scopolamine (nausea).   (Reporting by Diane Bartz; Editing by Peter Cooney and Sandra Maler)",2015-11-03,MYL,"Tue Nov 3, 2015 | 4:10pm EST",UPDATE 1-FTC approves Mylan's hostile bid for Perrigo with conditions,http://www.reuters.com//article/perrigo-mylan-ftc-idUSL1N12Y2H120151103?type=companyNews
233,"  WASHINGTON Nov 3 Mylan received U.S. antitrust approval for a hostile takeover of Irish-based generic drugmaker Perrigo Co, the Federal Trade Commission said on Tuesday.Netherlands-based Mylan made a bid for Perrigo in April and went hostile in September. Perrigo shareholders have until Nov. 13 to accept its tender offer. Under Irish law, Mylan needs 80 percent of shareholders' votes to take control of Perrigo.  The FTC approved the prospective deal on condition the companies sell rights to seven generic medicines.   (Reporting by Diane Bartz; Editing by Peter Cooney) ",2015-11-03,MYL,"Tue Nov 3, 2015 | 2:20pm EST",FTC approves hostile Mylan takeover of Perrigo with conditions,http://www.reuters.com//article/perrigo-mylan-ftc-idUSL1N12Y2C020151103?type=companyNews
234,"   By Steven Scheer | TEL AVIV  TEL AVIV Mylan will likely win its bid to take over Irish-based generic drugmaker Perrigo Co, but if the bid fails the company can live without seeking an alternative acquisition, its chairman said on Wednesday.Mylan made an offer for Perrigo in April, which was rejected, and went hostile in September with its $25 billion all-share offer. Perrigo shareholders have until Nov. 13 to accept. Under Irish takeover rules, Mylan needs 80 percent of shareholders' votes to take control of Perrigo.Chairman Robert Coury said Mylan should receive at least 50 percent and Mylan will run Perrigo as a separate entity if it receives more than 50 percent but less than 80 percent.""As long as Mylan's share price is going up the opportunity becomes larger and larger and larger,"" Coury told reporters in Israel, where Mylan's shares began trading on Wednesday.""People don't tender until the last 24 hours so we have quite a very very strong chance for a lot of activity in the last week."" Coury said that while the purchase of Perrigo was good for both companies, Mylan can survive without it. ""We don't need acquisitions,"" he said, pointing to the very strong market position of EpiPen, its biggest-selling branded product, which  treats emergency anaphylactic reactions to allergens.""The EpiPen situation couldn't have come at a more opportune time,"" he said, referring to a recall of rival Auvi-Q injectors made by Sanofi.He also expressed doubt that a generic version of EpiPen by Israel's Teva Pharmaceutical Industries would come to market by 2016, if ever. In addition he said Mylan is hoping for a fast track approval process by U.S. regulators for its generic version of GlaxoSmithKline's asthma treatment Advair.Mylan will apply to the Food & Drug Administration by the end of the year and believes a launch of the generic version of Advair could be possible in 2017.""I will absolutely continue to look at M&A stuff but not as a requirement - as something that could be additive as part of our longer term strategy,"" he said. Coury added that Mylan also expects to launch a generic version of Teva's multiple sclerosis drug Copaxone in 2016.Despite a legal challenge by Perrigo, shares in Mylan made their debut on the Tel Aviv Stock Exchange on Wednesday, rising 1.9 percent. It is the second-biggest company by market value on the bourse and in January is expected to join the blue-chip TA-25 index <0#.TA25>.""Israel is a natural next step for our (global) expansion,"" Coury said, citing the country's high-tech and biotech expertise. ""This is my first (dual-listing). It's the right place to do it given the size of what I am doing with Perrigo. I am going to watch and see the benefits, or not, of dual-listing."" (Editing by Greg Mahlich)",2015-11-04,MYL,"Wed Nov 4, 2015 | 11:51am EST",Mylan not relying on acquisitions if Perrigo bid fails: chairman,http://www.reuters.com//article/us-mylan-nl-m-a-perrigo-idUSKCN0ST2AR20151104?type=companyNews
235,"   By Steven Scheer | TEL AVIV  TEL AVIV Nov 4 Mylan will likely win its bid to take over Irish-based generic drugmaker Perrigo Co , but if the bid fails the company can live without seeking an alternative acquisition, its chairman said on Wednesday.Mylan made an offer for Perrigo in April, which was rejected, and went hostile in September with its $25 billion all-share offer. Perrigo shareholders have until Nov. 13 to accept. Under Irish takeover rules, Mylan needs 80 percent of shareholders' votes to take control of Perrigo.Chairman Robert Coury said Mylan should receive at least 50 percent and Mylan will run Perrigo as a separate entity if it receives more than 50 percent but less than 80 percent.""As long as Mylan's share price is going up the opportunity becomes larger and larger and larger,"" Coury told reporters in Israel, where Mylan's shares began trading on Wednesday.""People don't tender until the last 24 hours so we have quite a very very strong chance for a lot of activity in the last week."" Coury said that while the purchase of Perrigo was good for both companies, Mylan can survive without it. ""We don't need acquisitions,"" he said, pointing to the very strong market position of EpiPen, its biggest-selling branded product, which  treats emergency anaphylactic reactions to allergens.""The EpiPen situation couldn't have come at a more opportune time,"" he said, referring to a recall of rival Auvi-Q injectors made by Sanofi. He also expressed doubt that a generic version of EpiPen by Israel's Teva Pharmaceutical Industries would come to market by 2016, if ever.In addition he said Mylan is hoping for a fast track approval process by U.S. regulators for its generic version of GlaxoSmithKline's asthma treatment Advair.Mylan will apply to the Food & Drug Administration by the end of the year and believes a launch of the generic version of Advair could be possible in 2017. ""I will absolutely continue to look at M&A stuff but not as a requirement - as something that could be additive as part of our longer term strategy,"" he said.Coury added that Mylan also expects to launch a generic version of Teva's multiple sclerosis drug Copaxone in 2016.Despite a legal challenge by Perrigo, shares in Mylan  made their debut on the Tel Aviv Stock Exchange on Wednesday, rising 1.9 percent. It is the second-biggest company by market value on the bourse and in January is expected to join the blue-chip TA-25 index.""Israel is a natural next step for our (global) expansion,"" Coury said, citing the country's high-tech and biotech expertise. ""This is my first (dual-listing). It's the right place to do it given the size of what I am doing with Perrigo. I am going to watch and see the benefits, or not, of dual-listing.""   (Editing by Greg Mahlich)",2015-11-04,MYL,"Wed Nov 4, 2015 | 11:17am EST",Mylan not relying on acquisitions if Perrigo bid fails -chairman,http://www.reuters.com//article/mylan-nl-ma-perrigo-idUSL8N12Z3PM20151104?type=companyNews
236,"   By Diane Bartz | WASHINGTON  WASHINGTON Mylan received U.S. antitrust approval for its hostile bid for Irish-based generic drugmaker Perrigo Co under the condition Mylan sells seven drugs to Alvogen Group Inc, the Federal Trade Commission said on Tuesday.Netherlands-based Mylan made an offer for Perrigo in April, which was rejected, and went hostile in September. Perrigo shareholders have until Nov. 13 to accept its tender offer. Under Irish law, Mylan needs 80 percent of shareholders' votes to take control of Perrigo. In a letter to shareholders on Tuesday, Perrigo Chief Executive Joseph Papa reiterated his opposition to a deal with Mylan, calling its offer ""grossly inadequate"" and accusing Mylan of ""poor corporate governance practices.""Mylan has been criticized for using a type of poison pill available under Dutch law called ""stichting"" to fend off an offer by Teva this year. It was also criticized for giving the chairman of the board of directors the power to essentially veto shareholders' decision to fire him or her. Mylan Executive Chairman Robert Coury reiterated on Tuesday that if the deal with Perrigo goes through that Mylan would allow shareholders to vote to scrap both practices. He also said that he was ""very confident"" that Perrigo shareholders would side with Mylan. ""We are delighted to have received FTC clearance, making our offer for Perrigo now unconditional other than the one final step, which now rests solely in the hands of Perrigo shareholders,"" he said.The seven drugs that Mylan has agreed to sell are bromocriptine mesylate (diabetes and Parkinson's disease), clindamycin phosphate/benzoyl peroxide (acne), liothyronine sodium (thyroid ailments) polyethylene glycol 3350 (a laxative), acyclovir (herpes), hydromorphone hydrochloride (pain) and scopolamine (nausea).",2015-11-04,MYL,"Tue Nov 3, 2015 | 7:05pm EST",FTC approves Mylan's hostile bid for Perrigo with conditions,http://www.reuters.com//article/perrigo-mylan-ftc-idUSL1N12Z00H20151104?type=companyNews
237,"  WASHINGTON Mylan (MYL.O) received U.S. antitrust approval for its hostile bid for Irish-based generic drugmaker Perrigo Co (PRGO.N) under the condition Mylan sells seven drugs to Alvogen Group Inc, the Federal Trade Commission said on Tuesday. Netherlands-based Mylan made an offer for Perrigo in April, which was rejected, and went hostile in September. Perrigo shareholders have until Nov. 13 to accept its tender offer. Under Irish law, Mylan needs 80 percent of shareholders' votes to take control of Perrigo.In a letter to shareholders on Tuesday, Perrigo Chief Executive Joseph Papa reiterated his opposition to a deal with Mylan, calling its offer ""grossly inadequate"" and accusing Mylan of ""poor corporate governance practices.""Mylan has been criticized for using a type of poison pill available under Dutch law called ""stichting"" to fend off an offer by Teva this year. It was also criticized for giving the chairman of the board of directors the power to essentially veto shareholders' decision to fire him or her. Mylan Executive Chairman Robert Coury reiterated on Tuesday that if the deal with Perrigo goes through that Mylan would allow shareholders to vote to scrap both practices. He also said that he was ""very confident"" that Perrigo shareholders would side with Mylan. ""We are delighted to have received FTC clearance, making our offer for Perrigo now unconditional other than the one final step, which now rests solely in the hands of Perrigo shareholders,"" he said.The seven drugs that Mylan has agreed to sell are bromocriptine mesylate (diabetes and Parkinsons disease), clindamycin phosphate/benzoyl peroxide (acne), liothyronine sodium (thyroid ailments) polyethylene glycol 3350 (a laxative), acyclovir (herpes), hydromorphone hydrochloride (pain) and scopolamine (nausea).  (Reporting by Diane Bartz; Editing by Sandra Maler and Cynthia Osterman)",2015-11-04,MYL,"Tue Nov 3, 2015 | 7:05pm EST",FTC approves Mylan's hostile bid for Perrigo with conditions,http://www.reuters.com//article/us-perrigo-mylan-ftc-idUSKCN0SS2JH20151104?type=companyNews
238,"  (Adds details on corporate governance dispute)WASHINGTON Nov 3 Mylan received U.S. antitrust approval for its hostile bid for Irish-based generic drugmaker Perrigo Co under the condition Mylan sells seven drugs to Alvogen Group Inc, the Federal Trade Commission said on Tuesday.Netherlands-based Mylan made an offer for Perrigo in April, which was rejected, and went hostile in September. Perrigo shareholders have until Nov. 13 to accept its tender offer. Under Irish law, Mylan needs 80 percent of shareholders' votes to take control of Perrigo. In a letter to shareholders on Tuesday, Perrigo Chief Executive Joseph Papa reiterated his opposition to a deal with Mylan, calling its offer ""grossly inadequate"" and accusing Mylan of ""poor corporate governance practices.""Mylan has been criticized for using a type of poison pill available under Dutch law called ""stichting"" to fend off an offer by Teva this year. It was also criticized for giving the chairman of the board of directors the power to essentially veto shareholders' decision to fire him or her. Mylan Executive Chairman Robert Coury reiterated on Tuesday that if the deal with Perrigo goes through that Mylan would allow shareholders to vote to scrap both practices. He also said that he was ""very confident"" that Perrigo shareholders would side with Mylan. ""We are delighted to have received FTC clearance, making our offer for Perrigo now unconditional other than the one final step, which now rests solely in the hands of Perrigo shareholders,"" he said.The seven drugs that Mylan has agreed to sell are bromocriptine mesylate (diabetes and Parkinson's disease), clindamycin phosphate/benzoyl peroxide (acne), liothyronine sodium (thyroid ailments) polyethylene glycol 3350 (a laxative), acyclovir (herpes), hydromorphone hydrochloride (pain) and scopolamine (nausea).   (Reporting by Diane Bartz; Editing by Sandra Maler and Cynthia Osterman)",2015-11-04,MYL,"Tue Nov 3, 2015 | 7:03pm EST",UPDATE 2-FTC approves Mylan's hostile bid for Perrigo with conditions,http://www.reuters.com//article/perrigo-mylan-ftc-idUSL1N12Y2H120151104?type=companyNews
239,"   By Greg Roumeliotis and Carl O'Donnell  Perrigo Company Plc (PRGO.N), the Irish-based generic drugmaker trying to fend off a hostile bid by Mylan NV (MYL.O), held unsuccessful talks to acquire Endo International Plc (ENDP.O) in an all-stock deal, according to people familiar with the matter.The negotiations show how Perrigo has been on the M&A prowl seeking to present its shareholders with an alternative to a deal with Mylan, as well as its willingness to walk away if it cannot reach terms that it considers to be attractive.The talks earlier this fall, first reported on by the Wall Street Journal, were advanced enough for major issues such as the role of Endo's chief executive Rajiv De Silva and how the companies could be integrated to have been addressed, the people said on Thursday.But Perrigo ended the talks when Endo asked for too much stock for its shareholders, representing a larger premium than what Perrigo was willing to offer, the people said.  Perrigo concluded that it would generate better returns by sticking with its disciplined approach to M&A, which it believes has generated a lot of value over the years, the people added. Perrigo also considered other smaller acquisitions, the people said. It will look at several acquisition targets of all sizes if Mylan's tender offer, which ends on Friday, fails, the people added. The sources asked not to be identified because the deliberations were confidential. Perrigo declined to comment, while Endo did not immediately respond to a request for comment.Mylan, which first made a bid for Perrigo in April, went hostile in September, offering $75 in cash and 2.3 of its shares for each Perrigo share held. This translates into $176 per share based on Mylan's current share price of $44 per share. Perrigo shares were trading at around $163 in early Thursday afternoon trading in New York.  While the tender offer expires on Friday, Perrigo shareholders who do not tender will have two more weeks to accept Mylan's offer if the minimum acceptance threshold of more than 50 percent of Perrigo ordinary shares is reached.Perrigo reported a better-than-expected profit for the third quarter last month, and said it would lay off 6 percent of its global workforce and buy back shares worth $2 billion. (Reporting by Greg Roumeliotis and Carl O'Donnell in New York; Editing by Chris Reese)",2015-11-12,MYL,"Thu Nov 12, 2015 | 12:40pm EST",Mylan-targeted Perrigo held merger talks with Endo: sources,http://www.reuters.com//article/us-endo-m-a-perrigo-idUSKCN0T129220151112?type=companyNews
240,"   By Greg Roumeliotis and Carl O'Donnell  Nov 12 Perrigo Company Plc, the Irish-based generic drugmaker trying to fend off a hostile bid by Mylan NV, held unsuccessful talks to acquire Endo International Plc in an all-stock deal, according to people familiar with the matter.The negotiations show how Perrigo has been on the M&A prowl seeking to present its shareholders with an alternative to a deal with Mylan, as well as its willingness to walk away if it cannot reach terms that it considers to be attractive.The talks earlier this fall, first reported on by the Wall Street Journal, were advanced enough for major issues such as the role of Endo's chief executive Rajiv De Silva and how the companies could be integrated to have been addressed, the people said on Thursday. But Perrigo ended the talks when Endo asked for too much stock for its shareholders, representing a larger premium than what Perrigo was willing to offer, the people said.Perrigo concluded that it would generate better returns by sticking with its disciplined approach to M&A, which it believes has generated a lot of value over the years, the people added. Perrigo also considered other smaller acquisitions, the people said. It will look at several acquisition targets of all sizes if Mylan's tender offer, which ends on Friday, fails, the people added.The sources asked not to be identified because the deliberations were confidential. Perrigo declined to comment, while Endo did not immediately respond to a request for comment. Mylan, which first made a bid for Perrigo in April, went hostile in September, offering $75 in cash and 2.3 of its shares for each Perrigo share held. This translates into $176 per share based on Mylan's current share price of $44 per share. Perrigo shares were trading at around $163 in early Thursday afternoon trading in New York.While the tender offer expires on Friday, Perrigo shareholders who do not tender will have two more weeks to accept Mylan's offer if the minimum acceptance threshold of more than 50 percent of Perrigo ordinary shares is reached.Perrigo reported a better-than-expected profit for the third quarter last month, and said it would lay off 6 percent of its global workforce and buy back shares worth $2 billion.     (Reporting by Greg Roumeliotis and Carl O'Donnell in New York; Editing by Chris Reese)",2015-11-12,MYL,"Thu Nov 12, 2015 | 12:17pm EST",Mylan-targeted Perrigo held merger talks with Endo -sources,http://www.reuters.com//article/endo-ma-perrigo-idUSL8N1375YS20151112?type=companyNews
241,"   By Ankur Banerjee  Perrigo Co Plc's (PRGO.N) shareholders rejected Mylan NV's (MYL.O) $26 billion hostile bid, ending the Netherlands-based generic drug maker's seven-month pursuit of its smaller rival. Mylan's offer expired on Friday with just 40 percent of Perrigo shares tendered, below the required minimum 50 percent, ensuring victory for Perrigo Chief Executive Joseph Papa.Mylan shares rose as much as 14.4 percent, while Perrigo shares fell as much as 10 percent.  Perrigo can re-enter the M&A arena with much less uncertainty, increasing the odds of a mid-sized to large deal, Jefferies analyst David Steinberg wrote in a note.  Reuters reported on Thursday that the Dublin-based company had held talks with Endo International Plc (ENDP.O), another Ireland-based drugmaker.Healthcare deals worth a record $477 billion had been announced by the end of October, according to Thomson Reuters data, as companies consolidate to cut costs and gain scale. Perrigo, with a large portfolio of consumer products, infant formulas and over-the-counter generic topical drugs, has long been seen as a takeover target. To convince investors to rebuff Mylan's offer, Perrigo had announced job cuts and a $2 billion share buyback plan last month.Perrigo said on Friday it would immediately start buying back shares, helping pull its stock off a more than one-year low. MYLAN MOVING ON    Mylan Executive Chairman Robert Coury, who snubbed an offer from Teva Pharmaceutical Industries Ltd (TEVA.TA) to pursue Perrigo, said the company was ready to move on.Mylan is well-positioned to ""quickly execute on the next strategic, value-enhancing opportunities,"" some of which it has already identified, Coury said in a statement.Raymond James analyst Elliot Wilbur, however, said he did not expect an immediate deal.  ""Mylan won't necessarily be immediately opening up its checkbook for the next company it can buy and instead will step back, take a breather, and focus on the companies or assets it should buy,"" he wrote in a note. Mylan shares were up 13.4 percent at $48.98 in afternoon trading, while Perrigo shares were down 7 percent at $145.50.Mylan first made its interest in Perrigo public in April and went hostile in September, offering $75 plus 2.3 of its shares for each Perrigo share held. Based on Mylan's Thursday close, the offer worked out to about $174.36 per share for Perrigo.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Ted Kerr and Kirti Pandey)",2015-11-13,MYL,"Fri Nov 13, 2015 | 2:18pm EST",Perrigo shareholders snub drugmaker Mylan's $26 billion hostile bid,http://www.reuters.com//article/us-perrigo-company-m-a-mylan-nl-idUSKCN0T21KA20151113?type=companyNews
242,"  * 40 pct Perrigo shares tendered; below 50 pct threshold* Mylan shares rise as much as 14.4 pct* Perrigo shares fall as much as 10 pct   (Adds analysts comments, background; updates shares)By Ankur BanerjeeNov 13 Perrigo Co Plc's shareholders rejected Mylan NV's $26 billion hostile bid, ending the Netherlands-based generic drug maker's seven-month pursuit of its smaller rival.Mylan's offer expired on Friday with just 40 percent of Perrigo shares tendered, below the required minimum 50 percent, ensuring victory for Perrigo Chief Executive Joseph Papa.Mylan shares rose as much as 14.4 percent, while Perrigo shares fell as much as 10 percent.Perrigo can re-enter the M&A arena with much less uncertainty, increasing the odds of a mid-sized to large deal, Jefferies analyst David Steinberg wrote in a note.Reuters reported on Thursday that the Dublin-based company had held talks with Endo International Plc, another Ireland-based drugmaker. Healthcare deals worth a record $477 billion had been announced by the end of October, according to Thomson Reuters data, as companies consolidate to cut costs and gain scale.Perrigo, with a large portfolio of consumer products, infant formulas and over-the-counter generic topical drugs, has long been seen as a takeover target.To convince investors to rebuff Mylan's offer, Perrigo had announced job cuts and a $2 billion share buyback plan last month.Perrigo said on Friday it would immediately start buying back shares, helping pull its stock off a more than one-year low. MYLAN MOVING ON Mylan Executive Chairman Robert Coury, who snubbed an offer from Teva Pharmaceutical Industries Ltd to pursue Perrigo, said the company was ready to move on.Mylan is well-positioned to ""quickly execute on the next strategic, value-enhancing opportunities,"" some of which it has already identified, Coury said in a statement. Raymond James analyst Elliot Wilbur, however, said he did not expect an immediate deal.""Mylan won't necessarily be immediately opening up its checkbook for the next company it can buy and instead will step back, take a breather, and focus on the companies or assets it should buy,"" he wrote in a note.Mylan shares were up 13.4 percent at $48.98 in afternoon trading, while Perrigo shares were down 7 percent at $145.50.Mylan first made its interest in Perrigo public in April and went hostile in September, offering $75 plus 2.3 of its shares for each Perrigo share held.Based on Mylan's Thursday close, the offer worked out to about $174.36 per share for Perrigo.(Reporting by Ankur Banerjee in Bengaluru; Editing by Ted Kerr and Kirti Pandey)",2015-11-13,MYL,"Fri Nov 13, 2015 | 1:23pm EST",UPDATE 3-Perrigo shareholders snub drugmaker Mylan's $26 bln hostile bid,http://www.reuters.com//article/perrigo-company-ma-mylan-nl-idUSL3N1384O520151113?type=companyNews
243,"  Drugmaker Mylan NV's (MYL.O) $26 billion hostile bid for Perrigo Co Plc (PRGO.N) failed on Friday, putting an end to the ongoing saga, which started more than seven months ago.Netherlands-based Mylan has made a number of attempts to buy Perrigo but was unsuccessful in securing at least half of Perrigo outstanding shares in a tender offer, which expired Friday, 8.00 a.m. ET.Through Thursday's close, Mylan's stock had lost about 37 percent of its value since it made public its offer to acquire Perrigo on April 8. Changes to Mylan stock price account for part of the change in total deal value.Following is a summary of key events highlighting the course of the offer:April 8, 2015: Mylan offers to buy Perrigo for about $29 billion in cash and stock in a move that some analysts suggested was an effort to help fend off a $40 billion acquisition by larger rival Teva Pharmaceuticals Industries (TEVA.TA) April 24, 2015: Mylan goes hostile with a sweetened bid of $60 plus 2.2 Mylan shares, valuing Perrigo at $31 billion; Perrigo rejects offerApril 29, 2015: Perrigo rejects Mylan's second raised bid of $75 and 2.3 Mylan shares for every Perrigo share, or $34.1 billionJuly 23, 2015: Dutch foundation linked to Mylan adopts poison pill in efforts to block takeover by Teva, citing potential job losses July 27, 2015: Teva drops its hostile pursuit of Mylan, decides to buy Allergan Plc's (AGN.N) generic business in a deal worth $40.5 billionAug. 13, 2015: Mylan lowers the percentage of Perrigo shares it needs to control the company to just over 50 percent from its original plan of 80 percentSept. 14, 2015: Mylan launches a tender offer in a move to lure Perrigo investors to support its take-over efforts Sept. 17, 2015: Perrigo recommends shareholders to reject Mylan's tender offer, which was set to expire on Nov. 13, saying it substantially undervalued the companyOct. 22, 2015: Perrigo announces its plans to lay off 6 percent of its global workforce and buy back shares worth $2 billionNov. 13, 2015: Mylan fails $26 billion bid in tender offer as it was unable to secure at least half of Perrigo's shares (Compiled by Samantha Kareen Nair; Editing by Anil D'Silva)",2015-11-13,MYL,"Fri Nov 13, 2015 | 12:35pm EST",Mylan fails in $26 billion takeover bid for Perrigo,http://www.reuters.com//article/us-mylan-nl-perrigo-company-timeline-idUSKCN0T221W20151113?type=companyNews
244,"  Nov 13 Drugmaker Mylan NV's $26 billion hostile bid for Perrigo Co Plc failed on Friday, putting an end to the ongoing saga, which started more than seven months ago.Netherlands-based Mylan has made a number of attempts to buy Perrigo but was unsuccessful in securing at least half of Perrigo outstanding shares in a tender offer, which expired Friday, 8.00 a.m. ET.Through Thursday's close, Mylan's stock had lost about 37 percent of its value since it made public its offer to acquire Perrigo on April 8. Changes to Mylan stock price account for part of the change in total deal value.Following is a summary of key events highlighting the course of the offer:April 8, 2015: Mylan offers to buy Perrigo for about $29 billion in cash and stock in a move that some analysts suggested was an effort to help fend off a $40 billion acquisition by larger rival Teva Pharmaceuticals Industries April 24, 2015: Mylan goes hostile with a sweetened bid of $60 plus 2.2 Mylan shares, valuing Perrigo at $31 billion; Perrigo rejects offerApril 29, 2015: Perrigo rejects Mylan's second raised bid of $75 and 2.3 Mylan shares for every Perrigo share, or $34.1 billion July 23, 2015: Dutch foundation linked to Mylan adopts poison pill in efforts to block takeover by Teva, citing potential job lossesJuly 27, 2015: Teva drops its hostile pursuit of Mylan, decides to buy Allergan Plc's generic business in a deal worth $40.5 billionAug. 13, 2015: Mylan lowers the percentage of Perrigo shares it needs to control the company to just over 50 percent from its original plan of 80 percent Sept. 14, 2015: Mylan launches a tender offer in a move to lure Perrigo investors to support its take-over effortsSept. 17, 2015: Perrigo recommends shareholders to reject Mylan's tender offer, which was set to expire on Nov. 13, saying it substantially undervalued the companyOct. 22, 2015: Perrigo announces its plans to lay off 6 percent of its global workforce and buy back shares worth $2 billionNov. 13, 2015: Mylan fails $26 billion bid in tender offer as it was unable to secure at least half of Perrigo's shares     (Compiled by Samantha Kareen Nair; Editing by Anil D'Silva)",2015-11-13,MYL,"Fri Nov 13, 2015 | 12:33pm EST",TIMELINE-Mylan fails in $26 bln takeover bid for Perrigo,http://www.reuters.com//article/mylan-nl-perrigo-company-timeline-idUSL3N13853820151113?type=companyNews
245,"  * Cisco falls after weak forecast* Oct. retail sales up less than expected* Retailers hit by weak results, forecast* Indexes down: Dow 0.16 pct, S&P 0.19 pct, Nasdaq 0.37 pct   (Updates to open)By Abhiram NandakumarNov 13 U.S. stocks were lower on Friday after Cisco's disappointing forecast and as weaker-than-expected October retail sales data and forecast cuts by department store chains fueled fears of a slowdown in demand ahead of the key holiday shopping season.Dow component Cisco fell 5.6 percent to $26.27 after it gave a weak forecast, citing a slowdown in order growth and weak spending outside the United States. The stock was the second-biggest drag on the S&P and the Nasdaq. Data showed U.S. retail sales rose less than expected in October, suggesting a slowdown in consumer spending that could temper expectations of a strong pickup in fourth-quarter economic growth.The weak data follows disappointing reports from department store chains in the past two days. Macy's and Nordstrom  in particular have both reported disappointing results and lowered their full-year forecasts.""People's confidence that the consumer can somehow offset this industrial recession that we've had is really being shaken to the core with the disappointing numbers from some of these major retailers,"" said James Abate, CIO of Centre Funds.U.S. companies, already faced with a potential rate hike in December and a strong dollar, have been reporting signs of slowing demand. At 9:34 a.m. ET (1434 GMT), the Dow Jones industrial average  was down 28.66 points, or 0.16 percent, at 17,419.41.The S&P 500 was down 3.98 points, or 0.19 percent, at 2,041.99 and the Nasdaq Composite index was down 18.66 points, or 0.37 percent, at 4,986.42.Five of the 10 major S&P sectors were lower, with the consumer discretionary sector's 1.13 percent fall leading the decliners. Nordstrom sank 19.8 percent to $50.89. J.C. Penney  slipped 9.2 percent to $7.97 Dillard's was down 8.2 percent.Fossil dropped 27.6 percent to $36.91 after the watchmaker said sales in the current quarter could fall as much as 16 percent.The health sector rose 0.66 percent - the best among the 10 S&P sectors - boosted by Mylan.Mylan rose 9.5 percent to $47.30 after it said Perrigo  shareholders tendered fewer shares than targeted for its $26 billion hostile takeover offer. Perrigo fell 8.4 percent to $143.41. Mylan gave the biggest boost to the S&P and Nasdaq.Declining issues outnumbered advancing ones on the NYSE by 1,638 to 979. On the Nasdaq, 1,485 issues fell and 658 advanced.The S&P 500 index showed no new 52-week highs and 25 new lows, while the Nasdaq recorded five new highs and 66 new lows.   (Reporting by Abhiram Nandakumar in Bengaluru; Editing by Savio D'Souza)",2015-11-13,MYL,"Fri Nov 13, 2015 | 10:10am EST",US STOCKS-Wall St lower on fears of retail slowdown; Cisco drags,http://www.reuters.com//article/usa-stocks-idUSL3N1384PZ20151113?type=companyNews
246,"  Nov 13 Mylan NV said on Friday that 40 percent of Perrigo Co Plc's shares were tendered in its $26 billion hostile takeover offer, falling short of the goal of 50 percent.With the deadline for the offer expiring at 8 a.m. ET (1300 GMT) on Friday, Mylan said 58 million Perrigo ordinary shares had been validly tendered. Netherlands-based Mylan made its first public offer for Dublin-based Perrigo in April and pursued a hostile takeover when it was rejected. Mylan's offer of $75 plus 2.3 Mylan shares was worth about $174.36 per share, based on Mylan's Thursday close of $43.20,   or about $26 billion for all outstanding Perrigo shares. (Reporting by Ankur Banerjee in Bengaluru; Editing by Ted Kerr)",2015-11-13,MYL,"Fri Nov 13, 2015 | 8:50am EST","Mylan says 40 percent of Perrigo shares tendered, misses goal",http://www.reuters.com//article/perrigo-company-ma-mylan-nl-idUSL3N1384ND20151113?type=companyNews
247,"  * Futures down: Dow 50 pts, S&P 5 pts, Nasdaq 17.5 ptsBy Abhiram NandakumarNov 13 U.S. stock index futures were slightly lower on Friday, a day after a sharp selloff that saw S&P 500 and the Dow close below a key technical level, and ahead of retail sales and consumer sentiment data, amid growing concerns of a slowdown in demand.* Wall Street suffered its worst session in over a month on Thursday as lower commodity prices weighed on energy and materials stocks and comments by a Federal Reserve policymaker hinted at an approaching interest-rate hike.* The Dow and S&P 500 closed below their 200-day moving averages, which some traders believe portends additional declines.* Concerns of a global economic slowdown continued to weigh on commodity prices on Friday, but crude prices recovered slightly from a sharp drop on Friday.* U.S. companies, already faced with a potential rate hike in December and a strong dollar, have been reporting signs of slowing demand.* Cisco, late on Thursday, said order growth was slowing and its enterprise business outside the United States was weakening. Department store chain Nordstrom followed Macy's  in cutting its full-year forecast. * Dow component Cisco's shares fell 5 percent to $26.42 premarket after the network equipment maker forecast adjusted profit and revenue growth below estimates.* Nordstrom sank 20.75 percent to $50.30 after its weak results and forecast. Fossil dropped 19.6 percent to $41.06 after the watchmaker said sales in the holiday quarter could fall as much as 16 percent.* Economic data due on Friday is expected to show that U.S. retail sales rose 0.3 percent in October after inching up 0.1 percent in September. The data is due at 8:30 a.m. ET (1330 GMT).* Also scheduled for the same time is the Labor Department's producer price index for October, which is expected to have gained 0.2 percent, after falling 0.5 percent in September. * The University of Michigan's preliminary consumer sentiment index is forecast to have risen to 91.5 in November. The data is slated for release at 10:00 a.m.* With 90 percent of the S&P 500 companies having reported quarterly results, investors will turn their focus to economic data for a clearer picture of the state of the economy ahead of the Fed's meeting in December.* The central bank is widely expected to lift rates off near-zero levels, as economic data appears to support its view that the economy was strong enough to withstand higher rates. * Perrigo dropped 8.3 percent to $143.50 after Reuters reported that Mylan's $26 billion hostile bid for generic drug maker was not likely to succeed. Mylan was up 8.8 percent at $47.10.* Yum Brands rose 4.7 percent to $70.25 after its same-store sales in China grew 5 percent in October.Futures snapshot at 6:47 a.m. ET:* S&P 500 e-minis were down 5 points, or 0.25 percent, with 141,220 contracts traded.* Nasdaq 100 e-minis were down 17.5 points, or 0.38 percent, on volume of 19,893 contracts.* Dow e-minis were down 50 points, or 0.29 percent, with 18,090 contracts changing hands.   (Reporting by Abhiram Nandakumar in Bengaluru; Editing by Savio D'Souza)",2015-11-13,MYL,"Fri Nov 13, 2015 | 7:34am EST","US STOCKS-Futures drop ahead of retail sales, consumer sentiment data",http://www.reuters.com//article/usa-stocks-idUSL3N13844U20151113?type=companyNews
248,"   By Greg Roumeliotis  Generic drug maker Mylan NV's (MYL.O) $26 billion hostile bid for peer Perrigo Company Plc (PRGO.N) looked unlikely to succeed late on Thursday, a few hours before it was set to expire, according to people familiar with the matter.If confirmed, the outcome would represent a major victory for Perrigo's defiant Chief Executive Joseph Papa, and a bitter blow to Mylan's Executive Chairman Robert Coury, who snubbed an acquisition offer from Teva Pharmaceutical Industries Ltd (TEVA.TA) to pursue Perrigo. Around 40 percent of Perrigo's ordinary shares had been tendered ten hours before the tender offer was due to expire on Friday, significantly short of Mylan's acceptance threshold of more than 50 percent, the people said.While more shares could still be tendered, many large institutional investors would have tendered their shares at this stage if they were going to accept the offer, the people added.  The sources declined to be identified because the tally is not yet official. Perrigo declined to comment, while representatives for Mylan did not immediately respond to requests for comment.Mylan, which first made a bid for Perrigo in April, went hostile in September, offering $75 in cash and 2.3 of its shares for each Perrigo share. The deal's rejection will now focus investors' attention on Perrigo's standalone strategy. Papa has said he is open to dealmaking, and sources familiar with the matter said earlier on Thursday Perrigo had held merger talks with Endo International Plc (ENDP.O) earlier in the fall.Perrigo reported a better-than-expected profit for the third quarter last month, and said it would lay off 6 percent of its global workforce and buy back shares worth $2 billion. Mylan had used a Dutch poison pill-style defense to fight a $40 billion takeover by Teva, arguing that a deal was ""without sound industrial logic or cultural fit"" and that it would face regulatory hurdles.Coury said last week that, while the purchase of Perrigo was good for both companies, Mylan could survive without it. He pointed to the very strong market position of EpiPen, Mylan's biggest-selling branded product, which treats emergency anaphylactic reactions to allergens. (Reporting by Greg Roumeliotis in New York; Editing by Miral Fahmy)",2015-11-13,MYL,"Thu Nov 12, 2015 | 11:45pm EST",Mylan's tender offer for Perrigo unlikely to succeed: sources,http://www.reuters.com//article/us-perrigo-m-a-mylan-idUSKCN0T20C020151113?type=companyNews
249,"  (Updates sourcing, adds more details)By Greg RoumeliotisNov 12 Generic drug maker Mylan NV's $26 billion hostile bid for peer Perrigo Company Plc looked unlikely to succeed late on Thursday, a few hours before it was set to expire, according to people familiar with the matter.If confirmed, the outcome would represent a major victory for Perrigo's defiant Chief Executive Joseph Papa, and a bitter blow to Mylan's Executive Chairman Robert Coury, who snubbed an acquisition offer from Teva Pharmaceutical Industries Ltd  to pursue Perrigo.Around 40 percent of Perrigo's ordinary shares had been tendered ten hours before the tender offer was due to expire on Friday, significantly short of Mylan's acceptance threshold of more than 50 percent, the people said. While more shares could still be tendered, many large institutional investors would have tendered their shares at this stage if they were going to accept the offer, the people added.The sources declined to be identified because the tally is not yet official. Perrigo declined to comment, while representatives for Mylan did not immediately respond to requests for comment. Mylan, which first made a bid for Perrigo in April, went hostile in September, offering $75 in cash and 2.3 of its shares for each Perrigo share.The deal's rejection will now focus investors' attention on Perrigo's standalone strategy. Papa has said he is open to dealmaking, and sources familiar with the matter said earlier on Thursday Perrigo had held merger talks with Endo International Plc earlier in the fall. Perrigo reported a better-than-expected profit for the third quarter last month, and said it would lay off 6 percent of its global workforce and buy back shares worth $2 billion.Mylan had used a Dutch poison pill-style defense to fight a $40 billion takeover by Teva, arguing that a deal was ""without sound industrial logic or cultural fit"" and that it would face regulatory hurdles.Coury said last week that, while the purchase of Perrigo was good for both companies, Mylan could survive without it. He pointed to the very strong market position of EpiPen, Mylan's biggest-selling branded product, which treats emergency anaphylactic reactions to allergens.    (Reporting by Greg Roumeliotis in New York; Editing by Miral Fahmy)",2015-11-13,MYL,"Thu Nov 12, 2015 | 11:37pm EST",UPDATE 1-Mylan's tender offer for Perrigo unlikely to succeed -sources,http://www.reuters.com//article/perrigo-ma-mylan-idUSL1N13808M20151113?type=companyNews
250,"  Generic Drugmaker Mylan NV MYL.N plans to buy back shares worth up to $1 billion, after Perrigo Co Plc'S (PRGO.N) shareholders spurned its $26 billion hostile bid.The buyback program expires on Aug. 27, 2016, Mylan said in a statement on Monday. Perrigo shareholders rejected Mylan's bid on Friday, ending the Netherlands-based generic drug maker's seven-month pursuit of its smaller rival.   (Reporting by Rosmi Shaji in Bengaluru; Editing by Savio D'Souza)",2015-11-16,MYL,"Mon Nov 16, 2015 | 11:55am EST",Mylan to buy back $1 billion in stock,http://www.reuters.com//article/us-mylan-nl-buyback-idUSKCN0T521220151116?type=companyNews
251,"  Nov 16 Generic Drugmaker Mylan NV plans to buy back shares worth up to $1 billion, after Perrigo Co Plc'S shareholders spurned its $26 billion hostile bid.The buyback program expires on Aug. 27, 2016, Mylan said in a statement on Monday.  Perrigo shareholders rejected Mylan's bid on Friday, ending the Netherlands-based generic drug maker's seven-month pursuit of its smaller rival.    (Reporting by Rosmi Shaji in Bengaluru; Editing by Savio D'Souza) ",2015-11-16,MYL,"Mon Nov 16, 2015 | 11:53am EST",Mylan to buy back $1 bln in stock,http://www.reuters.com//article/mylan-nl-buyback-idUSL3N13B50H20151116?type=companyNews
252,"  Dec 4 Mylan N.V. said on Friday it had been subpoenaed by the antitrust division of the U.S. Department of Justice, seeking information related to the marketing, pricing and sale of its generic doxycycline products.The company, which said it intends to cooperate with the federal agency, added that the DoJ also sought information on any communication with competitors about the anti-bacterial products.  (Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila) ",2015-12-04,MYL,"Fri Dec 4, 2015 | 8:28am EST",Mylan receives subpoena from Department of Justice,http://www.reuters.com//article/mylan-nl-subpoena-idUSL3N13T44D20151204?type=companyNews
253,"  (In paragraph 7, corrects Morgan Stanley's North American ranking from No. 2 to No. 3)By Mike Stone and Olivia OranDec 2 Morgan Stanley named John Collins as the co-head of its global healthcare banking group, according to an internal memo on Wednesday. He replaces Clint Gartin, who will become  chairman of investment banking.A veteran mergers and acquisitions banker, Collins most recently served as global operations officer in the investment banking division. Collins started his career at Morgan Stanley in 1990 as an analyst and was promoted to managing director in 2004. He left to join Moelis & Co in 2010 before rejoining Morgan Stanley in 2013. Collins will work alongside healthcare banking co-head Michele Colocci and will focus on building out the firm's global client base. He will start at his new role in January.Gartin joined Morgan Stanley in 1981 and became a managing director in 1991. He has held a number of roles within the firm, including chief administrative officer of investment banking and most recently, vice chairman of investment banking and global co-head of healthcare. A Morgan Stanley spokeswoman confirmed the contents of the memo.Morgan Stanley ranks No.3 in North America and No.2 globally in the M&A advisory league tables, according to Thomson Reuters data. The healthcare group has advised on high profile deals recently including Pfizer Inc's $160 billion deal for Allergan PLC and Shire PLC's and Perrigo Company PLC's successful defense against a $31 billion hostile takeover attempt by Mylan NV.    (Reporting by Mike Stone and Olivia Oran in New York; Editing by Frances Kerry)",2015-12-07,MYL,"Mon Dec 7, 2015 | 3:02pm EST",CORRECTED-Morgan Stanley names Collins to global healthcare banking co-head role: memo,http://www.reuters.com//article/morgan-stanley-collins-idUSL1N13R2EV20151207?type=companyNews
254,"  Feb 10 Generic drug maker Mylan NV said it would buy Sweden's Meda AB for about $9.9 billion, including debt, in a combination of cash and stock. Mylan said the offer, recommended by Meda's board, was for 165 Swedish crowns per share.  ($1 = 8.4062 Swedish crowns)   (Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb Chakrabarty)  ",2016-02-10,MYL,"Wed Feb 10, 2016 | 4:12pm EST",Mylan says to buy Sweden's Meda,http://www.reuters.com//article/meda-ma-mylan-nl-idUSL3N15P34S?type=companyNews
255,"   By Natalie Grover  Generic drugmaker Mylan NV (MYL.O) said it would acquire Meda AB MEDAa.ST in a $7.2 billion cash-and-stock deal in its third attempt to buy the Swedish company.The move comes three months after Mylan gave up on its seven-month-long pursuit of smaller rival Perrigo (PRGO.N).Mylan's stock fell about 8 pct in extended trading, after it announced the 165 Swedish crowns per share offer. That works out to be nearly twice Meda's last traded price, which had some analysts questioning the high premium.""The deal may be earnings accretive, but Mylan is paying a huge premium in a deteriorating market,"" Clinical Assistant Professor Erik Gordon, from the Ross School of Business at the University of Michigan, told Reuters. The announcement of the takeover came alongside the company's fourth-quarter results, which underwhelmed analysts' estimates both in terms of profit and revenue. Mylan is still on the prowl for deals, Chief Executive Heather Bresch indicated over a post-earnings conference call with analysts. Meda makes branded, over-the-counter and generic drugs. It already handles European sales of EpiPen, Mylan's emergency shot for severe allergic reactions and its biggest selling branded product.Mylan said the offer, recommended by Meda's board, valued the company at $9.9 billion, including debt. Meda's two largest shareholders, who own about 30 percent of the specialty pharmaceutical's outstanding shares, have accepted the offer, Mylan added.In 2014, Meda spurned takeover offers from Mylan after its biggest shareholder rejected the deal. (reut.rs/1SJ3eFx)Stena Sessan Rederi AB, controlled by the Olsson business  family, is the biggest shareholder in Meda, with a 20.7 percent stake. ""Both companies have changed considerably since then,"" Meda's board chairman Martin Svalstedt told Reuters, highlighting recent acquisitions made by both drugmakers.Last year, Mylan completed its purchase of Abbott Inc's (ABT.N) specialty and generics business in developed markets outside the United States, which helped it shift its tax address to the Netherlands. Meda in July 2014 unveiled its biggest deal ever - the $3.1 purchase of Rottapharm - weeks after the Italian firm scrapped flotation plans.""We have now a stronger business fit.but the industrial landscape is the biggest change since 2014,"" said Svalstedt. Mylan said it would finance the cash portion of the offer via a bridge credit facility arranged by Deutsche Bank and Goldman Sachs.The transaction, due to be completed by the third quarter, should immediately add to Mylan's earnings, the company said.Mylan shares traded at $46.60 in after-market trading. They closed at $50.54 Wednesday on the Nasdaq, while Meda's shares closed at 86.05 crowns.Centerview Partners was Mylan's financial adviser and Cravath, Swaine & Moore LLP, Vinge, and NautaDutilh its legal advisers. Rothschild & Co served as Meda's financial adviser. (Additional reporting by Shailesh Kuber in Bengaluru; Editing by Saumyadeb Chakrabarty, Anil D'Silva and Sunil Nair)",2016-02-11,MYL,"Thu Feb 11, 2016 | 1:05pm EST",Mylan to buy Swedish drugmaker Meda in $7.2 billion deal,http://www.reuters.com//article/us-meda-m-a-mylan-nl-idUSKCN0VJ2IK?type=companyNews
256,"   By Natalie Grover  Generic drugmaker Mylan NV (MYL.O) said it would acquire Meda AB MEDAa.ST in a $7.2 billion cash-and-stock deal in its third attempt to buy the Swedish company.The move comes three months after Mylan gave up on its seven-month-long pursuit of smaller rival Perrigo (PRGO.N).Mylan's stock fell about 8 pct in extended trading, after it announced the 165 Swedish crowns per share offer. That works out to be nearly twice Meda's last traded price, which had some analysts questioning the high premium.""The deal may be earnings accretive, but Mylan is paying a huge premium in a deteriorating market,"" Clinical Assistant Professor Erik Gordon, from the Ross School of Business at the University of Michigan, told Reuters. The announcement of the takeover came alongside the company's fourth-quarter results, which underwhelmed analysts' estimates both in terms of profit and revenue. Mylan is still on the prowl for deals, Chief Executive Heather Bresch indicated over a post-earnings conference call with analysts. Meda makes branded, over-the-counter and generic drugs. It already handles European sales of EpiPen, Mylan's emergency shot for severe allergic reactions and its biggest selling branded product.Mylan said the offer, recommended by Meda's board, valued the company at $9.9 billion, including debt. Meda's two largest shareholders, who own about 30 percent of the specialty pharmaceutical's outstanding shares, have accepted the offer, Mylan added.In 2014, Meda spurned takeover offers from Mylan after its biggest shareholder rejected the deal. (reut.rs/1SJ3eFx)Stena Sessan Rederi AB, controlled by the Olsson business  family, is the biggest shareholder in Meda, with a 20.7 percent stake. ""Both companies have changed considerably since then,"" Meda's board chairman Martin Svalstedt told Reuters, highlighting recent acquisitions made by both drugmakers.Last year, Mylan completed its purchase of Abbott Inc's (ABT.N) specialty and generics business in developed markets outside the United States, which helped it shift its tax address to the Netherlands. Meda in July 2014 unveiled its biggest deal ever - the $3.1 purchase of Rottapharm - weeks after the Italian firm scrapped flotation plans.""We have now a stronger business fit.but the industrial landscape is the biggest change since 2014,"" said Svalstedt. Mylan said it would finance the cash portion of the offer via a bridge credit facility arranged by Deutsche Bank and Goldman Sachs.The transaction, due to be completed by the third quarter, should immediately add to Mylan's earnings, the company said.Mylan shares traded at $46.60 in after-market trading. They closed at $50.54 Wednesday on the Nasdaq, while Meda's shares closed at 86.05 crowns.Centerview Partners was Mylan's financial adviser and Cravath, Swaine & Moore LLP, Vinge, and NautaDutilh its legal advisers. Rothschild & Co served as Meda's financial adviser. (Additional reporting by Shailesh Kuber in Bengaluru; Editing by Saumyadeb Chakrabarty, Anil D'Silva and Sunil Nair)",2016-02-11,MYL,"Thu Feb 11, 2016 | 1:05pm EST",UPDATE 3-Mylan to buy Swedish drugmaker Meda in $7.2 bln deal,http://www.reuters.com//article/meda-ma-mylan-nl-idUSL3N15P359?type=companyNews
257,"  March 21 Acorda Therapeutics Inc* United states court of appeals for federal circuit upheld a lower court ruling * Court of appeals upheld ruling that co's ANDA litigation against Mylan N.V. can continue in district court of Delaware  * All ANDA litigation related to Ampyra tablets, 10 mg patents will continue to proceed in district court of Delaware  Source text - bit.ly/1U1elKn Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-03-21,MYL,"Mon Mar 21, 2016 | 9:54am EDT",BRIEF-Acorda Therapeutics says court upheld ruling in co's ANDA litigation against Mylan,http://www.reuters.com//article/idUSFWN16T07B?type=companyNews
258,"  March 28 Mylan N.V.* U.S. launch of Tramadol Hydrochloride extended-release tablets USP, 100 mg, 200 mg and 300 mg  * Tramadol Hydrochloride extended-release tablets USP, 100 mg, 200 mg, 300 mg, is generic version of Valeant's Ultram extended-release tablets  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom; +1 646 223 8780; ) ",2016-03-28,MYL,"Mon Mar 28, 2016 | 1:36pm EDT",BRIEF-Mylan launches generic Ultram extended-release tablets,http://www.reuters.com//article/idUSASC08II2?type=companyNews
259,"  April 6 Mylan NV:* Mylan launches generic Epivir tablets  * U.S. launch of Lamivudine Tablets USP, 150 mg and 300 mg, which is generic version of ViiV Healthcare's Epivir tablets  Source text for Eikon:  Further company coverage: ",2016-04-06,MYL,"Wed Apr 6, 2016 | 11:25am EDT",BRIEF-Mylan launches generic Epivir tablets in U.S.,http://www.reuters.com//article/idUSASC08K1M?type=companyNews
260,"  April 11 Mylan Nv * u.s. Launch of metoprolol tartrate tablets usp, 37.5 mg and 75 mg, which is generic version of novartis' lopressor tablets  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ",2016-04-11,MYL,"Mon Apr 11, 2016 | 7:24am EDT",BRIEF-Mylan NV launches intermediate dosage strengths of generic Lopressor tablets,http://www.reuters.com//article/idUSASC08KIC?type=companyNews
261,  April 14 Mylan Nv* Says former CFO John D. Sheehan and Mylan Inc. entered into a retirement and consulting agreement - SEC Filing  * Says Sheehan will provide consulting services to co for 1 year following his retirement date  Source - 1.usa.gov/1Q9FseI Further company coverage:    (Bengaluru Newsroom; +1 646 223 8780) ,2016-04-14,MYL,"Thu Apr 14, 2016 | 10:47am EDT",BRIEF-Mylan NV former CFO John D. Sheehan enters into retirement and consulting agreement,http://www.reuters.com//article/idUSFWN17H0O6?type=companyNews
262,  May 5 Mylan Nv* Chief Executive Officer Heather Bresch's total 2015 compensation $13.1 million versus $25.8 million in 2014 * Former CFO John Sheehan's total 2015 compensation $4.4 million versus $6.3 million in 2014 * President Rajiv Malik's total 2015 compensation $15 million versus $25.2 million in 2014 * Executive chairman Robert Coury's total 2015 compensation $13.4 million versus $22.5 million in 2014  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780),2016-05-05,MYL,"Thu May 5, 2016 | 6:33pm EDT",BRIEF-Mylan NV says CEO Heather Bresch's total 2015 compensation $13.1 mln,http://www.reuters.com//article/idUSFWN18219U?type=companyNews
263,"  May 5 Mylan Nv* Mylan launches generic apresoline injection  * u.s. Launch of hydralazine hydrochloride injection usp, 20 mg/ml  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom +1-646-223-8780) ",2016-05-05,MYL,"Thu May 5, 2016 | 7:48am EDT",BRIEF-Mylan launches generic version of Novartis' hypertension drug,http://www.reuters.com//article/idUSASC08N7M?type=companyNews
264,  May 12 Mylan Nv :* U.S. Launch of Frovatriptan Succinate tablets 2.5 mg  * Mylan launches generic frova tablets  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-05-12,MYL,"Thu May 12, 2016 | 7:35am EDT",BRIEF-Mylan launches generic Frova tablets,http://www.reuters.com//article/idUSASC08P5S?type=companyNews
265,"  Mylan NV (MYL.O) said it would buy a part of the topicals-focused drug business of Renaissance Acquisition Holdings LLC for $950 million to expand its dermatological product portfolio.The deal comes three months after Mylan said it would acquire Swedish drugmaker Meda, which also has a sizeable dermatology business.    Dermatology and topical drugs have long been an area of focus for Mylan, Chief Executive Heather Bresch said in a statement on Friday.The Renaissance business is complementary to Meda's, she said.The deal will add about 25 branded and generic non-sterile topical products, the company said.Renaissance, majority owned by private equity firm RoundTable Healthcare Partners, will retain its sterile-focused businesses and associated manufacturing facility. The deal, which is expected to close by the end of the third quarter, includes additional contingent payment of up to $50 million.The unit generated revenue of about $370 million in 2015 and employed about 1,200, Mylan said. Topical drugs are usually applied directly to the skin and are prescribed for a wide range of dermatological conditions.Mylan said it expects to finance the deal using a combination of cash on hand and borrowings under existing credit facilities. Cravath, Swaine & Moore LLP served as legal adviser.  Mylan's shares were down slightly at $38.58 in morning trade. (Reporting by Ankur Banerjee and Amrutha Penumudi in Bengaluru; Editing by Sriraj Kalluvila)",2016-05-13,MYL,"Fri May 13, 2016 | 10:12am EDT",Mylan to buy Renaissance's topical business for $950 million,http://www.reuters.com//article/us-mylan-nl-deals-idUSKCN0Y41PK?type=companyNews
266,"  Mylan NV (MYL.O) said it would buy a part of the topicals-focused drug business of Renaissance Acquisition Holdings LLC for $950 million to expand its dermatological product portfolio.The deal comes three months after Mylan said it would acquire Swedish drugmaker Meda, which also has a sizeable dermatology business.    Dermatology and topical drugs have long been an area of focus for Mylan, Chief Executive Heather Bresch said in a statement on Friday.The Renaissance business is complementary to Meda's, she said.The deal will add about 25 branded and generic non-sterile topical products, the company said.Renaissance, majority owned by private equity firm RoundTable Healthcare Partners, will retain its sterile-focused businesses and associated manufacturing facility. The deal, which is expected to close by the end of the third quarter, includes additional contingent payment of up to $50 million.The unit generated revenue of about $370 million in 2015 and employed about 1,200, Mylan said. Topical drugs are usually applied directly to the skin and are prescribed for a wide range of dermatological conditions.Mylan said it expects to finance the deal using a combination of cash on hand and borrowings under existing credit facilities. Cravath, Swaine & Moore LLP served as legal adviser.  Mylan's shares were down slightly at $38.58 in morning trade. (Reporting by Ankur Banerjee and Amrutha Penumudi in Bengaluru; Editing by Sriraj Kalluvila)",2016-05-13,MYL,"Fri May 13, 2016 | 10:12am EDT",UPDATE 1-Mylan to buy Renaissance's topical business for $950 mln,http://www.reuters.com//article/mylan-nl-deals-idUSL3N18A4QL?type=companyNews
267,"  May 13 Drugmaker Mylan NV said it would buy Renaissance Acquisition Holdings LLC's non-sterile, topicals-focused specialty and generics business for $950 million.The deal will add about 25 branded and generic topical products, the company said on Friday.  The deal, which is expected to close by the end of the third quarter, includes additional contingent payment of up to $50 million.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila) ",2016-05-13,MYL,"Fri May 13, 2016 | 9:21am EDT",Mylan to buy Renaissance's topical business for $950 mln,http://www.reuters.com//article/mylan-nl-deals-idUSL3N18A4P3?type=companyNews
268,"  May 31 Mylan Nv* Mylan announces pricing of senior notes* Pricing of a private placement of $6 .5 billion aggregate principal amount of senior notes * Says completion of offering of notes, Mylan intends to reduce commitments under its bridge credit agreement * Intends to use net proceeds from offering of notes to finance its previously announced public offer * Pricing of senior notes, comprised of $1.0 billion aggregate principal amount of 2.50% senior notes due 2019 at an issue price of 99.888%  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-05-31,MYL,"Tue May 31, 2016 | 5:40pm EDT",BRIEF-Mylan prices senior notes,http://www.reuters.com//article/idUSASC08S0N?type=companyNews
269,"  June 1 Mylan NV:* Mylan launches first generic of nuvigil tablets  * Announced U.S. launch of armodafinil tablets, 50 mg, 150 mg, 250 mg, a generic version of Cephalon's nuvigil  Source text for Eikon:  Further company coverage: ",2016-06-01,MYL,"Wed Jun 1, 2016 | 12:44pm EDT",BRIEF-Mylan launches first generic of nuvigil tablets in U.S.,http://www.reuters.com//article/idUSASC08S6R?type=companyNews
270,"  June 2 Mylan NV* Mylan launches generic rythmol sustained-release capsules  * U.S. launch of propafenone hydrochloride extended-release capsules USP, 225 mg, 325 mg, 425 mg, a generic version of glaxosmithkline's Rythmol Sr  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780) ",2016-06-02,MYL,"Thu Jun 2, 2016 | 7:12am EDT",BRIEF-Mylan launches generic rythmol sustained-release capsules,http://www.reuters.com//article/idUSASC08SD2?type=companyNews
271,"  BRUSSELS - European Union antitrust regulators will rule by July 6 whether to allow U.S. generic drugmaker Mylan NV to buy Swedish peer Meda or open a full-scale investigation.Mylan, which is making its third takeover attempt, sought EU approval on June 1, according to a filing on the European Commission website on Thursday. The company can submit concessions in the preliminary review should the Commission express competition concerns. Some firms, however, prefer to wait for an extensive investigation so that they can tailor concessions to address specific worries.   (Reporting by Foo Yun Chee; editing by Jason Neely)",2016-06-02,MYL,"Thu Jun 2, 2016 | 5:37am EDT",EU regulators to rule on Mylan's $7.2 billion Meda bid by July 6,http://www.reuters.com//article/us-meda-m-a-mylan-nl-eu-idUSKCN0YO0ZU?type=companyNews
272,"  BRUSSELS - European Union antitrust regulators will rule by July 6 whether to allow U.S. generic drugmaker Mylan NV to buy Swedish peer Meda or open a full-scale investigation.Mylan, which is making its third takeover attempt, sought EU approval on June 1, according to a filing on the European Commission website on Thursday. The company can submit concessions in the preliminary review should the Commission express competition concerns. Some firms, however, prefer to wait for an extensive investigation so that they can tailor concessions to address specific worries.   (Reporting by Foo Yun Chee; editing by Jason Neely)",2016-06-02,MYL,"Thu Jun 2, 2016 | 5:37am EDT",EU regulators to rule on Mylan's $7.2 bln Meda bid by July 6,http://www.reuters.com//article/meda-ma-mylan-nl-eu-idUSL8N18U1QY?type=companyNews
273,"  June 3 (Reuters) -* Mylan and Biocon to present phase 3 trastuzumab biosimilar data at the American Society Of Clinical Oncology (ASCO) annual meeting * Mylan NV says  heritage study successfully met predefined endpoints of response equivalency  * Mylan NV says study confirmed efficacy, safety and immunogenicity of MYL-1401O in comparison to branded trastuzumab  Source text for Eikon:  Further company coverage: [ ]   (Bengaluru Newsroom; +1 646 223 8780; )",2016-06-03,MYL,"Fri Jun 3, 2016 | 2:05pm EDT",BRIEF-Mylan and Biocon to present phase 3 trastuzumab biosimilar data at ASCO annual meeting,http://www.reuters.com//article/idUSASC08SMG?type=companyNews
274,"  June 20 Mylan Nv :* Says confirmed that Attorney General of Netherlands has rejected request of Dutch group VEB * ""Attorney General's decision supports our position that our acquisition of Meda is not subject to approval by Mylan shareholders"" Source text for Eikon: Further company coverage:    (Bengaluru Newsroom)",2016-06-20,MYL,"Mon Jun 20, 2016 | 11:01am EDT",BRIEF-Mylan NV confirms that Attorney General of Netherlands has rejected request of VEB,http://www.reuters.com//article/idUSFWN19B02H?type=companyNews
275,"  June 24 Mylan NV:* Mylan launches generic Avodart capsules  * U.S. launch of Dutasteride capsules, 0.5 mg, generic version of GlaxoSmithKline's avodart capsules  Source text for Eikon:  Further company coverage: ",2016-06-24,MYL,"Fri Jun 24, 2016 | 11:48am EDT",BRIEF-Mylan launches generic version of GSK's avodart capsules,http://www.reuters.com//article/idUSASC08VA7?type=companyNews
276,"  BRUSSELS - U.S. generic drugmaker Mylan NV (MYL.O) has offered concessions in a bid to allay concerns by EU competition regulators over its proposed $7.2-billion acquisition of Swedish rival Meda MEDAa.ST, the European Commission said on Thursday.The Commission, which did not provide details about the concessions, said it is now expected to seek the views of rivals and consumers before deciding whether to accept the offer and clear the deal. It can also demand more concessions depending on the response or open a full investigation into the deal. The EU extended its deadline for a decision to July 20 from July 6.   (Reporting by Foo Yun Chee; Editing by Greg Mahlich)",2016-06-30,MYL,"Thu Jun 30, 2016 | 10:28am EDT",Mylan offers EC concessions to get approval for $7.2 bln Meda buy,http://www.reuters.com//article/meda-ma-mylan-eu-idUSL8N19M4TF?type=companyNews
277,"  July 6 Mylan Nv* Mylan launches generic Fenoglide tablets * u.s. Launch of fenofibrate tablets usp, 40 mg and 120 mg, which is a generic version of santarus's fenoglide  * Mylan launches generic Fenoglide tablets  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom +1-646-223-8780)",2016-07-06,MYL,"Wed Jul 6, 2016 | 7:44am EDT",BRIEF-Mylan launches generic Fenoglide tablets,http://www.reuters.com//article/idUSASC08W60?type=companyNews
278,"  BRUSSELS, July 6 The following are mergers under review by the European Commission and a brief guide to the EU merger process:APPROVALS AND WITHDRAWALS NoneNEW LISTINGS -- U.S. paint company Sherwin-Williams Co to acquire U.S. rival Valspar Corp (notified July 5/deadline Aug. 10)-- Investment company Partners Group-led consortium to acquire French property management services provider Foncia from private equity firms Bridgepoint and Eurazeo (notified July 4/deadline Aug. 9)EXTENSIONS AND OTHER CHANGES -- British mobile telephony operator Vodafone and U.S. cable company Liberty Global to merge their Dutch operations (notified June 14/deadline extended to Aug. 3 from July 19 after the Dutch competition authority asked to take over the case)FIRST-STAGE REVIEWS BY DEADLINE JULY 7 -- Spanish bank Banco Santander to acquire some of Portuguese lende Banif's assets (notified June 2/deadline July 7)JULY 11 -- French company Plastic Omnium to acquire French car parts maker Faurecia's auto exteriors business (notified May 23/deadline extended to July 11 from June 27 after Omnium offered concessions)JULY 13 -- German company Boehringer Ingelheim to acquire French pharmaceutical company Sanofi's animal health buisness (notified June 8/deadline July 13)JULY 15 -- Private equity firm PIA Partners-owned R&R Ice Cream and Nestle to set up a joint venture to sell ice cream and frozen food (notified June 10/deadline July 15)-- Polish investment company Kulczyk Holding S.A. and construction company Strabag Sp. z.o.o., which is a unit of Austrian construction group Strabag SE, to set up a joint venture (notified June 10/deadline July 15/simplified)JULY 19 -- Dutch investment company NPM Capital and Thijs Hendrix Beheer B.V. to jointly acquire animal and fish breeder Hendrix Genetics, which is now controlled by Thijs Hendrix Beheer (notified June 14/deadline July 19/simplified)JULY 20 -- U.S. generic drugmaker Mylan to acquire Swedish peer Meda (notified June 1/deadline extended to July 20 from July 6 after Mylan offered concessions)-- U.S. private equity firm AEA to acquire Danish freight forwarder Scan Global Logistics (notified June 15/deadline July 20/simplified) -- Private investor firms Partners Group and Infrared Capital Partners to jointly acquire Merkur Offshore (notified June 15/deadline July 20/simplified)-- French drugmaker Sanofi to acquire Germany company Boehringer Ingelheim's consumer healthcare business (notified June 15/deadline July 20)JULY 22 -- Spanish online bank Bancopopular-e, which is 49-percent owned by Banco Popular Espanol, to acquire Portuguese lender Banco Popular Portugal's payment cards' buisness (notified June 16/deadline July 22/simplified)-- Private investment company Maxburg Investments II GmbH & Co and VR Equity Partner to jointly acquire German fabric producer Norafin Verwaltungs GmbH (notified June 16/deadline July 22/simplified)-- Investment bank Goldman Sachs and Deutsche Bank  to jointly acquire some assets from National Bank of Greece (notified June 16/deadline July 22/simplified)JULY 25 -- French oil and gas producer Total to acquire sole control of French industrial battery maker Saft Groupe S.A.  (notified June 17/deadline July 25/simplified)-- Finnish crane maker Konecranes to acquire U.S. crane maker Terex's cranes business for ports and factories (MHPS) (deadline June 17/deadline July 25)-- U.S. private equity firm Warburg Pincus and French investment firm Wendel to set up a joint venture (notified June 17/deadline July 25/simplified)JULY 26 -- Japanese trading house Sumitomo Corp and Japanese marketing company MonotaRO Co to set up an Indonesian joint venture (notified June 20/deadline July 26/simplified)-- Czech energy group Energeticky a prumyslovy holding, a.s (EPH) to acquire Italian utility Enel's Slovakian company Slovenske elektrarne a.s (notified June 20/deadline July 26) JULY 27 -- Investment firms IK and Five Arrows Managers to jointly acquire French real estate intermediary I@D (notified June 21/deadline July 27/simplified)-- Novy Invest, BNP Paribas Fortis, Sofindev IV and DHAM NV to jointly acquire kitchen appliances makerNovy International (notified June 21/deadline July 27/simplified)JULY 28 - U.S. chemicals company Dow Chemical to merge with DuPont (notified June 22/deadline July 28)JULY 29 -- Jones Lang LaSalle to acquire UK management services provider Integral UK Holding (notified June 23/deadline July 29/simplified)-- General Motors France and French car retailer Groupe Dubreuil Claro to set up a joint venture (notified June 23/July 29/simplified)AUG 1 -- Sony Corp to buy out the Michael Jackson estate's stake in its music publishing joint venture (notified June 24/deadline Aug. 1)-- Private equity firm Thoma Bravo to acquire business intelligence software company Qlik Technologies  (notified June 24/deadline Aug. 1/simplified) AUG 2 -- Italian refinery Raffineria di Milazzo S.C.p.A., which is jointly controlled by Italian oil producer Eni S.p.A.  and Kuwait Petroleum Italia S.p.A., to joint Italian thermal power plant Termica Milazzo from Italian energy group Edison S.p.A. (notified June 27/dateline Aug. 2/simplified)-- Chinese gaming group Tencent Holdings Ltd to acquire Finnish mobile game maker Supercell from Japanese Internet and telecoms group SoftBank Group (notified June 27/deadline Aug. 2/simplified)AUG 4 -- Australian investment bank Macquarie and Swiss Life Group to acquire joint control of Italian transmission system operator Societa Gasdoti Italia S.p.A. (notified June 29/deadline Aug. 4/simplified)-- Swedish carmaker Volvo to acquire joint control of financial services provider Volvofinans Bank (notified June 29/deadline Aug. 4/simplified)AUG 9 -- Japanese tyre maker Bridgestone Corp and German tyre retailer Pneuhage  Management GmbH & Co. KG to set up a joint venture (notified July 4/deadline Aug. 9/simplified)-- Dutch paints and coating producer Akzo Nobel to acquire German chemicals maker BASF's industrial coatings business (notified July 4/deadline Aug. 9)AUG 10 -- Airbus Safran Launchers, a 50/50 joint venture between Airbus and Safran, to acquire sole control of satellite group Arianespace (notified on Jan. 8/deadline extended to Aug. 10 from July 27/concessions offered May 4)SEPT 8 -- CK Hutchison Holdings Ltd and Vimpelcom  to merge their Italian mobile operations (notified Feb. 5/deadline extended to Sept. 8 from Aug 18)OCT 18 -- U.S. rail equipment maker Wabtec Corp to acquire French peer Faiveley Transport SA (notified April 4/deadline extended for the second time to Oct 18 from Sept. 20)SUSPENDED -- SOCAR, Azerbaijan's state energy company, to buy stakes in Greek natural gas grid operator DESFA from Greek natural gas utility DEPA (notified Oct. 1/deadline suspended on Jan. 21GUIDE TO EU MERGER PROCESS DEADLINES: The European Commission has 25 working days after a deal is  filed for a first-stage review. It may extend that by 10 working days to 35 working days, to consider either a company's proposed remedies or an EU member state's request to handle the case.Most mergers win approval but occasionally the Commission opens a detailed second-stage investigation for up to 90 additional working days, which it may extend to 105 working days.SIMPLIFIED: Under the simplified procedure, the Commission announces the clearance of uncontroversial first-stage mergers without giving any reason for its decision. Cases may be reclassified as non-simplified - that is, ordinary first-stage reviews - until they are approved.   (Compiled by Foo Yun Chee)",2016-07-06,MYL,"Wed Jul 6, 2016 | 6:28am EDT",EU mergers and takeovers (July 6),http://www.reuters.com//article/eu-mergers-idUSL8N19S21V?type=companyNews
279,"  July 11 Mylan Nv :* Mylan launches generic Temodar capsules  * U.S. Launch of Temozolomide capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which is a generic version of Merck's Temodar  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ",2016-07-11,MYL,"Mon Jul 11, 2016 | 7:54am EDT",BRIEF-Mylan launches generic Temodar capsules,http://www.reuters.com//article/idUSASC08WHZ?type=companyNews
280,"   By Foo Yun Chee  U.S. generic drugmaker Mylan is expected to win conditional EU antitrust approval for its planned takeover of Swedish rival Meda AB after agreeing to shed some assets, two people familiar with the matter said on Friday.Mylan's cash-and-stock offer was worth $7.2 billion when the offer was made in February. This is the third attempt by the U.S. company to acquire Meda, which makes branded, over-the-counter and generic drugs. The acquisition will give Mylan entry into a number of emerging markets where it does not have a presence, including  China, Southeast Asia, Russia and the Middle East.Mylan offered concessions to the European Commission on June 29 to address competition concerns but did not provide details. Drugmakers typically offer to sell overlapping assets and transfer licensing deals to assuage regulators. The EU competition watchdog, which is scheduled to decide on the deal by July 20, and Mylan declined to comment. Mylan shares were up 0.7 percent to $45.70 in early trade on Friday. Meda shares rose immediately after the Reuters report and were 0.7 percent higher to 154.40 Swedish crowns in late trade.The pharmaceutical industry has seen a wave of consolidation since the start of 2014 on the back of cheap finance and the need to bulk up to compete more effectively with rivals.   (Additional reporting by Caroline Humer in New York, Sven Nordenstam in Stockholm and Ludwig Burger in Frankfurt.)",2016-07-15,MYL,"Fri Jul 15, 2016 | 11:47am EDT",Mylan to get EU green light for Swedish drugmaker deal -sources,http://www.reuters.com//article/meda-ma-mylan-nl-eu-idUSL1N1A112G?type=companyNews
281,"   By Foo Yun Chee | BRUSSELS  BRUSSELS U.S. generic drugmaker Mylan (MYL.O) is expected to win conditional EU antitrust approval for its planned takeover of Swedish rival Meda AB MEDAa.ST after agreeing to shed some assets, two people familiar with the matter said on Friday.Mylan's cash-and-stock offer was worth $7.2 billion when the offer was made in February. This is the third attempt by the U.S. company to acquire Meda, which makes branded, over-the-counter and generic drugs.The acquisition will give Mylan entry into a number of emerging markets where it does not have a presence, including  China, Southeast Asia, Russia and the Middle East. Mylan offered concessions to the European Commission on June 29 to address competition concerns but did not provide details. Drugmakers typically offer to sell overlapping assets and transfer licensing deals to assuage regulators.The EU competition watchdog, which is scheduled to decide on the deal by July 20, and Mylan declined to comment. Mylan shares were up 0.7 percent to $45.70 in early trade on Friday. Meda shares rose immediately after the Reuters report and were 0.7 percent higher to 154.40 Swedish crowns in late trade. The pharmaceutical industry has seen a wave of consolidation since the start of 2014 on the back of cheap finance and the need to bulk up to compete more effectively with rivals. (Additional reporting by Caroline Humer in New York, Sven Nordenstam in Stockholm and Ludwig Burger in Frankfurt. Editing by Jane Merriman)",2016-07-15,MYL,"Fri Jul 15, 2016 | 11:44am EDT",Exclusive: Mylan to get EU green light for Swedish drugmaker deal - sources,http://www.reuters.com//article/us-meda-m-a-mylan-nl-eu-exclusive-idUSKCN0ZV1TA?type=companyNews
282,  July 19 Pulmatrix Inc* Pulmatrix led pilot pharmacokinetic clinical study and supportive development work with collaborative support from Mylan * Financial terms of agreement are confidential * Announced positive topline data from a phase 1 pilot pharmacokinetic bioavailability trial of PUR0200 * Mylan has retained an option for PUR0200 EX-U.S. rights based on successful completion of clinical study  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780),2016-07-19,MYL,"Tue Jul 19, 2016 | 9:13am EDT",BRIEF-Pulmatrix and Mylan collaborate for pilot pharmacokinetic clinical study,http://www.reuters.com//article/idUSFWN1A50K0?type=companyNews
283,"  BRUSSELS EU antitrust regulators said on Wednesday they had cleared generic drugmaker Mylan's planned cash-and-stock purchase of Sweden's Meda subject to it selling certain assets.The approval is conditional on the divestment of a number of businesses in Austria, Belgium, Estonia, France, Luxembourg, Ireland, Italy, Norway, Portugal, Spain and the UK.Reuters last week reported that Mylan was set to get the green light after offering concessions.   The Commission said it had identified 15 markets where it had competition concerns, because of the strong position of the two companies and the lack of sufficient alternatives.The deal, worth some $7.2 billion, was made in February and is the third attempt by the U.S. company to buy Meda, which makes branded, over-the-counter and generic drugs. The acquisition will give Mylan entry into a number of emerging markets where it does not have a presence, including China, Southeast Asia, Russia and the Middle East.   (Reporting By Philip Blenkinsop)",2016-07-20,MYL,"Wed Jul 20, 2016 | 10:42am EDT","Mylan gets EU approval for Meda purchase, subject to conditions",http://www.reuters.com//article/us-meda-m-a-mylan-nl-eu-idUSKCN1001X8?type=companyNews
284,"  BRUSSELS EU antitrust regulators said on Wednesday they had cleared generic drugmaker Mylan's planned cash-and-stock purchase of Sweden's Meda subject to it selling certain assets.The approval is conditional on the divestment of a number of businesses in Austria, Belgium, Estonia, France, Luxembourg, Ireland, Italy, Norway, Portugal, Spain and the UK.Reuters last week reported that Mylan was set to get the green light after offering concessions.   The Commission said it had identified 15 markets where it had competition concerns, because of the strong position of the two companies and the lack of sufficient alternatives.The deal, worth some $7.2 billion, was made in February and is the third attempt by the U.S. company to buy Meda, which makes branded, over-the-counter and generic drugs. The acquisition will give Mylan entry into a number of emerging markets where it does not have a presence, including China, Southeast Asia, Russia and the Middle East.   (Reporting By Philip Blenkinsop)",2016-07-20,MYL,"Wed Jul 20, 2016 | 10:42am EDT","Mylan gets EU approval for Meda purchase, subject to conditions",http://www.reuters.com//article/meda-ma-mylan-nl-eu-idUSB5N18F00J?type=companyNews
285,  July 21 Mylan Nv * Mylan and Biocon announce regulatory submission for proposed Biosimilar Pegfilgrastim accepted for review by European Medicines Agency  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom; +1 646 223 8780)  ,2016-07-21,MYL,"Thu Jul 21, 2016 | 10:25am EDT",BRIEF-Mylan and Biocon announce regulatory submission accepted for review by EMA,http://www.reuters.com//article/idUSFWN1A70QT?type=companyNews
286,  July 27 Mylan Nv* Mylan receives U.S. FTC clearance for proposed Meda acquisition  * Says has now received all antitrust regulatory clearances to acquire Meda  Source text for Eikon:  Further company coverage:    (Bangalore Newsroom : +1 646 223 8780) ,2016-07-27,MYL,"Wed Jul 27, 2016 | 5:37pm EDT",BRIEF-Mylan gets U.S. FTC clearance for proposed Meda buy,http://www.reuters.com//article/idUSFWN1AD17T?type=companyNews
287,  Aug 1 Mylan Nv :* Mylan launches generic Dexedrine capsules  * Mylan launches generic Dexedrine capsules  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom : +1-646-223-8780) ,2016-08-01,MYL,"Mon Aug 1, 2016 | 7:38am EDT",BRIEF-Mylan launches generic Dexedrine capsules,http://www.reuters.com//article/idUSASC08ZO8?type=companyNews
288,  Aug 2 Mylan NV : * Meda shareholders representing approximately 94% of Meda shares accept Mylan offer  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ,2016-08-02,MYL,"Tue Aug 2, 2016 | 9:13am EDT",BRIEF-Meda shareholders accept Mylan offer,http://www.reuters.com//article/idUSFWN1AJ0MZ?type=companyNews
289,"  Aug 9 Mylan NV on Tuesday reported higher second quarter  profit on increased demand for its generic medicines and specialty drugs.However, for the second successive quarter the company kept in place its full-year forecast for adjusted earnings of $4.85 to $5.15 per share. Excluding items, Mylan said it had adjusted earnings of $1.16 per share. Analysts on average expected $1.13 per share, according to Thomson Reuters I/B/E/S.  Revenue for the quarter rose 8 percent to $2.56, just shy of Wall Street estimates of $2.57 billion.   (Reporting by Bill Berkrot; Editing by Sandra Maler)",2016-08-09,MYL,"Tue Aug 9, 2016 | 4:23pm EDT",Mylan 2nd quarter profit rises; 2016 EPS forecast unchanged,http://www.reuters.com//article/mylan-results-idUSL1N1AQ1QL?type=companyNews
290,"  Perrigo Co Plc (PRGO.N) slashed its full-year earnings forecast for the second time, citing pricing pressure in its generic drugs business, sending its shares down as much as 13 percent and wiping out about $1.77 billion of market value.Perrigo's shares have halved since the company's stockholders rejected a $26 billion hostile bid from Netherlands-based Mylan NV (MYL.O) in November, raising concerns about the drugmaker's future as a standalone company.Dublin-based Perrigo, which also reported a lower-than-expected quarterly profit for the second time in three quarters, also said on Wednesday it had lower performance expectations for its branded consumer drugs business as it reorganizes.Chief Executive John Hendrickson has been working to stabilize Perrigo since he took over in May from longtime CEO Joseph Papa, who left to lead troubled Canadian drugmaker Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N). Perrigo's announcement in May that it was cutting its forecast unleashed skepticism about Papa's tenure at Perrigo.  The latest forecast revision showed that things are not yet on the mend, said Wells Fargo analyst David Maris.""We were surprised by the magnitude of the guidance revision, given management's prior conviction in the business,"" Maris wrote in a client note. Perrigo, with its large portfolio of consumer products, infant formulas and over-the-counter generic topical drugs, has long been seen as a potential takeover target.The company, which had a market capitalization of $13.62 billion as of Tuesday's close, said it now expected adjusted earnings of $6.85-$7.15 per share for the year, down from its earlier estimate of $8.20-$8.60. Perrigo shares were down 10 percent at $85.18 in afternoon trading after falling as much as 13 percent to touch 5-year low of $82.50.Up to Tuesday's close, Perrigo's stock had fallen 34 percent this year, making it the second-worst performing share in the S&P 500 healthcare index .SPXHC in percentage terms. (Reporting by Ankur Banerjee in Bengaluru; Editing by Ted Kerr)",2016-08-10,MYL,"Wed Aug 10, 2016 | 1:09pm EDT","Perrigo slashes full-year forecast again, shares plunge",http://www.reuters.com//article/us-perrigo-company-results-idUSKCN10L1VL?type=companyNews
291,"   By Brendan Pierson | NEW YORK  NEW YORK Mylan NV faced new scrutiny over price hikes for its anti-allergy EpiPen on Tuesday, with U.S. lawmakers calling for a probe of oversight of the company's rebates to government healthcare plans, while West Virginia said it was investigating whether Mylan defrauded its Medicaid department.Mylan is grappling with a growing backlash from U.S. consumers, lawmakers and prosecutors over EpiPen prices, which have risen from about $100 in 2007 to more than $600 for a pair of the devices. The EpiPen delivers a dose of epinephrine, an antidote to a severe and potentially deadly allergic reaction to anything from nuts to bee stings.The rising cost has made it difficult for many families to afford, prompting a public outcry that has resonated with  legislators.Mylan Chief Executive Heather Bresch is to testify about EpiPen price hikes on Wednesday before an oversight committee of the House of Representatives. Bresch is the daughter of Senator Joe Manchin, a Democrat from West Virginia.In her written prepared testimony, released on Tuesday, Bresch said Mylan was already moving to address concerns about price by expanding discount programs and launching a $300 generic version. She also said that, after rebates, fees and costs, the company makes only about $100 per EpiPen pack, and that a majority of consumers pay less than $50 out of pocket for a pack.Ahead of the hearing, Republicans on the Senate Finance Committee said they were concerned that Mylan was allowed to inappropriately classify EpiPen as a generic drug, reducing the potential discounts to the government's Medicaid health program for the poor.""We are concerned that the controls in place, if any, are inadequate to ensure that Medicaid is receiving the full amount of rebates afforded to it by law,"" the Senate Republicans, led by Orrin Hatch of Utah, said in a letter to the U.S. Department of Health and Human Services Inspector General. Under current law, branded drugs, and generic drugs available from a single source, are subject to a rebate of at least 23.1 percent of the average manufacturer price for Medicaid. Non-innovator drugs are subject to a much lower 13 percent rebate.The Finance Committee Republicans are asking Inspector General Daniel Levinson to examine the federal health agency's oversight of the rebate program. Mylan has said it has complied with all laws and regulations regarding rebates.Also on Tuesday, West Virginia Attorney General Patrick Morrisey said he was investigating the rebates and the possibility that Mylan violated the state's antitrust law when it sued and settled with a would-be generic competitor.Mylan spokeswoman Nina Devlin said the company was cooperating with the investigation.EpiPen has also posed a cost burden to the federal Medicare health program for the elderly, according to an analysis from the Kaiser Family Foundation, a health policy research group. Before rebates, EpiPen costs for Medicare Part D shot up more than 1,000 percent between 2007 and 2014, from $7 million to $87.9 million, the report said.While rebates to Medicare, which are not disclosed by the program, would have offset the cost to a degree, it was still far higher than a 164 percent increase in EpiPen prescriptions to Medicare patients, the report said.",2016-09-20,MYL,"Tue Sep 20, 2016 | 6:58pm EDT",Senate Republicans seek probe of Mylan EpiPen oversight,http://www.reuters.com//article/mylan-nl-epipen-west-virginia-idUSL2N1BW1EM?type=companyNews
292,"   By Brendan Pierson | NEW YORK  NEW YORK Mylan NV faced new scrutiny over price hikes for its anti-allergy EpiPen on Tuesday, with U.S. lawmakers calling for a probe of oversight of the company's rebates to government healthcare plans, while West Virginia said it was investigating whether Mylan defrauded its Medicaid department.Mylan is grappling with a growing backlash from U.S. consumers, lawmakers and prosecutors over EpiPen prices, which have risen from about $100 in 2007 to more than $600 for a pair of the devices. The EpiPen delivers a dose of epinephrine, an antidote to a severe and potentially deadly allergic reaction to anything from nuts to bee stings.The rising cost has made it difficult for many families to afford, prompting a public outcry that has resonated with  legislators.Mylan Chief Executive Heather Bresch is to testify about EpiPen price hikes on Wednesday before an oversight committee of the House of Representatives. Bresch is the daughter of Senator Joe Manchin, a Democrat from West Virginia.In her written prepared testimony, released on Tuesday, Bresch said Mylan was already moving to address concerns about price by expanding discount programs and launching a $300 generic version. She also said that, after rebates, fees and costs, the company makes only about $100 per EpiPen pack, and that a majority of consumers pay less than $50 out of pocket for a pack.Ahead of the hearing, Republicans on the Senate Finance Committee said they were concerned that Mylan was allowed to inappropriately classify EpiPen as a generic drug, reducing the potential discounts to the government's Medicaid health program for the poor.""We are concerned that the controls in place, if any, are inadequate to ensure that Medicaid is receiving the full amount of rebates afforded to it by law,"" the Senate Republicans, led by Orrin Hatch of Utah, said in a letter to the U.S. Department of Health and Human Services Inspector General. Under current law, branded drugs, and generic drugs available from a single source, are subject to a rebate of at least 23.1 percent of the average manufacturer price for Medicaid. Non-innovator drugs are subject to a much lower 13 percent rebate.The Finance Committee Republicans are asking Inspector General Daniel Levinson to examine the federal health agency's oversight of the rebate program. Mylan has said it has complied with all laws and regulations regarding rebates.Also on Tuesday, West Virginia Attorney General Patrick Morrisey said he was investigating the rebates and the possibility that Mylan violated the state's antitrust law when it sued and settled with a would-be generic competitor.Mylan spokeswoman Nina Devlin said the company was cooperating with the investigation.EpiPen has also posed a cost burden to the federal Medicare health program for the elderly, according to an analysis from the Kaiser Family Foundation, a health policy research group. Before rebates, EpiPen costs for Medicare Part D shot up more than 1,000 percent between 2007 and 2014, from $7 million to $87.9 million, the report said.While rebates to Medicare, which are not disclosed by the program, would have offset the cost to a degree, it was still far higher than a 164 percent increase in EpiPen prescriptions to Medicare patients, the report said.",2016-09-20,MYL,"Tue Sep 20, 2016 | 6:38pm EDT",Senate Republicans seek probe of Mylan EpiPen oversight,http://www.reuters.com//article/mylan-nl-epipen-west-virginia-idUSL2N1BW284?type=companyNews
293,"   By Brendan Pierson | NEW YORK  NEW YORK Mylan NV faced new scrutiny over price hikes for its anti-allergy EpiPen on Tuesday, with U.S. lawmakers calling for a probe of oversight of the company's rebates to government healthcare plans, while West Virginia said it was investigating whether Mylan defrauded its Medicaid department.Mylan is grappling with a growing backlash from U.S. consumers, lawmakers and prosecutors over EpiPen prices, which have risen from about $100 in 2007 to more than $600 for a pair of the devices. The EpiPen delivers a dose of epinephrine, an antidote to a severe and potentially deadly allergic reaction to anything from nuts to bee stings.The rising cost has made it difficult for many families to afford, prompting a public outcry that has resonated with  legislators.Mylan Chief Executive Heather Bresch is to testify about EpiPen price hikes on Wednesday before an oversight committee of the House of Representatives. Bresch is the daughter of Senator Joe Manchin, a Democrat from West Virginia.In her written prepared testimony, released on Tuesday, Bresch said Mylan was already moving to address concerns about price by expanding discount programs and launching a $300 generic version. She also said that, after rebates, fees and costs, the company makes only about $100 per EpiPen pack, and that a majority of consumers pay less than $50 out of pocket for a pack.Ahead of the hearing, Republicans on the Senate Finance Committee said they were concerned that Mylan was allowed to inappropriately classify EpiPen as a generic drug, reducing the potential discounts to the government's Medicaid health program for the poor.""We are concerned that the controls in place, if any, are inadequate to ensure that Medicaid is receiving the full amount of rebates afforded to it by law,"" the Senate Republicans, led by Orrin Hatch of Utah, said in a letter to the U.S. Department of Health and Human Services Inspector General. Under current law, branded drugs, and generic drugs available from a single source, are subject to a rebate of at least 23.1 percent of the average manufacturer price for Medicaid. Non-innovator drugs are subject to a much lower 13 percent rebate.The Finance Committee Republicans are asking Inspector General Daniel Levinson to examine the federal health agency's oversight of the rebate program. Mylan has said it has complied with all laws and regulations regarding rebates.Also on Tuesday, West Virginia Attorney General Patrick Morrisey said he was investigating the rebates and the possibility that Mylan violated the state's antitrust law when it sued and settled with a would-be generic competitor.Mylan spokeswoman Nina Devlin said the company was cooperating with the investigation.EpiPen has also posed a cost burden to the federal Medicare health program for the elderly, according to an analysis from the Kaiser Family Foundation, a health policy research group. Before rebates, EpiPen costs for Medicare Part D shot up more than 1,000 percent between 2007 and 2014, from $7 million to $87.9 million, the report said.While rebates to Medicare, which are not disclosed by the program, would have offset the cost to a degree, it was still far higher than a 164 percent increase in EpiPen prescriptions to Medicare patients, the report said.",2016-09-20,MYL,"Tue Sep 20, 2016 | 6:35pm EDT",Senate Republicans seek probe of Mylan EpiPen oversight,http://www.reuters.com//article/mylan-nl-epipen-west-virginia-idUSL2N1BW2B6?type=companyNews
294,"   By Lewis Krauskopf | NEW YORK  NEW YORK Shares of Mylan NV (MYL.O) are trading at historically low valuations as the company's chief executive officer is set to face a congressional grilling on Wednesday over the price of its EpiPen emergency allergy treatment. The stock is trading at 7.5 times estimated earnings for the next 12 months, holding near its lowest in at least 30 years and well below its five-year average of 11 times, according to Thomson Reuters Datastream.Since late August, when the EpiPen price increases came into the spotlight, Mylan shares have fallen about 15 percent. For the year, they are off about 23 percent, against a nearly 4 percent decline for the NYSE Arca Pharmaceutical index .DRG, a broad gauge of large and small drugmakers.A test for the shares looms on Wednesday, when Mylan CEO Heather Bresch testifies before the U.S. House of Representatives Oversight Committee over price increases of EpiPen, an auto-injector of allergy medicine.  The hearing will come the day after West Virginia disclosed an investigation into whether Mylan violated antitrust laws or defrauded the state's Medicaid program. A probe into EpiPen pricing by a U.S. Senate subcommittee was also announced on Sept. 7.The stock ""is just not working because of the overhang from all the headline stuff on EpiPen,"" said Guggenheim Securities analyst Louise Chen, who rates the shares ""neutral"".One concern among analysts is how fallout over EpiPen pricing will affect Mylan's roughly $1 billion in annual sales of the device.  Mylan said last month that it would introduce the first generic version of EpiPen for $300, half the price of the branded product, as it tries to quell the backlash. Further competition looms from Teva Pharmaceutical Industries (TEVA.TA), which hopes to start selling an EpiPen-like device by 2018.Chen also said investors were unsure of the benefits from Mylan's recently completed $7 billion acquisition of Swedish drugmaker Meda, which some had deemed expensive. Deutsche Bank analyst Gregg Gilbert stuck to his ""buy"" rating on Mylan stock earlier this month, noting its valuation. But in a research note, Gilbert cautioned: ""Investors will have little patience if execution falters on the base business and/or the newly acquired Meda business.""     (Reporting by Lewis Krauskopf; Editing by Lisa Von Ahn)",2016-09-20,MYL,"Tue Sep 20, 2016 | 10:18pm EDT",Mylan shares languish at low valuation as EpiPen hearing nears,http://www.reuters.com//article/usa-stocks-mylan-idUSL2N1BW14K?type=companyNews
295,"  Sept 20 The state of West Virginia is investigating whether Mylan NV violated antitrust laws or defrauded the state's Medicaid program in connection with its EpiPen device. West Virginia Attorney General Patrick Morrisey disclosed the investigation on Tuesday, announcing he had petitioned a state court to order Mylan to comply with a subpoena his office issued in August.   (Reporting By Brendan Pierson in New York)  ",2016-09-20,MYL,"Tue Sep 20, 2016 | 11:53am EDT",West Virginia investigating Mylan over EpiPen pricing,http://www.reuters.com//article/mylan-nl-epipen-west-virginia-idUSFWN1BW0IR?type=companyNews
296,"   By Toni Clarke | WASHINGTON  WASHINGTON U.S. lawmakers on Wednesday blasted Mylan NV Chief Executive Heather Bresch for sharply increasing prices for the EpiPen emergency allergy treatment at a congressional hearing in which Republicans and Democrats questioned the reasons behind rising U.S. drug costs.The House Committee on Oversight and Government Reform called Bresch to testify in the wake of public outrage over EpiPen, whose list price has risen to $600 for a pair of the devices compared with $100 in 2007.Lawmakers in turn described the actions as ""sickening,"" ""disgusting"" and showing ""blatant disrespect"" for American families who can no longer afford the life-saving device for children susceptible to severe allergic reactions. At several points, they cut off Bresch's efforts to explain the intricacies of U.S. pharmaceutical pricing, including how health insurers and other payers take a percentage of treatment sales.  Several lawmakers noted EpiPen's growing profits over the same period as well as Bresch's annual salary, which has increased from around $2.5 million to more than $18 million. They also faulted the U.S. Food and Drug Administration for moving too slowly to allow competing products to reach the market.U.S. Representative Elijah Cummings, ranking Democrat on the committee, said Mylan ""jacked up"" the price of the product ""to get filthy rich at the expense of our constituents."" He questioned whether Mylan would change course in any way following the backlash over its pricing.""After Mylan takes our punches they'll fly back to their mansions in their private jets and laugh all the way to the bank,"" Cummings said.Bresch defended the price hikes, saying that after rebates, marketing costs and other expenses, Mylan earns about $100 for a pair of EpiPens. She emphasized that the company plans a half-price version of the device, that it provides them free to many schools and said that Mylan's generic medications combined have saved the U.S. healthcare system $180 billion in costs over a decade.""Our concern was absolutely that anyone who needs an EpiPen has one,"" Bresch told the hearing. Mylan will also soon seek approval for a new formulation that extends the shelf life of EpiPen from 18 months to at least 24 months, cutting down replacement costs, Bresch said.  GROWING SCRUTINY      The EpiPen is an automatic injector, delivering a dose of the generic medicine epinephrine through a quick jab in the thigh. It commands over 90 percent of the market, with no competition expected until next year at the earliest. ""I am a very conservative, pro-business Republican, but I am really sickened by what I ... heard here today,"" Representative John J. Duncan Jr. of Tennessee said at Wednesday's hearing. The EpiPen price increases ignited a national controversy in August following complaints by families. Congressional lawmakers have called on federal agencies to investigate Mylans business practices. Several U.S. states are probing the impact of the price increases on government healthcare programs such as Medicaid. The pricing furor has hurt company shares, bringing them to a historically low valuation. [nL2N1BW14K]At the hearing, Committee Chairman Jason Chaffetz of Utah questioned why Mylan could now afford to offer a generic version of EpiPen for about $300. ""Suddenly, feeling the heat, Mylan has offered a generic version and cut the price in half, so that does beg the question what was happening with that other $300?""Holding up an EpiPen, he said: ""the actual juice that's in here that you need costs about a dollar.""   In 2015, EpiPen accounted for $1 billion of Mylan's overall sales of $9.45 billion and about 20 percent of company profit. Critics say EpiPen would remain profitable at a lower price.  A recent analysis by the consumer watchdog Public Citizen found that an EpiPen two-pack costs $69 in the United Kingdom, $181.81 in Canada and $210.21 in Germany.Lawmakers are trying to determine whether Mylan made more money on EpiPen than warranted from state Medicaid programs by having it classified as a generic product, resulting in much smaller rebates to the government health plans. The FDA classifies EpiPen as branded but the Centers for Medicare and Medicaid Services deems it a generic for the purposes of Medicaid's drug rebate program. Participating companies pay 13 percent in rebates on generic drugs versus 23 percent on branded products.Mylan has said it complied with all laws and regulations regarding rebates.EpiPen has also increased the cost burden to the Medicare program for the elderly, according to an analysis from the Kaiser Family Foundation, a health policy research group. Before rebates, EpiPen costs for Medicare Part D increased more than 1,000 percent between 2007 and 2014, from $7 million to $87.9 million, the report said.   (Additional reporting by Caroline Humer in New York)",2016-09-21,MYL,"Wed Sep 21, 2016 | 6:05pm EDT",U.S. lawmakers blast Mylan CEO over 'sickening' EpiPen price hikes,http://www.reuters.com//article/us-mylan-nl-epipen-congress-idUSKCN11R2OG?type=companyNews
297,"   By Toni Clarke | WASHINGTON  WASHINGTON U.S. lawmakers on Wednesday blasted Mylan NV Chief Executive Heather Bresch for sharply increasing prices for the EpiPen emergency allergy treatment at a congressional hearing in which Republicans and Democrats questioned the reasons behind rising U.S. drug costs.The House Committee on Oversight and Government Reform called Bresch to testify in the wake of public outrage over EpiPen, whose list price has risen to $600 for a pair of the devices compared with $100 in 2007.Lawmakers in turn described the actions as ""sickening,"" ""disgusting"" and showing ""blatant disrespect"" for American families who can no longer afford the life-saving device for children susceptible to severe allergic reactions. At several points, they cut off Bresch's efforts to explain the intricacies of U.S. pharmaceutical pricing, including how health insurers and other payers take a percentage of treatment sales.  Several lawmakers noted EpiPen's growing profits over the same period as well as Bresch's annual salary, which has increased from around $2.5 million to more than $18 million. They also faulted the U.S. Food and Drug Administration for moving too slowly to allow competing products to reach the market.U.S. Representative Elijah Cummings, ranking Democrat on the committee, said Mylan ""jacked up"" the price of the product ""to get filthy rich at the expense of our constituents."" He questioned whether Mylan would change course in any way following the backlash over its pricing.""After Mylan takes our punches they'll fly back to their mansions in their private jets and laugh all the way to the bank,"" Cummings said.Bresch defended the price hikes, saying that after rebates, marketing costs and other expenses, Mylan earns about $100 for a pair of EpiPens. She emphasized that the company plans a half-price version of the device, that it provides them free to many schools and said that Mylan's generic medications combined have saved the U.S. healthcare system $180 billion in costs over a decade.""Our concern was absolutely that anyone who needs an EpiPen has one,"" Bresch told the hearing. Mylan will also soon seek approval for a new formulation that extends the shelf life of EpiPen from 18 months to at least 24 months, cutting down replacement costs, Bresch said.  GROWING SCRUTINY      The EpiPen is an automatic injector, delivering a dose of the generic medicine epinephrine through a quick jab in the thigh. It commands over 90 percent of the market, with no competition expected until next year at the earliest. ""I am a very conservative, pro-business Republican, but I am really sickened by what I ... heard here today,"" Representative John J. Duncan Jr. of Tennessee said at Wednesday's hearing. The EpiPen price increases ignited a national controversy in August following complaints by families. Congressional lawmakers have called on federal agencies to investigate Mylans business practices. Several U.S. states are probing the impact of the price increases on government healthcare programs such as Medicaid. The pricing furor has hurt company shares, bringing them to a historically low valuation. [nL2N1BW14K]At the hearing, Committee Chairman Jason Chaffetz of Utah questioned why Mylan could now afford to offer a generic version of EpiPen for about $300. ""Suddenly, feeling the heat, Mylan has offered a generic version and cut the price in half, so that does beg the question what was happening with that other $300?""Holding up an EpiPen, he said: ""the actual juice that's in here that you need costs about a dollar.""   In 2015, EpiPen accounted for $1 billion of Mylan's overall sales of $9.45 billion and about 20 percent of company profit. Critics say EpiPen would remain profitable at a lower price.  A recent analysis by the consumer watchdog Public Citizen found that an EpiPen two-pack costs $69 in the United Kingdom, $181.81 in Canada and $210.21 in Germany.Lawmakers are trying to determine whether Mylan made more money on EpiPen than warranted from state Medicaid programs by having it classified as a generic product, resulting in much smaller rebates to the government health plans. The FDA classifies EpiPen as branded but the Centers for Medicare and Medicaid Services deems it a generic for the purposes of Medicaid's drug rebate program. Participating companies pay 13 percent in rebates on generic drugs versus 23 percent on branded products.Mylan has said it complied with all laws and regulations regarding rebates.EpiPen has also increased the cost burden to the Medicare program for the elderly, according to an analysis from the Kaiser Family Foundation, a health policy research group. Before rebates, EpiPen costs for Medicare Part D increased more than 1,000 percent between 2007 and 2014, from $7 million to $87.9 million, the report said.   (Additional reporting by Caroline Humer in New York)",2016-09-21,MYL,"Wed Sep 21, 2016 | 6:05pm EDT",U.S. lawmakers blast Mylan CEO over 'sickening' EpiPen price hikes,http://www.reuters.com//article/mylan-nl-epipen-congress-idUSL2N1BX2L3?type=companyNews
298,"  (Adds comments from CEO, lawmakers)By Toni ClarkeWASHINGTON, Sept 21 U.S. lawmakers on Wednesday blasted Mylan NV Chief Executive Heather Bresch for sharply increasing prices for the EpiPen emergency allergy treatment at a congressional hearing in which Republicans and Democrats questioned the reasons behind rising U.S. drug costs.The House Committee on Oversight and Government Reform called Bresch to testify in the wake of public outrage over EpiPen, whose list price has risen to $600 for a pair of the devices compared with $100 in 2007.Lawmakers in turn described the actions as ""sickening,"" ""disgusting"" and showing ""blatant disrespect"" for American families who can no longer afford the life-saving device for children susceptible to severe allergic reactions.At several points, they cut off Bresch's efforts to explain the intricacies of U.S. pharmaceutical pricing, including how health insurers and other payers take a percentage of treatment sales.Several lawmakers noted EpiPen's growing profits over the same period as well as Bresch's annual salary, which has increased from around $2.5 million to more than $18 million. They also faulted the U.S. Food and Drug Administration for moving too slowly to allow competing products to reach the market.U.S. Representative Elijah Cummings, ranking Democrat on the committee, said Mylan ""jacked up"" the price of the product ""to get filthy rich at the expense of our constituents."" He questioned whether Mylan would change course in any way following the backlash over its pricing.""After Mylan takes our punches they'll fly back to their mansions in their private jets and laugh all the way to the bank,"" Cummings said.Bresch defended the price hikes, saying that after rebates, marketing costs and other expenses, Mylan earns about $100 for a pair of EpiPens. She emphasized that the company plans a half-price version of the device, that it provides them free to many schools and said that Mylan's generic medications combined have saved the U.S. healthcare system $180 billion in costs over a decade. ""Our concern was absolutely that anyone who needs an EpiPen has one,"" Bresch told the hearing. Mylan will also soon seek approval for a new formulation that extends the shelf life of EpiPen from 18 months to at least 24 months, cutting down replacement costs, Bresch said.GROWING SCRUTINY The EpiPen is an automatic injector, delivering a dose of the generic medicine epinephrine through a quick jab in the thigh. It commands over 90 percent of the market, with no competition expected until next year at the earliest. ""I am a very conservative, pro-business Republican, but I am really sickened by what I ... heard here today,"" Representative John J. Duncan Jr. of Tennessee said at Wednesday's hearing.The EpiPen price increases ignited a national controversy in August following complaints by families. Congressional lawmakers have called on federal agencies to investigate Mylan's business practices.Several U.S. states are probing the impact of the price increases on government healthcare programs such as Medicaid. The pricing furor has hurt company shares, bringing them to a historically low valuation.At the hearing, Committee Chairman Jason Chaffetz of Utah questioned why Mylan could now afford to offer a generic version of EpiPen for about $300.""Suddenly, feeling the heat, Mylan has offered a generic version and cut the price in half, so that does beg the question what was happening with that other $300?"" Holding up an EpiPen, he said: ""the actual juice that's in here that you need costs about a dollar.""In 2015, EpiPen accounted for $1 billion of Mylan's overall sales of $9.45 billion and about 20 percent of company profit. Critics say EpiPen would remain profitable at a lower price.A recent analysis by the consumer watchdog Public Citizen found that an EpiPen two-pack costs $69 in the United Kingdom, $181.81 in Canada and $210.21 in Germany.Lawmakers are trying to determine whether Mylan made more money on EpiPen than warranted from state Medicaid programs by having it classified as a generic product, resulting in much smaller rebates to the government health plans.The FDA classifies EpiPen as branded but the Centers for Medicare and Medicaid Services deems it a generic for the purposes of Medicaid's drug rebate program. Participating companies pay 13 percent in rebates on generic drugs versus 23 percent on branded products.Mylan has said it complied with all laws and regulations regarding rebates.EpiPen has also increased the cost burden to the Medicare program for the elderly, according to an analysis from the Kaiser Family Foundation, a health policy research group. Before rebates, EpiPen costs for Medicare Part D increased more than 1,000 percent between 2007 and 2014, from $7 million to $87.9 million, the report said.(Reporting by Toni Clarke in Washington and Bill Berkrot in New York; Additional reporting by Caroline Humer in New York; Editing by Diane Craft and Matthew Lewis)",2016-09-21,MYL,"Wed Sep 21, 2016 | 5:44pm EDT",UPDATE 2-U.S. lawmakers blast Mylan CEO over 'sickening' EpiPen price hikes,http://www.reuters.com//article/mylan-nl-epipen-congress-idUSL2N1BX269?type=companyNews
299,"   By Toni Clarke | WASHINGTON, Sept 21  WASHINGTON, Sept 21 U.S. lawmakers on Wednesday blasted steep price increases for Mylan's EpiPen emergency allergy treatment as they grilled the company's Chief Executive Heather Bresch at a congressional hearing.The House Committee on Oversight and Government Reform called Bresch to testify after the company raised the list price for a pair of EpiPens to $600 compared with $100 in 2007, when it acquired the product.Congressman Elijah Cummings, ranking Democrat on the committee, said Mylan ""jacked up"" the price of the life-saving product ""to get filthy rich at the expense of our constituents."" ""After Mylan takes our punches they'll fly back to their mansions in their private jets and laugh all the way to the bank,"" Cummings said.The EpiPen is an automatic injector designed to treat life-threatening allergic reactions to anything from nuts to bee stings, delivering a dose of epinephrine through a quick jab in the thigh. The price increases ignited a national controversy in August, as a growing number of families protested and said they were unable to afford the device through their health insurance. Committee Chairman Jason Chaffetz of Utah noted that Mylan said it would soon sell a generic version of EpiPen for about $300. ""Suddenly feeling the heat Mylan has offered a generic version and cut the price in half, so that does beg the question what was happening with that other $300?""Holding up an EpiPen, he said: ""the actual juice that's in here that you need costs about a dollar.""(Reporting by Toni Clarke in Washington and Bill Berkrot in New York; Editing by Diane Craft)",2016-09-21,MYL,"Wed Sep 21, 2016 | 3:56pm EDT",U.S. lawmakers grill Mylan CEO over EpiPen steep price increases,http://www.reuters.com//article/mylan-nl-epipen-congress-idUSL2N1BX10A?type=companyNews
300,"   By Brendan Pierson | NEW YORK  NEW YORK Mylan NV (MYL.O) faced new scrutiny over price hikes for its anti-allergy EpiPen on Tuesday, with U.S. lawmakers calling for a probe of oversight of the companys rebates to government healthcare plans, while West Virginia said it was investigating whether Mylan defrauded its Medicaid department.    Mylan is grappling with a growing backlash from U.S. consumers, lawmakers and prosecutors over EpiPen prices, which have risen from about $100 in 2007 to more than $600 for a pair of the devices. The EpiPen delivers a dose of epinephrine, an antidote to a severe and potentially deadly allergic reaction to anything from nuts to bee stings.The rising cost has made it difficult for many families to afford EpiPens, prompting a public outcry that has resonated with legislators.    Mylan Chief Executive Heather Bresch is to testify about the price hikes on Wednesday before an oversight committee of the House of Representatives. Bresch is the daughter of Senator Joe Manchin, a Democrat from West Virginia.In her prepared testimony, released on Tuesday, Bresch said Mylan was already moving to address concerns about price by expanding discount programs and launching a $300 generic version.She said that, after rebates, fees and costs, the company makes only about $100 per EpiPen pack, and that a majority of consumers pay less than $50 out of pocket for a pack.     Ahead of the hearing, Republicans on the Senate Finance Committee said they were concerned that Mylan was allowed to inappropriately classify EpiPen as a generic drug, reducing the potential discounts to the governments Medicaid health program for the poor.    We are concerned that the controls in place, if any, are inadequate to ensure that Medicaid is receiving the full amount of rebates afforded to it by law, the Senate Republicans, led by Orrin Hatch of Utah, said in a letter to the U.S. Department of Health and Human Services Inspector General.    Under current law, branded drugs, and generic drugs available from a single source, are subject to a rebate of at least 23.1 percent of the average manufacturer price for Medicaid. Non-innovator drugs are subject to a much lower 13 percent rebate. The Finance Committee Republicans are asking Inspector General Daniel Levinson to examine the federal health agency's oversight of the rebate program.    Mylan has said it has complied with all laws and regulations regarding rebates.    Also on Tuesday, West Virginia Attorney General Patrick Morrisey said he was investigating the rebates and the possibility that Mylan violated the state's antitrust law when it sued and settled with a would-be generic competitor.    Mylan spokeswoman Nina Devlin said the company was cooperating with the investigation.     EpiPen has also posed a cost burden to the federal Medicare health program for the elderly, according to an analysis from the Kaiser Family Foundation, a health policy research group. Before rebates, EpiPen costs for Medicare Part D shot up more than 1,000 percent between 2007 and 2014, from $7 million to $87.9 million, the report said. Devlin, in an emailed statement, said that from 2010 to 2015, rebates to Medicare Part D plans were up 440 percent, which would reduce the increase stated by the Kaiser Family report. She said that any analysis that does not take those specific rebates into account is fundamentally flawed.While rebates to Medicare, which are not disclosed by the program, would have offset the cost to a degree, it was still far higher than a 164 percent increase in EpiPen prescriptions to Medicare patients, the Kaiser Family report said. (Reporting By Brendan Pierson and Caroline Humer in New York; Editing by Dan Grebler and Alan Crosby)",2016-09-21,MYL,"Wed Sep 21, 2016 | 3:45pm EDT",Senate Republicans seek probe of Mylan EpiPen oversight,http://www.reuters.com//article/us-mylan-nl-epipen-west-virginia-idUSKCN11Q25U?type=companyNews
301,"   By Lewis Krauskopf | NEW YORK  NEW YORK Shares of Mylan NV (MYL.O) are trading at historically low valuations as the company's chief executive officer is set to face a congressional grilling on Wednesday over the price of its EpiPen emergency allergy treatment. The stock is trading at 7.5 times estimated earnings for the next 12 months, holding near its lowest in at least 30 years and well below its five-year average of 11 times, according to Thomson Reuters Datastream.Since late August, when the EpiPen price increases came into the spotlight, Mylan shares have fallen about 15 percent. For the year, they are off about 23 percent, against a nearly 4 percent decline for the NYSE Arca Pharmaceutical index .DRG, a broad gauge of large and small drugmakers.A test for the shares looms on Wednesday, when Mylan CEO Heather Bresch testifies before the U.S. House of Representatives Oversight Committee over price increases of EpiPen, an auto-injector of allergy medicine.  The hearing will come the day after West Virginia disclosed an investigation into whether Mylan violated antitrust laws or defrauded the state's Medicaid program. A probe into EpiPen pricing by a U.S. Senate subcommittee was also announced on Sept. 7.The stock ""is just not working because of the overhang from all the headline stuff on EpiPen,"" said Guggenheim Securities analyst Louise Chen, who rates the shares ""neutral"".One concern among analysts is how fallout over EpiPen pricing will affect Mylan's roughly $1 billion in annual sales of the device.  Mylan said last month that it would introduce the first generic version of EpiPen for $300, half the price of the branded product, as it tries to quell the backlash. Further competition looms from Teva Pharmaceutical Industries (TEVA.TA), which hopes to start selling an EpiPen-like device by 2018.Chen also said investors were unsure of the benefits from Mylan's recently completed $7 billion acquisition of Swedish drugmaker Meda, which some had deemed expensive. Deutsche Bank analyst Gregg Gilbert stuck to his ""buy"" rating on Mylan stock earlier this month, noting its valuation. But in a research note, Gilbert cautioned: ""Investors will have little patience if execution falters on the base business and/or the newly acquired Meda business.""     (Reporting by Lewis Krauskopf; Editing by Lisa Von Ahn)",2016-09-21,MYL,"Tue Sep 20, 2016 | 10:18pm EDT",Mylan shares languish at low valuation as EpiPen hearing nears,http://www.reuters.com//article/us-usa-stocks-mylan-idUSKCN11Q2HZ?type=companyNews
302,"  NEW YORK U.S. government spending on Mylan Inc's (MYL.O) EpiPen in the Medicare program for seniors and the disabled rose 1,151 percent from 2007 through 2014, while the number of EpiPen users grew 164 percent, the Kaiser Family Foundation said on Tuesday in an analysis.The spending figure excludes after-market manufacturer rebates that Mylan paid to the private insurers who manage the Medicare Part D program for pharmacy drugs on behalf of the government, it said.In 2007, when Mylan purchased EpiPen, the Medicare program spent $7 million on the product for 79,980 users, Kaiser said. In 2014, that spending rose to $87.9 million for 211,500 users, Kaiser said.  Kaiser Family Foundation is a health policy research organization.       (Reporting by Caroline Humer; Editing by Alan Crosby)",2016-09-21,MYL,"Tue Sep 20, 2016 | 10:18pm EDT",Medicare EpiPen spending outpaces prescription growth: Kaiser report,http://www.reuters.com//article/us-mylan-nl-epipen-medicare-idUSKCN11Q2LM?type=companyNews
303,"   By Brendan Pierson | NEW YORK  NEW YORK Mylan NV (MYL.O) faced new scrutiny over price hikes for its anti-allergy EpiPen on Tuesday, with U.S. lawmakers calling for a probe of oversight of the companys rebates to government healthcare plans, while West Virginia said it was investigating whether Mylan defrauded its Medicaid department.    Mylan is grappling with a growing backlash from U.S. consumers, lawmakers and prosecutors over EpiPen prices, which have risen from about $100 in 2007 to more than $600 for a pair of the devices. The EpiPen delivers a dose of epinephrine, an antidote to a severe and potentially deadly allergic reaction to anything from nuts to bee stings.The rising cost has made it difficult for many families to afford EpiPens, prompting a public outcry that has resonated with legislators.    Mylan Chief Executive Heather Bresch is to testify about the price hikes on Wednesday before an oversight committee of the House of Representatives. Bresch is the daughter of Senator Joe Manchin, a Democrat from West Virginia.In her prepared testimony, released on Tuesday, Bresch said Mylan was already moving to address concerns about price by expanding discount programs and launching a $300 generic version.She said that, after rebates, fees and costs, the company makes only about $100 per EpiPen pack, and that a majority of consumers pay less than $50 out of pocket for a pack.     Ahead of the hearing, Republicans on the Senate Finance Committee said they were concerned that Mylan was allowed to inappropriately classify EpiPen as a generic drug, reducing the potential discounts to the governments Medicaid health program for the poor.    We are concerned that the controls in place, if any, are inadequate to ensure that Medicaid is receiving the full amount of rebates afforded to it by law, the Senate Republicans, led by Orrin Hatch of Utah, said in a letter to the U.S. Department of Health and Human Services Inspector General.    Under current law, branded drugs, and generic drugs available from a single source, are subject to a rebate of at least 23.1 percent of the average manufacturer price for Medicaid. Non-innovator drugs are subject to a much lower 13 percent rebate. The Finance Committee Republicans are asking Inspector General Daniel Levinson to examine the federal health agency's oversight of the rebate program.    Mylan has said it has complied with all laws and regulations regarding rebates.    Also on Tuesday, West Virginia Attorney General Patrick Morrisey said he was investigating the rebates and the possibility that Mylan violated the state's antitrust law when it sued and settled with a would-be generic competitor.    Mylan spokeswoman Nina Devlin said the company was cooperating with the investigation.     EpiPen has also posed a cost burden to the federal Medicare health program for the elderly, according to an analysis from the Kaiser Family Foundation, a health policy research group. Before rebates, EpiPen costs for Medicare Part D shot up more than 1,000 percent between 2007 and 2014, from $7 million to $87.9 million, the report said. Devlin, in an emailed statement, said that from 2010 to 2015, rebates to Medicare Part D plans were up 440 percent, which would reduce the increase stated by the Kaiser Family report. She said that any analysis that does not take those specific rebates into account is fundamentally flawed.While rebates to Medicare, which are not disclosed by the program, would have offset the cost to a degree, it was still far higher than a 164 percent increase in EpiPen prescriptions to Medicare patients, the Kaiser Family report said. (Reporting By Brendan Pierson and Caroline Humer in New York; Editing by Dan Grebler and Alan Crosby)",2016-09-21,MYL,"Wed Sep 21, 2016 | 3:45pm EDT",UPDATE 4-Senate Republicans seek probe of Mylan EpiPen oversight,http://www.reuters.com//article/mylan-nl-epipen-west-virginia-idUSL2N1BW18K?type=companyNews
304,"   By Dave McKinney | CHICAGO  CHICAGO When Mylan NV recruited food allergy bloggers to learn about its campaign to get allergic shock antidotes into schools, many were eager to join the maker of the EpiPens they carry in purses and stash in book bags to protect their children against potentially lethal attacks.The bloggers, more than a dozen mothers of children with serious allergies, embraced the effort Mylan outlined in a series of ""summits"" it held for them beginning in 2013.They wrote impassioned posts on blogs shared with tens of thousands of followers on social media. Their personal testimony helped persuade a number of state lawmakers to pass bills to get schools to stock epinephrine injectors, such as the EpiPen, according to legislators and others familiar with the lobbying effort.During the same period, the company was marking up its EpiPen to more than $600 per twin pack, six times the 2007 price, creating a burden for many of the bloggers' followers, other parents of children whose lives are threatened by bee stings and peanuts.At least four of the bloggers told Reuters they believe Mylan took advantage of their goodwill. Some have joined public criticism of those price hikes.""I personally believe that Mylan held the summits to gain blogger trust and then used those bloggers to spread word about their initiatives. They raised prices while those initiatives gained traction,"" Ruth LovettSmith, a former food-allergy blogger from Massachusetts who attended three summits, said in an email.Mylan spokeswoman Lauren Kashtan declined to comment on the criticism.But in an email, she said the company regretted that it had not anticipated ""the potential financial issues for the growing minority of patients"" whose EpiPens are not covered by insurance or a patient assistance program.Mylan now offers coupons to more families to cover out-of-pocket costs and said it would soon release a half-price EpiPen.Kashtan also said the blogger summits served a worthy purpose.""Mylan aimed to provide access to information, resources and expertise about anaphylaxis and life-threatening allergies,"" said Kashtan, who represented the company at four summits. ""We are proud to have brought together such a passionate and dedicated group of advocates.""Chief executive Heather Bresch was blasted Wednesday at a hearing before U.S. lawmakers who, along with prosecutors in several states, are investigating the price hikes.EpiPen sales exceed $1 billion a year and command more than 90 percent of the market. STEAKS AND BLOG POLISHING Theeffort to get epinephrine injectors into schools is a point of pride for Mylan, which has credited its alliances with advocates for its success.""We have collaborated with government officials, leading advocacy organizations, parents, caregivers and healthcare professionals to successfully champion legislation and policies,"" Mylan said in a 2015 report on its social responsibility efforts.LovettSmith, whose son has nut allergies, went to her first Mylan blogger summit in January 2013 at a boutique midtown Manhattan hotel overlooking the Empire State Building.It was the first of at least four summits, each involving about 15 bloggers, some of whom attended more than one event. They wrote about being treated to three-course dinners featuring pan-seared yellow fin tuna or marinated grilled hanger steak. At a 2014 summit at the company's Canonsburg, Pa., headquarters, Mylan brought an outside communications consultant to help the women polish their blogs, advocate to policymakers, practice on-camera television interviews and speak at public events,participants told Reuters.Homa Woodrum, a lawyer in Las Vegas whose 8-year-old daughter relies on EpiPens for nut and oat allergies, attended that summit. But she skipped an invitation to a May 2015 event at California's Disneyland, uncomfortable with the shift in venue to a resort.""It starts to seem a little like you're being buttered up,"" Woodrum said.Bloggers who attended summits testified on behalf of schools' bills in Nevada, Maine and Michigan, according to interviews and legislative records. In all, 48 states adopted laws requiring or enabling schools to stock epinephrine injectors. In many cases, Mylan subsequently donated EpiPens to schools.Stanley Short, a Democratic representative who co-sponsored the Maine bill, credited a blogger with alerting him to the issue. The woman, who attended the Disneyland summit, brought her son to a legislative hearing, where he demonstrated how he would press an EpiPen into his thigh to stop an allergic reaction.Mylan's lobbyist attended the hearing, but the boy's show-and-tell ""sealed the deal,"" Short said. ""With me and most of the legislators, it's that first-hand experience of a mother talking about her child and a child talking about what they go through personally that did it."" MIXED REACTIONS Bloggers who went to Disneyland told Reuters pricing was not on the drugmaker's agenda. By then, some were aware of the hikes and brought them up. Mylan talked about the role of other parties, including insurers, in determining what consumers pay, they said.Blogger Kelly Rudnicki's food allergy advocacy led to work as a paid Mylan spokeswoman. But, she said in an email, she quit last month because of the pricing controversy. She said she believes Mylan should apologize and cut its prices on EpiPens, and Bresch should step down.Rudnicki, whose 14-year-old son has severe food allergies, said the bloggers supported Mylan because they believed it ""had our back and manufactured a device that we couldn't live without.""Mylan declined to discuss Rudnicki's criticism. The company confirmed she resigned, adding it had thanked her for her work.Some bloggers like Caroline Moassessi, a food allergy activist from Reno, Nev., take a more nuanced view.She attended three summits and testified in Nevada to allow schools and other public venues to stock epinephrine.She also has felt the full effect of price hikes. As a small business owner, she paid $3,000 in 2015 for EpiPens for her son and daughter. Each child carries two pens at all times and keeps two more at school. Moassessi also carries two injectors.While Moassessi would rather pay less, she said she recognizes that Mylan is in business to make a profit.""I know they're a business trying to make as much as they can, like Ford, Chevy, Macy's,"" she said. ""I'm not naive about that, whatsoever."" (Reporting by Dave McKinney; Editing by Michele Gershberg and Lisa Girion)",2016-09-23,MYL,"Fri Sep 23, 2016 | 12:04pm EDT",Parent bloggers question role in Mylans EpiPen schools push,http://www.reuters.com//article/us-mylan-epipen-bloggers-idUSKCN11T0EJ?type=companyNews
305,"  (Repeating for additional clients with no changes to text)By Dave McKinneyCHICAGO, Sept 23 When Mylan NV recruited food allergy bloggers to learn about its campaign to get allergic shock antidotes into schools, many were eager to join the maker of the EpiPens they carry in purses and stash in book bags to protect their children against potentially lethal attacks.The bloggers, more than a dozen mothers of children with serious allergies, embraced the effort Mylan outlined in a series of ""summits"" it held for them beginning in 2013.They wrote impassioned posts on blogs shared with tens of thousands of followers on social media. Their personal testimony helped persuade a number of state lawmakers to pass bills to get schools to stock epinephrine injectors, such as the EpiPen, according to legislators and others familiar with the lobbying effort.During the same period, the company was marking up its EpiPen to more than $600 per twin pack, six times the 2007 price, creating a burden for many of the bloggers' followers, other parents of children whose lives are threatened by bee stings and peanuts.At least four of the bloggers told Reuters they believe Mylan took advantage of their goodwill. Some have joined public criticism of those price hikes.""I personally believe that Mylan held the summits to gain blogger trust and then used those bloggers to spread word about their initiatives. They raised prices while those initiatives gained traction,"" Ruth LovettSmith, a former food-allergy blogger from Massachusetts who attended three summits, said in an email.Mylan spokeswoman Lauren Kashtan declined to comment on the criticism.But in an email, she said the company regretted that it had not anticipated ""the potential financial issues for the growing minority of patients"" whose EpiPens are not covered by insurance or a patient assistance program.Mylan now offers coupons to more families to cover out-of-pocket costs and said it would soon release a half-price EpiPen.Kashtan also said the blogger summits served a worthy purpose.""Mylan aimed to provide access to information, resources and expertise about anaphylaxis and life-threatening allergies,"" said Kashtan, who represented the company at four summits. ""We are proud to have brought together such a passionate and dedicated group of advocates."" Chief executive Heather Bresch was blasted Wednesday at a hearing before U.S. lawmakers who, along with prosecutors in several states, are investigating the price hikes.EpiPen sales exceed $1 billion a year and command more than 90 percent of the market.STEAKS AND BLOG POLISHING The effort to get epinephrine injectors into schools is a point of pride for Mylan, which has credited its alliances with advocates for its success.""We have collaborated with government officials, leading advocacy organizations, parents, caregivers and healthcare professionals to successfully champion legislation and policies,"" Mylan said in a 2015 report on its social responsibility efforts.LovettSmith, whose son has nut allergies, went to her first Mylan blogger summit in January 2013 at a boutique midtown Manhattan hotel overlooking the Empire State Building. It was the first of at least four summits, each involving about 15 bloggers, some of whom attended more than one event. They wrote about being treated to three-course dinners featuring pan-seared yellow fin tuna or marinated grilled hanger steak.At a 2014 summit at the company's Canonsburg, Pa., headquarters, Mylan brought an outside communications consultant to help the women polish their blogs, advocate to policymakers, practice on-camera television interviews and speak at public events, participants told Reuters.Homa Woodrum, a lawyer in Las Vegas whose 8-year-old daughter relies on EpiPens for nut and oat allergies, attended that summit. But she skipped an invitation to a May 2015 event at California's Disneyland, uncomfortable with the shift in venue to a resort.""It starts to seem a little like you're being buttered up,"" Woodrum said.Bloggers who attended summits testified on behalf of schools' bills in Nevada, Maine and Michigan, according to interviews and legislative records. In all, 48 states adopted laws requiring or enabling schools to stock epinephrine injectors. In many cases, Mylan subsequently donated EpiPens to schools.Stanley Short, a Democratic representative who co-sponsored the Maine bill, credited a blogger with alerting him to the issue. The woman, who attended the Disneyland summit, brought her son to a legislative hearing, where he demonstrated how he would press an EpiPen into his thigh to stop an allergic reaction. Mylan's lobbyist attended the hearing, but the boy's show-and-tell ""sealed the deal,"" Short said. ""With me and most of the legislators, it's that first-hand experience of a mother talking about her child and a child talking about what they go through personally that did it.""MIXED REACTIONS Bloggers who went to Disneyland told Reuters pricing was not on the drugmaker's agenda. By then, some were aware of the hikes and brought them up. Mylan talked about the role of other parties, including insurers, in determining what consumers pay, they said.Blogger Kelly Rudnicki's food allergy advocacy led to work as a paid Mylan spokeswoman. But, she said in an email, she quit last month because of the pricing controversy. She said she believes Mylan should apologize and cut its prices on EpiPens, and Bresch should step down.Rudnicki, whose 14-year-old son has severe food allergies, said the bloggers supported Mylan because they believed it ""had our back and manufactured a device that we couldn't live without.""Mylan declined to discuss Rudnicki's criticism. The company confirmed she resigned, adding it had thanked her for her work.Some bloggers like Caroline Moassessi, a food allergy activist from Reno, Nev., take a more nuanced view.She attended three summits and testified in Nevada to allow schools and other public venues to stock epinephrine.She also has felt the full effect of price hikes. As a small business owner, she paid $3,000 in 2015 for EpiPens for her son and daughter. Each child carries two pens at all times and keeps two more at school. Moassessi also carries two injectors.While Moassessi would rather pay less, she said she recognizes that Mylan is in business to make a profit.""I know they're a business trying to make as much as they can, like Ford, Chevy, Macy's,"" she said. ""I'm not naive about that, whatsoever.""   (Reporting by Dave McKinney; Editing by Michele Gershberg and Lisa Girion)",2016-09-23,MYL,"Fri Sep 23, 2016 | 7:00am EDT",Parent bloggers question role in Mylan's EpiPen schools push,http://www.reuters.com//article/mylan-epipen-bloggers-idUSL2N1BY2AQ?type=companyNews
306,"   By Dave McKinney | CHICAGO  CHICAGO When Mylan NV recruited food allergy bloggers to learn about its campaign to get allergic shock antidotes into schools, many were eager to join the maker of the EpiPens they carry in purses and stash in book bags to protect their children against potentially lethal attacks.The bloggers, more than a dozen mothers of children with serious allergies, embraced the effort Mylan outlined in a series of ""summits"" it held for them beginning in 2013.They wrote impassioned posts on blogs shared with tens of thousands of followers on social media. Their personal testimony helped persuade a number of state lawmakers to pass bills to get schools to stock epinephrine injectors, such as the EpiPen, according to legislators and others familiar with the lobbying effort.During the same period, the company was marking up its EpiPen to more than $600 per twin pack, six times the 2007 price, creating a burden for many of the bloggers' followers, other parents of children whose lives are threatened by bee stings and peanuts.At least four of the bloggers told Reuters they believe Mylan took advantage of their goodwill. Some have joined public criticism of those price hikes.""I personally believe that Mylan held the summits to gain blogger trust and then used those bloggers to spread word about their initiatives. They raised prices while those initiatives gained traction,"" Ruth LovettSmith, a former food-allergy blogger from Massachusetts who attended three summits, said in an email.Mylan spokeswoman Lauren Kashtan declined to comment on the criticism.But in an email, she said the company regretted that it had not anticipated ""the potential financial issues for the growing minority of patients"" whose EpiPens are not covered by insurance or a patient assistance program.Mylan now offers coupons to more families to cover out-of-pocket costs and said it would soon release a half-price EpiPen.Kashtan also said the blogger summits served a worthy purpose.""Mylan aimed to provide access to information, resources and expertise about anaphylaxis and life-threatening allergies,"" said Kashtan, who represented the company at four summits. ""We are proud to have brought together such a passionate and dedicated group of advocates.""Chief executive Heather Bresch was blasted Wednesday at a hearing before U.S. lawmakers who, along with prosecutors in several states, are investigating the price hikes.EpiPen sales exceed $1 billion a year and command more than 90 percent of the market. STEAKS AND BLOG POLISHING Theeffort to get epinephrine injectors into schools is a point of pride for Mylan, which has credited its alliances with advocates for its success.""We have collaborated with government officials, leading advocacy organizations, parents, caregivers and healthcare professionals to successfully champion legislation and policies,"" Mylan said in a 2015 report on its social responsibility efforts.LovettSmith, whose son has nut allergies, went to her first Mylan blogger summit in January 2013 at a boutique midtown Manhattan hotel overlooking the Empire State Building.It was the first of at least four summits, each involving about 15 bloggers, some of whom attended more than one event. They wrote about being treated to three-course dinners featuring pan-seared yellow fin tuna or marinated grilled hanger steak. At a 2014 summit at the company's Canonsburg, Pa., headquarters, Mylan brought an outside communications consultant to help the women polish their blogs, advocate to policymakers, practice on-camera television interviews and speak at public events,participants told Reuters.Homa Woodrum, a lawyer in Las Vegas whose 8-year-old daughter relies on EpiPens for nut and oat allergies, attended that summit. But she skipped an invitation to a May 2015 event at California's Disneyland, uncomfortable with the shift in venue to a resort.""It starts to seem a little like you're being buttered up,"" Woodrum said.Bloggers who attended summits testified on behalf of schools' bills in Nevada, Maine and Michigan, according to interviews and legislative records. In all, 48 states adopted laws requiring or enabling schools to stock epinephrine injectors. In many cases, Mylan subsequently donated EpiPens to schools.Stanley Short, a Democratic representative who co-sponsored the Maine bill, credited a blogger with alerting him to the issue. The woman, who attended the Disneyland summit, brought her son to a legislative hearing, where he demonstrated how he would press an EpiPen into his thigh to stop an allergic reaction.Mylan's lobbyist attended the hearing, but the boy's show-and-tell ""sealed the deal,"" Short said. ""With me and most of the legislators, it's that first-hand experience of a mother talking about her child and a child talking about what they go through personally that did it."" MIXED REACTIONS Bloggers who went to Disneyland told Reuters pricing was not on the drugmaker's agenda. By then, some were aware of the hikes and brought them up. Mylan talked about the role of other parties, including insurers, in determining what consumers pay, they said.Blogger Kelly Rudnicki's food allergy advocacy led to work as a paid Mylan spokeswoman. But, she said in an email, she quit last month because of the pricing controversy. She said she believes Mylan should apologize and cut its prices on EpiPens, and Bresch should step down.Rudnicki, whose 14-year-old son has severe food allergies, said the bloggers supported Mylan because they believed it ""had our back and manufactured a device that we couldn't live without.""Mylan declined to discuss Rudnicki's criticism. The company confirmed she resigned, adding it had thanked her for her work.Some bloggers like Caroline Moassessi, a food allergy activist from Reno, Nev., take a more nuanced view.She attended three summits and testified in Nevada to allow schools and other public venues to stock epinephrine.She also has felt the full effect of price hikes. As a small business owner, she paid $3,000 in 2015 for EpiPens for her son and daughter. Each child carries two pens at all times and keeps two more at school. Moassessi also carries two injectors.While Moassessi would rather pay less, she said she recognizes that Mylan is in business to make a profit.""I know they're a business trying to make as much as they can, like Ford, Chevy, Macy's,"" she said. ""I'm not naive about that, whatsoever."" (Reporting by Dave McKinney; Editing by Michele Gershberg and Lisa Girion)",2016-09-23,MYL,"Fri Sep 23, 2016 | 12:04pm EDT",Parent bloggers question role in Mylan's EpiPen schools push,http://www.reuters.com//article/mylan-epipen-bloggers-idUSL2N1BX2J5?type=companyNews
307,"   By Toni Clarke and Natalie Grover  Mylan NV (MYL.O) faced questions on Monday about the profit on its EpiPen emergency allergy treatment, following a report that the company makes 60 percent more on the injector than it had told Congress.Mylan has been widely criticized for sharply raising the price of EpiPens, which are carried by people with life-threatening allergies. Mylan, which acquired the product in 2007, has raised the list price for a pair of EpiPens to $600 from about $100 in 2008.Lawmakers are trying to determine whether Mylan made more money on EpiPen than warranted from state Medicaid programs by having it classified as a generic product, resulting in much smaller rebates to the government health plans.Mylan Chief Executive Heather Bresch testified last week under oath that Mylan pockets roughly $100 for a two-pen pack. She did not state that the figure included taxes, which the company acknowledged on Monday.The Wall Street Journal reported on Monday that Mylan had significantly reduced its calculation of EpiPen profits by applying the statutory U.S. tax rate of 37.5 percent. Mylan's overall effective tax rate was 7.4 percent in 2015 and 4.2 percent in 2014, according to annual regulatory filings.Lawmakers on the House Committee on Oversight and Government Reform last week excoriated Bresch for raising the price of EpiPen sixfold since 2008 and were skeptical of her profit analysis.""We didn't believe Mylan's numbers last week during their CEO's testimony, and we don't believe them this week either,"" Representative Elijah Cummings, the ranking Democrat on the committee, said in a statement on Monday. Mylan said on Monday it was standard practice to include taxes in a profitability analysis and to use the U.S. statutory rate when analyzing income in that country. It filed a copy of the analysis with the U.S. Securities and Exchange Commission on Monday.""Just as we did not use a blended global tax rate, we also did not allocate corporate expenses associated with running the business, which would have further reduced its profitability,"" Nina Devlin, a Mylan spokeswoman, said in an email. Mylan has tried to stem criticism by offering more discounts to consumers. An increasing number of families have said that the treatment has become unaffordable. It plans shortly to market a half-price generic EpiPen.Mylan's U.S. EpiPen profit is expected to reach $419 million in 2016, according to the company's regulatory filing, up from $3 million in 2008. It estimated sales of 8 million pens in 2016, up from 4.3 million in 2008. (Reporting by Toni Clarke in Washington and Natalie Grover in Bengaluru; Editing by Michele Gershberg and Richard Chang)",2016-09-26,MYL,"Mon Sep 26, 2016 | 3:39pm EDT",Mylan faces scrutiny over EpiPen profit data shown to Congress,http://www.reuters.com//article/us-mylan-nl-epipen-idUSKCN11W21F?type=companyNews
308,"  Sept 26 Mylan Nv :* Mylan NV sees 2016 sales for EpiPen in U.S. $1,100 MLN - SEC Filing* Says in U.S., sees EpiPen 2016 estimated gross profit of $825 million - SEC Filing * For EpiPen , sees 8 million U.S. Pens sold in 2016 * Sees 2016 EpiPen operating profit in U.S. (not all regions) of $671 million versus reported 2015 operating profit of $498 million * ""Does not intend in the future to provide product level profitabilty analysis for EpiPen ""* Sees 2016 EpiPen net product profitability in U.S. (not all regions) of $419 million versus reported net product profitability for EpiPen of $312 million in 2015  Source text - bit.ly/2cFNVh2 Further company coverage:",2016-09-26,MYL,"Mon Sep 26, 2016 | 1:03pm EDT","BRIEF-Mylan NV sees 2016 sales for EpiPen in U.S. of $1,100 mln - SEC Filing",http://www.reuters.com//article/idUSL8N1C24SS?type=companyNews
309,"  Sept 26 Under fire generic drugmaker Mylan NV  reiterated it makes a net profit of $104, after taxes, for a pair of its EpiPen emergency allergy treatment sold in the United States, the company said in a filing on Monday.The unexpected filing comes after the Wall Street Journal reported earlier in the day that the company substantially reduced its calculation of EpiPen profits by applying the statutory U.S. tax rate of 37.5 percent during a congressional hearing on Wednesday. (bit.ly/2dmnPhw) U.S. lawmakers at the hearing lambasted Mylan Chief Executive Heather Bresch for sharply increasing prices for the  treatment to $600 for a pair from $100 in 2007.  ""Without the tax-related reduction, Mylan's profits on the EpiPen two-pack would be closer to $160, or 60 percent higher than the figure the company gave Congress,"" the WSJ report said.   (Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb Chakrabarty)",2016-09-26,MYL,"Mon Sep 26, 2016 | 12:58pm EDT",Mylan reiterates profit on EpiPen two-pack in US,http://www.reuters.com//article/mylan-nl-epipen-idUSL3N1C24B8?type=companyNews
310,"   By Diane Bartz | WASHINGTON  WASHINGTON A U.S. federal health agency said on Wednesday it had ""expressly advised"" Mylan NV (MYL.O) that the drugmaker had improperly classified its EpiPen emergency allergy treatment in a way that allowed it to pay lower rebates to state health programs.The disclosure comes as U.S. lawmakers and prosecutors are investigating Mylan over steep price hikes for the EpiPen device which have rendered the drug unaffordable for a growing number of families. A least one state has launched an investigation into whether Mylan failed to pay proper rebates to the Medicaid program for the poor.The Centers for Medicare and Medicaid Services, or CMS, said in a statement it had ""on multiple occasions, provided guidance to the industry and Mylan on the proper classification of drugs and has expressly advised Mylan that their classification of EpiPen for purposes of the Medicaid Drug Rebate program was incorrect.""CMS, part of the U.S. Department of Health and Human Services, declined to say what action it took to push for the misclassification to be corrected or when it spoke to Mylan. Mylan classified EpiPen with the Medicaid Drug Rebate Program as a generic treatment, which provides a rebate of 13 percent to state Medicaid programs, rather than as a branded drug, which pays a minimum rebate of 23.1 percent. Mylan has said it complied with CMS rules. The company did not immediately respond to requests for comment on the CMS statement. Mylan has been heavily criticized for sharply raising the price of EpiPen devices, which are carried by people with life-threatening allergies. Mylan acquired the product in 2007 and has raised the list price for a pair of EpiPens to $600 from about $100 in 2008.Earlier on Wednesday, U.S. Senators Richard Blumenthal, Charles Grassley and Amy Klobuchar asked the U.S. Department of Justice to investigate a possible misclassification. ""The facts ... suggest that Mylan may have knowingly misclassified EpiPens, potentially in violation of the False Claims Act and other statutes,"" the lawmakers said in a letter to Attorney General Loretta Lynch. The False Claims Act is used to pursue companies that defraud the federal government. (Editing by Alan Crosby and Matthew Lewis)",2016-09-28,MYL,"Wed Sep 28, 2016 | 8:00pm EDT",U.S. agency told Mylan that EpiPen was misclassified,http://www.reuters.com//article/us-congress-mylan-nl-idUSKCN11Y1X5?type=companyNews
311,"   By Diane Bartz | WASHINGTON  WASHINGTON A U.S. federal health agency said on Wednesday it had ""expressly advised"" Mylan NV (MYL.O) that the drugmaker had improperly classified its EpiPen emergency allergy treatment in a way that allowed it to pay lower rebates to state health programs.The disclosure comes as U.S. lawmakers and prosecutors are investigating Mylan over steep price hikes for the EpiPen device which have rendered the drug unaffordable for a growing number of families. A least one state has launched an investigation into whether Mylan failed to pay proper rebates to the Medicaid program for the poor.The Centers for Medicare and Medicaid Services, or CMS, said in a statement it had ""on multiple occasions, provided guidance to the industry and Mylan on the proper classification of drugs and has expressly advised Mylan that their classification of EpiPen for purposes of the Medicaid Drug Rebate program was incorrect.""CMS, part of the U.S. Department of Health and Human Services, declined to say what action it took to push for the misclassification to be corrected or when it spoke to Mylan. Mylan classified EpiPen with the Medicaid Drug Rebate Program as a generic treatment, which provides a rebate of 13 percent to state Medicaid programs, rather than as a branded drug, which pays a minimum rebate of 23.1 percent. Mylan has said it complied with CMS rules. The company did not immediately respond to requests for comment on the CMS statement. Mylan has been heavily criticized for sharply raising the price of EpiPen devices, which are carried by people with life-threatening allergies. Mylan acquired the product in 2007 and has raised the list price for a pair of EpiPens to $600 from about $100 in 2008.Earlier on Wednesday, U.S. Senators Richard Blumenthal, Charles Grassley and Amy Klobuchar asked the U.S. Department of Justice to investigate a possible misclassification. ""The facts ... suggest that Mylan may have knowingly misclassified EpiPens, potentially in violation of the False Claims Act and other statutes,"" the lawmakers said in a letter to Attorney General Loretta Lynch. The False Claims Act is used to pursue companies that defraud the federal government. (Editing by Alan Crosby and Matthew Lewis)",2016-09-28,MYL,"Wed Sep 28, 2016 | 8:00pm EDT",UPDATE 2-U.S. agency told Mylan that EpiPen was misclassified,http://www.reuters.com//article/mylan-nl-epipen-idUSL2N1C41II?type=companyNews
312,"  WASHINGTON A U.S. health agency said on Wednesday it had ""expressly advised"" Mylan  that the company had misclassified the EpiPen in a way that led to the company paying a lower rebate to states.The Centers for Medicare and Medicaid Services, part of the U.S. Department of Health and Human Services, said in a statement it has ""on multiple occasions, provided guidance to the industry and Mylan on the proper classification of drugs and has expressly advised Mylan that their classification of EpiPen for purposes of the Medicaid Drug Rebate program was incorrect."" Mylan classified the EpiPen with the Medicaid Drug Rebate Program as a non-innovator multiple source drug, which pays a rebate of 13 percent to states, rather than innovator, which pays a rebate of a minimum of 23.1 percent.   (Reporting by Diane Bartz; Editing by David Gregorio)",2016-09-28,MYL,"Wed Sep 28, 2016 | 5:17pm EDT",U.S. agency says it advised Mylan that EpiPen was misclassified,http://www.reuters.com//article/us-mylan-nl-epipen-cms-idUSKCN11Y2YZ?type=companyNews
313,"  WASHINGTON A U.S. health agency said on Wednesday it had ""expressly advised"" Mylan  that the company had misclassified the EpiPen in a way that led to the company paying a lower rebate to states.The Centers for Medicare and Medicaid Services, part of the U.S. Department of Health and Human Services, said in a statement it has ""on multiple occasions, provided guidance to the industry and Mylan on the proper classification of drugs and has expressly advised Mylan that their classification of EpiPen for purposes of the Medicaid Drug Rebate program was incorrect."" Mylan classified the EpiPen with the Medicaid Drug Rebate Program as a non-innovator multiple source drug, which pays a rebate of 13 percent to states, rather than innovator, which pays a rebate of a minimum of 23.1 percent.   (Reporting by Diane Bartz; Editing by David Gregorio)",2016-09-28,MYL,"Wed Sep 28, 2016 | 5:17pm EDT",U.S. agency says it advised Mylan that EpiPen was misclassified,http://www.reuters.com//article/mylan-nl-epipen-cms-idUSL2N1C42BS?type=companyNews
314,"   By Diane Bartz | WASHINGTON  WASHINGTON A U.S. federal health agency said on Wednesday it had ""expressly advised"" Mylan NV (MYL.O) that the drugmaker had improperly classified its EpiPen emergency allergy treatment in a way that allowed it to pay lower rebates to state health programs.The disclosure comes as U.S. lawmakers and prosecutors are investigating Mylan over steep price hikes for the EpiPen device which have rendered the drug unaffordable for a growing number of families. A least one state has launched an investigation into whether Mylan failed to pay proper rebates to the Medicaid program for the poor.The Centers for Medicare and Medicaid Services, or CMS, said in a statement it had ""on multiple occasions, provided guidance to the industry and Mylan on the proper classification of drugs and has expressly advised Mylan that their classification of EpiPen for purposes of the Medicaid Drug Rebate program was incorrect.""CMS, part of the U.S. Department of Health and Human Services, declined to say what action it took to push for the misclassification to be corrected or when it spoke to Mylan. Mylan classified EpiPen with the Medicaid Drug Rebate Program as a generic treatment, which provides a rebate of 13 percent to state Medicaid programs, rather than as a branded drug, which pays a minimum rebate of 23.1 percent. Mylan has said it complied with CMS rules. The company did not immediately respond to requests for comment on the CMS statement. Mylan has been heavily criticized for sharply raising the price of EpiPen devices, which are carried by people with life-threatening allergies. Mylan acquired the product in 2007 and has raised the list price for a pair of EpiPens to $600 from about $100 in 2008.Earlier on Wednesday, U.S. Senators Richard Blumenthal, Charles Grassley and Amy Klobuchar asked the U.S. Department of Justice to investigate a possible misclassification. ""The facts ... suggest that Mylan may have knowingly misclassified EpiPens, potentially in violation of the False Claims Act and other statutes,"" the lawmakers said in a letter to Attorney General Loretta Lynch. The False Claims Act is used to pursue companies that defraud the federal government. (Editing by Alan Crosby and Matthew Lewis)",2016-09-29,MYL,"Wed Sep 28, 2016 | 8:00pm EDT",U.S. agency told Mylan that EpiPen was misclassified,http://www.reuters.com//article/us-congress-mylan-nl-idUSKCN11Y1X5?type=companyNews
315,  Sept 30 Mylan NV* Mylan launches generic Fortamet tablets  * Received final approval from U.S. FDA for its abbreviated new drug application for metformin hydrochloride extended-release tablets USP  Source text for Eikon:  Further company coverage: ,2016-09-30,MYL,"Fri Sep 30, 2016 | 10:04am EDT",BRIEF-Mylan launches generic Fortamet tablets,http://www.reuters.com//article/idUSASC099TA?type=companyNews
316,"   By Brendan Pierson  A Johnson & Johnson unit and Gilead Sciences Inc can pursue a lawsuit seeking to stop Mylan NV from making a generic version of Gilead's HIV drug Complera in Delaware federal court, a judge has ruled. U.S. District Judge Sue Robinson in Delaware on Thursday rejected Mylan's argument that the case should proceed in U.S. District Court for the Northern District of West Virginia, where one of the two Mylan subsidiaries named as defendants is incorporated and where it is facing a nearly identical lawsuit, denying Mylan's motion to dismiss.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2deXFj4",2016-09-30,MYL,"Fri Sep 30, 2016 | 7:05am EDT",Lawsuit over generic HIV drug can stay in Delaware - judge,http://www.reuters.com//article/health-complera-idUSL2N1C60E0?type=companyNews
317,"   By Deena Beasley  Mylan NV (MYL.O) on Friday said it will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment, which has come under intense scrutiny after a series of drastic price increases.Mylan has been lambasted by consumers and lawmakers for raising prices on the lifesaving EpiPen sixfold to over $600 for a package of two in less than a decade, making the devices unaffordable for a growing number of families.Lawmakers were trying to determine whether Mylan made more money on EpiPen than warranted from state Medicaid programs by having it classified as a generic product, resulting in much smaller rebates to the government health plans.Mylan Chief Executive Heather Bresch was grilled by the House Committee on Oversight and Government Reform for the price increase and they were skeptical of her profit analysis of the product.The Centers for Medicare and Medicaid Services, in response to a request from U.S. Senator Amy Klobuchar of Minnesota, said this week that the Medicaid plan for the poor spent $797 million on EpiPen between 2011 and 2015, including rebates provided by Mylan, or $960 million before rebates.Lawmakers have contended that Mylan underpaid Medicaid rebates by misclassifying EpiPen as a generic instead of a branded drug. The Medicaid rebate for a generic is 13 percent compared with a minimum 23.1 percent for a branded drug. ""I am glad the Department of Justice pursued this so quickly,"" Klobuchar said in a statement. ""If other drugs are misclassified, and surely EpiPen isn't the only one ... the taxpayers need to get their money back.""Senator Richard Blumenthal of Connecticut blasted the settlement as too small and said Congress should investigate whether Mylan violated the law. ""This settlement is a shadow of what it should be - lacking real accountability for Mylans apparent lawbreaking,"" he said in a statement.Mylan said in a regulatory filing on Friday that EpiPen will be classified as a branded drug as of April 1, 2017. Bresch told lawmakers this week that Mylan plans to launch a $300 generic version of EpiPen as soon as possible this year.Mylan also lowered its 2016 earnings outlook, but the drugmaker affirmed its 2018 forecast and its shares rose 11 percent to $39.90 after hours.""Kudos to management for fast action,"" AB Bernstein analyst Ronny Gal said in a video message to investors. ""This was one of the major risks everyone was focusing on ... now it is essentially off the table."" Mylan said it will record a pretax charge of about $465 million in the quarter ended Sept. 30. The company, which will make the payment to the Department of Justice and other government agencies, said the settlement does not include any finding of wrongdoing.Mylan, citing changes to the EpiPen consumer discount program and upcoming launch of a generic version, said it now expects full-year 2016 adjusted earnings per share of $4.70 to $4.90, down from $4.85 to $5.15.Mylan said it ""remains committed"" to its target of at least $6.00 in adjusted earnings per share in 2018. (Reporting by Narottam Medhora in Bengaluru and Deena Beasley in Los Angeles; additional reporting by Eric Beech in Washington; Editing by Don Sebastian, Cynthia Osterman and Bernard Orr)",2016-10-07,MYL,"Fri Oct 7, 2016 | 8:13pm EDT",Mylan pays $465 million to settle EpiPen Medicaid rebate dispute,http://www.reuters.com//article/us-mylan-nl-epipen-idUSKCN1272DX?type=companyNews
318,"  Oct 7 Mylan NV said it agreed to a $465 million settlement with the U.S. Department of Justice related to the manner in which it had improperly classified its EpiPen emergency allergy treatment to pay lower rebates to state health programs.Mylan will record a pre-tax charge of about $465 million in the quarter ended Sept. 30 as a result of the settlement, it said on Friday.  The company also lowered its full-year adjusted profit forecast to $4.70-$4.90 per share from $4.85-$5.15.    (Reporting by Narottam Medhora in Bengaluru; Editing by Don Sebastian) ",2016-10-07,MYL,"Fri Oct 7, 2016 | 5:01pm EDT",Mylan agrees to $465 mln settlement over EpiPen classification,http://www.reuters.com//article/mylan-nl-epipen-idUSL3N1CD39N?type=companyNews
319,  Oct 26 Mylan Nv : * Mylan launches first generics of Benicar and Benicar HCT Tablets  Source text for Eikon:  Further company coverage:  ,2016-10-26,MYL,"Wed Oct 26, 2016 | 1:27pm EDT",BRIEF-Mylan launches first generics of Benicar and Benicar HCT Tablets,http://www.reuters.com//article/idUSFWN1CW1A4?type=companyNews
320,"   By Deena Beasley  Privately held drugmaker Kaleo Inc announced on Wednesday plans for a U.S. relaunch of its Auvi-Q injector for life-threatening allergic reactions in the first half of next year.Auvi-Q, designed to deliver the same epinephrine drug as Mylan NV's EpiPen, was recalled from the market last year amid concerns about accuracy of the dosage delivered.French pharmaceutical company Sanofi SA had licensed and made Auvi-Q, but it returned rights to the product to Kaleo in February after the recall.Mylan has come under fire from lawmakers and consumer groups for raising the list price for a pair of EpiPens to more than $600 this year from $100 in 2007 when Mylan acquired the product.Mylan said last month it plans to launch, at a list price of $300, its own generic EpiPen by the end of this year. Officials at Kaleo declined to comment on a planned list price for the relaunched Auvi-Q.""We are working on what is the right price to assure that the ultimate patient co-pay is low,"" Kaleo Chief Executive Officer Spencer Williamson told Reuters in a telephone interview. Unlike the pen-shaped EpiPen, Auvi-Q, which includes a voice prompt system to guide users, is the length and width of a credit card with the thickness of a small cellphone. The Kaleo device also has a needle that automatically retracts after the device has been used.Williamson said Auvi-Q will be manufactured at an automated robotic production line located in the Midwestern United States. Kaleo also sells Evzio, a hand-held device designed to automatically deliver a set dose of naloxone, a drug approved to treat an overdose of opioid painkillers.Evzio has a current list price of $3,750 for two active devices and one training device. (Reporting by Deena Beasley in Los Angeles; Editing by Cynthia Osterman)",2016-10-26,MYL,"Wed Oct 26, 2016 | 7:59am EDT",EpiPen rival plans return to U.S. market in first-half 2017,http://www.reuters.com//article/us-kaleo-auviq-epipen-idUSKCN12Q1IC?type=companyNews
321,"   By Caroline Humer and Ruthy Munoz | NEW YORK/WASHINGTON  NEW YORK/WASHINGTON Mylan NV's price hikes on EpiPens have added millions to U.S. Department of Defense spending since 2008 as the agency covered more prescriptions for the lifesaving allergy shot at near retail prices, government data provided to Reuters shows.Pentagon spending rose to $57 million over the past year from $9 million in 2008 - an increase driven both by volume and by price hikes that had a bigger bite on prescriptions filled at retail pharmacies, according to the previously unreported data.The Pentagon gets a government discount on EpiPens dispensed at military treatment facilities and by mail order. But nearly half of itsspending was at retail pharmacies where it most recently paid an average of $509 for EpiPen and $528 for EpiPen Jr two-packs - three times higher than its discounted rate, the data shows.That may change. Both the Pentagon and Mylan told Reuters that discussions are underway that could extend the military discount to EpiPens filled at retail pharmacies through the use of rebates.Mylan spokeswoman Nina Devlin declined to comment on the specific Department of Defense spending. She said in an emailed statement that talks were underway to address ""any questions or concerns from the agency.""She declined to say if any repayment was on the table.A Reuters analysis of the data estimated a difference of about $54 million between what the agency paid for EpiPens at retail pharmacies from 2009 through 2016 and what it would have paid at military clinics.Mylan Chief Executive Officer Heather Bresch has drawn public scrutiny for raising the U.S. list price on a pack of two injectors nearly six-fold to $600 since 2008.Affordability has become a bigger issue with the increased diagnosis and awareness of food allergies. Families who rely on EpiPens to safeguard their children against possibly fatal allergic reactions often purchase several to carry with them, keep at school and with caregivers.In response to the criticism, Mylan is providing more families with coupons to pay for EpiPens and plans to market a half-price version. The drugmaker also agreed to pay $465 million to settle questions over whether the Medicaid program for the poor overpaid because EpiPens were classified as a generic treatment, a category that allows manufacturers to give smaller rebates to government agencies.While Medicaid providers don't take issue with the increased use of EpiPens, they have bristled over the price hikes.""The rate of increases in their cost is not justifiable,""  said Dr. J. Mario Molina, chief executive of Molina Healthcare, which runs Medicaid plans in California and 11 other states. (For graphic of Pentagon spending on EpiPen, click tmsnrt.rs/2eg5Qi2)  THE FULL PICTURE The impact of Mylan's price hikes on government health programs, such as Medicaid, has been obscured by highly complex pharmaceutical pricing and opaque negotiations.The Centers for Medicare and Medicaid Services, as well as several large state Medicaid programs, have released partial details on their spending, saying full information on rebates is confidential under U.S. law. Without such details, it is impossible to discern what price an agency is paying for EpiPen. At Reuters' request, the Defense Department provided the most comprehensive picture of EpiPen spending by a government agency, including fiscal year expenditures since 2008, average price per pack and the number of prescriptions filled by type of dispensing location for all EpiPens obtained by military service members, their families and retirees.The department's spending on EpiPens has increased fivefold since 2008, far outpacing the 130 percent growth in prescriptions, the data shows.Defense spending on the injectors at retail pharmacies - which accounted for 53,500 of 226,000 EpiPen prescriptions for the last fiscal year that ended Sept. 30 - has grown more than tenfold, to $28 million from $2.4 million in 2008.While EpiPen spending represents a fraction of a percent of the Defense Department's $49 billion annual healthcare budget, the data illustrates the premium it was paying for EpiPens at retail outlets.""Lawmakers would not be terribly happy to hear that DoD is paying more at retail,"" said Brian Bruen, a drug economics researcher at George Washington University's Milken Institute School of Public Health.  DISCOUNT BY DEFINITION The Defense Department and Department of Veterans Affairs, typically pay among the lowest drug prices in the country because of discounts mandated by law, as well as rebates negotiated with drugmakers, Bruen said.Indeed, the Pentagon has paid $173 for an EpiPen two-pack filled through mail order and $169 at military facilities in  fiscal year 2016.A key factor for government discounts is whether a drug is patent protected and has market exclusivity, or it is a generic, made cheaper by competition.The EpiPen, which packages a generic allergy antidote in a patented, easy-to-use injector, is somewhat of a hybrid. For the Defense Department, pharmaceutical companies pay rebates on brand name drugs dispensed by retail pharmacies, reducing the final cost to the agency's discounted rate.EpiPen's classification as a generic drug prevents it from receiving mandated rebates. Mylan provided documentation it said showed the military had accepted the generic classification for EpiPen in 2008.Under Mylan's settlement with the federal government, Medicaid will classify EpiPen as a branded drug, Devlin said. That will qualify Medicaid for a 23 percent rebate, up from the 13 percent it gets on generics. Any price hikes will be capped at the inflation rate, a protection not afforded generic drug purchases.""It was always our intention that the reclassification would benefit all government agencies impacted by the classification, including the VA and Tricare (Defense) programs,"" Devlin said. (Additional reporting by Deena Beasley in Los Angeles; Editing by Michele Gershberg and Lisa Girion)",2016-10-28,MYL,"Fri Oct 28, 2016 | 2:34pm EDT",Exclusive: EpiPen price hikes add millions to Pentagon costs,http://www.reuters.com//article/us-mylan-epipen-pentagon-exclusive-idUSKCN12S0EI?type=companyNews
322,"   By Sarah N. Lynch | WASHINGTON  WASHINGTON West Virginia Attorney General Patrick Morrisey on Wednesday blasted Mylan NV's  announced $465 million settlement with the U.S. Justice Department over the drugmaker's classification of its lifesaving allergy treatment EpiPen as a generic, saying the amount was ""woefully deficient.""The department has not acknowledged such a deal almost a month after Mylan announced it, and department spokeswoman Nicole Navas declined to comment on Wednesday.A spokesperson for Mylan did not respond to requests for comment.In a Nov. 2 letter to Attorney General Loretta Lynch, Morrisey said there were no reports that such a deal had been finalized. But he urged the department to reject the $465 million figure because it ""does not nearly pay for the damage done by Mylan.""Mylan has come under fire for hiking the price of EpiPen to more than $600 for a package of two in less than a decade. Mylan's Oct. 7 announcement about the settlement came just months after congressional scrutiny into the issue began.For years, the company had classified EpiPen as a generic drug instead of a branded one, resulting in smaller rebates to state and federal Medicaid programs.Morrisey said Mylan should not be allowed to receive a ""windfall after flagrantly defrauding the Medicaid Drug Rebate Program."" The Medicaid rebate for a generic is 13 percent compared with a minimum 23.1 percent for a branded drug.Morrisey in August started conducting an investigation into the rebates and antitrust concerns as to whether Mylan took steps to block market competition. The probe became public in September after Morrisey filed an action against Mylan for allegedly refusing to comply with a subpoena.Curtis Johnson, a spokesman for his office, confirmed the investigation was still ongoing. The New York Attorney General is also investigating whether Mylan broke antitrust laws in writing contracts to provide EpiPens to school systems.Centers for Medicare and Medicaid Services Acting Administrator Andrew Slavitt revealed in an Oct. 5 letter to lawmakers that the centers had on ""multiple occasions"" provided guidance to the industry and Mylan about the proper classification of drugs.Until Oct. 7, the company had not told shareholders about the possible misclassification of the EpiPen or the pending settlement with the Justice Department.That day, Mylan also revealed that the U.S. Securities and Exchange Commission had launched an investigation and was seeking copies of its communications with the centers and documents related to the Medicaid rebate program. Senate Judiciary Chairman Charles Grassley, an Iowa Republican, plans to hold a hearing on Nov. 30 to scrutinize the terms of the purported settlement. One topic that could also come up at the hearing is the question of how EpiPen price spikes have affected the U.S. military's spending.Last week, Reuters reported that nearly half of the Pentagon's spending on EpiPens was at retail pharmacies, which do not give the same government discounts as medical treatment centers.As a result, Pentagon spending on EpiPens rose to $57 million over the past year, from $9 million in 2008.Grassley, as well as Senate Democrats Amy Klobuchar and Richard Blumenthal, have responded by sending letters to the Department of Defense and Department of Veterans Affairs seeking further details to determine whether they might be owed rebates.On Tuesday, 17 U.S. Senate Democrats sent a letter to Mylan asking a variety of questions and demanding copies of all of the guidance that Mylan received from the centers about the classification since 2007, when Mylan acquired the company that owned the EpiPen.(additional reporting by Caroline Humer in New York)",2016-11-02,MYL,"Wed Nov 2, 2016 | 4:58pm EDT",West Virginia urges Justice Dept to reject settlement with Mylan,http://www.reuters.com//article/mylan-epipen-settlement-idUSL1N1D311S?type=companyNews
323,"   By Sarah N. Lynch | WASHINGTON  WASHINGTON West Virginia Attorney General Patrick Morrisey on Wednesday blasted Mylan NV's announced $465 million settlement with the U.S. Justice Department over the drugmaker's classification of its lifesaving allergy treatment EpiPen as a generic, saying the amount was ""woefully deficient.""The department has not acknowledged such a deal almost a month after Mylan announced it, and department spokeswoman Nicole Navas declined to comment on Wednesday.A spokesperson for Mylan did not respond to requests for comment.In a Nov. 2 letter to Attorney General Loretta Lynch, Morrisey said there were no reports that such a deal had been finalized. But he urged the department to reject the $465 million figure because it ""does not nearly pay for the damage done by Mylan.""Mylan has come under fire for hiking the price of EpiPen to more than $600 for a package of two in less than a decade. Mylan's Oct. 7 announcement about the settlement came just months after congressional scrutiny into the issue began.For years, the company had classified EpiPen as a generic drug instead of a branded one, resulting in smaller rebates to state and federal Medicaid programs.Morrisey said Mylan should not be allowed to receive a ""windfall after flagrantly defrauding the Medicaid Drug Rebate Program."" The Medicaid rebate for a generic is 13 percent compared with a minimum 23.1 percent for a branded drug.Morrisey in August started conducting an investigation into the rebates and antitrust concerns as to whether Mylan took steps to block market competition. The probe became public in September after Morrisey filed an action against Mylan for allegedly refusing to comply with a subpoena.Curtis Johnson, a spokesman for his office, confirmed the investigation was still ongoing.The New York Attorney General is also investigating whether Mylan broke antitrust laws in writing contracts to provide EpiPens to school systems. Centers for Medicare and Medicaid Services Acting Administrator Andrew Slavitt revealed in an Oct. 5 letter to lawmakers that the centers had on ""multiple occasions"" provided guidance to the industry and Mylan about the proper classification of drugs.Until Oct. 7, the company had not told shareholders about the possible misclassification of the EpiPen or the pending settlement with the Justice Department.That day, Mylan also revealed that the U.S. Securities and Exchange Commission had launched an investigation and was seeking copies of its communications with the centers and documents related to the Medicaid rebate program. Senate Judiciary Chairman Charles Grassley, an Iowa Republican, plans to hold a hearing on Nov. 30 to scrutinize the terms of the purported settlement. One topic that could also come up at the hearing is the question of how EpiPen price spikes have affected the U.S. military's spending.Last week, Reuters reported that nearly half of the Pentagon's spending on EpiPens was at retail pharmacies, which do not give the same government discounts as medical treatment centers.As a result, Pentagon spending on EpiPens rose to $57 million over the past year, from $9 million in 2008.Grassley, as well as Senate Democrats Amy Klobuchar and Richard Blumenthal, have responded by sending letters to the Department of Defense and Department of Veterans Affairs seeking further details to determine whether they might be owed rebates.On Tuesday, 17 U.S. Senate Democrats sent a letter to Mylan asking a variety of questions and demanding copies of all of the guidance that Mylan received from the centers about the classification since 2007, when Mylan acquired the company that owned the EpiPen. (Reporting by Sarah N. Lynch; additional reporting by Caroline Humer in New York; Editing by Richard Chang)",2016-11-02,MYL,"Wed Nov 2, 2016 | 4:42pm EDT",West Virginia urges Justice Dept to reject settlement with Mylan,http://www.reuters.com//article/us-mylan-epipen-settlement-idUSKBN12X220?type=companyNews
324,"   By Sarah N. Lynch | WASHINGTON  WASHINGTON West Virginia Attorney General Patrick Morrisey on Wednesday blasted Mylan NV's announced $465 million settlement with the U.S. Justice Department over the drugmaker's classification of its lifesaving allergy treatment EpiPen as a generic, saying the amount was ""woefully deficient.""The department has not acknowledged such a deal almost a month after Mylan announced it, and department spokeswoman Nicole Navas declined to comment on Wednesday.A spokesperson for Mylan did not respond to requests for comment.In a Nov. 2 letter to Attorney General Loretta Lynch, Morrisey said there were no reports that such a deal had been finalized. But he urged the department to reject the $465 million figure because it ""does not nearly pay for the damage done by Mylan.""Mylan has come under fire for hiking the price of EpiPen to more than $600 for a package of two in less than a decade. Mylan's Oct. 7 announcement about the settlement came just months after congressional scrutiny into the issue began.For years, the company had classified EpiPen as a generic drug instead of a branded one, resulting in smaller rebates to state and federal Medicaid programs.Morrisey said Mylan should not be allowed to receive a ""windfall after flagrantly defrauding the Medicaid Drug Rebate Program."" The Medicaid rebate for a generic is 13 percent compared with a minimum 23.1 percent for a branded drug.Morrisey in August started conducting an investigation into the rebates and antitrust concerns as to whether Mylan took steps to block market competition. The probe became public in September after Morrisey filed an action against Mylan for allegedly refusing to comply with a subpoena.Curtis Johnson, a spokesman for his office, confirmed the investigation was still ongoing.The New York Attorney General is also investigating whether Mylan broke antitrust laws in writing contracts to provide EpiPens to school systems. Centers for Medicare and Medicaid Services Acting Administrator Andrew Slavitt revealed in an Oct. 5 letter to lawmakers that the centers had on ""multiple occasions"" provided guidance to the industry and Mylan about the proper classification of drugs.Until Oct. 7, the company had not told shareholders about the possible misclassification of the EpiPen or the pending settlement with the Justice Department.That day, Mylan also revealed that the U.S. Securities and Exchange Commission had launched an investigation and was seeking copies of its communications with the centers and documents related to the Medicaid rebate program. Senate Judiciary Chairman Charles Grassley, an Iowa Republican, plans to hold a hearing on Nov. 30 to scrutinize the terms of the purported settlement. One topic that could also come up at the hearing is the question of how EpiPen price spikes have affected the U.S. military's spending.Last week, Reuters reported that nearly half of the Pentagon's spending on EpiPens was at retail pharmacies, which do not give the same government discounts as medical treatment centers.As a result, Pentagon spending on EpiPens rose to $57 million over the past year, from $9 million in 2008.Grassley, as well as Senate Democrats Amy Klobuchar and Richard Blumenthal, have responded by sending letters to the Department of Defense and Department of Veterans Affairs seeking further details to determine whether they might be owed rebates.On Tuesday, 17 U.S. Senate Democrats sent a letter to Mylan asking a variety of questions and demanding copies of all of the guidance that Mylan received from the centers about the classification since 2007, when Mylan acquired the company that owned the EpiPen. (Reporting by Sarah N. Lynch; additional reporting by Caroline Humer in New York; Editing by Richard Chang)",2016-11-02,MYL,"Wed Nov 2, 2016 | 4:42pm EDT",UPDATE 3-West Virginia urges Justice Dept to reject settlement with Mylan,http://www.reuters.com//article/mylan-epipen-settlement-idUSL1N1D30YO?type=companyNews
325,"  Nov 2 Mylan NV* Two U.S. Senators seek answers on how Mylan price spikes on EpiPen have impacted U.S. military's budget * Senators Klobuchar, Blumenthal ask Department of Defense and Department of Veterans Affairs how much money might be owed if EpiPen was misclassified  * Request by lawmakers came after Reuters reported that Mylan's price spikes helped drive Pentagon spending on EpiPen to $57 million over the past year from $9 million in 2008   Further company coverage:    (Reporting by Sarah N. Lynch)",2016-11-02,MYL,"Wed Nov 2, 2016 | 3:55pm EDT",BRIEF-Lawmakers seek details on U.S. military's spending on EpiPens,http://www.reuters.com//article/idUSL1N1D31KN?type=companyNews
326,"  (Refiles to correct typo in headline)By Sarah N. Lynch WASHINGTON Nov 2 West Virginia Attorney General Patrick Morrisey on Wednesday blasted a pending $465 million settlement between Mylan NV and the U.S. Justice Department over the misclassification of the EpiPen, saying it is ""woefully deficient.""  In a November 2 letter to Attorney General Loretta Lynch, Morrisey said the amount likely falls short of how much the company owes Medicaid, and that Mylan should ""not be allowed to receive a windfall after flagrantly defrauding the Medicaid Drug Rebate Program.""   (Reporting by Sarah N. Lynch)",2016-11-02,MYL,"Wed Nov 2, 2016 | 12:38pm EDT","REFILE-West Virginia urges Justice Dept to reject ""sweetheart"" settlement with Mylan",http://www.reuters.com//article/mylan-epipen-settlement-idUSL1N1D30WM?type=companyNews
327,"  Nov 2 Momenta Pharmaceuticals Inc* Mylan nv - momenta has achieved milestone necessary to earn a $25 million payment from mylan. * Mylan nv - companies plan to report top-line data from study by end of 2017.  * Momenta and mylan initiate phase 1 clinical trial for m834, a proposed biosimilar of orencia (abatacept)  Source text for Eikon:  Further company coverage:",2016-11-02,MYL,"Wed Nov 2, 2016 | 8:12am EDT",BRIEF-Momenta and Mylan initiate early-stage study for proposed biosimilar of Orencia,http://www.reuters.com//article/idUSASC09F7G?type=companyNews
328,  Nov 3 Biocon Ltd - * Mylan and Biocon announce regulatory submission for insulin glargine accepted for review by European Medicines Agency  Source text for Eikon:  Further company coverage:  ,2016-11-03,MYL,"Thu Nov 3, 2016 | 9:27am EDT",BRIEF-Mylan and Biocon announce regulatory submission for insulin glargine,http://www.reuters.com//article/idUSFWN1D414C?type=companyNews
329,"  Nov 3 Biocon Ltd* Mylan and Biocon announce regulatory submission for insulin glargine accepted for review by European Medicines Agency * Filing includes analytical, functional, pre-clinical data, results from pk, efficacy/safety global clinical trial in type 2 diabetes patients  * Mylan and Biocon look forward to offering another insulin treatment option for diabetic patients,  Further company coverage:",2016-11-03,MYL,"Thu Nov 3, 2016 | 9:14am EDT",BRIEF-Biocon says EMA accepts for review Mylan's regulatory submission for insulin glargine,http://www.reuters.com//article/idUSFWN1D4163?type=companyNews
330,"  Nov 3 Strides Shasun Ltd* Strides Shasun Ltd says co, Mylan agree to settle regulatory and general claims on Agila transaction * Strides Shasun Ltd says after payment to Mylan, co to get about US$ 30 million from regulatory escrow  * Strides Shasun Ltd says co, Mylan agreed to full, final settlement of warranty, indemnity claims  Source text - (bit.ly/2eWOMeC) Further company coverage:    (Bengaluru newsroom)",2016-11-03,MYL,"Wed Nov 2, 2016 | 11:47pm EDT","BRIEF-Strides Shasun, Mylan agree to settle regulatory, general claims on Agila deal",http://www.reuters.com//article/idUSFWN1D315H?type=companyNews
331,"   By Sarah N. Lynch | WASHINGTON  WASHINGTON The U.S. Senate Judiciary Committee urged federal antitrust regulators on Monday to launch a probe into whether EpiPen maker Mylan NV broke the law by preventing schools from purchasing competing allergy treatments.The bipartisan request to the Federal Trade Commission by Senate Judiciary Chairman Charles Grassley and Ranking Member Patrick Leahy comes just a few weeks before the committee is slated to convene a hearing to scrutinize a pending $465 million settlement that Mylan has said will resolve claims it underpaid rebates to state and federal Medicaid programs.""Due to the dramatic increase of the price of drugs across the board, the FTC should be vigilant in its scrutiny of this market,"" the lawmakers wrote.In a statement emailed to Reuters, a Mylan spokeswoman defended the company's 'EpiPen4Schools' program, saying it has no purchase requirement for schools to participate and that it offers schools four free EpiPens per calendar year also without purchase restrictions. Previously, schools that wished to purchase additional EpiPens could do so in some cases with a discount and a ""limited purchase restriction,"" but no such restriction remains in place today, she added.A spokeswoman for the FTC declined to comment on the letter. Mylan has come under fire in recent months by lawmakers for hiking the price of EpiPen to more than $600 for a package of two in less than a decade.Last month, it said it had reached a $465 million settlement with the Justice Department to resolve claims it misclassified the EpiPen as a generic drug instead of a branded one, thereby underpaying rebates for Medicaid. The Justice Department has yet to publicly acknowledge the settlement, which will be discussed at the Nov. 30 hearing.Also on Monday, three members of the Senate Judiciary Committee asked the company when it plans to reimburse the Department of Defense for any overcharging on EpiPen.Separately, the West Virginia Attorney General's Office is investigating Mylan over antitrust concerns and the rebates, while the New York Attorney General is scrutinizing Mylan's contracts with schools for the EpiPen for possible violations of state antitrust laws.",2016-11-07,MYL,"Mon Nov 7, 2016 | 5:56pm EST",U.S. Senate panel urges FTC to launch antitrust probe of Mylan,http://www.reuters.com//article/senate-mylan-nl-epipen-idUSL1N1D81YS?type=companyNews
332,"   By Sarah N. Lynch | WASHINGTON  WASHINGTON The U.S. Senate Judiciary Committee urged federal antitrust regulators on Monday to launch a probe into whether EpiPen maker Mylan NV broke the law by preventing schools from purchasing competing allergy treatments.The bipartisan request to the Federal Trade Commission by Senate Judiciary Chairman Charles Grassley and Ranking Member Patrick Leahy comes just a few weeks before the committee is slated to convene a hearing to scrutinize a pending $465 million settlement that Mylan has said will resolve claims it underpaid rebates to state and federal Medicaid programs.""Due to the dramatic increase of the price of drugs across the board, the FTC should be vigilant in its scrutiny of this market,"" the lawmakers wrote.In a statement emailed to Reuters, a Mylan spokeswoman defended the company's 'EpiPen4Schools' program, saying it has no purchase requirement for schools to participate and that it offers schools four free EpiPens per calendar year also without purchase restrictions. Previously, schools that wished to purchase additional EpiPens could do so in some cases with a discount and a ""limited purchase restriction,"" but no such restriction remains in place today, she added.A spokeswoman for the FTC declined to comment on the letter.Mylan has come under fire in recent months by lawmakers for hiking the price of EpiPen to more than $600 for a package of two in less than a decade. Last month, it said it had reached a $465 million settlement with the Justice Department to resolve claims it misclassified the EpiPen as a generic drug instead of a branded one, thereby underpaying rebates for Medicaid. The Justice Department has yet to publicly acknowledge the settlement, which will be discussed at the Nov. 30 hearing. Also on Monday, three members of the Senate Judiciary Committee asked the company when it plans to reimburse the Department of Defense for any overcharging on EpiPen.Separately, the West Virginia Attorney General's Office is investigating Mylan over antitrust concerns and the rebates, while the New York Attorney General is scrutinizing Mylan's contracts with schools for the EpiPen for possible violations of state antitrust laws. (Reporting by Sarah N. Lynch; Editing by Chris Reese and Bill Rigby)",2016-11-07,MYL,"Mon Nov 7, 2016 | 5:54pm EST",U.S. Senate panel urges FTC to launch antitrust probe of Mylan,http://www.reuters.com//article/us-senate-mylan-nl-epipen-idUSKBN1322NF?type=companyNews
333,"   By Sarah N. Lynch | WASHINGTON  WASHINGTON The U.S. Senate Judiciary Committee urged federal antitrust regulators on Monday to launch a probe into whether EpiPen maker Mylan NV broke the law by preventing schools from purchasing competing allergy treatments.The bipartisan request to the Federal Trade Commission by Senate Judiciary Chairman Charles Grassley and Ranking Member Patrick Leahy comes just a few weeks before the committee is slated to convene a hearing to scrutinize a pending $465 million settlement that Mylan has said will resolve claims it underpaid rebates to state and federal Medicaid programs.""Due to the dramatic increase of the price of drugs across the board, the FTC should be vigilant in its scrutiny of this market,"" the lawmakers wrote.In a statement emailed to Reuters, a Mylan spokeswoman defended the company's 'EpiPen4Schools' program, saying it has no purchase requirement for schools to participate and that it offers schools four free EpiPens per calendar year also without purchase restrictions. Previously, schools that wished to purchase additional EpiPens could do so in some cases with a discount and a ""limited purchase restriction,"" but no such restriction remains in place today, she added.A spokeswoman for the FTC declined to comment on the letter.Mylan has come under fire in recent months by lawmakers for hiking the price of EpiPen to more than $600 for a package of two in less than a decade. Last month, it said it had reached a $465 million settlement with the Justice Department to resolve claims it misclassified the EpiPen as a generic drug instead of a branded one, thereby underpaying rebates for Medicaid. The Justice Department has yet to publicly acknowledge the settlement, which will be discussed at the Nov. 30 hearing. Also on Monday, three members of the Senate Judiciary Committee asked the company when it plans to reimburse the Department of Defense for any overcharging on EpiPen.Separately, the West Virginia Attorney General's Office is investigating Mylan over antitrust concerns and the rebates, while the New York Attorney General is scrutinizing Mylan's contracts with schools for the EpiPen for possible violations of state antitrust laws. (Reporting by Sarah N. Lynch; Editing by Chris Reese and Bill Rigby)",2016-11-07,MYL,"Mon Nov 7, 2016 | 5:54pm EST",UPDATE 1-U.S. Senate panel urges FTC to launch antitrust probe of Mylan,http://www.reuters.com//article/senate-mylan-nl-epipen-idUSL1N1D81WU?type=companyNews
334,"   By Ransdell Pierson  Three members of the U.S. Senate Judiciary Committee, ahead of a planned hearing late this month, said Mylan NV appears to have greatly overcharged the military for its lifesaving allergy treatment EpiPen and asked the pharmaceutical company when it plans to reimburse the Department of Defense.The reimbursement demand came in a letter on Monday to Mylan Chief Executive Heather Bresch, from Senate Judiciary Chairman Charles Grassley, an Iowa Republican, and committee members Richard Blumenthal of Connecticut and Amy Klobuchar of Minnesota, both Democrats.""We are alarmed that Mylan may have overcharged our military for this life-saving drug,"" the Senators wrote. They said Mylan for years may have knowingly misclassified EpiPen as a generic product in order to avoid higher rebates the company would have had to pay state and federal Medicaid programs had it been classified as a branded product. The Medicaid rebate for a generic is 13 percent compared with a minimum of 23.1 percent for a branded medicine.Mylan spokeswoman Nina Devlin declined to comment on the letter, or its demands. The drug company has come under fire from consumers and politicians in recent months for raising the U.S. list price on a pack of two EpiPen injectors nearly six-fold to $600 since 2008. Lawmakers, including Grassley, have called for investigations into Mylan's pricing, helping put the product in the spotlight amid a larger debate over big drug price increases in the United States. Pentagon spending on EpiPen jumped to $57 million over the past year from $9 million in 2008, an increase driven by volume and by hefty price hikes that had a bigger bite on prescriptions filled at retail pharmacies, Reuters reported on Oct. 28, citing previously unreported data.The Pentagon gets a government discount on EpiPens dispensed at military treatment facilities and by mail order. But nearly half of its spending was at retail pharmacies where it most recently paid an average of $509 for EpiPen and $528 for EpiPen Jr two-packs - three times higher than its discounted rate, according to the data.The Senate Judiciary Committee is slated to hold a hearing  Nov. 30 on EpiPen pricing and related matters.",2016-11-07,MYL,"Mon Nov 7, 2016 | 5:41pm EST",Three U.S. senators ask Mylan for EpiPen military reimbursements,http://www.reuters.com//article/mylan-nl-epipen-senate-idUSL1N1D81Y8?type=companyNews
335,"  Three members of the U.S. Senate Judiciary Committee, ahead of a planned hearing late this month, said Mylan NV appears to have greatly overcharged the military for its lifesaving allergy treatment EpiPen and asked the pharmaceutical company when it plans to reimburse the Department of Defense.The reimbursement demand came in a letter on Monday to Mylan Chief Executive Heather Bresch, from Senate Judiciary Chairman Charles Grassley, an Iowa Republican, and committee members Richard Blumenthal of Connecticut and Amy Klobuchar of Minnesota, both Democrats.""We are alarmed that Mylan may have overcharged our military for this life-saving drug,"" the Senators wrote. They said Mylan for years may have knowingly misclassified EpiPen as a generic product in order to avoid higher rebates the company would have had to pay state and federal Medicaid programs had it been classified as a branded product.The Medicaid rebate for a generic is 13 percent compared with a minimum of 23.1 percent for a branded medicine. Mylan spokeswoman Nina Devlin declined to comment on the letter, or its demands.The drug company has come under fire from consumers and politicians in recent months for raising the U.S. list price on a pack of two EpiPen injectors nearly six-fold to $600 since 2008. Lawmakers, including Grassley, have called for investigations into Mylan's pricing, helping put the product in the spotlight amid a larger debate over big drug price increases in the United States.  Pentagon spending on EpiPen jumped to $57 million over the past year from $9 million in 2008, an increase driven by volume and by hefty price hikes that had a bigger bite on prescriptions filled at retail pharmacies, Reuters reported on Oct. 28, citing previously unreported data.  The Pentagon gets a government discount on EpiPens dispensed at military treatment facilities and by mail order. But nearly half of its spending was at retail pharmacies where it most recently paid an average of $509 for EpiPen and $528 for EpiPen Jr two-packs - three times higher than its discounted rate, according to the data. The Senate Judiciary Committee is slated to hold a hearing  Nov. 30 on EpiPen pricing and related matters.    (Reporting by Ransdell Pierson; Editing by Bill Rigby)",2016-11-07,MYL,"Mon Nov 7, 2016 | 5:34pm EST",Three U.S. senators ask Mylan for EpiPen military reimbursements,http://www.reuters.com//article/us-mylan-nl-epipen-senate-idUSKBN1322O1?type=companyNews
336,"  Three members of the U.S. Senate Judiciary Committee, ahead of a planned hearing late this month, said Mylan NV appears to have greatly overcharged the military for its lifesaving allergy treatment EpiPen and asked the pharmaceutical company when it plans to reimburse the Department of Defense.The reimbursement demand came in a letter on Monday to Mylan Chief Executive Heather Bresch, from Senate Judiciary Chairman Charles Grassley, an Iowa Republican, and committee members Richard Blumenthal of Connecticut and Amy Klobuchar of Minnesota, both Democrats.""We are alarmed that Mylan may have overcharged our military for this life-saving drug,"" the Senators wrote. They said Mylan for years may have knowingly misclassified EpiPen as a generic product in order to avoid higher rebates the company would have had to pay state and federal Medicaid programs had it been classified as a branded product.The Medicaid rebate for a generic is 13 percent compared with a minimum of 23.1 percent for a branded medicine. Mylan spokeswoman Nina Devlin declined to comment on the letter, or its demands.The drug company has come under fire from consumers and politicians in recent months for raising the U.S. list price on a pack of two EpiPen injectors nearly six-fold to $600 since 2008. Lawmakers, including Grassley, have called for investigations into Mylan's pricing, helping put the product in the spotlight amid a larger debate over big drug price increases in the United States.  Pentagon spending on EpiPen jumped to $57 million over the past year from $9 million in 2008, an increase driven by volume and by hefty price hikes that had a bigger bite on prescriptions filled at retail pharmacies, Reuters reported on Oct. 28, citing previously unreported data.  The Pentagon gets a government discount on EpiPens dispensed at military treatment facilities and by mail order. But nearly half of its spending was at retail pharmacies where it most recently paid an average of $509 for EpiPen and $528 for EpiPen Jr two-packs - three times higher than its discounted rate, according to the data. The Senate Judiciary Committee is slated to hold a hearing  Nov. 30 on EpiPen pricing and related matters.    (Reporting by Ransdell Pierson; Editing by Bill Rigby)",2016-11-07,MYL,"Mon Nov 7, 2016 | 5:34pm EST",Three U.S. senators ask Mylan for EpiPen military reimbursements,http://www.reuters.com//article/us-mylan-nl-epipen-senate-idUSKBN1322O3?type=companyNews
337,"  Three members of the U.S. Senate Judiciary Committee, ahead of a planned hearing late this month, said Mylan NV appears to have greatly overcharged the military for its lifesaving allergy treatment EpiPen and asked the pharmaceutical company when it plans to reimburse the Department of Defense.The reimbursement demand came in a letter on Monday to Mylan Chief Executive Heather Bresch, from Senate Judiciary Chairman Charles Grassley, an Iowa Republican, and committee members Richard Blumenthal of Connecticut and Amy Klobuchar of Minnesota, both Democrats.""We are alarmed that Mylan may have overcharged our military for this life-saving drug,"" the Senators wrote. They said Mylan for years may have knowingly misclassified EpiPen as a generic product in order to avoid higher rebates the company would have had to pay state and federal Medicaid programs had it been classified as a branded product.The Medicaid rebate for a generic is 13 percent compared with a minimum of 23.1 percent for a branded medicine. Mylan spokeswoman Nina Devlin declined to comment on the letter, or its demands.The drug company has come under fire from consumers and politicians in recent months for raising the U.S. list price on a pack of two EpiPen injectors nearly six-fold to $600 since 2008. Lawmakers, including Grassley, have called for investigations into Mylan's pricing, helping put the product in the spotlight amid a larger debate over big drug price increases in the United States.  Pentagon spending on EpiPen jumped to $57 million over the past year from $9 million in 2008, an increase driven by volume and by hefty price hikes that had a bigger bite on prescriptions filled at retail pharmacies, Reuters reported on Oct. 28, citing previously unreported data.  The Pentagon gets a government discount on EpiPens dispensed at military treatment facilities and by mail order. But nearly half of its spending was at retail pharmacies where it most recently paid an average of $509 for EpiPen and $528 for EpiPen Jr two-packs - three times higher than its discounted rate, according to the data. The Senate Judiciary Committee is slated to hold a hearing  Nov. 30 on EpiPen pricing and related matters.    (Reporting by Ransdell Pierson; Editing by Bill Rigby)",2016-11-07,MYL,"Mon Nov 7, 2016 | 5:34pm EST",Three U.S. senators ask Mylan for EpiPen military reimbursements,http://www.reuters.com//article/mylan-nl-epipen-senate-idUSL1N1D81UZ?type=companyNews
338,"   By Sarah N. Lynch | WASHINGTON  WASHINGTON The internal watchdog at the U.S. Department of Health and Human Services warned the office tasked with administering federal health insurance programs that Mylan NV's EpiPen was improperly classified as a generic drug in 2009, Senator Charles Grassley said on Tuesday.In a press release, Grassley's office said the HHS Inspector General confirmed in discussions with Senate aides that the watchdog office notified the Centers for Medicare and Medicaid Services about the problematic classification, which was highlighted in a report. Mylan said last month it intends to pay $465 million to settle with the U.S. Justice Department over charges it misclassified the EpiPen as a generic instead of a branded drug, thereby underpaying rebates owed to state and federal Medicaid programs.A Justice Department spokeswoman declined to comment to Reuters on the purported settlement, though a Senate aide said Grassley's office was previously told by the department that no deal with Mylan had been finalized.A settlement will be the subject of a Nov. 30 hearing before the Senate Judiciary Committee, which Grassley chairs. HHS Inspector General Daniel Levinson, as well as officials from the Justice Department, the Centers and Mylan have all been invited to testify. The timing of the watchdog's disclosure to the Centers is significant. It raises questions about why it has taken so long for Mylan to correct the error, how promptly the government told Mylan of its concerns, and, if Mylan knew of the problem, why it never told its investors.U.S. securities regulators have since subpoenaed the company for its communications with the Centers. The taxpayers deserve answers on what happened between 2009 and now, Grassley said in a statement. It appears the EpiPen was misclassified for years, and CMS was notified of the problem. If no one did anything about the misclassification, why not?"" Representatives from Mylan did not respond to requests for comment. A spokesman for the Centers for Medicare and Medicaid Services reiterated that ""on multiple occasions,"" it advised Mylan about the proper classification of drugs and ""expressly advised"" Mylan about the EpiPen misclassification.  Mylan has come under fire in recent months for hiking the price of the lifesaving allergy treatment to more than $600 for a package of two in less than a decade.Earlier this month, West Virginia's attorney general sent a letter to the Justice Department urging the government to reject the purported $465 million settlement, calling it ""woefully deficient."" (Reporting by Sarah N. Lynch; Editing by Dan Grebler)",2016-11-08,MYL,"Tue Nov 8, 2016 | 4:36pm EST","U.S. watchdog told Medicare, Medicaid that EpiPen was misclassified in 2009: senator",http://www.reuters.com//article/us-senate-mylan-idUSKBN1332F4?type=companyNews
339,"   By Sarah N. Lynch | WASHINGTON  WASHINGTON The internal watchdog at the U.S. Department of Health and Human Services warned the office tasked with administering federal health insurance programs that Mylan NV's EpiPen was improperly classified as a generic drug in 2009, Senator Charles Grassley said on Tuesday.In a press release, Grassley's office said the HHS Inspector General confirmed in discussions with Senate aides that the watchdog office notified the Centers for Medicare and Medicaid Services about the problematic classification, which was highlighted in a report. Mylan said last month it intends to pay $465 million to settle with the U.S. Justice Department over charges it misclassified the EpiPen as a generic instead of a branded drug, thereby underpaying rebates owed to state and federal Medicaid programs.A Justice Department spokeswoman declined to comment to Reuters on the purported settlement, though a Senate aide said Grassley's office was previously told by the department that no deal with Mylan had been finalized.A settlement will be the subject of a Nov. 30 hearing before the Senate Judiciary Committee, which Grassley chairs. HHS Inspector General Daniel Levinson, as well as officials from the Justice Department, the Centers and Mylan have all been invited to testify. The timing of the watchdog's disclosure to the Centers is significant. It raises questions about why it has taken so long for Mylan to correct the error, how promptly the government told Mylan of its concerns, and, if Mylan knew of the problem, why it never told its investors.U.S. securities regulators have since subpoenaed the company for its communications with the Centers. The taxpayers deserve answers on what happened between 2009 and now, Grassley said in a statement. It appears the EpiPen was misclassified for years, and CMS was notified of the problem. If no one did anything about the misclassification, why not?"" Representatives from Mylan did not respond to requests for comment. A spokesman for the Centers for Medicare and Medicaid Services reiterated that ""on multiple occasions,"" it advised Mylan about the proper classification of drugs and ""expressly advised"" Mylan about the EpiPen misclassification.  Mylan has come under fire in recent months for hiking the price of the lifesaving allergy treatment to more than $600 for a package of two in less than a decade.Earlier this month, West Virginia's attorney general sent a letter to the Justice Department urging the government to reject the purported $465 million settlement, calling it ""woefully deficient."" (Reporting by Sarah N. Lynch; Editing by Dan Grebler)",2016-11-08,MYL,"Tue Nov 8, 2016 | 4:36pm EST","UPDATE 2-U.S. watchdog told Medicare, Medicaid that EpiPen was misclassified in 2009 -senator",http://www.reuters.com//article/senate-mylan-idUSL1N1D91GI?type=companyNews
340,"  WASHINGTON Nov 8 The internal watchdog at the U.S. Department of Health and Human Services warned the office tasked with administering federal health insurance programs that Mylan NV's EpiPen was improperly classified as a generic drug in 2009, Senator Charles Grassley said Tuesday.In a press release, Grassley's office said the HHS Inspector General confirmed in discussions with Senate aides that the watchdog office notified the Centers for Medicare and Medicaid Services about the problematic classification, which was highlighted in a report. Mylan has since said it intends to pay $465 million to settle with the U.S. Justice Department over charges it misclassified the EpiPen as a generic instead of a branded drug, thereby underpaying rebates owed to state and federal Medicaid programs.  (Reporting by Sarah N. Lynch; Editing by Dan Grebler)",2016-11-08,MYL,"Tue Nov 8, 2016 | 1:48pm EST","Internal watchdog told Medicare, Medicaid centers EpiPen was misclassified in 2009",http://www.reuters.com//article/senate-mylan-idUSL1N1D91EL?type=companyNews
341,  Nov 8 Biocon Ltd * Biocon Ltd says Mylan and Biocon announce U.S. FDA submission for proposed biosimilar trastuzumab  Source text - (bit.ly/2eA3Db3) Further company coverage:  ,2016-11-08,MYL,"Tue Nov 8, 2016 | 7:24am EST",BRIEF-Biocon and Mylan announce U.S. FDA submission for proposed biosimilar Trastuzumab,http://www.reuters.com//article/idUSFWN1D90NB?type=companyNews
342,"   By Bill Berkrot  Generic drugmaker Mylan NV said on Wednesday it was working to finalize a settlement with the U.S. government over Medicaid rebates for its EpiPen emergency allergy treatment, adding that money set aside for the settlement led to a third quarter loss.The company had previously said it agreed to terms of a settlement set at $465 million. However the U.S. Justice Department and other agencies have yet to confirm any such agreement.The dispute involves the classification of EpiPen as a generic rather than a branded product, which led to significantly smaller rebates to state Medicaid programs.Mylan has been under investigation and faced harsh criticism over steep price increases for its life-saving auto-injector used for severe allergic reactions.Chief Executive Heather Bresch, on a conference call with analysts, said high deductible health plans and pricing pressure had created U.S. headwinds for its business.""We wish we had better anticipated the acceleration of rising out-of-pocket costs"" for our customers, she said. With the distraction of the U.S. presidential election over, Bresch said she hoped to be part of a discussion aimed at finding solutions to better transparency around the complexities of drug pricing.Mylan's announcement earlier this year of a near doubling of the price for a pair of EpiPen injectors to $600 set off a firestorm of criticism from parents, politicians and patient advocates.The company said it expects EpiPen to account for 6 percent of total sales in 2017. Mylan has virtually had the market for emergency allergy auto-injectors to itself. However, competition is coming.      Last month, privately held Kaleo Inc announced plans for a U.S. relaunch of its Auvi-Q injector in the first half of next year following a product recall.While Mylan works to integrate recent acquisitions, Bresch said business development plans will focus on smaller bolt-on acquisitions, perhaps to enhance a particular therapeutic area.""It's buyer's market. I think there's great assets out there,"" Bresch said. ""We don't need to do any big acquisitions."" Mylan posted a net loss of $119.8 million for the third quarter, or 23 cents per share, compared with a profit of $428.6 million, or 83 cents per share, a year ago.Excluding items, such as the settlement expense, Mylan said it had adjusted earnings of $1.38 per share. Analysts on average expected $1.45, according to Thomson Reuters I/B/E/S.Mylan stuck with its recently lowered full-year forecast for adjusted earnings of $4.70 to $4.90 per share, and maintained its 2018 earnings projection of $6 per share.It said it expects to see generic drugs price erosion in the mid-single digits range for the rest of the year.Revenue for the quarter of $3.06 billion was just short of Wall Street estimates of $3.12 billion.",2016-11-09,MYL,"Wed Nov 9, 2016 | 6:51pm EST",Mylan working to finalize EpiPen Medicaid settlement-CFO,http://www.reuters.com//article/mylan-nl-results-idUSL1N1DA3ZJ?type=companyNews
343,"   By Bill Berkrot  Generic drugmaker Mylan NV said on Wednesday it was working to finalize a settlement with the U.S. government over Medicaid rebates for its EpiPen emergency allergy treatment, adding that money set aside for the settlement led to a third quarter loss.The company had previously said it agreed to terms of a settlement set at $465 million. However the U.S. Justice Department and other agencies have yet to confirm any such agreement.The dispute involves the classification of EpiPen as a generic rather than a branded product, which led to significantly smaller rebates to state Medicaid programs.Mylan has been under investigation and faced harsh criticism over steep price increases for its life-saving auto-injector used for severe allergic reactions.Chief Executive Heather Bresch, on a conference call with analysts, said high deductible health plans and pricing pressure had created U.S. headwinds for its business.""We wish we had better anticipated the acceleration of rising out-of-pocket costs"" for our customers, she said.With the distraction of the U.S. presidential election over, Bresch said she hoped to be part of a discussion aimed at finding solutions to better transparency around the complexities of drug pricing. Mylan's announcement earlier this year of a near doubling of the price for a pair of EpiPen injectors to $600 set off a firestorm of criticism from parents, politicians and patient advocates.  The company said it expects EpiPen to account for 6 percent of total sales in 2017.Mylan has virtually had the market for emergency allergy auto-injectors to itself. However, competition is coming.      Last month, privately held Kaleo Inc announced plans for a U.S. relaunch of its Auvi-Q injector in the first half of next year following a product recall. While Mylan works to integrate recent acquisitions, Bresch said business development plans will focus on smaller bolt-on acquisitions, perhaps to enhance a particular therapeutic area.""It's buyer's market. I think there's great assets out there,"" Bresch said. ""We don't need to do any big acquisitions.""Mylan posted a net loss of $119.8 million for the third quarter, or 23 cents per share, compared with a profit of $428.6 million, or 83 cents per share, a year ago.Excluding items, such as the settlement expense, Mylan said it had adjusted earnings of $1.38 per share. Analysts on average expected $1.45, according to Thomson Reuters I/B/E/S. Mylan stuck with its recently lowered full-year forecast for adjusted earnings of $4.70 to $4.90 per share, and maintained its 2018 earnings projection of $6 per share.It said it expects to see generic drugs price erosion in the mid-single digits range for the rest of the year.Revenue for the quarter of $3.06 billion was just short of Wall Street estimates of $3.12 billion. (Reporting by Bill Berkrot in New York; Editing by Lisa Shumaker and Tom Brown)",2016-11-09,MYL,"Wed Nov 9, 2016 | 6:45pm EST",Mylan working to finalize EpiPen Medicaid settlement: CFO,http://www.reuters.com//article/us-mylan-nl-results-idUSKBN1343JN?type=companyNews
344,"   By Bill Berkrot  Generic drugmaker Mylan NV said on Wednesday it was working to finalize a settlement with the U.S. government over Medicaid rebates for its EpiPen emergency allergy treatment, adding that money set aside for the settlement led to a third quarter loss.The company had previously said it agreed to terms of a settlement set at $465 million. However the U.S. Justice Department and other agencies have yet to confirm any such agreement.The dispute involves the classification of EpiPen as a generic rather than a branded product, which led to significantly smaller rebates to state Medicaid programs.Mylan has been under investigation and faced harsh criticism over steep price increases for its life-saving auto-injector used for severe allergic reactions.Chief Executive Heather Bresch, on a conference call with analysts, said high deductible health plans and pricing pressure had created U.S. headwinds for its business.""We wish we had better anticipated the acceleration of rising out-of-pocket costs"" for our customers, she said.With the distraction of the U.S. presidential election over, Bresch said she hoped to be part of a discussion aimed at finding solutions to better transparency around the complexities of drug pricing. Mylan's announcement earlier this year of a near doubling of the price for a pair of EpiPen injectors to $600 set off a firestorm of criticism from parents, politicians and patient advocates.  The company said it expects EpiPen to account for 6 percent of total sales in 2017.Mylan has virtually had the market for emergency allergy auto-injectors to itself. However, competition is coming.      Last month, privately held Kaleo Inc announced plans for a U.S. relaunch of its Auvi-Q injector in the first half of next year following a product recall. While Mylan works to integrate recent acquisitions, Bresch said business development plans will focus on smaller bolt-on acquisitions, perhaps to enhance a particular therapeutic area.""It's buyer's market. I think there's great assets out there,"" Bresch said. ""We don't need to do any big acquisitions.""Mylan posted a net loss of $119.8 million for the third quarter, or 23 cents per share, compared with a profit of $428.6 million, or 83 cents per share, a year ago.Excluding items, such as the settlement expense, Mylan said it had adjusted earnings of $1.38 per share. Analysts on average expected $1.45, according to Thomson Reuters I/B/E/S. Mylan stuck with its recently lowered full-year forecast for adjusted earnings of $4.70 to $4.90 per share, and maintained its 2018 earnings projection of $6 per share.It said it expects to see generic drugs price erosion in the mid-single digits range for the rest of the year.Revenue for the quarter of $3.06 billion was just short of Wall Street estimates of $3.12 billion. (Reporting by Bill Berkrot in New York; Editing by Lisa Shumaker and Tom Brown)",2016-11-09,MYL,"Wed Nov 9, 2016 | 6:45pm EST",UPDATE 2-Mylan working to finalize EpiPen Medicaid settlement-CFO,http://www.reuters.com//article/mylan-nl-results-idUSL1N1DA3O2?type=companyNews
345,  Nov 9 Mylan* Mylan sees generic drugs price erosion in mid single digits for rest of year* Mylan says believes authorized generic EpiPen at wholesale cost of $300 will generate cost savings for customers * Mylan CFO says continues to work with U.S. government to finalize EpiPen settlement over Medicaid rebates * CEO says future business development to emphasize bolt-on deals * Mylan CEO sees EpiPen accounting for 6 percent of 2017 sales* Mylan says has 16 biosimilars and insulin products in development  Source text for Eikon:  Further company coverage:    (Reporting By Bill Berkrot),2016-11-09,MYL,"Wed Nov 9, 2016 | 5:47pm EST",BRIEF-Mylan CEO sees EpiPen accounting for 6 pct of 2017 sales,http://www.reuters.com//article/idUSL1N1DA3Q0?type=companyNews
346,"  Nov 9 Mylan Nv -* We continue to see pricing across very broad generics portfolio to be in line with expectations* Remain committed to recently updated full year 2016 adjusted eps guidance range of $4.70 to $4.90* Effective October 1, 2016, we are expanding reportable segments* Change in segment reporting will begin with consolidated financial statements for year ending December 31, 2016* Remain committed to  $6.00 adjusted earnings per share target in 2018* Comparative segment financial information will be recast for prior periods to conform to revised segment structure * In specialty segment, epipen auto-injector scripts grew quarter-over-quarter, volumes were down due to lack of wholesaler purchases in quarter* Though epipen auto-injector scripts grew q-o-q, volumes were down due to lack of wholesaler purchases in quarter in anticipation of generic launch* ""Continue to anticipate price erosion in mid-single digits for remainder of year"" * FY2016 earnings per share view $4.78 -- Thomson Reuters I/B/E/S* Mylan reports third quarter 2016 results* Q3 adjusted earnings per share $3.31 * Q3 gaap loss per share $0.23* Q3 earnings per share view $1.46 -- Thomson Reuters I/B/E/S* Sees FY 2016 adjusted earnings per share $4.70 to $4.90* Sees FY 2018 adjusted earnings per share $6.00* Q3 revenue $3.06 billion versus I/B/E/Si/b/e/s view $3.12 billion  Source text for Eikon:  Further company coverage:",2016-11-09,MYL,"Wed Nov 9, 2016 | 4:27pm EST",BRIEF-Mylan reports Q3 loss per share $0.23,http://www.reuters.com//article/idUSASC09HK7?type=companyNews
347,"  Nov 9 Generic drugmaker Mylan NV, which is under investigation and has faced harsh criticism over steep price increases for its EpiPen emergency allergy treatment, on Wednesday reported a third quarter loss due the cost of a proposed settlement with the U.S. department of Justice and other government agencies.Mylan posted a net loss of $119.8 million, or 23 cents per share, compared with a profit of $428.6 million, or 83 cents per share, a year ago.  Excluding items, such as the $465 settlement expense, Mylan said it had adjusted earnings of $1.38 per share. Analysts on average expected $1.45 (vs $1.43) per share, according to Thomson Reuters I/B/E/S.   (Reporting by Bill Berkrot; Editing by Chris Reese) ",2016-11-09,MYL,"Wed Nov 9, 2016 | 4:20pm EST",Mylan posts 3rd-quarter loss on proposed settlement costs,http://www.reuters.com//article/mylan-nl-results-idUSL1N1DA3MP?type=companyNews
348,"   By Lewis Krauskopf and Ben Hirschler | NEW YORK/LONDON  NEW YORK/LONDON Pharmaceutical and biotechnology shares soared on Wednesday as Republican Donald Trump's U.S. presidential election calmed investor fears of tough action on drug pricing that has pressured the sector for more than a year.Hospital shares tumbled as a Republican sweep of Congress raised prospects for a rollback of the Affordable Care Act (ACA), which expanded the number of patients in government health plans.Fears of a win by Hillary Clinton and Democrats gaining power in Congress had clouded the outlook for biotech and pharma shares and contributed to general underperformance for the U.S. healthcare sector this year.On Wednesday, the stocks also were fueled by the defeat of a Californian ballot proposal aimed at reining in rising prices for prescription drugs.Clinton ""not being in the White House removes the notion of some sort of price controls off the table,"" said Tony Butler, an analyst at Guggenheim Securities in New York. ""From the perspective of pharmaceutical, biotechnology, generic (drug) stocks, (the election) went about as well as could be expected.""Shares of drugmaker Pfizer (PFE.N) rose 8.5 percent and biotech Celgene (CELG.O) jumped 10.4 percent, while specialty drugmaker Mallinckrodt (MNK.N) surged 10 percent.  European drug stocks also gained, with Switzerland's Roche (ROG.S) and France's Sanofi (SASY.PA) both rising more than 5 percent.The Nasdaq Biotechnology index .NBI advanced 9 percent and was on track for its biggest single-day gain in more than eight years.Biotech sentiment was also lifted by the prospect of Republican-led legislation to free up cash currently held overseas for tax reasons by large U.S. pharmaceutical companies. Analysts said that could pave the way for acquisitions in the sector.  Biotech and pharmaceutical investors have been on edge since September 2015, when Clinton tweeted about specialty drug ""price gouging."" Over that time, Nasdaq-listed biotech shares had lost more than one-fourth of their value through Tuesday.Trump has said less on the topic. But he has suggested support for importation of cheaper drugs and advocated increased scrutiny over drug price increases and a bigger role for negotiating down the cost of medicines.Some Republican lawmakers have also seized on high drug prices in the past year, including for Mylan's (MYL.O) EpiPen emergency allergy treatment, suggesting the issue may not go away.  Even with a Trump administration, ""we do believe there is an overall shift toward greater pricing scrutiny that will continue to reduce potential revenue growth purely from price increases,"" Jefferies analyst Brian Abrahams said in a research note.Shares of hospital chains Tenet Healthcare (THC.N) and HCA Holdings (HCA.N) tumbled 25 percent and 12 percent, respectively, while health insurer Centene (CNC.N), which specializes in the government's Medicaid health program that was expanded under the healthcare law, dropped 17.3 percent. ""We see extreme risk of ACA repeal/replace, loss of the Medicaid expansion, a primary driver of results for both hospitals and health plans,"" Mizuho Securities analyst Sheryl Skolnick said in a research note. (Additional reporting by Deena Beasley in Los Angeles, John Miller in Zurich and Annabella Pultz Nielsen in Copenhagen; Editing by Pravin Char and Jeffrey Benkoe)",2016-11-09,MYL,"Wed Nov 9, 2016 | 2:37pm EST","UPDATE 4-Pharma, biotech shares soar as Trump win calms pricing talk",http://www.reuters.com//article/usa-election-pharmaceuticals-idUSL8N1DA4H5?type=companyNews
349,"  Perrigo Co Plc reported a higher-than-expected adjusted quarterly profit and said it would review strategic options for royalty rights from sales of multiple sclerosis drug Tysabri.Shares of the Dublin-based company, which specializes in generic and over-the-counter drugs, were up about 4 percent at $86.75 in premarket trading on Thursday.Perrigo has been under pressure from activist investor Starboard Value LP to make changes - including exploring options for Tysabri - that will boost its stock price.Starboard disclosed a 4.6 percent stake in Perrigo in September. The company's stock had lost about 42 percent of its value through Wednesday's close of $83.51 and the company has cut its earnings forecast twice.Perrigo has blamed much of its troubles on former Chief Executive Joseph Papa who convinced investors to reject a $205 per share cash-and-stock bid from Mylan NV, worth about $26 billion when it was rejected last November. Papa, now CEO of Valeant Pharmaceuticals International Inc, said Perrigo would be better off on its own.Perrigo recognized $93 million of royalty revenue in the third quarter related to global net sales of Tysabri. The drug is marketed through a partnership with Biogen Inc, which paid more than $300 million in royalties to Perrigo.Perrigo, run by CEO John Hendrickson, has hired Morgan Stanley as financial adviser to lead the review process forTysabri. Royalty Pharma, a privately held company that specializes in acquiring drug royalties, is among potential buyers, Reuters reported in September, citing people familiar with the matter.Perrigo reported a net loss of $1.26 billion, or $8.76 per share, for the third quarter ended Oct. 1, compared with a profit of $113 million, or 77 cents per share, a year earlier. The net loss includes a goodwill impairment charge of $804million and a brand intangible assets impairment charge of $866million related to its $3 billion acquisition of Belgian over-the-counter drugmaker Omega Pharma.  On an adjusted basis, the company earned $1.80 per share, beating analysts' average estimate of $1.58, according to Thomson Reuters I/B/E/S.Revenue rose 1 percent to $1.35 billion, including sales of $22 million from held-for-sale businesses. Analysts on average were expecting revenue of $1.28 billion.The company said it expected to report a net loss of $9.04 to $9.34 per share for all of 2016. (Reporting By Aurindom Mukherjee and Akankshita Mukhopadhyay in Bengaluru; Editing by Gopakumar Warrier and Ted Kerr)",2016-11-10,MYL,"Thu Nov 10, 2016 | 7:41am EST",UPDATE 2-Perrigo to review options for Multiple Sclerosis drug Tysabri,http://www.reuters.com//article/perrigo-company-tysabri-idUSL4N1DB2TW?type=companyNews
350,"  Nov 14 Greenlight Capital* Ups share stake in Mylan NV by 29.4 percent to 6.4 million shares - SEC filing* cuts share stake in General Motors Co by 1.2 percent to 17.0 million shares * dissolves share stake in Community Health Systems * cuts share stake in PVH Corp by 13.9 percent to 529,170 shares * Cuts share stake in Take-Two Interactive Software by 49.6 percent to 1.4 million shares  Source text for quarter ended Sept 30, 2016:  bit.ly/2ez9IcP   Source text for quarter ended June 30, 2016: bit.ly/2aVdzdO   Further company coverage:",2016-11-14,MYL,"Mon Nov 14, 2016 | 4:43pm EST","BRIEF-Greenlight Capital ups stake in Mylan, cuts in GM",http://www.reuters.com//article/idUSFWN1DF1KH?type=companyNews
351,"   By Laura Benitez  LONDON, Nov 14 (IFR) - US pharmaceuticals AbbVie and Mylan have set their sights on Europe's bond market to sell debut euro bonds, taking advantage of positive sentiment for the sector after last week's unexpected Donald Trump victory in the US election.Bonds in that space were among the biggest gainers last Wednesday as investors looked to pick potential beneficiaries of the policies of a Trump presidency and his more lenient views on drugs pricing.However, the two issuers will have to contend with a volatile market backdrop, where government bonds have brutally sold off as investors fear that monetary easing may come to an end.After meeting investors last week, AbbVie is selling a triple-tranche euro deal today, expected to total around 3bn in size, while Mylan is planning its return to the market after withdrawing its potential debut euro in September.TRICKY TIMING These trades - and euro-denominated bond issuance in general - are expected to come at a price this week, due to increased European rates volatility. The 10-year German Bund yield rose to its highest level since January. It has jumped from 0.15% to 0.37% in the last week alone.""It's a very tough market and the AbbVie deal is looking very cheap for investors right now,"" one banker said. ""The huge moves in rates are worrying investors and making them defensive,"" one banker said.AbbVie started marketing a three-year tranche at 70bp area, a long seven-year at 110bp area and a 12-year at 135bp area, all over mid-swaps. This was revised to 55bp-70bp, 100bp area and 125bp-130bp,  respectively.Higher Bund yields and the approaching year-end are also forcing investors to reduce risk at the long end of the curve.""We like the credit but the volatility in rates leaves us on the sidelines in the near term,"" said one UK based portfolio manager.""There is a rush to get many of these deals done by year-end, and ahead of Thanksgiving, but [I'm] not sure there will be huge appetite from investors until the Bund curve stabilises."" Barclays, Bank of America Merrill Lynch, Deutsche Bank, JP Morgan are bookrunners on the deal, with Morgan Stanley also acting as global coordinator.The deal follows European fixed income investor meetings that were held from November 9.SECOND TIME LUCKY?  Mylan is also trying to cash in on the post-election pharmaceutical rally to return to the European market for a debut euro.The US company met investors from September 7-9 for a potential benchmark multi-tranche debut offering, rumoured to be around 3bn in size.It decided not to proceed with its euro bond plans after it came under intense scrutiny for sharply raising the price of its EpiPen allergy auto-injector.The company has continued to court controversy with the US Senate Judiciary Committee urging federal antitrust regulators to launch a probe into whether it broke the law by preventing schools from purchasing competing allergy treatments .""This could be a tough one, given DoJ investigation headlines regarding potential collusion in generic drug pricing,"" another investor said.""It's very difficult to prejudge the outcome but our concern is this has the potential to threaten its investment-grade ratings.""The borrower has indicated its intention to sell a multi-tranche benchmark transaction, comprising a two-year FRN and four, eight and/or 12-year fixed-rate notes.Rated Baa3/BBB-/BBB-, Mylan has mandated Deutsche Bank, Citigroup, ING and JP Morgan for the upcoming deal.      (Reporting By Laura Benitez; Editing by Philip Wright and Helene Durand)",2016-11-14,MYL,"Mon Nov 14, 2016 | 8:10am EST",US pharmas eye Europe's bond market amid rates volatility,http://www.reuters.com//article/pharmaceuticals-bonds-idUSL8N1DF3S6?type=companyNews
352,"  Mylan NV (MYL.O) has declined a U.S. Senate committee request to testify about a $465 million pending settlement to resolve charges the company underpaid government healthcare programs by misclassifying its the EpiPen emergency allergy treatment.In a Nov. 18 letter to the Senate Judiciary Committee released on Monday, Mylan said the company would not attend since government agencies had also refused to testify.Senator Chuck Grassley, who chairs the committee and had scheduled the hearing for Nov. 30, said in a statement on Monday that Mylan was ""ducking responsibility.""Mylan has come under fire for raising the price of a pair of EpiPens to $600 from $100 in 2008 and listing it with Medicaid as a generic product even though it is listed with the U.S. Food and Drug Administration as a branded product. Companies pay smaller rebates to Medicaid for generics.Following months of Congressional scrutiny, Mylan in October announced a settlement with the Justice Department.The settlement has not yet been executed, however. ""This seems to contradict Mylan's claim that all potential liability claims have been resolved,"" Grassley said.Officials at the Justice Department and the Centers for Medicare and Medicaid Services, which administers Medicare and Medicaid, have declined to testify at the hearing. Grassley may reschedule the hearing and has the power to issue subpoenas, Jill Gerber, a spokeswoman for Grassley, said in an email. The authority is rarely used and would require a vote or the unanimous consent of the committee, she added.""One way or another, I intend to get answers for patients and taxpayers,"" Grassley said in the statement.Separately, Grassley wrote on Monday to the Securities and Exchange Commission encouraging it to investigate, if it was not already doing so, whether Mylan misled investors when it announced its settlement with the Justice Department. He asked the SEC to let the committee know by Nov. 29 whether it was investigating.The SEC declined to comment. A Mylan spokeswoman did not immediately respond to a request for comment. (Reporting by Toni Clarke in Washington; Editing by Richard Chang)",2016-11-21,MYL,"Mon Nov 21, 2016 | 3:10pm EST",Mylan declines Senate committee request to testify about EpiPen,http://www.reuters.com//article/us-mylan-nl-epipen-hearing-idUSKBN13G28P?type=companyNews
353,"  Mylan NV (MYL.O) has declined a U.S. Senate committee request to testify about a $465 million pending settlement to resolve charges the company underpaid government healthcare programs by misclassifying its the EpiPen emergency allergy treatment.In a Nov. 18 letter to the Senate Judiciary Committee released on Monday, Mylan said the company would not attend since government agencies had also refused to testify.Senator Chuck Grassley, who chairs the committee and had scheduled the hearing for Nov. 30, said in a statement on Monday that Mylan was ""ducking responsibility.""Mylan has come under fire for raising the price of a pair of EpiPens to $600 from $100 in 2008 and listing it with Medicaid as a generic product even though it is listed with the U.S. Food and Drug Administration as a branded product. Companies pay smaller rebates to Medicaid for generics.Following months of Congressional scrutiny, Mylan in October announced a settlement with the Justice Department.The settlement has not yet been executed, however. ""This seems to contradict Mylan's claim that all potential liability claims have been resolved,"" Grassley said.Officials at the Justice Department and the Centers for Medicare and Medicaid Services, which administers Medicare and Medicaid, have declined to testify at the hearing. Grassley may reschedule the hearing and has the power to issue subpoenas, Jill Gerber, a spokeswoman for Grassley, said in an email. The authority is rarely used and would require a vote or the unanimous consent of the committee, she added.""One way or another, I intend to get answers for patients and taxpayers,"" Grassley said in the statement.Separately, Grassley wrote on Monday to the Securities and Exchange Commission encouraging it to investigate, if it was not already doing so, whether Mylan misled investors when it announced its settlement with the Justice Department. He asked the SEC to let the committee know by Nov. 29 whether it was investigating.The SEC declined to comment. A Mylan spokeswoman did not immediately respond to a request for comment. (Reporting by Toni Clarke in Washington; Editing by Richard Chang)",2016-11-21,MYL,"Mon Nov 21, 2016 | 3:10pm EST",Mylan declines Senate committee request to testify about EpiPen,http://www.reuters.com//article/mylan-nl-epipen-hearing-idUSL1N1DM1BP?type=companyNews
354,  Nov 21 U.S. Senator Chuck Grassley: * Says Mylan declining to testify at judiciary committee hearing on potential settlement between Mylan and DOJ  Source text - (bit.ly/2fy1MoP) Further company coverage:  ,2016-11-21,MYL,"Mon Nov 21, 2016 | 11:54am EST",BRIEF-U.S. senator Chuck Grassley says Mylan declining to testify at judiciary committee hearing,http://www.reuters.com//article/idUSFWN1DM0GN?type=companyNews
355,"   By Laura Benitez and Hillary Flynn  LONDON, Nov 21 (IFR) - Corporate borrowers on both sides of the Atlantic shrugged off concerns about global volatility last week with pharmaceutical companies leading the charge, although they had to pay significantly higher premiums.Bond markets have been badly shaken since the US election, with Donald Trump's victory accelerating a sell-off in rates sparked by fears that his expansionary fiscal policies will weaken US government finances.But some investment-grade corporates in both the US and Europe have launched deals partly because things may get even worse, and partly because they are more sensitive to spreads than rates - with cash spreads proving more resilient than yields.""It's a day-by-day market and funding opportunities remain, but with only limited chances for borrowers to comfortably issue before the break, the question is how many 2016 corporate funding exercises will now get pushed back into next year,"" said Mark Lynagh, head of European corporate DCM at BNP Paribas.However, pharmaceutical companies spotted an opportunity, with the industry relieved that Hillary Clinton, who campaigned to bring down drug prices, lost the election. Companies such as Teva, Allergan and Mylan had seen their spreads tighten following the election.Mylan (Baa3/BBB-/BBB-) was one of two US pharmaceuticals issuing reverse Yankees last week, selling a 3bn four-tranche trade. It followed a 3.6bn triple-tranche deal from Abbvie (Baa2/A-) last Monday.Mylan hit the market after withdrawing a potential euro deal in September, when it came under intense scrutiny for sharply raising the price of its EpiPen allergy auto-injector. Abbvie's deal paved the way for its return.""The market needed a pragmatic US borrower like Abbvie selling a well-sized bond to give  some confidence during the unstable backdrop,"" another banker said. Both companies, though, had to offer generous concessions to lure investors with their debut euro offerings. The deals came about 25bp back of their US dollar curves, taking into account the cross-currency swap.Bankers thought both companies' decision to issue 12-year notes as part of their transactions was misguided given the back-up in rates, with lower-rated Mylan, in particular, coming in for stick.While Abbvie and Mylan turned to euros, other healthcare issuers went to the dollar market instead.Pfizer sold a US$6bn bond on a difficult day when the sell-off in Treasuries finally began to impact on the primary market. The deal last Monday was slow to price as 10-year Treasuries reached 2.30% and the 30-year yield nudged over 3% for the first time since the beginning of the year.But the bond - Pfizer's largest since 2009 - got done on the back of a US$14bn book.""People are seeing this sector rally and wondering how far it will go now that Trump is President-elect,"" one investor told IFR. ""Now is the time to get in.""Pfizer's strong book and subsequent performance in secondary - the bonds tightened on the break - gave other healthcare names the confidence to come to market. Abbott Laboratories, for example, finally decided to sell bonds to finance its US$25bn acquisition of St Jude on Thursday. The deal had been in the pipeline for months.The medical device maker issued US$15.1bn through six tranches. Leads were able to tighten pricing across the curve after amassing a US$34.6bn order book.This came despite investor concerns about higher leverage for a company that could soon drop sharply from its Single A ratings after targeting both St Jude and Alere for purchase.  Pricing, however, reflected that falling ratings trajectory, with leads offering investors a new issue concession of 15bp. The bonds are expected to be rated Baa3/BBB-.""That's a good sign of the health of the market that a low Triple B got US$15.1bn done. There were some reservations about how the market would react to the rates move but getting this deal through shows it's strong,"" a lead banker said.  COUGHING UP Issuance wasn't just restricted to pharmaceutical companies. Eastman Chemical became the third US company to issue in euros last week, with a 500m 10-year and 200m tap of its 550m 1.5% May 2023s.Like others during week, the borrower had to cough up, paying a hefty 30bp premium, but was still unable to tighten guidance from initial price thoughts. The order book size was undisclosed, which leads said was due to SEC regulations.A lead bank was bidding the 10-year at 130bp over swaps by Friday, after pricing it at 125bp on Wednesday.More deals are in the pipeline, though many in euros, at least, may get pushed into 2017. ""This year could set a record for the number of deals that have to get booted into the following year,"" said one banker.Corporate treasurers will be cognisant of commodity trader Louis Dreyfus, which pulled a five-year euro deal on Thursday, blaming a sharp increase in funding costs on volatile market conditions.   (Reporting By Laura Benitez and Hillary Flynn, editing by Julian Baker, Matthew Davies and Sudip Roy)",2016-11-21,MYL,"Mon Nov 21, 2016 | 8:51am EST",Corporates stay strong despite market rout,http://www.reuters.com//article/corporatebonds-rates-idUSL8N1DM3GI?type=companyNews
356,"  WASHINGTON The U.S. Senate Judiciary Committee on Monday postponed a hearing planned for next week to discuss Mylan NV's (MYL.O) pending $465 million settlement to resolve charges that it underpaid government healthcare programs by misclassifying its EpiPen emergency allergy treatment.Mylan, the Justice Department and the Centers for Medicare and Medicaid Services had all declined to send officials to the Nov. 30 hearing, the committee said in a statement. ""Unfortunately, because of the unconventional refusal by these three entities to attend, we must now consider compelling their participation,"" committee Chairman Charles Grassley said in the statement. ""This committee will not stop until our questions are answered and any appropriate actions are taken."" Mylan has come under fire for raising the price of a pair of EpiPens to $600 from $100 in 2008 and listing it with Medicaid as a generic product even though it is listed with the U.S. Food and Drug Administration as a branded product. Companies pay smaller rebates to Medicaid for generics.   (Reporting by Diane Bartz; Editing by Richard Chang)",2016-11-24,MYL,"Thu Nov 24, 2016 | 12:07pm EST",Senate panel postpones Mylan hearing,http://www.reuters.com//article/us-mylan-nl-epipen-hearing-idUSKBN13I2HM?type=companyNews
357,"  Nov 29 Mylan Nv* Mylan NV says on November 22, 2016, entered into a revolving credit agreement * Mylan - new senior revolving credit agreement contains revolving credit facility under which co may obtain extensions of credit not to exceed $2 billion  * Mylan NV -new senior revolving facility includes a $200 million subfacility for issuance of letters of credit and a $175 million sublimit for swingline borrowings  Source text for Eikon:  Further company coverage:",2016-11-29,MYL,"Tue Nov 29, 2016 | 5:16pm EST",BRIEF-Mylan NV enters into a revolving credit agreement,http://www.reuters.com//article/idUSFWN1DU0PY?type=companyNews
358,"   By Ransdell Pierson and Natalie Grover  Generic drugmaker Mylan NV (MYL.O), which has been under fire for price hikes on the life-saving EpiPen allergy treatment, said on Wednesday that it expected to cut less than 10 percent of its workforce in a restructuring to integrate acquisitions.Mylan, whose shares were down more than 3 percent in mid-afternoon trading, has been under investigation by the U.S. government, and its chief executive officer was called before Congress to testify on raising the price of a pair of EpiPens to more than $600 from $100 in 2008.The company said in a regulatory filing that it would implement restructuring programs in certain locations. At Tuesday's market close, its shares had fallen 25 percent since August, when it first came under public scrutiny by former U.S. presidential candidate Hillary Clinton.Mylan, which has about 35,000 employees, said in the filing that it would take cost-cutting measures, including job cuts, after a significant number of acquisitions. It bought Sweden's Meda earlier this year and Abbott Laboratories' (ABT.N) branded specialty and generics business in non-U.S. developed markets in 2015.The company said it would disclose costs and other details of the restructuring as it finalizes the plans. Mylan spokeswoman Nina Devlin declined to comment further.Morningstar analyst Michael Waterhouse said that the move could have other motivations beyond integrating recent acquisitions.""Pricing pressure in the generic drug industry combined with generic threats on EpiPen in 2017 are also likely leading management to find more areas to cut costs and preserve profitability, Waterhouse said. Mylan has been criticized for classifying EpiPen as a generic product, which led to its paying significantly smaller rebates to state Medicaid programs for the poor than if the drug were classified as branded. The company said in October that it would pay $465 million to settle questions on the impact of the classification on U.S. government healthcare costs.  Mylan, one of the largest U.S. generic-drug makers, last month reported a third-quarter loss. The Canonsburg, Pennsylvania-based company said it expected EpiPen to account for 6 percent of total sales in 2017. It plans to introduce a generic version that will sell for $300 for a two-pack.Drug price increases were a hot political topic among U.S. presidential candidates during the past two years. President-elect Donald Trump in a Time magazine article published early on Wednesday said that he will ""bring down drug prices."" (Reporting by Natalie Grover in Bengaluru and Ransdell Pierson and Caroline Humer in New York; Editing by Lisa Von Ahn and Jim Finkle)",2016-12-07,MYL,"Wed Dec 7, 2016 | 2:44pm EST","EpiPen maker Mylan to restructure, cut workforce",http://www.reuters.com//article/us-mylan-nl-redundancies-idUSKBN13W1ON?type=companyNews
